

**CUMULATIVE
SUPPLEMENT 11
NOVEMBER 2004**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

24th EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

RM
301.45
.A66
2004
v.24
suppl.11

2004

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

Library Use Only

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

Cumulative Supplement 11

November 2004

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Ribavirin 200mg Oral Capsule.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Change Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms.....	B-1

Please Note:

The 24th Edition of the Orange Book will be the last paper version. All the components of the paper Orange Book are and have been available on the Internet since 1997. Refer to the Introduction 1.3, Availability of the Edition, for specific locations. The 25th Edition of the Orange Book will be available in a downloadable format. Additional information will be provided in the December Cumulative Supplement.

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

CUMULATIVE SUPPLEMENT 11
November 2004

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 24th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is then dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

ALPHARMA INC
(ALPHARMA)
ALPHARMA USPD INC
(ALPHARMA)
AMERSHAM HEALTH
(AMERSHAM)
BERLEX
(BERLEX)

ALPHARMA US PHARMACEUTICALS DIVISION
(ALPHARMA US PHARMS)
ALPHARMA US PHARMACEUTICALS DIVISION
(ALPHARMA US PHARMS)
GE HEALTHCARE
(GE HEALTHCARE)
BERLEX INC
(BERLEX INC)

BERLEX LABORATORIES INC
(BERLEX LABS)
BERLEX LABORATORIES INC SUB SCHERING AG
(BERLEX)
GENSIA INC
(GENSIA)
GENSIA LABORATORIES LTD
(GENSIA)
GENSIA SICOR PHARMACEUTICALS INC
(GENSIA SICOR PHARMS)
PUREPAC PHARMACEUTICAL COMPANY DIVISION
OF PUREPAC INC
(PUREPAC PHARM)

BERLEX INC
(BERLEX INC)
BERLEX INC
(BERLEX INC)
SICOR PHARMACEUTICALS INC
(SICOR PHARMS)
SICOR PHARMACEUTICALS INC
(SICOR PHARMS)
SICOR PHARMACEUTICALS INC
(SICOR PHARMS)
PUREPAC INC
(PUREPAC PHARM)

1.3 RIBAVIRIN 200MG ORAL CAPSULE

The footnote for Ribavirin 200MG capsule product 001 was inadvertently omitted from the 24th Edition. The footnote: Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187) and Unithrod (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King/Jones Pharma NDA 021301) tablets.

Novothyrox (Genpharm NDA 021292) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Thyro-Tabs (Lloyd NDA 021116) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Levolet (Vintage NDA 021137) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

The chart outlines TE codes for all 0.025mg products with other products being similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	JONES PHARMA	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	JONES PHARMA	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
NOVOTHYROX	GENPHARM	0.025MG	BX	21292	001
THYRO-TABS	LLOYD	0.025MG	BX	21116	001
LEVOLET	VINTAGE PHARMS	0.025MG	BX	21137	001

1.5 AVAILABILITY OF THE EDITION

The 24th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is \$110.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at <http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the monthly supplement is at <http://www.fda.gov/cder/orange/supplement/cspreface.htm>.

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B text files of the paper annual Orange Book are updated quarterly.

The 24th annual edition of the 2003 Orange Book Patent and Exclusivity List is at <http://www.fda.gov/cder/orange/24bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at <http://www.fda.gov/cder/orange/docket.pdf>. It is updated approximately weekly. Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from Program Support Center Forms Download Website, <http://forms/psc.gov/forms/FDA/fda.html>

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2003) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

<u>CATEGORIES COUNTED</u>	<u>COUNTS CUMULATIVE BY QUARTER</u>			
	<u>DEC 2003</u>	<u>MAR 2004</u>	<u>JUN 2004</u>	<u>SEP 2004</u>
DRUG PRODUCTS LISTED	10665	10668	10702	10822
SINGLE SOURCE	2423 (22.7%)	2404 (22.5%)	2385 (22.3%)	2385 (22.0%)
MULTISOURCE	8134 (76.3%)	8156 (76.5%)	8209 (76.7%)	8329 (77.0%)
THERAPEUTICALLY EQUIVALENT	7856 (73.7%)	7885 (73.9%)	7995 (74.7%)	8116 (75.0%)
NOT THERAPEUTICALLY EQUIVALENT	278 (2.6%)	271 (2.5%)	214 (2.0%)	213 (2.0%)
EXCEPTIONS ¹	108 (1.0%)	108 (1.0%)	108 (1.0%)	108 (1.0%)
NEW MOLECULAR ENTITIES APPROVED	6	3	1	1
NUMBER OF APPLICANTS	601	586	602	605

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change

	in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL

EPZICOM
+ SMITHKLINE BEECHAM EQ 600MG BASE;300MG N21652 001 Aug 02, 2004 Aug NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

CAMPRAL
+ FOREST LABS 333MG N21431 001 Jul 29, 2004 Sep CAHN
+ LIPHA 333MG N21431 001 Jul 29, 2004 Jul NEWA

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

PHRENILIN FORTE
AB + VALEANT 650MG;50MG N88831 001 Jun 19, 1985 Aug CAHN

TABLET; ORAL

PHRENILIN
AB + VALEANT 325MG;50MG N87811 001 Jun 19, 1985 Aug CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE
AB ANABOLIC LABS 325MG;50MG;40MG;30MG N76560 001 Jun 10, 2004 Jun NEWA

PHRENILIN WITH CAFFEINE AND CODEINE

AB VALEANT 325MG;50MG;40MG;30MG N74911 001 Aug 22, 2001 Aug CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC-A
@ LEITNER PHARMS 356.4MG;30MG;16MG N89166 001 May 14, 1986 Oct CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE
AA + AMARIN PHARMS 120MG/5ML;12MG/5ML N86024 001 Apr CRLD
AA + VALEANT 120MG/5ML;12MG/5ML N86024 001 Aug CAHN

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE
@ MUTUAL PHARM 300MG;15MG N85795 001 Aug CAHN
@ 300MG;30MG N85794 001 Aug CAHN
@ 300MG;60MG N89673 001 Feb 10, 1988 Aug DISC

ACETAMINOPHEN W/ CODEINE

@ MUTUAL PHARM 300MG;60MG N87653 001 Apr 13, 1982 Aug CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE
@ CENT PHARMS 500MG;5MG N88898 001 Mar 27, 1985 Aug DISC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN
+ MIKART 300MG;10MG N40556 001 Jun 23, 2004 Jun NEWA
AA MUTUAL PHARM 500MG;5MG N40236 001 Sep 25, 1997 Aug CAHN
AA 650MG;7.5MG N40240 002 Nov 26, 1997 Aug CAHN

	TABLET; ORAL							
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
AA	MUTUAL PHARM	650MG;10MG			N40240 001	Nov 26, 1997	Aug	CAHN
AA		750MG;7.5MG			N40236 002	Sep 25, 1997	Aug	CAHN
	<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE</u>							
	CAPSULE; ORAL							
	OXYCODONE AND ACETAMINOPHEN							
AA	MUTUAL PHARM	500MG;5MG			N40219 001	Jan 22, 1998	Aug	CAHN
	TABLET; ORAL							
	OXYCODONE AND ACETAMINOPHEN							
AA	MALLINCKRODT	325MG;7.5MG			N40545 001	Jun 30, 2004	Jun	NEWA
AA		325MG;10MG			N40545 002	Jun 30, 2004	Jun	NEWA
AA		500MG;7.5MG			N40550 001	Jun 30, 2004	Jun	NEWA
AA		650MG;10MG			N40550 002	Jun 30, 2004	Jun	NEWA
	<u>ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE</u>							
	TABLET; ORAL							
	WYGESIC							
AA	+ LEITNER PHARMS	650MG;65MG			N84999 001		Oct	CAHN
	<u>ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE</u>							
	TABLET; ORAL							
	DARVOCET A500							
	AAIPHARMA							
AB		500MG;100MG			N76429 001	Sep 10, 2003	May	CRLD
		500MG;100MG			N76429 001	Sep 10, 2003	Jun	CFTG
	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN							
>A>	AB	ANDRX PHARMS	650MG;100MG		N76609 001	Nov 16, 2004	Nov	NEWA
	AB	@ MUTUAL PHARM	325MG;50MG		N70115 001	Jun 12, 1985	Aug	CAHN
	AB	@	650MG;100MG		N70116 001	Jun 12, 1985	Aug	CAHN
	AB		650MG;100MG		N70615 001	Mar 21, 1986	Aug	CAHN
	AB		650MG;100MG		N70771 001	Mar 21, 1986	Aug	CAHN
	AB		650MG;100MG		N70775 001	Mar 21, 1986	Aug	CAHN
	AB	VINTAGE PHARMS	325MG;100MG		N76743 001	May 07, 2004	May	NEWA
	AB		500MG;100MG		N76750 001	Jun 28, 2004	Jun	NEWA
	<u>ACETAZOLAMIDE SODIUM</u>							
	INJECTABLE; INJECTION							
	ACETAZOLAMIDE SODIUM							
AP	HOSPIRA	EQ 500MG BASE/VIAL			N40108 001	Oct 30, 1995	May	CAHN
	<u>ACETIC ACID, GLACIAL</u>							
	SOLUTION; IRRIGATION, URETHRAL							
	ACETIC ACID 0.25% IN PLASTIC CONTAINER							
AT	HOSPIRA	250MG/100ML			N17656 001		May	CAHN
	<u>ACETYLCYSTEINE</u>							
	INJECTABLE; INTRAVENOUS							
	ACETADOTE							
	+ CUMBERLAND PHARMS	6GM /30ML(200MG/ML)			N21539 001	Jan 23, 2004	Jan	NEWA
	SOLUTION; INHALATION, ORAL							
	ACETYLCYSTEINE							
AN	HOSPIRA	10%			N73664 001	Aug 30, 1994	May	CAHN
AN		20%			N74037 001	Aug 30, 1994	May	CAHN

ACITRETINCAPSULE; ORAL
SORIATANE
CONNETICS

+

10MG
25MGN19821 001 Oct 28, 1996 Mar CAHN
N19821 002 Oct 28, 1996 Mar CAHNACYCLOVIR SODIUMINJECTABLE; INJECTION
ACYCLOVIR SODIUMAP HOSPIRA
AP
AP
AP
AP
AP MAYNE PHARMA USAEQ 500MG BASE/VIAL
EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL
EQ 1GM BASE/VIAL
EQ 50MG BASE/MLN74663 001 Apr 22, 1997 May CAHN
N74758 001 Apr 22, 1997 May CAHN
N74663 002 Apr 22, 1997 May CAHN
N74758 002 Apr 22, 1997 May CAHN
N75065 001 Feb 25, 1999 Apr CAHNADENOSINEINJECTABLE; INJECTION
ADENOCARDAP + FUJISAWA HLTHCARE
ADENOSINE
AP BAXTER HLTHCARE
AP
AP BEDFORD
AP SICOR PHARMS3MG/ML
3MG/ML
3MG/ML
3MG/ML
3MG/MLN19937 002 Oct 30, 1989 Jun CFTG
N76500 001 Jun 16, 2004 Jun NEWA
N76501 001 Jun 16, 2004 Jun NEWA
N76404 001 Jun 16, 2004 Jun NEWA
N76564 001 Jun 16, 2004 Jun NEWAALATROFLOXACIN MESYLATEINJECTABLE; INJECTION
TROVAN PRESERVATIVE FREE@ PFIZER
@EQ 200MG BASE/VIAL
EQ 300MG BASE/VIALN20760 001 Dec 18, 1997 Jun DISC
N20760 002 Dec 18, 1997 Jun DISCALBUMIN IODINATED I-125 SERUMINJECTABLE; INJECTION
JEANATOPE

ISO TEX

+

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125
@ MALLINCKRODT100UCI/10ML (10UCI/ML)
500uCi/0.5ML
1,000uCi/ML
10uCi/MLN17836 003 Jun 08, 2004 Jun NEWA
N17836 001 Jun CMFD
N17836 002 Jun CMFD
N17844 001 Jun DISCALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

>D> ALBUTEROL SULFATE

>D> BX + IVAX RES
BX +EQ 0.09MG BASE/INH
EQ 0.09MG BASE/INHN21457 001 Oct 29, 2004 Nov CTNA
N21457 001 Oct 29, 2004 Oct NEWA>A> ALBUTEROL SULFATE HFA
>A> BX + IVAX RES

EQ 0.09MG BASE/INH

N21457 001 Oct 29, 2004 Nov CTNA

SOLUTION; INHALATION
ACCUNEBAN + DEY
ALBUTEROL SULFATE
AN + BAUSCH AND LOMB
AN +
AN NEPHRON
PROVENTIL
@ SCHERINGEQ 0.042% BASE
EQ 0.083% BASE
EQ 0.5% BASE
EQ 0.042% BASE
EQ 0.083% BASEN20949 001 Apr 30, 2001 Jun CFTG
N75358 001 Mar 29, 2000 Jun CRLD
N75050 001 Jun 18, 1998 Jun CRLD
N76355 001 Jun 28, 2004 Jun NEWA
N19243 002 Jan 14, 1987 Jun DISC

	SOLUTION; INHALATION							
	PROVENTIL							
	@ SCHERING		EQ 0.5% BASE		N19243 001	Jan 14, 1987	Jun	DISC
	SYRUP; ORAL							
	ALBUTEROL SULFATE							
AA	+	TEVA	EQ 2MG BASE/5ML		N73419 001	Mar 30, 1992	Sep	CRLD
	TABLET, EXTENDED RELEASE; ORAL							
	ALBUTEROL SULFATE							
>D>	+	PLIVA	EQ 4MG BASE		N76130 002	Sep 26, 2002	Nov	CRLD
>A>			EQ 4MG BASE		N76130 002	Sep 26, 2002	Nov	CRLD
	+		EQ 4MG BASE		N76130 002	Sep 26, 2002	Jan	CRLD
	+		EQ 8MG BASE		N76130 003	Sep 26, 2002	Jan	CRLD
	VOLMAX							
	@ MURO		EQ 4MG BASE		N19604 002	Dec 23, 1992	Jan	DISC
	@		EQ 8MG BASE		N19604 001	Dec 23, 1992	Jan	DISC
	<u>ALCLOMETASONE DIPROPIONATE</u>							
	OINTMENT; TOPICAL							
	ACLOVATE							
AB	+	GLAXOSMITHKLINE	0.05%		N18702 001	Dec 14, 1982	Jul	CFTG
	ALCLOMETASONE DIPROPIONATE							
AB		TARO	0.05%		N76730 001	Jul 29, 2004	Jul	NEWA
	<u>ALCOHOL; DEXTROSE</u>							
	INJECTABLE; INJECTION							
	ALCOHOL 5% IN D5-W							
AP		HOSPIRA	5ML/100ML;5GM/100ML		N83263 001		May	CAHN
	<u>ALFENTANIL HYDROCHLORIDE</u>							
	INJECTABLE; INJECTION							
	ALFENTANIL							
AP		HOSPIRA	EQ 0.5MG BASE/ML		N75221 001	Oct 28, 1999	May	CAHN
	<u>ALLOPURINOL</u>							
	TABLET; ORAL							
	ALLOPURINOL							
	@ MUTUAL PHARM		100MG		N70466 001	Dec 24, 1985	Aug	CAHN
	@		300MG		N70467 001	Dec 24, 1985	Aug	CAHN
	<u>ALLOPURINOL SODIUM</u>							
	INJECTABLE; INJECTION							
	ALLOPURINOL SODIUM							
AP		BEDFORD LABS	EQ 500MG BASE/VIAL		N76870 001	Aug 26, 2004	Aug	NEWA
	ALOPRIM							
AP	+	NABI	EQ 500MG BASE/VIAL		N20298 001	May 17, 1996	Aug	CFTG
	+		EQ 500MG BASE/VIAL		N20298 001	May 17, 1996	Jun	CAHN
	<u>ALMOTRIPTAN MALATE</u>							
	TABLET; ORAL							
	AXERT							
	ORTHO MCNEIL PHARM		EQ 6.25MG BASE		N21001 001	May 07, 2001	Jul	CAHN
	+		EQ 12.5MG BASE		N21001 002	May 07, 2001	Jul	CAHN

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

>A>	@ PFIZER	0.005MG/ML	N20755 001	Oct 31, 1997	Nov	CAHN
>A>	@	0.01MG/ML	N20755 002	Oct 01, 1997	Nov	CAHN
>A>	@	0.02MG/ML	N20755 003	Oct 01, 1997	Nov	CAHN
>D>	@ PHARMACIA AND UPJOHN	0.005MG/ML	N20755 001	Oct 31, 1997	Nov	CAHN
>D>	@	0.01MG/ML	N20755 002	Oct 01, 1997	Nov	CAHN
>D>	@	0.02MG/ML	N20755 003	Oct 01, 1997	Nov	CAHN

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HCL

AA	SILARX	50MG/5ML	N76352 001	Sep 10, 2004	Sep	NEWA
----	--------	----------	------------	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

	@ BAXTER HLTHCARE	EQ 50MG BASE/ML	N63274 001	May 18, 1992	Aug	CAHN
	@	EQ 250MG BASE/ML	N63275 001	May 18, 1992	Aug	CAHN
AP	HOSPIRA	EQ 50MG BASE/ML	N63263 001	Nov 30, 1994	May	CAHN
		EQ 62.5MG BASE/ML	N63283 001	Oct 31, 1994	May	CAHN
AP		EQ 250MG BASE/ML	N63264 001	Nov 30, 1994	May	CAHN
AP		EQ 250MG BASE/ML	N64098 001	Jun 26, 1995	May	CAHN
	@	EQ 250MG BASE/ML	N64099 001	Jun 20, 1995	May	CAHN
	AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	HOSPIRA	EQ 500MG BASE/100ML	N64146 001	Apr 02, 1997	May	CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

	HOSPIRA	5.2% (5.2GM/100ML)	N18901 001	Apr 06, 1984	Aug	CAHN
	AMINOSYN 10%					
	HOSPIRA	10% (10GM/100ML)	N17673 003		May	CAHN
	AMINOSYN 10% (PH6)					
	HOSPIRA	10% (10GM/100ML)	N17673 008	Nov 18, 1985	May	CAHN
	AMINOSYN 3.5%					
	HOSPIRA	3.5% (3.5GM/100ML)	N17789 004		May	CAHN
	AMINOSYN 5%					
	HOSPIRA	5% (5GM/100ML)	N17673 001		May	CAHN
	AMINOSYN 7%					
	@ HOSPIRA	7% (7GM/100ML)	N17673 002		May	CAHN
	AMINOSYN 7% (PH6)					
	HOSPIRA	7% (7GM/100ML)	N17673 006	Nov 18, 1985	May	CAHN
	AMINOSYN 8.5%					
	@ HOSPIRA	8.5% (8.5GM/100ML)	N17673 004		May	CAHN
	AMINOSYN 8.5% (PH6)					
	HOSPIRA	8.5% (8.5GM/100ML)	N17673 007	Nov 18, 1985	May	CAHN
	AMINOSYN II 10%					
	HOSPIRA	10% (10GM/100ML)	N19438 005	Apr 03, 1986	May	CAHN
	AMINOSYN II 10% IN PLASTIC CONTAINER					
	HOSPIRA	10% (10GM/100ML)	N20015 001	Dec 19, 1991	May	CAHN
	AMINOSYN II 15% IN PLASTIC CONTAINER					
	HOSPIRA	15% (15GM/100ML)	N20041 001	Dec 19, 1991	May	CAHN
	AMINOSYN II 3.5%					
	@ HOSPIRA	3.5% (3.5GM/100ML)	N19438 001	Apr 03, 1986	May	CAHN

INJECTABLE; INJECTION

AMINOSYN II 5%								
@ HOSPIRA	5% (5GM/100ML)		N19438 002	Apr 03, 1986	May	CAHN		
AMINOSYN II 7%								
HOSPIRA	7% (7GM/100ML)		N19438 003	Apr 03, 1986	May	CAHN		
AMINOSYN II 8.5%								
HOSPIRA	8.5% (8.5GM/100ML)		N19438 004	Apr 03, 1986	May	CAHN		
AMINOSYN-HBC 7%								
HOSPIRA	7% (7GM/100ML)		N19374 001	Jul 12, 1985	May	CAHN		
AMINOSYN-HF 8%								
HOSPIRA	8% (8GM/100ML)		N20345 001	Apr 04, 1996	May	CAHN		
AMINOSYN-PF 10%								
HOSPIRA	10% (10GM/100ML)		N19492 002	Oct 17, 1986	May	CAHN		
AMINOSYN-PF 7%								
HOSPIRA	7% (7GM/100ML)		N19398 001	Sep 06, 1985	May	CAHN		
AMINOSYN-RF 5.2%								
HOSPIRA	5.2% (5.2GM/100ML)		N18429 001		May	CAHN		
NEOPHAM 6.4%								
@ HOSPIRA	6.4% (6.4GM/100ML)		N18792 001	Jan 17, 1984	Aug	CAHN		
NOVAMINE 11.4%								
HOSPIRA	11.4% (11.4GM/100ML)		N17957 003	Aug 09, 1982	Aug	CAHN		
NOVAMINE 15%								
HOSPIRA	15% (15GM/100ML)		N17957 004	Nov 28, 1986	Aug	CAHN		
NOVAMINE 8.5%								
@ HOSPIRA	8.5% (8.5GM/100ML)		N17957 002	Aug 09, 1982	Aug	CAHN		

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER								
HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML		N19683 001	Nov 07, 1988	May	CAHN		
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER								
HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML		N19683 002	Nov 07, 1988	May	CAHN		
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER								
HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML		N19683 003	Nov 07, 1988	May	CAHN		
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER								
@ HOSPIRA	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML		N19683 004	Nov 07, 1988	May	CAHN		

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER								
HOSPIRA	3.5%;25GM/100ML		N19681 001	Nov 01, 1988	May	CAHN		
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER								
HOSPIRA	3.5%;5GM/100ML		N19681 002	Nov 01, 1988	May	CAHN		
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER								
HOSPIRA	4.25%;10GM/100ML		N19681 004	Nov 01, 1988	May	CAHN		
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER								
HOSPIRA	4.25%;20GM/100ML		N19681 005	Nov 01, 1988	May	CAHN		
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER								
HOSPIRA	4.25%;25GM/100ML		N19681 003	Nov 01, 1988	May	CAHN		
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER								
HOSPIRA	5%;25GM/100ML		N19681 006	Nov 01, 1988	May	CAHN		

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER
 HOSPIRA 4.25%; 10GM/100ML; 51MG/100ML; 176.5 N19682 003 Nov 01, 1988 May CAHN
 MG/100ML; 22.4MG/100ML; 104.5MG/100
 ML; 205MG/100ML

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
 HOSPIRA 3.5%; 5GM/100ML; 30MG/100ML; 97MG/10 N19682 001 Nov 01, 1988 May CAHN
 OML; 120MG/100ML; 49.3MG/100ML

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER
 HOSPIRA 4.25%; 5GM/100ML; 30MG/100ML; 97MG/1 N19682 002 Nov 01, 1988 May CAHN
 00ML; 120MG/100ML; 49.3MG/100ML

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M
 HOSPIRA 3.5%; 21MG/100ML; 40MG/100ML; 128MG/ N17789 003 May CAHN
 100ML; 234MG/100ML

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M
 HOSPIRA 3.5%; 21MG/100ML; 128MG/100ML; 234MG N17789 005 May CAHN
 /100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%
 HOSPIRA 8%; 61MG/100ML; 211MG/100ML; 56MG/10 N17957 001 Aug CAHN
 OML; 388MG/100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES
 HOSPIRA 10%; 102MG/100ML; 45MG/100ML; 522MG/ N19437 004 Apr 03, 1986 May CAHN
 100ML; 410MG/100ML

AMINOSYN II 7% W/ ELECTROLYTES
 HOSPIRA 7%; 102MG/100ML; 45MG/100ML; 522MG/1 N19437 006 Apr 03, 1986 May CAHN
 00ML; 410MG/100ML

AMINOSYN II 8.5% W/ ELECTROLYTES
 HOSPIRA 8.5%; 102MG/100ML; 45MG/100ML; 522MG N19437 005 Apr 03, 1986 May CAHN
 /100ML; 410MG/100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M
 HOSPIRA 3.5%; 30MG/100ML; 97MG/100ML; 120MG/ N19437 007 Apr 03, 1986 May CAHN
 100ML; 49MG/100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES
 HOSPIRA 7%; 102MG/100ML; 522MG/100ML; 410MG/ N17789 002 May CAHN
 100ML

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ ELECTROLYTES

HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N17673 005			May	CAHN
---------	--	------------	--	--	-----	------

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

AP	HOSPIRA	250MG/ML	N70888 001	Jun 16, 1988	May	CAHN
	AMINOCAPROIC ACID IN PLASTIC CONTAINER					
AP	HOSPIRA	250MG/ML	N70010 001	Mar 09, 1987	May	CAHN

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP	HOSPIRA	25MG/ML	N87242 001	Oct 26, 1983	May	CAHN
AP	+	25MG/ML	N87601 001	Jul 23, 1982	May	CAHN
	AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%					
+	HOSPIRA	100MG/100ML	N88147 002	May 03, 1983	May	CAHN
+		200MG/100ML	N88147 003	May 03, 1983	May	CAHN
	AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	@ HOSPIRA	100MG/100ML	N18924 001	Dec 12, 1984	May	CAHN
	@	200MG/100ML	N18924 002	Dec 12, 1984	May	CAHN
	@	400MG/100ML	N18924 003	Dec 12, 1984	May	CAHN
	@	500MG/100ML	N18924 004	Dec 12, 1984	May	CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP	HOSPIRA	50MG/ML	N75955 001	Oct 18, 2002	May	CAHN
	AMIODARONE HYDROCHLORIDE					
AP	INTL MEDICATION SYS	50MG/ML	N21594 001	Feb 04, 2004	Feb	NEWA
	TABLET; ORAL					
	AMIODARONE HCL					
	@ TARO	400MG	N76362 001	Nov 29, 2002	Jul	DISC

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ELAVIL

	@ ASTRAZENECA	10MG/ML	N12704 001		Sep	DISC
--	---------------	---------	------------	--	-----	------

TABLET; ORAL

AMITRIPTYLINE HCL

	@ MUTUAL PHARM	10MG	N85744 001		Aug	CAHN
	@	25MG	N85627 001		Aug	CAHN
	@	50MG	N85745 001		Aug	CAHN
	@	75MG	N85743 001		Aug	CAHN
	@	100MG	N85742 002	May 11, 1982	Aug	CAHN
	@	150MG	N89423 001	Feb 17, 1987	Aug	CAHN
AB	+	SANDOZ	25MG	N85966 001	Oct	CRLD
	ELAVIL					
	@ ASTRAZENECA	10MG	N12703 001		Jul	DISC
	@	25MG	N12703 003		Jul	DISC
	@	50MG	N12703 004		Jul	DISC
	@	75MG	N12703 005		Jul	DISC
	@	100MG	N12703 006		Jul	DISC
	@	150MG	N12703 007		Jul	DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

@ MUTUAL PHARM EQ 12.5MG BASE;5MG
 @ EQ 25MG BASE;10MG

N70765 001 Dec 10, 1986 Aug CAHN
 N70766 001 Dec 10, 1986 Aug CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

@ MUTUAL PHARM 10MG;2MG
 @ 10MG;4MG
 @ 25MG;2MG
 @ 25MG;4MG

N71077 001 Nov 12, 1986 Aug CAHN
 N71078 001 Nov 12, 1986 Aug CAHN
 N70297 001 Nov 12, 1986 Aug CAHN
 N71079 001 Nov 12, 1986 Aug CAHN

AMLEXANOX

PATCH; TOPICAL

AMLEXANOX

+ ACCESS PHARMS 2MG

N21727 001 Sep 29, 2004 Sep NEWA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

CADUET

PFIZER

EQ 2.5MG BASE;EQ 10MG BASE
 EQ 2.5MG BASE;EQ 20MG BASE
 EQ 2.5MG BASE;EQ 40MG BASE
 EQ 5MG BASE;EQ 10MG BASE
 EQ 5MG BASE;EQ 20MG BASE
 EQ 5MG BASE;EQ 40MG BASE
 EQ 5MG BASE;EQ 80MG BASE
 EQ 10MG BASE;EQ 10MG BASE
 EQ 10MG BASE;EQ 20MG BASE
 EQ 10MG BASE;EQ 40MG BASE
 EQ 10MG BASE;EQ 80MG BASE

N21540 009 Jul 29, 2004 Aug NEWA
 N21540 010 Jul 29, 2004 Aug NEWA
 N21540 011 Jul 29, 2004 Aug NEWA
 N21540 001 Jan 30, 2004 Jan NEWA
 N21540 002 Jan 30, 2004 Jan NEWA
 N21540 003 Jan 30, 2004 Jan NEWA
 N21540 004 Jan 30, 2004 Jan NEWA
 N21540 005 Jan 30, 2004 Jan NEWA
 N21540 006 Jan 30, 2004 Jan NEWA
 N21540 007 Jan 30, 2004 Jan NEWA
 N21540 008 Jan 30, 2004 Jan NEWA

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

@ DR REDDYS LABS INC 2.5MG
 @ 5MG
 @ 10MG

N21435 001 Oct 31, 2003 Mar DISC
 N21435 002 Oct 31, 2003 Mar DISC
 N21435 003 Oct 31, 2003 Mar DISC

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA 5MEQ/ML

N88366 001 Jun 13, 1984 May CAHN

AMMONIUM LACTATE

LOTION; TOPICAL

AMMONIUM LACTATE

AB CLAY PARK EQ 12% BASE
 AB TARO EQ 12% BASE

N75570 001 Jun 23, 2004 Jun NEWA
 N76216 001 May 28, 2004 May NEWA

NEW BRUNSWICK COUNTY REGISTER OF DEEDS

AMOXICILLIN

TABLET, CHEWABLE; ORAL

AMOXIL

@	GLAXOSMITHKLINE	125MG	N50542 002	Aug	DISC
@		250MG	N50542 001	Aug	DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	TEVA	200MG/5ML;EQ 28.5MG BASE/5ML	N65089 001	May 25, 2004	May	NEWA	
AB		400MG/5ML;EQ 57MG BASE/5ML	N65089 002	May 25, 2004	May	NEWA	
AB		600MG/5ML;EQ 42.9MG BASE/5ML	N65162 001	Mar 12, 2004	Mar	NEWA	
AUGMENTIN ES-600							
AB	+	GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755 001	Jun 22, 2001	Mar	CPTG
TABLET, EXTENDED RELEASE; ORAL							
AUGMENTIN XR							
+		GLAXOSMITHKLINE	1GM;EQ 62.5MG BASE	N50785 001	Sep 25, 2002	Sep	CPOT

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	IBI	EQ 2GM BASE/VIAL	N62797 002	Jul 12, 1993	Aug	CMFD
AP	+	SANDOZ	EQ 125MG BASE/VIAL	N61395 001	Jun	CAHN
AP	+		EQ 250MG BASE/VIAL	N61395 002	Jun	CAHN
AP	+		EQ 500MG BASE/VIAL	N61395 003	Jun	CAHN
AP	+		EQ 1GM BASE/VIAL	N61395 004	Jun	CAHN
AP	+		EQ 2GM BASE/VIAL	N61395 005	Jun	CAHN
AP	+		EQ 10GM BASE/VIAL	N61395 006	Jun	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	BAXTER HLTHCARE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65074 001	Mar 19, 2002	Aug	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65074 002	Mar 19, 2002	Aug	CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N65076 001	Mar 19, 2002	Aug	CAHN

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

	BERTEK	20MG/2ML (10MG/ML)	N21264 001	Apr 20, 2004	Apr	NEWA
+		30MG/3ML (10MG/ML)	N21264 002	Apr 20, 2004	Apr	NEWA
	MYLAN BERTEK	20MG/2ML (10MG/ML)	N21264 001	Apr 20, 2004	Aug	CAHN
+		30MG/3ML (10MG/ML)	N21264 002	Apr 20, 2004	Aug	CAHN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+	SABEX 2002	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646 001	Jan 29, 2004	Jan	NEWA
---	------------	---	------------	--------------	-----	------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
 NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
 HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC
 + MAYNE PHARMA USA 80MG/VIAL;0.02MG/VIAL;0.001MG/VIA N18920 001 Sep 21, 2000 Apr CAHN
 L;5MG/VIAL;0.01MG/VIAL;0.14MG/VIA
 L;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1
 .4MG/VIAL;EQ 1.2MG
 BASE/VIAL;0.7MG/VIAL;7MG/VIAL

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
 NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE;
 VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12
 + MAYNE PHARMA USA 10MG/ML;0.006MG/ML;0.5UGM/ML;1.5 N08809 004 Aug 08, 1985 Apr CAHN
 G/ML;20
 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0
 .36MG/ML;0.3MG/ML;330 UNITS/ML;1
 IU/ML

M.V.I.-12 (WITHOUT VITAMIN K)
 + MAYNE PHARMA USA 20MG/ML;0.006MG/ML;0.05UGM/ML;1.5 N08809 006 Sep 09, 2004 Sep NEWA
 MG/ML;0.0005MG/ML;0.06MG/ML;4MG/M
 L;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1
 MG/ML;1MG/ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
 NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE;
 VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT
 + AAIPHARMA LLC 200MG/VIAL;0.06MG/VIAL;0.005MG/VI N21625 001 Jan 30, 2004 Jan NEWA
 AL;15MG/VIAL;0.005MG/VIAL;0.6MG/V
 IAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL
 ;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15
 MG/VIAL

+ MAYNE PHARMA USA 200MG/VIAL;0.06MG/VIAL;0.005MG/VI N21625 001 Jan 30, 2004 Apr CAHN
 AL;15MG/VIAL;0.005MG/VIAL;0.6MG/V
 IAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL
 ;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15
 MG/VIAL

M.V.I. ADULT (PHARMACY BULK PACKAGE)
 + AAIPHARMA LLC 200MG/5ML;0.06MG/5ML;0.005MG/5ML; N21643 001 Feb 18, 2004 Feb NEWA
 15MG/5ML;0.005MG/5ML;0.6MG/5ML;40
 MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;
 1MG/5ML;10MG/5ML;0.15MG/5ML

+ MAYNE PHARMA USA 200MG/5ML;0.06MG/5ML;0.005MG/5ML; N21643 001 Feb 18, 2004 Apr CAHN
 15MG/5ML;0.005MG/5ML;0.6MG/5ML;40
 MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;
 1MG/5ML;10MG/5ML;0.15MG/5ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
 NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A;
 VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12
 + MAYNE PHARMA USA 20MG/ML;0.006MG/ML;0.5UGM/ML;1.5 N08809 005 Apr 22, 2004 May NEWA
 G/ML;20
 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.
 36MG/ML;0.6MG/ML;330 UNITS/ML;1
 IU/ML

SEE LEAHNS COLLEGE OF PHARMACY 1130A 800

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

@ HOSPIRA

80MG/VIAL;0.02MG/VIAL;0.001MG/VIA N20176 001 Dec 29, 1993 Aug CAHN
L;400
IU/10ML;0.14MG/VIAL;17MG/VIAL;5MG
/VIAL;0.2MG/10ML;1MG/VIAL;1.4MG/V
IAL;1.2MG/VIAL;EQ 2,300 UNITS
BASE/10ML;7 IU/10ML

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+ LEITNER PHARMS 356.4MG;30MG;16MG

N11483 004 Sep 06, 1983 Sep CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON COMPOUND

@ AAIPHARMA LLC

389MG;32.4MG;32MG

N10996 006 Mar 08, 1983 Jun DISC

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

+ LEITNER PHARMS 325MG;200MG

N11702 003 Dec 29, 1983 Sep CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA MUTUAL PHARM

325MG;4.5MG;0.38MG

N40260 001 Jul 17, 1998 Aug CAHN

AA

325MG;4.5MG;0.38MG

N87794 001 May 26, 1982 Aug CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

AB ABLE

25MG

N76907 001 Jul 30, 2004 Jul NEWA

AB

50MG

N76907 002 Jul 30, 2004 Jul NEWA

AB

100MG

N76907 003 Jul 30, 2004 Jul NEWA

AB

TEVA

25MG

N74056 003 Jul 19, 2004 Jul NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP BAXTER HLTHCARE

10MG/ML

N74824 001 Sep 30, 1997 Aug CAHN

AP

HOSPIRA

10MG/ML

N74632 001 Dec 23, 1996 May CAHN

ATRACURIUM BESYLATE PRESERVATIVE FREE

@ BAXTER HLTHCARE

10MG/ML

N74825 001 Sep 30, 1997 Aug CAHN

AP

HOSPIRA

10MG/ML

N74633 001 Dec 23, 1996 May CAHN

AP

10MG/ML

N74639 001 Mar 25, 1997 May CAHN

TRACRIUM

AP + HOSPIRA

10MG/ML

N18831 002 Jun 20, 1985 May CAHN

TRACRIUM PRESERVATIVE FREE

AP + HOSPIRA

10MG/ML

N18831 001 Nov 23, 1983 May CAHN

ATROPINE

INJECTABLE; INJECTION

ATROPEN

+ MERIDIAN MEDCL TECHN EQ 0.25MG SULFATE/0.3ML N17106 004 Sep 17, 2004 Sep NEWA

ATROPINE SULFATE

INJECTABLE; IM-IV-SC

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

HOSPIRA 0.05MG/ML N21146 002 Jul 09, 2001 May CAHN

+ 0.1MG/ML N21146 001 Jul 09, 2001 May CAHN

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+ VALEANT 0.025MG;1MG N17744 002 May CAHN

MOTOFEN HALF-STRENGTH

@ VALEANT 0.025MG;0.5MG N17744 001 May CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

@ MUTUAL PHARM 0.025MG;2.5MG N85506 001 Aug CAHN

AZACITIDINE

INJECTABLE; SUBCUTANEOUS

VIDAZA

+ PHARMION 100MG/VIAL N50794 001 May 19, 2004 May NEWA

AZATADINE MALEATE

TABLET; ORAL

OPTIMINE

@ SCHERING 1MG N17601 001 May DISC

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

TRINALIN

@ SCHERING 1MG;120MG N18506 001 Mar 23, 1982 May DISC

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

+ BEDFORD EQ 100MG BASE/VIAL N74419 001 Mar 31, 1995 May CRLD

IMURAN

@ PROMETHEUS LABS EQ 100MG BASE/VIAL N17391 001 May DISC

AZITHROMYCIN

CAPSULE; ORAL

ZITHROMAX

@ PFIZER EQ 250MG BASE N50670 001 Nov 01, 1991 Mar DISC

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

+ BRISTOL MYERS SQUIBB 500MG/VIAL N50580 001 Dec 31, 1986 Jul CMFD

+ 1GM/VIAL N50580 002 Dec 31, 1986 Jul CMFD

INJECTABLE; INJECTION

AZACTAM

+	BRISTOL MYERS SQUIBB	2GM/VIAL	N50580 003	Dec 31, 1986	Jul	CMFD
---	----------------------	----------	------------	--------------	-----	------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

AT	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50416 002		Mar	CRLD
----	----------------	---	------------	--	-----	------

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT	+	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N64068 001	Oct 30, 1995	Mar	CRLD
----	---	-----------------	---	------------	--------------	-----	------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATE AND BACITRACIN ZINC

AT	AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N65088 001	Feb 06, 2004	Feb	NEWA
----	-------	--	------------	--------------	-----	------

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	+	BAUSCH AND LOMB	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N64064 001	Oct 30, 1995	Mar	CRLD
----	---	-----------------	--	------------	--------------	-----	------

NEOSPORIN

AT	MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50417 001		Mar	CRLD
----	----------------	--	------------	--	-----	------

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	+	BAUSCH AND LOMB	500 UNITS/GM;10,000 UNITS/GM	N64046 001	Jan 26, 1995	Mar	CRLD
----	---	-----------------	------------------------------	------------	--------------	-----	------

POLYSPORIN

AT	MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM	N61229 001		Mar	CRLD
----	----------------	------------------------------	------------	--	-----	------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

VANCERIL

+	SCHERING	0.042MG/INH	N17573 001		Jun	CTEC
---	----------	-------------	------------	--	-----	------

VANCERIL DOUBLE STRENGTH

@	SCHERING	0.084MG/INH	N20486 001	Dec 24, 1996	Jun	DISC
---	----------	-------------	------------	--------------	-----	------

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

+	GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N19389 001	Jul 27, 1987	Jun	CTEC
---	-----------------	-------------------------	------------	--------------	-----	------

VANCENASE AQ

@	SCHERING	EQ 0.042MG DIPROP/SPRAY	N19589 001	Dec 23, 1987	Jun	DISC
---	----------	-------------------------	------------	--------------	-----	------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HCL

AB	ANDRX PHARMS	5MG	N76267 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76267 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76267 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76267 004	Feb 11, 2004	Feb	NEWA
AB	EON	5MG	N76402 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76402 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76402 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76402 004	Feb 11, 2004	Feb	NEWA
AB	GENPHARM	5MG	N76476 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76476 002	Feb 11, 2004	Feb	NEWA

		TABLET; ORAL							
		BENAZEPRIL HCL							
CMFD	AB	GENPHARM	20MG	N76476	003	Feb 11, 2004	Feb	NEWA	
	AB		40MG	N76476	004	Feb 11, 2004	Feb	NEWA	
	AB	IVAX PHARMS	5MG	N76333	001	Feb 11, 2004	Feb	NEWA	
	AB		10MG	N76333	002	Feb 11, 2004	Feb	NEWA	
	AB		20MG	N76333	003	Feb 11, 2004	Feb	NEWA	
CRLD	AB		40MG	N76333	004	Feb 11, 2004	Feb	NEWA	
	AB	KV PHARM	5MG	N76118	001	Feb 11, 2004	Feb	NEWA	
	AB		10MG	N76118	002	Feb 11, 2004	Feb	NEWA	
CRLD	AB		20MG	N76118	003	Feb 11, 2004	Feb	NEWA	
	AB		40MG	N76118	004	Feb 11, 2004	Feb	NEWA	
	AB	MYLAN	5MG	N76430	001	Feb 11, 2004	Feb	NEWA	
	AB		10MG	N76430	002	Feb 11, 2004	Feb	NEWA	
	AB		20MG	N76430	003	Feb 11, 2004	Feb	NEWA	
NEWA	AB		40MG	N76430	004	Feb 11, 2004	Feb	NEWA	
	AB	RANBAXY	5MG	N76344	001	Feb 11, 2004	Feb	NEWA	
	AB		10MG	N76344	002	Feb 11, 2004	Feb	NEWA	
CRLD	AB		20MG	N76344	003	Feb 11, 2004	Feb	NEWA	
	AB		40MG	N76344	004	Feb 11, 2004	Feb	NEWA	
CRLD	AB	TEVA	5MG	N76211	001	Feb 11, 2004	Feb	NEWA	
	AB		10MG	N76211	002	Feb 11, 2004	Feb	NEWA	
	AB		20MG	N76211	003	Feb 11, 2004	Feb	NEWA	
	AB		40MG	N76211	004	Feb 11, 2004	Feb	NEWA	
		LOTENSIN							
	AB	NOVARTIS	5MG	N19851	001	Jun 25, 1991	Feb	CFTG	
CRLD	AB		10MG	N19851	002	Jun 25, 1991	Feb	CFTG	
	AB		20MG	N19851	003	Jun 25, 1991	Feb	CFTG	
CRLD	AB	+	40MG	N19851	004	Jun 25, 1991	Feb	CFTG	

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

		TABLET; ORAL							
		BENAZEPRIL HCL AND HYDROCHLOROTHIAZIDE							
CTEC	AB	ANDRX PHARMS	5MG; 6.25MG	N76342	001	Feb 11, 2004	Feb	NEWA	
	AB		10MG; 12.5MG	N76342	002	Feb 11, 2004	Feb	NEWA	
DISC	AB		20MG; 12.5MG	N76342	003	Feb 11, 2004	Feb	NEWA	
	AB		20MG; 25MG	N76342	004	Feb 11, 2004	Feb	NEWA	
	AB	EON	5MG; 6.25MG	N76631	001	Feb 11, 2004	Feb	NEWA	
	AB		10MG; 12.5MG	N76631	002	Feb 11, 2004	Feb	NEWA	
	AB		20MG; 12.5MG	N76631	003	Feb 11, 2004	Feb	NEWA	
CTEC	AB		20MG; 25MG	N76631	004	Feb 11, 2004	Feb	NEWA	
	AB	GENPHARM	5MG; 6.25MG	N76612	001	Feb 11, 2004	Feb	NEWA	
DISC	AB		10MG; 12.5MG	N76612	002	Feb 11, 2004	Feb	NEWA	
	AB		20MG; 12.5MG	N76612	003	Feb 11, 2004	Feb	NEWA	
	AB		20MG; 25MG	N76612	004	Feb 11, 2004	Feb	NEWA	
	AB	IVAX PHARMS	5MG; 6.25MG	N76348	001	Feb 11, 2004	Feb	NEWA	
	AB		10MG; 12.5MG	N76348	002	Feb 11, 2004	Feb	NEWA	
NEWA	AB		20MG; 12.5MG	N76348	003	Feb 11, 2004	Feb	NEWA	
NEWA	AB		20MG; 25MG	N76348	004	Feb 11, 2004	Feb	NEWA	
NEWA	AB	MYLAN	5MG; 6.25MG	N76688	001	Feb 11, 2004	Feb	NEWA	
NEWA	AB		10MG; 12.5MG	N76688	002	Feb 11, 2004	Feb	NEWA	
NEWA	AB		20MG; 12.5MG	N76688	003	Feb 11, 2004	Feb	NEWA	
NEWA	AB		20MG; 25MG	N76688	004	Feb 11, 2004	Feb	NEWA	
NEWA	AB	LOTENSIN HCT							
NEWA	AB	NOVARTIS	5MG; 6.25MG	N20033	001	May 19, 1992	Feb	CFTG	
NEWA	AB		10MG; 12.5MG	N20033	002	May 19, 1992	Feb	CFTG	
NEWA	AB		20MG; 12.5MG	N20033	004	May 19, 1992	Feb	CFTG	

ST. LOUIS COLLEGE OF PHARMACY

	TABLET; ORAL							
	LOTENSIN HCT							
AB	+	NOVARTIS	20MG;25MG		N20033 003	May 19, 1992	Feb	CFTG
	<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE</u>							
	GEL; TOPICAL							
	BENZACLIN							
>D>	+	DERMIK LABS	5%;EQ 1% BASE		N50756 001	Dec 21, 2000	Nov	CTEC
>A>	BT	+	5%;EQ 1% BASE		N50756 001	Dec 21, 2000	Nov	CTEC
	DUAC							
>D>	+	STIEFEL	5%;EQ 1% BASE		N50741 001	Aug 26, 2002	Nov	CTEC
>A>	BT	+	5%;EQ 1% BASE		N50741 001	Aug 26, 2002	Nov	CTEC
	<u>BENZOYL PEROXIDE; ERYTHROMYCIN</u>							
	GEL; TOPICAL							
	BENZAMYCIN							
AB	+	DERMIK LABS	5%;3%		N50557 001	Oct 26, 1984	Mar	CFTG
	ERYTHROMYCIN AND BENZOYL PEROXIDE							
AB		ATRIX	5%;3%		N65112 001	Mar 29, 2004	Mar	NEWA
	<u>BETAMETHASONE DIPROPIONATE</u>							
	CREAM, AUGMENTED; TOPICAL							
	BETAMETHASONE DIPROPIONATE							
AB		ATRIX	EQ 0.05% BASE		N76603 001	Jan 23, 2004	Jan	NEWA
	OINTMENT, AUGMENTED; TOPICAL							
	BETAMETHASONE DIPROPIONATE							
AB		TARO	EQ 0.05% BASE		N76753 001	Oct 12, 2004	Oct	NEWA
	<u>BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE</u>							
	LOTION; TOPICAL							
	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE							
AB		TARO	EQ 0.05% BASE;1%		N76493 001	Jul 28, 2004	Jul	NEWA
	LOTRISONE							
AB	+	SCHERING PLOUGH RES	EQ 0.05% BASE;1%		N20010 001	Dec 08, 2000	Jul	CFTG
	<u>BETAMETHASONE SODIUM PHOSPHATE</u>							
	INJECTABLE; INJECTION							
	BETAMETHASONE SODIUM PHOSPHATE							
		@ STERIS	EQ 3MG BASE/ML		N85738 001		Feb	DISC
	CELESTONE							
		@ SCHERING	EQ 3MG BASE/ML		N17561 001		Feb	DISC
	<u>BETAMETHASONE VALERATE</u>							
>A>	AEROSOL, FOAM; TOPICAL							
>A>	LUXIQ							
>A>	+	CONNETICS	EQ 0.12% BASE		N20934 001	Feb 28, 1999	Nov	CDFR
>D>	AEROSOL; TOPICAL							
>D>	LUXIQ							
>D>	+	CONNETICS	EQ 0.12% BASE		N20934 001	Feb 28, 1999	Nov	CDFR
	<u>BETHANECHOL CHLORIDE</u>							
	INJECTABLE; INJECTION							
	URECHOLINE							
		@ ODYSSEY PHARMS	5MG/ML		N06536 001		Jun	CAHN
	TABLET; ORAL							
	BETHANECHOL CHLORIDE							
AA		ABLE	5MG		N40492 001	Jul 27, 2004	Jul	NEWA

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	ABLE	10MG	N40483 001	Jul 27, 2004	Jul	NEWA
AA		25MG	N40485 001	Jul 27, 2004	Jul	NEWA
AA		50MG	N40509 001	Jul 27, 2004	Jul	NEWA
AA	AMIDE PHARM	5MG	N40552 001	Oct 28, 2004	Oct	NEWA
AA		10MG	N40553 001	Oct 28, 2004	Oct	NEWA
AA		25MG	N40554 001	Oct 28, 2004	Oct	NEWA
AA		50MG	N40551 001	Oct 28, 2004	Oct	NEWA

DUVOID

AA	WELLSPRING PHARM	10MG	N86262 001		Jul	CMFD
AA		25MG	N86263 001		Jul	CMFD

URECHOLINE

	@ ODYSSEY PHARMS	5MG	N06536 003		Jun	CAHN
	@	10MG	N06536 002		Jun	CAHN
	@	25MG	N06536 004		Jun	CAHN
	@	50MG	N06536 005		Jun	CAHN

BISACODYL; POLYETHYLENE GLYCOL; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; TABLET, DELAYED RELEASE; ORAL

HALFLYTELY

+	BRAINTREE	5MG;210GM;0.74GM;2.86GM;5.6GM	N21551 001	May 10, 2004	May	NEWA
---	-----------	-------------------------------	------------	--------------	-----	------

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

	@ HOSPIRA	50MG/ML	N19033 001	Apr 29, 1986	Jun	DISC
AP	+	50MG/ML	N19033 001	Apr 29, 1986	May	CAHN
AP	+	INTL MEDICATION	N70119 001	Apr 29, 1986	Jun	CRLD
	BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	+	HOSPIRA	N19008 002	Apr 29, 1986	May	CAHN
AP	+	400MG/100ML	N19008 003	Apr 29, 1986	May	CAHN
	@	800MG/100ML	N19008 001	Apr 29, 1986	May	CAHN
	BRETYLIUM TOSYLATE IN PLASTIC CONTAINER					
AP	+	HOSPIRA	N19030 001	Apr 29, 1986	May	CAHN

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AT	IVAX PHARMS	0.2%	N76372 001	Sep 10, 2004	Sep	NEWA
----	-------------	------	------------	--------------	-----	------

BROMOCRIPTINE MESYLATE

TABLET; ORAL

BROMOCRIPTINE MESYLATE

AB	MYLAN	EQ 2.5MG BASE	N76962 001	Sep 24, 2004	Sep	NEWA
----	-------	---------------	------------	--------------	-----	------

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP	HOSPIRA	0.25MG/ML	N74160 001	Oct 30, 1997	May	CAHN
AP		0.25MG/ML	N74332 001	Oct 31, 1994	May	CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HCL

AP	HOSPIRA	0.25%	N18053 002		May	CAHN
----	---------	-------	------------	--	-----	------

INJECTABLE; INJECTION						
BUPIVACAINE HCL						
AP	HOSPIRA	0.25%	N70583	001	Feb 17, 1987	May CAHN
AP		0.25%	N70586	001	Mar 03, 1987	May CAHN
AP		0.25%	N70590	001	Feb 17, 1987	May CAHN
AP		0.5%	N18053	001		May CAHN
AP		0.5%	N70584	001	Feb 17, 1986	May CAHN
AP		0.5%	N70597	001	Mar 03, 1987	May CAHN
AP		0.5%	N70609	001	Mar 03, 1987	May CAHN
AP		0.75%	N18053	003		May CAHN
AP		0.75%	N70585	001	Mar 03, 1987	May CAHN
AP		0.75%	N70587	001	Mar 03, 1987	May CAHN
BUPIVACAINE HCL KIT						
	@ HOSPIRA	0.075%	N19978	001	Sep 03, 1992	May CAHN
	@	0.114%	N19978	002	Sep 03, 1992	May CAHN
	@	0.23%	N19978	003	Sep 03, 1992	May CAHN
MARCAINE HCL						
AP	+ HOSPIRA	0.25%	N16964	001		May CAHN
AP	+	0.5%	N16964	006		May CAHN
MARCAINE HCL PRESERVATIVE FREE						
AP	+ HOSPIRA	0.25%	N16964	012		May CAHN
AP	+	0.5%	N16964	005		May CAHN
AP	+	0.75%	N16964	009		May CAHN
INJECTABLE; SPINAL						
BUPIVACAINE						
AP	HOSPIRA	0.75%	N71810	001	Dec 11, 1987	May CAHN
MARCAINE						
AP	+ HOSPIRA	0.75%	N18692	001	May 04, 1984	May CAHN
BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE						
INJECTABLE; INJECTION						
BUPIVACAINE HCL AND EPINEPHRINE						
+	HOSPIRA	0.25%;0.005MG/ML	N71165	001	Jun 16, 1988	May CAHN
		0.25%;0.005MG/ML	N71166	001	Jun 16, 1988	May CAHN
		0.25%;0.005MG/ML	N71167	001	Jun 16, 1988	May CAHN
+		0.5%;0.005MG/ML	N71168	001	Jun 16, 1988	May CAHN
		0.5%;0.005MG/ML	N71169	001	Jun 16, 1988	May CAHN
		0.5%;0.005MG/ML	N71170	001	Jun 16, 1988	May CAHN
+		0.75%;0.005MG/ML	N71171	001	Jun 16, 1988	May CAHN
BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE						
INJECTABLE; INJECTION						
MARCAINE HCL W/ EPINEPHRINE						
AP	+ HOSPIRA	0.25%;0.0091MG/ML	N16964	004		May CAHN
AP	+	0.5%;0.0091MG/ML	N16964	008		May CAHN
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE						
AP	+ HOSPIRA	0.25%;0.0091MG/ML	N16964	013		May CAHN
AP	+	0.5%;0.0091MG/ML	N16964	007		May CAHN
AP	+	0.75%;0.0091MG/ML	N16964	010		May CAHN
BUPRENORPHINE HYDROCHLORIDE						
INJECTABLE; INJECTION						
BUPRENORPHINE HCL						
AP	HOSPIRA	EQ 0.3MG BASE/ML	N74137	001	Jun 03, 1996	May CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
BUPROPION HCL

AB1	EON	100MG	N75932 001	Nov 25, 2003	May	CFTG	
AB		150MG	N75932 002	Mar 22, 2004	Mar	NEWA	
AB1		150MG	N75932 002	Mar 22, 2004	May	CTEC	
AB	IMPAX LABS	100MG	N75913 001	Jan 28, 2004	Jan	NEWA	
AB1		100MG	N75913 001	Jan 28, 2004	May	CTEC	
AB		150MG	N75913 002	Mar 22, 2004	Mar	NEWA	
AB1		150MG	N75913 002	Mar 22, 2004	May	CTEC	
AB2		150MG	N75914 001	May 27, 2004	May	NEWA	
WELLBUTRIN SR							
AB1	GLAXOSMITHKLINE	100MG	N20358 002	Oct 04, 1996	May	CTEC	
AB	+	150MG	N20358 003	Oct 04, 1996	Mar	CFTG	
AB1	+	150MG	N20358 003	Oct 04, 1996	Jun	CTEC	
AB	+	150MG	N20358 003	Oct 04, 1996	May	CTEC	
ZYBAN							
AB2	+	GLAXOSMITHKLINE	150MG	N20711 003	May 14, 1997	Jun	CTEC
AB	+		150MG	N20711 003	May 14, 1997	May	CFTG

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPIRONE HCL

AB	TEVA	30MG	N75022 004	Mar 25, 2004	Mar	NEWA
----	------	------	------------	--------------	-----	------

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

AP	HOSPIRA	1MG/ML	N75559 001	Mar 20, 2000	May	CAHN
AP		2MG/ML	N75559 002	Mar 20, 2000	May	CAHN
BUTORPHANOL TARTRATE PRESERVATIVE FREE						
AP	HOSPIRA	1MG/ML	N74620 001	Jan 22, 1997	May	CAHN
AP		1MG/ML	N74626 001	Jan 23, 1997	May	CAHN
AP		2MG/ML	N74620 002	Jan 22, 1997	May	CAHN
AP		2MG/ML	N74626 002	Jan 23, 1997	May	CAHN

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL

CAFCIT

+	MEAD JOHNSON	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N20793 001	Sep 21, 1999	Sep	CPOT
---	--------------	------------------------------------	------------	--------------	-----	------

SOLUTION; ORAL

CAFCIT

+	MEAD JOHNSON	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N20793 002	Apr 12, 2000	Sep	NEWA
---	--------------	------------------------------------	------------	--------------	-----	------

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

CAFERGOT

>A>	AA	+	SANDOZ	100MG;1MG	N84294 001	Nov	CTNA	
>D>			ERCATAB					
>D>	AA	+	SANDOZ	100MG;1MG	N84294 001	Nov	CTNA	
	AA	+		100MG;1MG	N84294 001	Oct	CTEC	
	AB	+		100MG;1MG	N84294 001	Sep	CFTG	
ERGOTAMINE TARTRATE AND CAFFEINE								
AB			WEST WARD	100MG;1MG	N40510 001	Sep 17, 2004	Sep	NEWA

TABLET; ORAL						
ERGOTAMINE TARTRATE AND CAFFEINE						
AA	WEST WARD	100MG;1MG	N40510 001	Sep 17, 2004	Oct	CTEC
<u>CALCITRIOL</u>						
INJECTABLE; INJECTION						
CALCITRIOL						
AP	MAYNE PHARMA USA	0.001MG/ML	N75816 001	Jan 16, 2004	Jan	NEWA
AP		0.002MG/ML	N75816 002	Jan 16, 2004	Jan	NEWA
<u>CALCIUM CHLORIDE</u>						
INJECTABLE; INJECTION						
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER						
+	HOSPIRA	100MG/ML	N21117 001	Jan 28, 2000	May	CAHN
<u>CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>						
INJECTABLE; INJECTION						
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER						
AP	HOSPIRA	33MG/100ML;5GM/100ML;30MG/100ML;8 60MG/100ML	N18254 001		May	CAHN
>D>	AP	DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER				
	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;8 60MG/100ML	N18256 001		Nov	DISC
>A>	@	33MG/100ML;5GM/100ML;30MG/100ML;8 60MG/100ML	N18256 001		Nov	DISC
<u>CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE</u>						
INJECTABLE; INJECTION						
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
AP	HOSPIRA	20MG/100ML;5GM/100ML;30MG/100ML;6 00MG/100ML;310MG/100ML	N17608 001		May	CAHN
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
@	HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML;310MG/100ML	N19685 005	Oct 17, 1988	May	CAHN
@		20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19685 006	Oct 17, 1988	May	CAHN
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
@	HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML	N19685 007	Oct 17, 1988	May	CAHN
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
AP	HOSPIRA	20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19685 002	Oct 17, 1988	May	CAHN
AP		20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML	N19685 008	Oct 17, 1988	May	CAHN
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
@	HOSPIRA	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML	N19685 003	Oct 17, 1988	May	CAHN
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
AP	HOSPIRA	20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML	N19685 004	Oct 17, 1988	May	CAHN
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
@	HOSPIRA	20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML;310MG/100ML	N19685 001	Oct 17, 1988	May	CAHN
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE</u>						
INJECTABLE; INJECTION						
TPN ELECTROLYTES IN PLASTIC CONTAINER						
	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121 MG/ML;16.1MG/ML	N18895 001	Jul 20, 1984	May	CAHN

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDESOLUTION; PERFUSION, CARDIAC
PLEGISOL IN PLASTIC CONTAINER

AT	+	HOSPIRA	17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML	N18608 001	Feb 26, 1982	May	CAHN
----	---	---------	--	------------	--------------	-----	------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION
RINGER'S IN PLASTIC CONTAINER

>D>	AP	B BRAUN	33MG/100ML;30MG/100ML;860MG/100ML	N18721 001	Nov 09, 1982	Nov	DISC
>A>		@	33MG/100ML;30MG/100ML;860MG/100ML	N18721 001	Nov 09, 1982	Nov	DISC
	AP	HOSPIRA	33MG/100ML;30MG/100ML;860MG/100ML	N18251 001		May	CAHN

SOLUTION; IRRIGATION
RINGER'S IN PLASTIC CONTAINER

AT		HOSPIRA	33MG/100ML;30MG/100ML;860MG/100ML	N17635 001		May	CAHN
----	--	---------	-----------------------------------	------------	--	-----	------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATEINJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

AP		HOSPIRA	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N17641 001		May	CAHN
----	--	---------	---	------------	--	-----	------

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER

AT		HOSPIRA	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N19416 001	Jan 17, 1986	May	CAHN
----	--	---------	---	------------	--------------	-----	------

CAPTOPRILTABLET; ORAL
CAPTOPRIL

AB		DURAMED PHARMS BARR	12.5MG	N74477 001	Feb 13, 1996	May	CAHN
AB			25MG	N74477 002	Feb 13, 1996	May	CAHN
AB			50MG	N74477 003	Feb 13, 1996	May	CAHN
AB			100MG	N74477 004	Feb 13, 1996	May	CAHN
AB		KALI LABS	12.5MG	N74477 001	Feb 13, 1996	Aug	CAHN
AB			25MG	N74477 002	Feb 13, 1996	Aug	CAHN
AB			50MG	N74477 003	Feb 13, 1996	Jul	CAHN
AB			100MG	N74477 004	Feb 13, 1996	Aug	CAHN

CARBAMAZEPINECAPSULE, EXTENDED RELEASE; ORAL
CARBATROL

		SHIRE PHARM	100MG	N20712 003	Sep 30, 1997	Mar	CRLD
			200MG	N20712 001	Sep 30, 1997	Mar	CRLD

SUSPENSION; ORAL
TERIL

AB		TARO	100MG/5ML	N76729 001	Sep 20, 2004	Sep	NEWA
----	--	------	-----------	------------	--------------	-----	------

CARBIDOPA; LEVODOPATABLET, EXTENDED RELEASE; ORAL
CARBIDOPA AND LEVODOPA

AB		IMPAX LABS	25MG;100MG	N76521 001	May 14, 2004	May	NEWA
AB			50MG;200MG	N76521 002	May 14, 2004	May	NEWA
AB		KV PHARM	50MG;200MG	N76663 001	Jun 24, 2004	Jun	NEWA
AB		TORPHARM	25MG;100MG	N76212 001	Jun 16, 2004	Jun	NEWA
AB			50MG;200MG	N76212 002	Jun 16, 2004	Jun	NEWA

SRI LANKA COLLEGE OF PHARMACY, COLOMBO

TABLET, ORALLY DISINTEGRATING; ORAL

PARCOPA

	SCHWARZ PHARMA	10MG;100MG	N76699 001	Aug 27, 2004	Aug	NEWA
		25MG;100MG	N76699 002	Aug 27, 2004	Aug	NEWA
+		25MG;250MG	N76699 003	Aug 27, 2004	Aug	NEWA

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	AM PHARM PARTNERS	50MG/VIAL	N76235 001	Oct 14, 2004	Oct	NEWA
AP		150MG/VIAL	N76235 002	Oct 14, 2004	Oct	NEWA
AP		450MG/VIAL	N76235 003	Oct 14, 2004	Oct	NEWA
AP	BEDFORD	50MG/VIAL	N76099 001	Oct 14, 2004	Oct	NEWA
AP		150MG/VIAL	N76099 002	Oct 14, 2004	Oct	NEWA
AP		450MG/VIAL	N76099 003	Oct 14, 2004	Oct	NEWA
AP	MAYNE PHARMA USA	50MG/VIAL	N76473 001	Oct 27, 2004	Oct	NEWA
AP		150MG/VIAL	N76473 002	Oct 27, 2004	Oct	NEWA
AP		450MG/VIAL	N76473 003	Oct 27, 2004	Oct	NEWA
AP	PHARMACHEMIE	50MG/VIAL	N76162 001	Oct 14, 2004	Oct	NEWA
AP		150MG/VIAL	N76162 002	Oct 14, 2004	Oct	NEWA
AP		450MG/VIAL	N76162 003	Oct 14, 2004	Oct	NEWA
>A>	AP	FLIVA	N76602 001	Nov 16, 2004	Nov	NEWA
>A>	AP		N76602 002	Nov 16, 2004	Nov	NEWA
>A>	AP		N76602 003	Nov 16, 2004	Nov	NEWA

PARAPLATIN

AP	+ BRISTOL MYERS SQUIBB	50MG/VIAL	N19880 001	Mar 03, 1989	Oct	CFTG
AP	+	150MG/VIAL	N19880 002	Mar 03, 1989	Oct	CFTG
AP	+	450MG/VIAL	N19880 003	Mar 03, 1989	Oct	CFTG

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	AM PHARM	EQ 50MG/5ML (10MG/ML)	N77247 001	Oct 21, 2004	Oct	NEWA
AP		EQ 150MG/15ML (10MG/ML)	N77247 002	Oct 21, 2004	Oct	NEWA
AP		EQ 450MG/45ML (10MG/ML)	N77247 003	Oct 21, 2004	Oct	NEWA
AP	BEDFORD LABS	EQ 50MG/5ML (10MG/ML)	N77244 001	Oct 15, 2004	Oct	NEWA
AP		EQ 150MG/15ML (10MG/ML)	N77244 002	Oct 15, 2004	Oct	NEWA
AP		EQ 450MG/45ML (10MG/ML)	N77244 003	Oct 15, 2004	Oct	NEWA
AP	MAYNE PHARMA USA	EQ 50MG/5ML (10MG/ML)	N76517 001	Oct 14, 2004	Oct	NEWA
AP		EQ 150MG/15ML (10MG/ML)	N76517 002	Oct 14, 2004	Oct	NEWA
AP		EQ 450MG/45ML (10MG/ML)	N76517 003	Oct 14, 2004	Oct	NEWA
>A>	AP	600MG/60ML (10MG/ML)	N77059 001	Nov 23, 2004	Nov	NEWA
AP	PHARMACHEMIE	EQ 50MG/5ML (10MG/ML)	N77269 001	Oct 14, 2004	Oct	NEWA
AP		EQ 150MG/15ML (10MG/ML)	N77269 002	Oct 14, 2004	Oct	NEWA
AP		EQ 450MG/45ML (10MG/ML)	N77269 003	Oct 14, 2004	Oct	NEWA

PARAPLATIN

AP	+ BRISTOL MYERS SQUIBB	EQ 50MG /5ML(10MG/ML)	N20452 001	Jul 14, 2003	Oct	CFTG
AP	+	EQ 150MG /15ML(10MG/ML)	N20452 002	Jul 14, 2003	Oct	CFTG
AP	+	EQ 450MG /45ML(10MG/ML)	N20452 003	Jul 14, 2003	Oct	CFTG
>D>	+	EQ 600MG /60ML(10MG/ML)	N20452 004	Jan 15, 2004	Nov	CFTG
>A>	AP	EQ 600MG /60ML(10MG/ML)	N20452 004	Jan 15, 2004	Nov	CFTG
	+	EQ 600MG /60ML(10MG/ML)	N20452 004	Jan 15, 2004	Jan	NEWA

CARTEOLOL HYDROCHLORIDE

TABLET; ORAL

CARTROL

® ABBOTT

®

2.5MG

5MG

N19204 001 Dec 28, 1988 Jun DISC

N19204 002 Dec 28, 1988 Jun DISC

CEFACTOR

CAPSULE; ORAL

CEFACTOR

AB	CARLSBAD	EQ 250MG BASE	N65146 001	Jan 22, 2004	Jan	NEWA
AB		EQ 500MG BASE	N65146 002	Jan 22, 2004	Jan	NEWA

FOR SUSPENSION; ORAL

CECLOR

AB	CEPH INTL	EQ 125MG BASE/5ML	N62206 001		May	CAHN
AB		EQ 187MG BASE/5ML	N62206 003	Apr 20, 1988	May	CAHN
AB		EQ 250MG BASE/5ML	N62206 002		May	CAHN
AB	+	EQ 375MG BASE/5ML	N62206 004	Apr 20, 1988	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD

@ LILLY

		EQ 500MG BASE	N50673 002	Jun 28, 1996	Jun	DISC
--	--	---------------	------------	--------------	-----	------

CEFACTOR

AB	+	IVAX PHARMS	EQ 500MG BASE	N65057 001	Jan 05, 2001	Jun	CRLD
----	---	-------------	---------------	------------	--------------	-----	------

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

@ LILLY

		EQ 1GM BASE/VIAL	N50504 002		Jul	DISC
--	--	------------------	------------	--	-----	------

@

		EQ 2GM BASE/VIAL	N50504 003		Jul	DISC
--	--	------------------	------------	--	-----	------

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

@ GLAXOSMITHKLINE

		EQ 500MG BASE/VIAL	N50461 002		Oct	DISC
--	--	--------------------	------------	--	-----	------

@

		EQ 5GM BASE/VIAL	N50461 004		Oct	DISC
--	--	------------------	------------	--	-----	------

CEFAZOLIN SODIUM

>D>	AP	+	AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N64169 001	Aug 14, 1998	Nov	CRLD
-----	----	---	-------------------	--------------------	------------	--------------	-----	------

>A>	AP			EQ 500MG BASE/VIAL	N64169 001	Aug 14, 1998	Nov	CRLD
-----	----	--	--	--------------------	------------	--------------	-----	------

	AP	+		EQ 500MG BASE/VIAL	N64169 001	Aug 14, 1998	Oct	CRLD
--	----	---	--	--------------------	------------	--------------	-----	------

>D>	AP			EQ 20GM BASE/VIAL	N64170 002	Mar 18, 1998	Nov	CRLD
-----	----	--	--	-------------------	------------	--------------	-----	------

>A>	AP	+		EQ 20GM BASE/VIAL	N64170 002	Mar 18, 1998	Nov	CRLD
-----	----	---	--	-------------------	------------	--------------	-----	------

	AP		HIKMA FARMACEUTICA	EQ 10GM BASE/VIAL	N65143 001	Oct 18, 2004	Oct	NEWA
--	----	--	--------------------	-------------------	------------	--------------	-----	------

@ MARSAM PHARMS LLC

				EQ 250MG BASE/VIAL	N62988 001	Dec 29, 1989	Jun	DISC
--	--	--	--	--------------------	------------	--------------	-----	------

@

				EQ 500MG BASE/VIAL	N62988 002	Dec 29, 1989	Jun	DISC
--	--	--	--	--------------------	------------	--------------	-----	------

@

				EQ 1GM BASE/VIAL	N62988 003	Dec 29, 1989	Jun	DISC
--	--	--	--	------------------	------------	--------------	-----	------

@

				EQ 5GM BASE/VIAL	N62989 001	Dec 29, 1989	Jun	DISC
--	--	--	--	------------------	------------	--------------	-----	------

@

				EQ 10GM BASE/VIAL	N62989 002	Dec 29, 1989	Jun	DISC
--	--	--	--	-------------------	------------	--------------	-----	------

@

				EQ 20GM BASE/VIAL	N62989 003	Dec 29, 1989	Jun	DISC
--	--	--	--	-------------------	------------	--------------	-----	------

KEFZOL

@ LILLY

				EQ 250MG BASE/VIAL	N61773 001		Jun	DISC
--	--	--	--	--------------------	------------	--	-----	------

@

				EQ 500MG BASE/VIAL	N61773 002		Jun	DISC
--	--	--	--	--------------------	------------	--	-----	------

@

				EQ 1GM BASE/VIAL	N61773 003		Jun	DISC
--	--	--	--	------------------	------------	--	-----	------

@

				EQ 10GM BASE/VIAL	N61773 004		Jun	DISC
--	--	--	--	-------------------	------------	--	-----	------

@

				EQ 20GM BASE/VIAL	N61773 005	Sep 08, 1987	Jun	DISC
--	--	--	--	-------------------	------------	--------------	-----	------

CEFDINIR

FOR SUSPENSION; ORAL

OMNICEF

ABBOTT

				125MG/5ML	N50749 001	Dec 04, 1997	Jul	CRLD
--	--	--	--	-----------	------------	--------------	-----	------

+

				250MG/5ML	N50749 002	Jul 29, 2004	Jul	NEWA
--	--	--	--	-----------	------------	--------------	-----	------

ST. LOUIS COLLEGE OF PHARMACY LIBRARY

CEFIXIME

SUSPENSION; ORAL

SUPRAX

+ LUPIN 100MG/5ML N65129 001 Feb 23, 2004 Feb NEWA

TABLET; ORAL

SUPRAX

+ LUPIN 400MG N65130 001 Feb 12, 2004 Feb NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

+ B BRAUN EQ 2GM BASE N50792 001 Jul 29, 2004 Jul NEWA

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

+ B BRAUN EQ 1GM BASE N50792 002 Jul 29, 2004 Jul NEWA

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AP ACS DOBFAR 500MG/VIAL N62640 001 Nov 20, 1985 Apr CTNA

AP 1GM/VIAL N62640 002 Nov 20, 1985 Apr CTNA

AP 2GM/VIAL N62640 003 Nov 20, 1985 Apr CTNA

TAZICEF

AP HOSPIRA 500MG/VIAL N62662 001 Mar 06, 1986 May CAHN

AP 1GM/VIAL N62662 002 Mar 06, 1986 May CAHN

AP 1GM/VIAL N64032 001 Oct 31, 1993 May CAHN

AP 2GM/VIAL N62662 003 Mar 06, 1986 May CAHN

AP 2GM/VIAL N64032 002 Oct 31, 1993 May CAHN

AP 6GM/VIAL N62662 004 Mar 06, 1986 May CAHN

TAZIDIME

8 LILLY 1GM/VIAL N62655 001 Nov 20, 1985 Apr DISC

8 2GM/VIAL N62655 002 Nov 20, 1985 Apr DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

+ SHIONOGI EQ 400MG BASE N50685 002 Dec 20, 1995 Sep CAHN

FOR SUSPENSION; ORAL

CEDAX

SHIONOGI EQ 90MG BASE/5ML N50686 001 Dec 20, 1995 Sep CAHN

+ EQ 180MG BASE/5ML N50686 002 Dec 20, 1995 Sep CAHN

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB SANDOZ EQ 250MG BASE N65126 001 Oct 28, 2003 Aug CAHN

AB EQ 500MG BASE N65126 002 Oct 28, 2003 Aug CAHN

AB TEVA EQ 250MG BASE N65190 001 Oct 18, 2004 Oct NEWA

AB EQ 500MG BASE N65190 002 Oct 18, 2004 Oct NEWA

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME

AB HIKMA FARMACEUTICA EQ 750MG BASE/VIAL N65048 001 Jan 09, 2004 Jan NEWA

KEFUROX

8 LILLY EQ 750MG BASE/VIAL N62591 001 Jan 10, 1986 Jun DISC

INJECTABLE; INJECTION

CEFUROXIME

AP	HIKMA FARMACEUTICA	EQ 1.5GM BASE/VIAL	N65048 002	Jan 09, 2004	Jan	NEWA
AP		EQ 7.5GM BASE/VIAL	N65046 001	Jan 09, 2004	Jan	NEWA
	KEFUROX					
	@ LILLY	EQ 1.5GM BASE/VIAL	N62591 002	Jan 10, 1986	Jun	DISC
	@	EQ 1.5GM BASE/VIAL	N62592 002	Jan 10, 1986	Jun	DISC
	@	EQ 7.5GM BASE/VIAL	N62591 003	Dec 17, 1987	Jun	DISC

INJECTABLE; INTRAVENOUS

KEFUROX

	@ LILLY	EQ 750MG BASE/VIAL	N62592 001	Jan 10, 1986	Jun	DISC
--	---------	--------------------	------------	--------------	-----	------

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

	@ MISSION PHARMA	300GM/BOT	N18757 003	Oct 16, 1984	Sep	DISC
--	------------------	-----------	------------	--------------	-----	------

CEPHALEXIN

CAPSULE; ORAL

KEFLEX

AB	ADVANCIS PHARM	EQ 250MG BASE	N50405 002		Jun	CAHN
AB	+	EQ 500MG BASE	N50405 003		Jun	CAHN

FOR SUSPENSION; ORAL

KEFLEX

	@ ADVANCIS PHARM	EQ 100MG BASE/ML	N50406 003		Jun	CAHN
	@	EQ 125MG BASE/5ML	N50406 001		Jun	CAHN
	@	EQ 250MG BASE/5ML	N50406 002		Jun	CAHN

TABLET; ORAL

CEPHALEXIN

>D>	AB	TEVA	EQ 250MG BASE	N63023 001	Jan 12, 1989	Nov	CTEC
>A>			EQ 250MG BASE	N63023 001	Jan 12, 1989	Nov	CTEC
		KEFLET					
		@ LILLY	EQ 250MG BASE	N50440 003	Feb 26, 1987	Jun	DISC

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB

	@ LILLY	EQ 500MG BASE	N50614 002	Oct 29, 1987	Jul	DISC
--	---------	---------------	------------	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL

ZYRTEC

	PFIZER	5MG	N21621 001	Mar 16, 2004	Mar	NEWA
	+	10MG	N21621 002	Mar 16, 2004	Mar	NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

EVOXAC

	+	DAIICHI	EQ 30MG BASE	N20989 002	Jan 11, 2000	Jun	CAHN
--	---	---------	--------------	------------	--------------	-----	------

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE; INJECTION

LIBRIUM

	@ VALEANT PHARM INTL	100MG/AMP	N12301 001		Jun	DISC
--	----------------------	-----------	------------	--	-----	------

CHLORHEXIDINE GLUCONATE

	SOLUTION; DENTAL					
	CHLORHEXIDINE GLUCONATE					
AT	MORTON GROVE	0.12%	N75006 001	Mar 03, 2004	Mar	NEWA

CHLOROPROCAINE HYDROCHLORIDE

	INJECTABLE; INJECTION					
	CHLOROPROCAINE HCL					
AP	HOSPIRA	2%	N87447 001	Apr 16, 1982	May	CAHN
AP		3%	N87446 001	Apr 16, 1982	May	CAHN
	NESACAINE					
AP	ASTRAZENECA	2%	N09435 002		Jun	CTEC

CHLOROTHIAZIDE

	SUSPENSION; ORAL					
	DIURIL					
	@ MERCK	250MG/5ML	N11870 001		Sep	DISC
	TABLET; ORAL					
	CHLOROTHIAZIDE					
AB	+ MYLAN	250MG	N84388 001		Sep	CRLD
	DIURIL					
	@ MERCK	250MG	N11145 004		Sep	DISC
	@	500MG	N11145 002		Sep	DISC

CHLORPHENIRAMINE MALEATE

	TABLET; ORAL					
	CHLORPHENIRAMINE MALEATE					
	@ MUTUAL PHARM	4MG	N80700 001		Aug	CAHN

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

	SUSPENSION, EXTENDED RELEASE; ORAL					
	CODEPREX					
+	CELLTECH PHARMS	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N21369 001	Jun 21, 2004	Jun	NEWA

CHLORTHALIDONE

	TABLET; ORAL					
	CHLORTHALIDONE					
	@ MUTUAL PHARM	25MG	N87292 001		Aug	CAHN
	@	50MG	N87293 001		Aug	CAHN

CHORIOGONADOTROPIN ALFA

	INJECTABLE; INJECTION					
	OVIDREL					
	@ SERONO INC	0.25MG/VIAL	N21149 001	Sep 20, 2000	May	DISC
	INJECTABLE; SUBCUTANEOUS					
	OVIDREL					
+	SERONO INC	EQ 0.25MG /0.5ML	N21149 002	Oct 06, 2003	Apr	CPOT

CHROMIC CHLORIDE

	INJECTABLE; INJECTION					
	CHROMIC CHLORIDE IN PLASTIC CONTAINER					
+	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N18961 001	Jun 26, 1986	May	CAHN

CICLOPIROX

SUSPENSION; TOPICAL

CICLOPIROX

AB	ALTANA	0.77%	N76422 001	Aug 06, 2004	Aug	NEWA
AT	+ LOPROX MEDICIS	0.77%	N19824 001	Dec 30, 1988	Aug	CFTG

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

>A>	AB	ALPHAPHARM	50MG	N77019 001	Nov 23, 2004	Nov	NEWA
>A>	AB		100MG	N77019 002	Nov 23, 2004	Nov	NEWA
>A>	AB	AMIDE PHARM	100MG	N77028 002	Nov 26, 2004	Nov	NEWA
>A>	AB	COREPHARMA	100MG	N77022 001	Nov 23, 2004	Nov	NEWA
>A>	AB	EON	100MG	N77021 001	Nov 23, 2004	Nov	NEWA
>A>	AB	TEVA	50MG	N77027 001	Nov 24, 2004	Nov	NEWA
>A>	AB		100MG	N77027 002	Nov 24, 2004	Nov	NEWA
>D>	+ PLETAL OTSUKA	50MG	N20863 001	Jan 15, 1999	Nov	CFTG	
>A>	AB		50MG	N20863 001	Jan 15, 1999	Nov	CFTG
>D>		100MG	N20863 002	Jan 15, 1999	Nov	CFTG	
>A>	AB		100MG	N20863 002	Jan 15, 1999	Nov	CFTG

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL

AP	HOSPIRA	EQ 300MG BASE/2ML	N74296 001	Mar 28, 1997	May	CAHN
AP		EQ 300MG BASE/2ML	N74344 001	Jan 31, 1995	May	CAHN
AP		EQ 300MG BASE/2ML	N74345 001	Jan 31, 1995	May	CAHN
AP		EQ 300MG BASE/2ML	N74412 001	Mar 28, 1997	May	CAHN
AP		EQ 300MG BASE/2ML	N74422 001	Jan 31, 1995	May	CAHN

CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HOSPIRA	EQ 6MG BASE/ML	N74269 001	Dec 27, 1994	May	CAHN
	+	EQ 90MG BASE/100ML	N74468 005	Dec 29, 1994	May	CAHN
	+	EQ 120MG BASE/100ML	N74468 006	Dec 29, 1994	May	CAHN
	+	EQ 180MG BASE/100ML	N74468 003	Dec 29, 1994	May	CAHN
	+	EQ 240MG BASE/100ML	N74468 004	Dec 29, 1994	May	CAHN
	+	EQ 360MG BASE/100ML	N74468 001	Dec 29, 1994	May	CAHN
	+	EQ 480MG BASE/100ML	N74468 002	Dec 29, 1994	May	CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR

AMGEN

+

		EQ 30MG BASE	N21688 001	Mar 08, 2004	Mar	NEWA
		EQ 60MG BASE	N21688 002	Mar 08, 2004	Mar	NEWA
		EQ 90MG BASE	N21688 003	Mar 08, 2004	Mar	NEWA

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

AT	+ ALCON	EQ 0.3% BASE	N19992 001	Dec 31, 1990	Sep	CFTG
AT	CIPROFLOXACIN BAUSCH AND LOMB	EQ 0.3% BASE	N76754 001	Jun 09, 2004	Jun	NEWA
AT	NOVEX	EQ 0.3% BASE	N75928 001	Jun 09, 2004	Jun	NEWA

TABLET: ORAL

CIPRO

AB	BAYER PHARMS	EQ 100MG BASE	N19537 001	Apr 08, 1996	Jun	CFTG
AB		EQ 250MG BASE	N19537 002	Oct 22, 1987	Jun	CFTG
AB		EQ 500MG BASE	N19537 003	Oct 22, 1987	Jun	CFTG
AB	+	EQ 750MG BASE	N19537 004	Oct 22, 1987	Jun	CFTG

CIPROFLOXACIN

AB	BARR	EQ 250MG BASE	N74124 001	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N74124 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N74124 003	Jun 09, 2004	Jun	NEWA	
AB	COBALT	EQ 250MG BASE	N76794 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N76794 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N76794 004	Jun 09, 2004	Jun	NEWA	
AB	DR REDDYS LABS LTD	EQ 100MG BASE	N75593 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 250MG BASE	N75593 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N75593 004	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N75593 001	Jun 09, 2004	Jun	NEWA	
AB	EON	EQ 250MG BASE	N76593 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N76593 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N76593 004	Jun 09, 2004	Jun	NEWA	
AB	GENPHARM	EQ 250MG BASE	N75817 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N75817 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N75817 004	Jun 09, 2004	Jun	NEWA	
AB	HIKMA	EQ 250MG BASE	N76558 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N76558 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N76558 004	Jun 09, 2004	Jun	NEWA	
AB	IVAX PHARMS	EQ 250MG BASE	N76089 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N76089 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N76089 004	Jun 09, 2004	Jun	NEWA	
AB	MARTEC	EQ 250MG BASE	N76138 001	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N76138 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N76138 003	Jun 09, 2004	Jun	NEWA	
AB	MYLAN	EQ 250MG BASE	N75685 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N75685 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N75685 001	Jun 09, 2004	Jun	NEWA	
AB	RANBAXY	EQ 250MG BASE	N75747 001	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N75747 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N75747 003	Jun 09, 2004	Jun	NEWA	
AB	SANDOZ	EQ 250MG BASE	N75939 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N75939 003	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N75939 004	Jun 09, 2004	Jun	NEWA	
AB	TARO	EQ 250MG BASE	N76912 002	Oct 06, 2004	Oct	NEWA	
AB		EQ 500MG BASE	N76912 003	Oct 06, 2004	Oct	NEWA	
AB		EQ 750MG BASE	N76912 004	Oct 06, 2004	Oct	NEWA	
AB	TEVA	EQ 250MG BASE	N76136 001	Jun 09, 2004	Jun	NEWA	
AB		EQ 500MG BASE	N76136 002	Jun 09, 2004	Jun	NEWA	
AB		EQ 750MG BASE	N76136 003	Jun 09, 2004	Jun	NEWA	
>A>	AB	TORPHARM	EQ 250MG BASE	N76896 001	Nov 04, 2004	Nov	NEWA
>A>	AB		EQ 500MG BASE	N76896 002	Nov 04, 2004	Nov	NEWA
>A>	AB		EQ 750MG BASE	N76896 003	Nov 04, 2004	Nov	NEWA
AB	UNIQUE PHARM LABS	EQ 250MG BASE	N76639 001	Sep 10, 2004	Sep	NEWA	
AB		EQ 500MG BASE	N76639 002	Sep 10, 2004	Sep	NEWA	
AB		EQ 750MG BASE	N76639 003	Sep 10, 2004	Sep	NEWA	

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

+ BAYER PHARMS 425.2MG;EQ 574.9MG BASE N21473 002 Aug 28, 2003 Feb CDFR

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CELEXA

AB	FOREST LABS	EQ 10MG BASE	N20822 001	Apr 27, 2000	Oct	CFTG
AB		EQ 20MG BASE	N20822 002	Jul 17, 1998	Oct	CFTG
AB	+	EQ 40MG BASE	N20822 003	Jul 17, 1998	Oct	CFTG

CITALOPRAM HYDROBROMIDE

>A>	AB	ALPHAPHARM	EQ 10MG BASE	N77037 001	Nov 05, 2004	Nov	NEWA
>A>	AB		EQ 20MG BASE	N77037 002	Nov 05, 2004	Nov	NEWA
>A>	AB		EQ 40MG BASE	N77037 003	Nov 05, 2004	Nov	NEWA
>A>	AB	APOTEX	EQ 10MG BASE	N77046 001	Nov 24, 2004	Nov	NEWA
>A>	AB		EQ 20MG BASE	N77046 002	Nov 24, 2004	Nov	NEWA
>A>	AB		EQ 40MG BASE	N77046 003	Nov 24, 2004	Nov	NEWA
	AB	AUROBINDO	EQ 10MG BASE	N77031 001	Oct 28, 2004	Oct	NEWA
	AB		EQ 20MG BASE	N77031 002	Oct 28, 2004	Oct	NEWA
	AB		EQ 40MG BASE	N77031 003	Oct 28, 2004	Oct	NEWA
>A>	AB	CARACO	EQ 10MG BASE	N77032 001	Nov 12, 2004	Nov	NEWA
>A>	AB		EQ 20MG BASE	N77032 002	Nov 12, 2004	Nov	NEWA
>A>	AB		EQ 40MG BASE	N77032 003	Nov 12, 2004	Nov	NEWA
	AB	COREPHARMA	EQ 10MG BASE	N77036 001	Oct 28, 2004	Oct	NEWA
	AB		EQ 20MG BASE	N77036 002	Oct 28, 2004	Oct	NEWA
	AB		EQ 40MG BASE	N77036 003	Oct 28, 2004	Oct	NEWA
	AB	DR REDDYS LABS LTD	EQ 10MG BASE	N77038 001	Oct 28, 2004	Oct	NEWA
	AB		EQ 20MG BASE	N77038 002	Oct 28, 2004	Oct	NEWA
	AB		EQ 40MG BASE	N77038 003	Oct 28, 2004	Oct	NEWA
	AB	EON	EQ 10MG BASE	N77035 001	Oct 28, 2004	Oct	NEWA
	AB		EQ 20MG BASE	N77035 002	Oct 28, 2004	Oct	NEWA
	AB		EQ 40MG BASE	N77035 003	Oct 28, 2004	Oct	NEWA
>A>	AB	IVAX PHARMS	EQ 10MG BASE	N77048 001	Nov 16, 2004	Nov	NEWA
>A>	AB		EQ 20MG BASE	N77048 002	Nov 16, 2004	Nov	NEWA
>A>	AB		EQ 40MG BASE	N77048 003	Nov 16, 2004	Nov	NEWA
>A>	AB	KALI LABS	EQ 10MG BASE	N77042 001	Nov 05, 2004	Nov	NEWA
>A>	AB		EQ 20MG BASE	N77042 002	Nov 05, 2004	Nov	NEWA
>A>	AB		EQ 40MG BASE	N77042 003	Nov 05, 2004	Nov	NEWA
	AB	PUREPAC PHARM	EQ 10MG BASE	N77033 001	Oct 28, 2004	Oct	NEWA
	AB		EQ 20MG BASE	N77033 002	Oct 28, 2004	Oct	NEWA
	AB		EQ 40MG BASE	N77033 003	Oct 28, 2004	Oct	NEWA
>A>	AB	ROXANE	EQ 10MG BASE	N77041 001	Nov 23, 2004	Nov	NEWA
>A>	AB		EQ 20MG BASE	N77041 002	Nov 23, 2004	Nov	NEWA
>A>	AB		EQ 40MG BASE	N77041 003	Nov 23, 2004	Nov	NEWA
>A>	AB	WATSON LABS	EQ 10MG BASE	N77044 001	Nov 05, 2004	Nov	NEWA
>A>	AB		EQ 20MG BASE	N77044 002	Nov 05, 2004	Nov	NEWA
>A>	AB		EQ 40MG BASE	N77044 003	Nov 05, 2004	Nov	NEWA

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

UROLOGIC G IN PLASTIC CONTAINER

AT	HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N18904 001	May 27, 1983	May	CAHN
----	---------	--------------------------------------	------------	--------------	-----	------

CLADRIBINE

INJECTABLE; INJECTION
CLADRIBINE
AP AM PHARM 1MG/ML N76571 001 Apr 22, 2004 Apr NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL
BIAKIN XL
AB + ABBOTT 500MG N50775 001 Mar 03, 2000 Jun CFTG
CLARITHROMYCIN
AB ANDRX PHARMS 500MG N65145 001 Jun 24, 2004 Jun NEWA
TABLET; ORAL
BIAKIN
AB + ABBOTT 250MG N50662 001 Oct 31, 1991 May CFTG
AB + 500MG N50662 002 Oct 31, 1991 May CFTG
CLARITHROMYCIN
AB RANBAXY 250MG N65174 001 Sep 24, 2004 Sep NEWA
AB 500MG N65174 002 Sep 24, 2004 Sep NEWA
AB ROXANE 250MG N65178 002 May 25, 2004 May NEWA
AB 500MG N65178 001 May 25, 2004 May NEWA

CLEMASTINE FUMARATE

TABLET; ORAL
CLEMASTINE FUMARATE
AB + TEVA 2.68MG N73283 001 Jan 31, 1992 Mar CRLD
TAVIST
@ NOVARTIS 2.68MG N17661 001 Mar DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HCL
AB COREPHARMA EQ 150MG BASE N65194 001 Mar 22, 2004 Mar NEWA
AB EQ 300MG BASE N65194 002 Mar 22, 2004 Mar NEWA

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL
CLEOCIN
+ PHARMACIA AND UPJOHN EQ 75MG BASE/5ML N62644 001 Apr 07, 1986 May CRLD

CLINDAMYCIN PHOSPHATE

>A> AEROSOL, FOAM; TOPICAL
>A> EVOCLIN
>A> + CONNETICS 1% N50801 001 Oct 22, 2004 Nov CDFR
>D> AEROSOL; TOPICAL
>D> EVOCLIN FOAM
>D> + CONNETICS 1% N50801 001 Oct 22, 2004 Nov CDFR
>D> + 1% N50801 001 Oct 22, 2004 Oct NEWA
CREAM; VAGINAL
>A> CLINDESSE
>A> KV PHARM EQ 2% BASE N50793 001 Nov 30, 2004 Nov NEWA
INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE
@ BAXTER HLTHCARE EQ 150MG BASE/ML N62953 001 Apr 21, 1988 Aug CAHN
AP BEDFORD EQ 150MG BASE/ML N65206 001 Sep 24, 2004 Sep NEWA
AP HOSPIRA EQ 150MG BASE/ML N62800 001 Jul 24, 1987 May CAHN
AP EQ 150MG BASE/ML N62801 001 Jul 24, 1987 May CAHN

INJECTABLE; INJECTION
 CLINDAMYCIN PHOSPHATE
 @ HOSPIRA EQ 150MG BASE/ML N62943 001 Sep 29, 1988 May CAHN

AT SOLUTION; TOPICAL
 CLINDAMYCIN PHOSPHATE
 TARO PHARM INDS EQ 1% BASE N65184 001 Mar 31, 2004 Mar NEWA

CLOBETASOL PROPIONATE

>A> AEROSOL, FOAM; TOPICAL
 >A> OLUX
 >A> + CONNETICS 0.05% N21142 001 May 26, 2000 Nov CDFR

>D> AEROSOL; TOPICAL
 >D> OLUX FOAM
 >D> + CONNETICS 0.05% N21142 001 May 26, 2000 Nov CDFR

SHAMPOO; TOPICAL
 CLOBEX
 + GALDERMA LABS 0.05% N21644 001 Feb 05, 2004 Feb NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
 DURACLON
 AAIPHARMA 0.1MG/ML N20615 001 Oct 02, 1996 Jun CRLD
 + 0.5MG/ML N20615 002 Apr 27, 1999 Jun NEWA

TABLET; ORAL

AB CLONIDINE HCL
 MUTUAL PHARM 0.1MG N70925 001 Sep 04, 1987 Aug CAHN
 @ 0.2MG N70924 001 Sep 04, 1987 Aug CAHN
 @ 0.3MG N70923 001 Sep 04, 1987 Aug CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
 CLORAZEPATE DIPOTASSIUM
 @ SANDOZ 7.5MG N72220 001 Aug 26, 1988 Aug DISC

TABLET; ORAL

AB CLORAZEPATE DIPOTASSIUM
 RANBAXY 3.75MG N76911 001 Sep 29, 2004 Sep NEWA
 AB 7.5MG N76911 002 Sep 29, 2004 Sep NEWA
 AB 15MG N76911 003 Sep 29, 2004 Sep NEWA

CLOTRIMAZOLE

TROCHE/LOZENGE; ORAL
 CLOTRIMAZOLE
 AB ROXANE 10MG N76387 001 Jul 29, 2004 Jul NEWA
 AB MYCELEX
 AB + BAYER PHARMS 10MG N18713 001 Jun 17, 1983 Jul CFTG

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO
 ALAMO PHARMS 25MG N21590 001 Feb 10, 2004 Feb NEWA
 + 100MG N21590 002 Feb 10, 2004 Feb NEWA
 FAZACLO ODT
 ALAMO PHARMS 25MG N21590 001 Feb 10, 2004 Jul CTNA
 + 100MG N21590 002 Feb 10, 2004 Jul CTNA

SRT LOANS COLLECTED BY PHARMACY 10/20/04

<u>COLISTIMETHATE SODIUM</u>						
INJECTABLE; INJECTION						
COLISTIMETHATE						
AP	PADDOCK	EQ 150MG BASE/VIAL	N65177 001	Mar 19, 2004	Mar	NEWA
<u>CROMOLYN SODIUM</u>						
AEROSOL, METERED; INHALATION						
INTAL						
+	KING PHARMS	0.8MG/INH	N18887 001	Dec 05, 1985	Jan	CAHN
SOLUTION; INHALATION						
INTAL						
AN	+	KING PHARMS	10MG/ML	N18596 001	May 28, 1982	Jan CAHN
<u>CUPRIC CHLORIDE</u>						
INJECTABLE; INJECTION						
CUPRIC CHLORIDE IN PLASTIC CONTAINER						
+	HOSPIRA	EQ 0.4MG COPPER/ML	N18960 001	Jun 26, 1986	May	CAHN
<u>CYANOCOBALAMIN</u>						
INJECTABLE; INJECTION						
CYANOCOBALAMIN						
AP	BIONICHE ANIM HLTH	1MG/ML	N40451 001	Sep 23, 2003	Apr	CAHN
AP	BIONICHE PHARMA	1MG/ML	N40451 001	Sep 23, 2003	Sep	CAHN
<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>						
TABLET; ORAL						
CYCLOBENZAPRINE HCL						
AB	MUTUAL PHARM	10MG	N73541 001	May 23, 1995	Aug	CAHN
<u>CYCLOSPORINE</u>						
SOLUTION; ORAL						
CYCLOSPORINE						
AB1	ABBOTT	100MG/ML	N65025 001	Mar 03, 2000	Sep	CTEC
AB2	MORTON GROVE	100MG/ML	N65133 001	Sep 17, 2004	Sep	NEWA
AB1	PLIVA	100MG/ML	N65054 001	Dec 18, 2001	Sep	CTEC
NEORAL						
AB1	+	NOVARTIS	100MG/ML	N50716 001	Jul 14, 1995	Sep CTEC
SANDIMMUNE						
AB2	+	NOVARTIS	100MG/ML	N50574 001	Nov 14, 1983	Sep CFTG
<u>CYPROHEPTADINE HYDROCHLORIDE</u>						
SYRUP; ORAL						
CYPROHEPTADINE HCL						
+	ALPHARMA	2MG/5ML	N86833 001		Aug	CRLD
PERIACTIN						
	@ MERCK	2MG/5ML	N13220 002		Aug	DISC
<u>CYSTEINE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
CYSTEINE HCL						
	@ HOSPIRA	7.25%	N19523 001	Oct 22, 1986	Aug	CAHN

CYTARABINE

	INJECTABLE; INJECTION						
	CYTARABINE						
AP	AM PHARM	100MG/ML	N76512 001	Jan 15, 2004	Jan	NEWA	
AP	+ MAYNE PHARMA USA	100MG/ML	N75383 001	Nov 22, 1999	Jan	CFTG	

DAUNORUBICIN HYDROCHLORIDE

	INJECTABLE; INJECTION						
	DAUNORUBICIN HCL						
AP	BIGMAR BIOREN PHARMS	EQ 20MG BASE/VIAL	N65000 001	May 25, 1999	Jul	CAHN	

DEFEROXAMINE MESYLATE

	INJECTABLE; INJECTION						
	DEFEROXAMINE MESYLATE						
AP	ABBOTT	500MG/VIAL	N76019 001	Mar 17, 2004	Mar	NEWA	
AP		2GM/VIAL	N76019 002	Mar 17, 2004	Mar	NEWA	
AP	HOSPIRA	500MG/VIAL	N76019 001	Mar 17, 2004	May	CAHN	
AP		2GM/VIAL	N76019 002	Mar 17, 2004	May	CAHN	
	DESFERAL						
AP	+ NOVARTIS	500MG/VIAL	N16267 001		Mar	CFTG	
AP		2GM/VIAL	N16267 002	May 25, 2000	Mar	CFTG	

DEMECLOCYCLINE HYDROCHLORIDE

	TABLET; ORAL						
	DECLOMYCIN						
AB	ESP PHARMA	150MG	N50261 002		Mar	CFTG	
AB		300MG	N50261 003		Mar	CFTG	
	DEMECLOCYCLINE HCL						
AB	IMPAX LABS	150MG	N65094 001	Mar 22, 2004	Mar	NEWA	
AB		300MG	N65094 002	Mar 22, 2004	Mar	NEWA	

DESERPIDINE; METHYLOTHIAZIDE

	TABLET; ORAL						
	ENDURONYL						
	@ ABBOTT	0.25MG; 5MG	N12775 001		Jun	DISC	
	ENDURONYL FORTE						
	@ ABBOTT	0.5MG; 5MG	N12775 002		Jun	DISC	

DESIRUDIN

	INJECTABLE; SUBCUTANEOUS						
	IPRIVASK						
	+ CANYON	15MG/VIAL	N21271 001	Apr 04, 2003	Apr	CAHN	

DESLOPATADINE

	SYRUP; ORAL						
	CLARINEX						
	+ SCHERING	0.5MG/ML	N21300 001	Sep 01, 2004	Sep	NEWA	

DESMOPRESSIN ACETATE

	INJECTABLE; INJECTION						
	DESMOPRESSIN ACETATE						
AP	HOSPIRA	0.004MG/ML	N75220 001	Aug 28, 2000	May	CAHN	
	SPRAY, METERED; NASAL						
	STIMATE						
	+ ZLB BEHRING	0.15MG/SPRAY	N20355 001	Mar 07, 1994	Sep	CAHN	

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28		CYCLESSA	
AB	+ ORGANON USA INC	0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG	N21090 001 Dec 20, 2000 Feb CFTG
VELIVET			
AB	DURAMED PHARMS BARR	0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG	N76455 001 Feb 24, 2004 Feb NEWA

DESOXIMETASONE

CREAM; TOPICAL		TOPICORT	
AB	+ TARO PHARMS NORTH	0.25%	N17856 001 Jun CAHN
TOPICORT LP			
AB	+ TARO PHARMS NORTH	0.05%	N18309 001 Jun CAHN
GEL; TOPICAL		TOPICORT	
AB	+ TARO PHARMS NORTH	0.05%	N18586 001 Mar 29, 1982 Jun CAHN
OINTMENT; TOPICAL		TOPICORT	
	@ TARO PHARMS NORTH	0.05%	N18594 001 Jan 17, 1985 Jun CAHN
AB	+	0.25%	N18763 001 Sep 30, 1983 Jun CAHN

DEXAMETHASONE

TABLET; ORAL		DECADRON	
	@ MERCK	0.25MG	N11664 004 Oct DISC
	@	1.5MG	N11664 003 Oct DISC
	@	4MG	N11664 005 Oct DISC
	@	6MG	N11664 006 Jul 30, 1982 Oct DISC
DEXAMETHASONE		@ MUTUAL PHARM	
	@	0.25MG	N84013 001 Aug CAHN
	@	0.25MG	N84764 001 Aug CAHN
	@	0.5MG	N84084 001 Aug CAHN
	@	0.5MG	N84766 001 Aug CAHN
	@	0.75MG	N84081 001 Aug CAHN
	@	0.75MG	N84765 001 Aug CAHN
	@	1.5MG	N84086 001 Aug CAHN
	@	1.5MG	N84763 001 Aug CAHN
BP	+ PAR PHARM	0.25MG	N88149 001 Apr 28, 1983 Oct CRLD
BP	+ ROXANE	6MG	N88316 001 Sep 15, 1983 Oct CRLD

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC		DECADRON	
	@ MERCK	EQ 0.1% PHOSPHATE	N11984 001 Sep DISC
DEXAMETHASONE SODIUM PHOSPHATE		@ ALCON UNIVERSAL	
AT	+	EQ 0.1% PHOSPHATE	N88771 001 Jan 16, 1985 Sep CRLD

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC		DEXACIDIN	
	@ NOVARTIS	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62544 001 Oct 29, 1984 Apr DISC

DEXMEDETOMIDINE

INJECTABLE; INJECTION

PRECEDEX

+ HOSPIRA EQ 100UGM BASE/ML N21038 001 Dec 17, 1999 May CAHN

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE

AP BEDFORD EQ 250MG BASE/VIAL N76068 001 Sep 28, 2004 Sep NEWA

AP EQ 500MG BASE/VIAL N76068 002 Sep 28, 2004 Sep NEWA

ZINECARD

AP + PHARMACIA AND UPJOHN EQ 250MG BASE/VIAL N20212 001 May 26, 1995 Sep CFTG

AP + EQ 500MG BASE/VIAL N20212 002 May 26, 1995 Sep CFTG

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

AB ABLE 5MG N76814 001 Aug 25, 2004 Aug NEWA

AB 10MG N76814 002 Aug 25, 2004 Aug NEWA

AB 15MG N76814 003 Aug 25, 2004 Aug NEWA

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

>D> AP B BRAUN 10GM/100ML N18046 001 Nov DISC

>A> @ 10GM/100ML N18046 001 Nov DISC

AP HOSPIRA 10GM/100ML N18080 001 May CAHN

DEXTROSE 2.5% IN PLASTIC CONTAINER

@ B BRAUN 2.5GM/100ML N18358 001 May DISC

DEXTROSE 20% IN PLASTIC CONTAINER

AP HOSPIRA 20GM/100ML N18564 001 Mar 23, 1982 May CAHN

DEXTROSE 25%

HOSPIRA 250MG/ML N19445 002 Nov 23, 1998 May CAHN

DEXTROSE 30% IN PLASTIC CONTAINER

AP HOSPIRA 30GM/100ML N19345 001 Jan 26, 1985 May CAHN

DEXTROSE 40% IN PLASTIC CONTAINER

AP HOSPIRA 40GM/100ML N18562 001 Mar 23, 1982 May CAHN

DEXTROSE 5% IN PLASTIC CONTAINER

AP HOSPIRA 50MG/ML N16367 002 May CAHN

AP 50MG/ML N19222 001 Jul 13, 1984 May CAHN

AP 5GM/100ML N19466 001 Jul 15, 1985 May CAHN

AP 5GM/100ML N19479 001 Sep 17, 1985 May CAHN

DEXTROSE 50% IN PLASTIC CONTAINER

@ HOSPIRA 500MG/ML N19445 001 Jun 03, 1986 May CAHN

AP 50GM/100ML N18563 001 Mar 23, 1982 May CAHN

AP 50GM/100ML N19894 001 Dec 26, 1989 May CAHN

DEXTROSE 60% IN PLASTIC CONTAINER

AP HOSPIRA 60GM/100ML N19346 001 Jan 25, 1985 May CAHN

DEXTROSE 70% IN PLASTIC CONTAINER

AP HOSPIRA 70GM/100ML N18561 001 Mar 23, 1982 May CAHN

AP 70GM/100ML N19893 001 Dec 26, 1989 May CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;21MG/100ML;128MG/100ML; 234MG/100ML	N17610 001	May	CAH
---------	--	------------	-----	-----

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19025 001	Dec 27, 1984	May DISC
-----------	---	------------	--------------	----------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML; 100MG/100ML;180MG/100ML;280MG/100 ML;16MG/100ML	N19515 001	May 08, 1986	May CAH
---------	---	------------	--------------	---------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;30MG/100ML;141MG/100ML; 15MG/100ML;260MG/100ML;25MG/100ML	N19513 001	May 08, 1986	May CAH
---------	--	------------	--------------	---------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;2 20MG/100ML;140MG/100ML	N18273 001	May	DISC
-----------	---	------------	-----	------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;3 70MG/100ML;530MG/100ML;500MG/100M L	N19843 001	Aug 09, 1993	Nov	CTEC
-----	----	---------	---	------------	--------------	-----	------

>A>			5GM/100ML;30MG/100ML;37MG/100ML;3 70MG/100ML;530MG/100ML;500MG/100M L	N19843 001	Aug 09, 1993	Nov	CTEC
-----	--	--	---	------------	--------------	-----	------

>D>	AP	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;3 70MG/100ML;530MG/100ML;500MG/100M L	N18274 001		Nov	DISC
-----	----	---------	---	------------	--	-----	------

>A>		@	5GM/100ML;30MG/100ML;37MG/100ML;3 70MG/100ML;530MG/100ML;500MG/100M L	N18274 001		Nov	DISC
-----	--	---	---	------------	--	-----	------

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML;30MG/100ML;37MG/100ML;2 22MG/100ML;526MG/100ML;502MG/100M L	N17609 001	May	CAH
---------	---	------------	-----	-----

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;3 68MG/100ML;526MG/100ML;502MG/100M L	N17451 001		Nov	CTEC
-----	----	-----------------	---	------------	--	-----	------

>A>			5GM/100ML;30MG/100ML;37MG/100ML;3 68MG/100ML;526MG/100ML;502MG/100M L	N17451 001		Nov	CTEC
-----	--	--	---	------------	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;149MG/100ML	N18371 001	May	CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;224MG/100ML	N18371 003	May	CAHN
AP	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;298MG/100ML	N18371 002	May	CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML ;146MG/100ML;207MG/100ML	N19514 001	May 08, 1986	May	CAHN
--	---------	---	------------	--------------	-----	------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

	@ B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML ;280MG/100ML;91MG/100ML	N18270 001		May	DISC
--	-----------	--	------------	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N18365 002	Jul 05, 1983	May	CAHN
		L				
		5GM/100ML;149MG/100ML;225MG/100ML	N18365 006	Mar 28, 1988	May	CAHN
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N18876 001	Jan 17, 1986	May	CAHN
		L				
		5GM/100ML;149MG/100ML;300MG/100ML	N18876 006	Mar 28, 1988	May	CAHN
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N18362 005	Mar 28, 1988	May	CAHN
		L				
AP		5GM/100ML;74.5MG/100ML;450MG/100ML	N18362 009	Jul 05, 1983	May	CAHN
		L				
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N19691 002	Mar 24, 1988	May	CAHN
		L				
AP		5GM/100ML;149MG/100ML;900MG/100ML	N19691 004	Mar 24, 1988	May	CAHN
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N18365 008	Mar 28, 1988	May	CAHN
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N18876 007	Mar 28, 1988	May	CAHN
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N18362 006	Mar 28, 1988	May	CAHN
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N19691 006	Mar 24, 1988	May	CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;149MG/100ML;225MG/100ML	N18365 001		May	CAHN
		5GM/100ML;298MG/100ML;225MG/100ML	N18365 009	Mar 28, 1988	May	CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N18876 008	Mar 28, 1988	May	CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;149MG/100ML;450MG/100ML	N18362 010	Jul 05, 1983	May	CAHN
AP		5GM/100ML;298MG/100ML;450MG/100ML	N18362 007	Mar 28, 1988	May	CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	HOSPIRA	5GM/100ML;149MG/100ML;900MG/100ML	N19691 005	Mar 24, 1988	May	CAHN

SUNY COLLEGE OF PHARMACY

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	HOSPIRA	5GM/100ML;298MG/100ML;900MG/100ML	N19691 008	Mar 24, 1988	May CAHN
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;149MG/100ML;300MG/100ML	N18876 002	Jan 17, 1986	May CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;224MG/100ML;225MG/100ML	N18365 003	Jul 05, 1983	May CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;224MG/100ML;300MG/100ML	N18876 003	Jan 17, 1986	May CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N18362 002		May CAHN
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N19691 007	Mar 24, 1988	May CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;298MG/100ML;225MG/100ML	N18365 004	Jul 05, 1983	May CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;298MG/100ML;300MG/100ML	N18876 004	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	HOSPIRA	5GM/100ML;298MG/100ML;450MG/100ML	N18362 003		May CAHN
	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	HOSPIRA	5GM/100ML;298MG/100ML;900MG/100ML	N19691 009	Mar 24, 1988	May CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;74.5MG/100ML;225MG/100ML	N18365 005	Mar 28, 1988	May CAHN
		L			
		5GM/100ML;149MG/100ML;225MG/100ML	N18365 007	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N18876 005	Mar 28, 1988	May CAHN
		L			
		5GM/100ML;149MG/100ML;300MG/100ML	N18876 009	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N18362 008	Mar 28, 1988	May CAHN
		L			
AP		5GM/100ML;149MG/100ML;450MG/100ML	N18362 004	Mar 28, 1988	May CAHN
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N19691 001	Mar 24, 1988	May CAHN
		L			
AP		5GM/100ML;149MG/100ML;900MG/100ML	N19691 003	Mar 24, 1988	May CAHN

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	HOSPIRA	2.5GM/100ML;450MG/100ML	N18096 001		May CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;225MG/100ML	N17606 001		May CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	HOSPIRA	5GM/100ML;300MG/100ML	N17799 001		May CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	HOSPIRA	5GM/100ML;450MG/100ML	N17607 001		May CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ABBOTT	5GM/100ML;900MG/100ML	N17585 001		May CAHN
AP	HOSPIRA	5GM/100ML;900MG/100ML	N17585 001		Aug CAHN

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

	HYPaque				
	@ GE HEALTHCARE	30%			May DISC
	RENO-DIP				
+	BRACCO	30%			May CRLD

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION		HYPAQUE-76	
AP	@ GE HEALTHCARE	66%;10%	N86505 001 Oct CMFD
	@	66%;10%	N86505 001 May DISC

DIAZEPAM

INJECTABLE; INJECTION		DIAZEPAM	
	@ BAXTER HLTHCARE	5MG/ML	N70311 001 Dec 16, 1985 Aug CAHN
	@	5MG/ML	N70312 001 Dec 16, 1985 Aug CAHN
	@	5MG/ML	N70313 001 Dec 16, 1985 Aug CAHN
AP	+ HOSPIRA	5MG/ML	N71583 001 Oct 13, 1987 May CAHN
AP		5MG/ML	N71584 001 Oct 13, 1987 May CAHN
AP		5MG/ML	N72079 001 Dec 20, 1988 May CAHN
AP	PARENTA PHARMS	5MG/ML	N76815 001 Apr 15, 2004 Apr NEWA
TABLET; ORAL		DIAZEPAM	
	@ PAR PHARM	10MG	N70464 001 Feb 25, 1986 Sep DISC

DICLOFENAC POTASSIUM

TABLET; ORAL		DICLOFENAC POTASSIUM	
AB	TORPHARM	50MG	N76561 001 Mar 18, 2004 Mar NEWA

DICLOFENAC SODIUM

GEL; TOPICAL		SOLARAZE	
+	BIOGLAN PHARMS CORP	3%	N21005 001 Oct 16, 2000 Aug CAHN
SOLUTION/DROPS; OPHTHALMIC		VOLTAREN	
+	NOVARTIS	0.1%	N20037 001 Mar 28, 1991 Aug CAHN

DICLOXACILLIN SODIUM

CAPSULE; ORAL		DICLOXACILLIN SODIUM	
AB	SANDOZ	EQ 125MG BASE	N61454 002 Mar CAHN
AB		EQ 250MG BASE	N61454 001 Mar CAHN
AB	+	EQ 500MG BASE	N61454 003 Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL		DICYCLOMINE HCL	
	@ MUTUAL PHARM	10MG	N84505 001 Oct 21, 1986 Aug CAHN
TABLET; ORAL		DICYCLOMINE HCL	
	@ MUTUAL PHARM	20MG	N84600 001 Jul 29, 1985 Aug CAHN

DIDANOSINE

FOR SOLUTION; ORAL		VIDEX	
+	BRISTOL MYERS SQUIBB	10MG/ML	N20156 001 Oct 09, 1991 Jun CRLD
	@	100MG/PACKET	N20155 003 Oct 09, 1991 Jun DISC
	@	167MG/PACKET	N20155 004 Oct 09, 1991 Jun DISC
	@	250MG/PACKET	N20155 005 Oct 09, 1991 Jun DISC

ST. LOUIS COLLEGE OF PHARMACY LIBRARY

TABLET, CHEWABLE; ORAL

VIDEX

	BRISTOL MYERS SQUIBB	25MG	N20154	002	Oct 09, 1991	Jul	CRLD
+		200MG	N20154	006	Oct 28, 1999	Jul	CRLD

DIENESTROL

CREAM; VAGINAL

DIENESTROL

	ORTHO MCNEIL PHARM	0.01%	N06110	005		Jul	CAHN
--	--------------------	-------	--------	-----	--	-----	------

DIGOXIN

ELIXIR; ORAL

DIGOXIN

+	ROXANE	0.05MG/ML	N21648	001	Aug 26, 2004	Aug	NEWA
---	--------	-----------	--------	-----	--------------	-----	------

INJECTABLE; INJECTION

DIGOXIN

AP	BAXTER HLTHCARE	0.25MG/ML	N83391	001		Aug	CAHN
AP	HOSPIRA	0.25MG/ML	N40093	001	May 16, 1996	May	CAHN
AP		0.25MG/ML	N40206	001	Aug 28, 1998	May	CAHN
	DIGOXIN PEDIATRIC						
AP	HOSPIRA	0.1MG/ML	N40092	001	Apr 25, 1996	May	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

>D>	@ AVENTIS PHARMS	60MG	N19471	001	Jan 23, 1989	Nov	CAHN
	@	60MG	N19471	001	Jan 23, 1989	Jun	DISC
>D>	@	90MG	N19471	002	Jan 23, 1989	Nov	CAHN
	@	90MG	N19471	002	Jan 23, 1989	Jun	DISC
>D>	@	120MG	N19471	003	Jan 23, 1989	Nov	CAHN
	@	120MG	N19471	003	Jan 23, 1989	Jun	DISC
>D>	@	180MG	N19471	004	Jan 23, 1989	Nov	CAHN
>A>	@ BIOVAIL	60MG	N19471	001	Jan 23, 1989	Nov	CAHN
>A>	@	90MG	N19471	002	Jan 23, 1989	Nov	CAHN
>A>	@	120MG	N19471	003	Jan 23, 1989	Nov	CAHN
>A>	@	180MG	N19471	004	Jan 23, 1989	Nov	CAHN

DILT-CD

AB3	TORPHARM	120MG	N76151	001	May 20, 2004	May	NEWA
AB3		180MG	N76151	002	May 20, 2004	May	NEWA
AB3		240MG	N76151	003	May 20, 2004	May	NEWA
AB3		300MG	N76151	004	May 20, 2004	May	NEWA

DILTIAZEM HCL

	@ BIOVAIL	60MG	N74845	001	Sep 15, 1999	Jun	DISC
	@	90MG	N74845	002	Sep 15, 1999	Jun	DISC
	@	120MG	N74845	003	Sep 15, 1999	Jun	DISC
+	MYLAN	60MG	N74910	001	May 02, 1997	Jun	CRLD
+		90MG	N74910	002	May 02, 1997	Jun	CRLD
+		120MG	N74910	003	May 02, 1997	Jun	CRLD
	@ TEVA	60MG	N74079	001	Nov 30, 1993	Jun	DISC
	@	90MG	N74079	002	Nov 30, 1993	Jun	DISC
	@	120MG	N74079	003	Nov 30, 1993	Jun	DISC

INJECTABLE; INJECTION

CARDIZEM

>D>	AP	+	AVENTIS PHARMS	100MG/VIAL	N20792	001	Sep 05, 1997	Nov	CAHN
>A>	AP	+	BIOVAIL	100MG/VIAL	N20792	001	Sep 05, 1997	Nov	CAHN

DILTIAZEM HCL

AP	HOSPIRA	5MG/ML	N74941	001	Apr 15, 1998	May	CAHN
----	---------	--------	--------	-----	--------------	-----	------

<u>INJECTABLE; INJECTION</u>						
DILTIAZEM HCL						
AP		HOSPIRA	5MG/ML	N75004 001	Feb 16, 2000	May CAHN
AP			100MG/VIAL	N75853 001	Dec 17, 2002	May CAHN
<u>TABLET, EXTENDED RELEASE; ORAL</u>						
CARDIZEM LA						
		BIOVAIL	120MG	N21392 001	Feb 06, 2003	Jan CRLD
			180MG	N21392 002	Feb 06, 2003	Jan CRLD
			240MG	N21392 003	Feb 06, 2003	Jan CRLD
			300MG	N21392 004	Feb 06, 2003	Jan CRLD
			360MG	N21392 005	Feb 06, 2003	Jan CRLD
<u>TABLET; ORAL</u>						
CARDIZEM						
>D>	AB	AVENTIS PHARMS	30MG	N18602 001	Nov 05, 1982	Nov CAHN
>D>	AB		60MG	N18602 002	Nov 05, 1982	Nov CAHN
>D>	AB		90MG	N18602 003	Dec 08, 1986	Nov CAHN
>D>	AB	+	120MG	N18602 004	Dec 08, 1986	Nov CAHN
>A>	AB	BIOVAIL	30MG	N18602 001	Nov 05, 1982	Nov CAHN
>A>	AB		60MG	N18602 002	Nov 05, 1982	Nov CAHN
>A>	AB		90MG	N18602 003	Dec 08, 1986	Nov CAHN
>A>	AB	+	120MG	N18602 004	Dec 08, 1986	Nov CAHN
<u>DIMENHYDRINATE</u>						
<u>INJECTABLE; INJECTION</u>						
DIMENHYDRINATE						
AP		AM PHARM	50MG/ML	N40519 001	Jun 23, 2004	Jun NEWA
AP	+	STERIS	50MG/ML	N80615 001		Jun CFTG
<u>DIMYRISTOYL LECITHIN; PERFLEXANE</u>						
<u>INJECTABLE; INTRAVENOUS</u>						
IMAGENT						
	+	IMCOR PH	0.92MG/VIAL;0.092MG/VIAL	N21191 001	May 31, 2002	Feb CAHN
<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>						
<u>CAPSULE; ORAL</u>						
DIPHENHYDRAMINE HCL						
AA		MUTUAL PHARM	25MG	N84506 001		Aug CAHN
<u>INJECTABLE; INJECTION</u>						
DIPHENHYDRAMINE HCL						
AP		HOSPIRA	50MG/ML	N40140 001	Nov 20, 1998	May CAHN
<u>DIPYRIDAMOLE</u>						
<u>INJECTABLE; INJECTION</u>						
DIPYRIDAMOLE						
AP		BAXTER HLTHCARE	5MG/ML	N74521 001	Oct 18, 1996	Aug CAHN
AP		HOSPIRA	5MG/ML	N74601 001	Dec 19, 1997	May CAHN
<u>DIRITHROMYCIN</u>						
<u>TABLET, DELAYED RELEASE; ORAL</u>						
DYNABAC						
		@ LILLY RES LABS	250MG	N50678 001	Jun 19, 1995	Jul DISC
<u>DISOPYRAMIDE PHOSPHATE</u>						
<u>CAPSULE; ORAL</u>						
DISOPYRAMIDE PHOSPHATE						
		@ MUTUAL PHARM	EQ 100MG BASE	N70351 001	Dec 17, 1985	Aug CAHN

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

@ MUTUAL PHARM

EQ 150MG BASE

N70352 001 Dec 17, 1985 Aug CAHN

DISULFIRAM

TABLET; ORAL

ANTABUSE

@ ODYSSEY PHARMS

250MG

N07883 003

Jun CAHN

@

500MG

N07883 002

Jun CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

ABBOTT

EQ 125MG VALPROIC ACID

N18723 003 Oct 26, 1984 Jan CRLD

EQ 250MG VALPROIC ACID

N18723 001 Mar 10, 1983 Jan CRLD

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

AP HOSPIRA

EQ 12.5MG BASE/ML

N74086 001 Nov 29, 1993 May CAHN

AP

EQ 12.5MG BASE/ML

N74292 001 Feb 16, 1995 May CAHN

AP

EQ 1.25GM BASE/100ML

N74634 001 Sep 27, 1996 May CAHN

DOBUTAMINE HCL IN DEXTROSE 5%

AP + HOSPIRA

EQ 50MG BASE/100ML

N20269 001 Oct 19, 1993 May CAHN

AP +

EQ 100MG BASE/100ML

N20269 002 Oct 19, 1993 May CAHN

AP +

EQ 200MG BASE/100ML

N20269 003 Oct 19, 1993 May CAHN

DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + HOSPIRA

EQ 50MG BASE/100ML

N20201 003 Oct 19, 1993 May CAHN

AP +

EQ 100MG BASE/100ML

N20201 002 Oct 19, 1993 May CAHN

AP +

EQ 200MG BASE/100ML

N20201 001 Oct 19, 1993 May CAHN

AP +

EQ 400MG BASE/100ML

N20201 006 Jul 07, 1994 May CAHN

DOBUTREX

@ LILLY

EQ 12.5MG BASE/ML

N17820 002

Jun DISC

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

+ EISAI MEDCL RES

5MG/5ML

N21719 001 Oct 18, 2004 Oct NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

+ EISAI MEDCL RES

5MG

N21720 001 Oct 18, 2004 Oct NEWA

+

10MG

N21720 002 Oct 18, 2004 Oct NEWA

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

AP + HOSPIRA

40MG/ML

N18132 001

May CAHN

AP

40MG/ML

N74403 001 May 23, 1996 May CAHN

AP +

80MG/100ML

N18132 002 Feb 04, 1982 May CAHN

AP +

80MG/ML

N18132 004 Jul 09, 1982 May CAHN

AP +

160MG/100ML

N18132 003 Feb 04, 1982 May CAHN

DOPAMINE HCL IN DEXTROSE 5%

@ HOSPIRA

1.6MG/ML

N20542 001 Aug 30, 1995 Jun DISC

AP +

1.6MG/ML

N20542 001 Aug 30, 1995 May CAHN

DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + HOSPIRA

80MG/100ML

N18826 001 Sep 30, 1983 May CAHN

AP +

160MG/100ML

N18826 002 Sep 30, 1983 May CAHN

INJECTABLE; INJECTION

DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA	320MG/100ML	N18826 003	Sep 30, 1983	May	CAHN
----	---	---------	-------------	------------	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB		CLONMEL HLTHCARE	EQ 1MG BASE	N76161 001	Jun 10, 2004	Jun	NEWA
AB			EQ 2MG BASE	N76161 002	Jun 10, 2004	Jun	NEWA
AB			EQ 4MG BASE	N76161 003	Jun 10, 2004	Jun	NEWA
AB			EQ 8MG BASE	N76161 004	Jun 10, 2004	Jun	NEWA

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

@ MUTUAL PHARM

EQ 25MG BASE

N71502 001 Feb 18, 1988 Aug CAHN

@

EQ 50MG BASE

N71653 001 Feb 18, 1988 Aug CAHN

@

EQ 75MG BASE

N71654 001 Feb 18, 1988 Aug CAHN

@

EQ 100MG BASE

N71521 001 Feb 18, 1988 Aug CAHN

@ SANDOZ

EQ 25MG BASE

N70827 001 May 15, 1986 Sep DISC

@

EQ 50MG BASE

N70828 001 May 15, 1986 Sep DISC

@

EQ 100MG BASE

N71562 001 Mar 02, 1987 Sep DISC

CONCENTRATE; ORAL

DOXEPIN HCL

PHARM ASSOC

EQ 10MG BASE/ML

N75924 001 Jan 15, 2004 Jan NEWA

CREAM; TOPICAL

ZONALON

>D>	+	BIOGLAN PHARMS CORP	5%	N20126 001	Apr 01, 1994	Nov	CAHN
	+		5%	N20126 001	Apr 01, 1994	Aug	CAHN
>A>	+	BRADLEY PHARMS	5%	N20126 001	Apr 01, 1994	Nov	CAHN

DOXERCALCIFEROL

CAPSULE; ORAL

HECTOROL

BONE CARE

0.5UGM

N20862 002 Apr 23, 2004 Apr NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN RDF

@ PHARMACIA AND UPJOHN

10MG/VIAL

N50467 001 Jun DISC

@

20MG/VIAL

N50467 003 May 20, 1985 Jun DISC

@

50MG/VIAL

N50467 002 Jun DISC

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB		WATSON LABS	EQ 50MG BASE	N65041 001	Apr 28, 2000	Apr	CAHN
AB			EQ 100MG BASE	N65041 002	Apr 28, 2000	Apr	CAHN

DOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL

DORYX

FH FAULDING CO LTD

EQ 75MG BASE

N50582 002 Aug 13, 2001 Jul CAHN

AB	+		EQ 100MG BASE	N50582 001	Jul 22, 1985	Jul	CAHN
----	---	--	---------------	------------	--------------	-----	------

SPL LOUIS COLLEGE OF PHARMACY LIBRARY

<u>CAPSULE; ORAL</u>						
DOXYCYCLINE HYCLATE						
	@ MUTUAL PHARM	EQ 50MG BASE	N62418 001	Jan 28, 1983	Aug	CAHN
	@	EQ 100MG BASE	N62418 002	Jan 28, 1983	Aug	CAHN
AB	WATSON LABS	EQ 50MG BASE	N61717 001		Apr	CAHN
AB		EQ 100MG BASE	N61717 002		Apr	CAHN
<u>TABLET; ORAL</u>						
DOXYCYCLINE HYCLATE						
	@ MUTUAL PHARM	EQ 100MG BASE	N62391 001	Sep 30, 1982	Aug	CAHN
<u>DROPERIDOL</u>						
INJECTABLE; INJECTION						
DROPERIDOL						
AP	HOSPIRA	2.5MG/ML	N71981 001	Feb 29, 1988	May	CAHN
AP		2.5MG/ML	N72272 001	Aug 31, 1995	May	CAHN
<u>DROPERIDOL; FENTANYL CITRATE</u>						
INJECTABLE; INJECTION						
FENTANYL CITRATE AND DROPERIDOL						
+	HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	N71982 001	May 04, 1988	May	CAHN
	@	2.5MG/ML;EQ 0.05MG BASE/ML	N71982 001	May 04, 1988	Sep	DISC
<u>DULOXETINE HYDROCHLORIDE</u>						
CAPSULE, DELAYED REL PELLETS; ORAL						
CYMBALTA						
	LILLY	EQ 20MG BASE	N21733 001	Sep 03, 2004	Sep	NEWA
		EQ 30MG BASE	N21733 002	Sep 03, 2004	Sep	NEWA
+		EQ 60MG BASE	N21733 004	Sep 03, 2004	Sep	NEWA
CAPSULE; ORAL						
CYMBALTA						
	LILLY	EQ 20MG BASE	N21427 001	Aug 03, 2004	Aug	NEWA
		EQ 30MG BASE	N21427 002	Aug 03, 2004	Aug	NEWA
+		EQ 60MG BASE	N21427 004	Aug 03, 2004	Aug	NEWA
<u>ECONAZOLE NITRATE</u>						
CREAM; TOPICAL						
ECONAZOLE NITRATE						
AB	CLAY PARK	1%	N76479 001	Jun 23, 2004	Jun	NEWA
<u>EDETATE DISODIUM</u>						
INJECTABLE; INJECTION						
EDETATE DISODIUM						
	@ STERIS	150MG/ML	N80391 001		Sep	DISC
	ENDRATE					
AP	+ HOSPIRA	150MG/ML	N11355 001		May	CAHN
<u>EDROPHONIUM CHLORIDE</u>						
INJECTABLE; INJECTION						
EDROPHONIUM CHLORIDE						
AP	HOSPIRA	10MG/ML	N40131 001	Feb 24, 1998	May	CAHN
<u>EFAVIRENZ</u>						
TABLET; ORAL						
SUSTIVA						
	@ BRISTOL MYERS SQUIBB	300MG	N21360 001	Feb 01, 2002	Jun	DISC

EFLORNITHINE HYDROCHLORIDECREAM; TOPICAL
VANIQA

+ SKINMEDICA 13.9% N21145 001 Jul 27, 2000 Jul CAHN

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
TRUVADA

+ GILEAD 200MG;300MG N21752 001 Aug 02, 2004 Aug NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDETABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDEAB APOTEX 5MG;12.5MG N76486 001 Oct 27, 2004 Oct NEWA
AB 10MG;25MG N76486 002 Oct 27, 2004 Oct NEWAENALAPRILATINJECTABLE; INJECTION
ENALAPRILATAP HOSPIRA 1.25MG/ML N75456 001 Aug 22, 2000 May CAHN
AP 1.25MG/ML N75458 001 Aug 22, 2000 May CAHNEPINEPHRINEINJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

+ HOLLISTER STIER LABS EQ 0.15MG /DELIVERY N20800 002 May 28, 2004 May NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
LIDOCAINE HCL AND EPINEPHRINEAP HOSPIRA 0.005MG/ML;0.5% N89635 001 Jun 21, 1988 May CAHN
AP 0.005MG/ML;1% N89649 001 Jun 21, 1988 May CAHN
AP 0.005MG/ML;1.5% N88571 001 Sep 13, 1985 May CAHN
AP 0.005MG/ML;1.5% N89645 001 Jun 21, 1988 May CAHN
AP 0.005MG/ML;1.5% N89650 001 Jun 21, 1988 May CAHN
AP 0.005MG/ML;2% N89651 001 Jun 21, 1988 May CAHN
AP 0.01MG/ML;1% N89644 001 Jun 21, 1988 May CAHN
AP 0.01MG/ML;2% N89646 001 Jun 21, 1988 May CAHNPATCH; IONTOPHORESIS
LIDOSITE TOPICAL SYSTEM KIT

+ VYTERIS 1.05MG/PATCH;100MG/PATCH N21504 001 May 06, 2004 May NEWA

SOLUTION; IONTOPHORESIS
LIDOCAINE HCL AND EPINEPHRINE

+ EMPI 0.01MG/ML;2% N21486 001 Oct 26, 2004 Oct NEWA

EPLERENONETABLET; ORAL
INSPRA>D> GD SEARLE LLC 50MG N21437 002 Sep 27, 2002 Nov CRLD
>A> + 50MG N21437 002 Sep 27, 2002 Nov CRLD
>D> + 100MG N21437 003 Sep 27, 2002 Nov DISC
>A> 0 100MG N21437 003 Sep 27, 2002 Nov DISC

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES
@ MUTUAL PHARM

1MG

N88891 001 Nov 01, 1985 Aug CAHN

TABLET; SUBLINGUAL

ERGOLOID MESYLATES
@ MUTUAL PHARM

0.5MG

N87407 001 Aug CAHN

@

1MG

N87552 001 Aug CAHN

>A> ERLOTINIB HYDROCHLORIDE

>A> TABLET; ORAL

>A> TARCEVA

>A> OSI PHARMS

EQ 25MG BASE

N21743 001 Nov 18, 2004 Nov NEWA

>A> EQ 100MG BASE

N21743 002 Nov 18, 2004 Nov NEWA

>A> + EQ 150MG BASE

N21743 003 Nov 18, 2004 Nov NEWA

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB WARNER CHILCOTT

250MG

N62338 001 Jan CMFD

GEL; TOPICAL

ERYGEL

AT + MERZ PHARMS

2%

N50617 001 Oct 21, 1987 Jul CAHN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT + FOUGERA

0.5%

N62447 001 Sep 26, 1983 Jul CRLD

ILOTYCIN

@ DISTA

0.5%

N50368 001 Jul DISC

SOLUTION; TOPICAL

C-SOLVE-2

@ BIOGLAN PHARMA

2%

N62468 001 Jul 03, 1985 Jun DISC

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA

EQ 125MG BASE/5ML

N62353 001 Nov 18, 1982 Jan CTEC

+ EQ 250MG BASE/5ML

N62409 001 Dec 16, 1982 Jan CRLD

ILOSONE

@ LILLY

EQ 125MG BASE/5ML

N50010 001 Jan DISC

@

EQ 250MG BASE/5ML

N50010 002 Jan DISC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

AP + HOSPIRA

EQ 500MG BASE/VIAL

N50182 002 May CAHN

AP EQ 500MG BASE/VIAL

N50609 001 Sep 24, 1986 May CAHN

AP EQ 500MG BASE/VIAL

N62638 001 Oct 31, 1986 May CAHN

AP + EQ 1GM BASE/VIAL

N50182 003 May CAHN

AP EQ 1GM BASE/VIAL

N50609 002 Sep 24, 1986 May CAHN

AP EQ 1GM BASE/VIAL

N62638 002 Oct 31, 1986 May CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL

LEXAPRO

FOREST LABS

5MG

N21323 001 Aug 14, 2002 Apr CMFD

ESMOLOL HYDROCHLORIDEINJECTABLE; INJECTION
BREVIBLOC

AP	+	BAXTER HLTHCARE CORP	10MG/ML	N19386 006	Feb 25, 2003	Aug	CFTG
AP		ESMOLOL HCL					
AP		BEDFORD LABS	10MG/ML	N76323 001	Aug 10, 2004	Aug	NEWA

ESTRADIOLFILM, EXTENDED RELEASE; TRANSDERMAL
MENOSTAR

	+	BERLEX LABS	0.014MG/24HR	N21674 001	Jun 08, 2004	Jun	NEWA
AB1	+	NOVARTIS	0.025MG/24HR	N20323 005	Aug 16, 2000	Jul	CTEC
	@		0.0375MG/24HR	N20323 001	Oct 28, 1994	Jul	DISC
	@		0.075MG/24HR	N20323 003	Oct 28, 1994	Jul	DISC
AB1		NOVARTIS	0.025MG/24HR	N20538 009	May 03, 2002	Jul	NEWA
BX			0.0375MG/24HR	N20538 005	Jan 08, 1999	Jul	CTEC
BX			0.075MG/24HR	N20538 007	Jan 08, 1999	Jul	CTEC

GEL, METERED; TOPICAL

ESTROGEL

SOLVAY

	+		0.06%	N21166 002	Feb 09, 2004	Feb	NEWA
			0.06%	N21166 002	Feb 09, 2004	Aug	CRLD

GEL; TOPICAL

ESTROGEL

@ SOLVAY

	+		0.06%	N21166 001	Feb 09, 2004	Aug	DISC
			0.06%	N21166 001	Feb 09, 2004	Mar	CRLD
			0.06%	N21166 001	Feb 09, 2004	Feb	NEWA

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

GALEN LTD

	+		EQ 0.05MG BASE/24HR	N21367 001	Mar 20, 2003	May	CPOT
			EQ 0.1MG BASE/24HR	N21367 002	Mar 20, 2003	May	CPOT

TABLET; ORAL

FEMTRACE

WARNER CHILCOTT

	+		0.45MG	N21633 001	Aug 20, 2004	Aug	NEWA
			0.9MG	N21633 002	Aug 20, 2004	Aug	NEWA
			1.8MG	N21633 003	Aug 20, 2004	Aug	NEWA

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

>A>	+	DURAMED	1MG, 1MG; 0.09MG	N21040 001	Oct 22, 1999	Nov	CAHN
>D>	+	KING PHARMS	1MG, 1MG; 0.09MG	N21040 001	Oct 22, 1999	Nov	CAHN

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

@ WYETH PHARMS INC

			2.5MG	N04782 002		May	DISC
--	--	--	-------	------------	--	-----	------

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

DURAMED

			0.45MG	N20992 005	Feb 05, 2004	Feb	NEWA
--	--	--	--------	------------	--------------	-----	------

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUWIA

@	DURAMED	0.625MG	N21443 003	May 10, 2004	Jul	DISC
		0.625MG	N21443 003	May 10, 2004	May	NEWA
@		1.25MG	N21443 004	May 10, 2004	Jul	DISC
+		1.25MG	N21443 004	May 10, 2004	May	NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

@	ELAN PHARMS	100MG	N16320 001		Feb	CAHN
@		200MG	N16320 002		Feb	CAHN
@		400MG	N16320 003		Feb	CAHN
@		500MG	N16320 004		Feb	CAHN
AB	STAT TRADE	100MG	N16320 001		May	CMFD
	@	200MG	N16320 002		May	CAHN
AB		400MG	N16320 003		May	CMFD
	@	500MG	N16320 004		May	CAHN

ETHINYL ESTRADIOL

TABLET; ORAL

ESTINYL

@	SCHERING	0.02MG	N05292 001		Apr	DISC
@		0.05MG	N05292 002		Apr	DISC
@		0.5MG	N05292 003		Apr	DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

PREVEN EMERGENCY CONTRACEPTIVE KIT

+	DURAMED	0.05MG;0.25MG	N20946 001	Sep 01, 1998	Feb	CAHN
@		0.05MG;0.25MG	N20946 001	Sep 01, 1998	Jul	DISC

TABLET; ORAL-21

ALESSE

@	WYETH PHARMS INC	0.02MG;0.1MG	N20683 001	Mar 27, 1997	Aug	DISC
---	------------------	--------------	------------	--------------	-----	------

AVIANE-21

+	DURAMED PHARMS BARR	0.02MG;0.1MG	N75796 002	Apr 30, 2001	Aug	CRLD
---	---------------------	--------------	------------	--------------	-----	------

LEVLITE

AB2	+	BERLEX	0.02MG;0.1MG	N20860 001	Jul 13, 1998	May	CTEC
-----	---	--------	--------------	------------	--------------	-----	------

>D> TRIPHASIL-21

>D>	AB	+	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N19192 001	Nov 01, 1984	Nov	DISC
-----	----	---	------------------	---	------------	--------------	-----	------

>A>		@		0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N19192 001	Nov 01, 1984	Nov	DISC
-----	--	---	--	---	------------	--------------	-----	------

TABLET; ORAL-28

ALESSE

AB1	+	WYETH PHARMS INC	0.02MG;0.1MG	N20683 002	Mar 27, 1997	Jul	CRLD
-----	---	------------------	--------------	------------	--------------	-----	------

LESSINA-28

AB2		BARR	0.02MG;0.1MG	N75803 002	Mar 20, 2002	May	CTEC
-----	--	------	--------------	------------	--------------	-----	------

LEVLITE

AB2	+	BERLEX	0.02MG;0.1MG	N20860 002	Jul 13, 1998	Jul	CRLD
-----	---	--------	--------------	------------	--------------	-----	------

AB2			0.02MG;0.1MG	N20860 002	Jul 13, 1998	May	CTEC
-----	--	--	--------------	------------	--------------	-----	------

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A>	AB1		WATSON LABS	0.02MG;0.1MG	N76625 001	Nov 18, 2004	Nov	NEWA
-----	-----	--	-------------	--------------	------------	--------------	-----	------

TRIPHASIL-28

>D>		@	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N19190 001	Nov 01, 1984	Nov	CMFD
-----	--	---	------------------	---	------------	--------------	-----	------

TABLET; ORAL-28
TRIPHASIL-28

>A>	AB	+	WYETH PHARMS INC	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	N19190 001	Nov 01, 1984	Nov	CMFD
			®	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	N19190 001	Nov 01, 1984	Aug	DISC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
BALZIVA-21

	AB		BARR	0.035MG; 0.4MG	N76198 001	Apr 22, 2004	Apr	NEWA
>D>			NORCEPT-E 1/35 21					
>D>	AB		GYNOPHARMA	0.035MG; 1MG	N71545 001	Feb 09, 1989	Nov	DISC
>A>			® ORTHO MCNEIL PHARM	0.035MG; 1MG	N71545 001	Feb 09, 1989	Nov	DISC
			OVCON-35					
	AB	+	WARNER CHILCOTT	0.035MG; 0.4MG	N18127 001		Apr	CFTG

TABLET; ORAL-28
ARANELLE

	AB		BARR	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N76783 001	Sep 29, 2004	Sep	NEWA
			BALZIVA-28					
	AB		BARR	0.035MG; 0.4MG	N76238 001	Apr 22, 2004	Apr	NEWA
>D>			NORCEPT-E 1/35 28					
>D>	AB		GYNOPHARMA	0.035MG; 1MG	N71546 001	Feb 09, 1989	Nov	DISC
>A>			® ORTHO MCNEIL PHARM	0.035MG; 1MG	N71546 001	Feb 09, 1989	Nov	DISC
			ORTHO-NOVUM 1/35-28					
	AB	+	ORTHO MCNEIL PHARM	0.035MG; 1MG	N17919 002		Mar	CRLD
>A>			ORTHO-NOVUM 10/11-28					
>A>	AB		ORTHO MCNEIL PHARM	0.035MG, 0.035MG; 0.5MG, 1MG	N18354 002	Jan 11, 1982	Nov	CTNA
>D>			ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER					
>D>	AB		ORTHO MCNEIL PHARM	0.035MG, 0.035MG; 0.5MG, 1MG	N18354 002	Jan 11, 1982	Nov	CTNA
			OVCON-35					
	AB	+	WARNER CHILCOTT	0.035MG; 0.4MG	N17716 001		Apr	CFTG
			TRI-NORINYL 28-DAY					
	AB	+	WATSON LABS	0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG	N18977 002	Apr 13, 1984	Sep	CFTG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
FEMHRT

		+	WARNER CHILCOTT	0.005MG; 1MG	N21065 002	Oct 15, 1999	Aug	CAHN
			TABLET; ORAL-21					
			ESTROSTEP 21					
			® WARNER CHILCOTT	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	N20130 001	Oct 09, 1996	Aug	CAHN
			LOESTRIN 21 1.5/30					
	AB	+	WARNER CHILCOTT	0.03MG; 1.5MG	N17875 001		Aug	CAHN
			LOESTRIN 21 1/20					
	AB	+	WARNER CHILCOTT	0.02MG; 1MG	N17876 001		Aug	CAHN
			TABLET; ORAL-28					
			ESTROSTEP FE					
		+	WARNER CHILCOTT	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	N20130 002	Oct 09, 1996	Aug	CAHN
			LOESTRIN FE 1.5/30					
	AB	+	WARNER CHILCOTT	0.03MG; 1.5MG	N17355 001		Aug	CAHN
			LOESTRIN FE 1/20					
	AB	+	WARNER CHILCOTT	0.02MG; 1MG	N17354 001		Aug	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

	TABLET; ORAL-28 ORTHO TRI-CYCLEN LO								
	+ ORTHO MCNEIL PHARM	0.025MG,0.025MG,0.25MG;0.18MG,0.215MG,0.25MG	N21241	001	Aug 22, 2002	Jun	CAHN		
AB	PREVIFEM ANDRX PHARMS	0.035MG;0.25MG	N76334	001	Jan 09, 2004	Jan	NEWA		
AB	TRI-PREVIFEM ANDRX PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	N76335	001	Mar 26, 2004	Mar	NEWA		

ETHINYL ESTRADIOL; NORGESTREL

	TABLET; ORAL-21 LO/OVRAL @ WYETH PHARMS INC	0.03MG;0.3MG	N17612	001		Aug	DISC		
AB	+ LOW-OGESTREL-21 WATSON LABS	0.03MG;0.3MG	N75288	001	Jul 28, 1999	Aug	CRLD		
	+ OGESTREL 0.5/50-21 WATSON LABS	0.05MG;0.5MG	N75406	001	Dec 15, 1999	Aug	CRLD		
	OVRAL @ WYETH PHARMS INC	0.05MG;0.5MG	N16672	001		Aug	DISC		
AB	TABLET; ORAL-28 OGESTREL 0.5/50-28 WATSON LABS	0.05MG;0.5MG	N75406	002	Dec 15, 1999	Aug	CRLD		

ETIDRONATE DISODIUM

	INJECTABLE; INJECTION DIDRONEL @ MGI PHARMA INC	50MG/ML	N19545	001	Apr 20, 1987	Jun	DISC		
--	---	---------	--------	-----	--------------	-----	------	--	--

ETODOLAC

	TABLET, EXTENDED RELEASE; ORAL LODINE XL								
AB	WYETH PHARMS INC	400MG	N20584	001	Oct 25, 1996	May	CRLD		
AB	+	500MG	N20584	003	Jan 20, 1998	Jul	CRLD		
AB		500MG	N20584	003	Jan 20, 1998	May	CRLD		
	@	600MG	N20584	002	Oct 25, 1996	Jul	DISC		

ETOMIDATE

	INJECTABLE; INJECTION AMIDATE								
AP	+ HOSPIRA	2MG/ML	N18227	001	Sep 07, 1982	May	CAHN		

ETOPOSIDE

	INJECTABLE; INJECTION ETOPOSIDE								
AP	HOSPIRA	20MG/ML	N74320	001	Aug 30, 1995	May	CAHN		
AP		20MG/ML	N74351	001	Aug 30, 1995	May	CAHN		

EZETIMIBE; SIMVASTATIN

	TABLET; ORAL VYTORIN MSP SINGAPORE	10MG;10MG	N21687	001	Jul 23, 2004	Jul	NEWA		
		10MG;20MG	N21687	002	Jul 23, 2004	Jul	NEWA		
		10MG;40MG	N21687	003	Jul 23, 2004	Jul	NEWA		
	+	10MG;80MG	N21687	004	Jul 23, 2004	Jul	NEWA		

FAMOTIDINEINJECTABLE; INJECTION
FAMOTIDINE

AP	HOSPIRA	10MG/ML	N75870 001	Nov 23, 2001	May	CAHN
AP		10MG/ML	N75905 001	Nov 23, 2001	May	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
FLUXID

	SCHWARZ PHARMA	20MG	N21712 001	Sep 24, 2004	Sep	NEWA
+		40MG	N21712 002	Sep 24, 2004	Sep	NEWA

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

>A>	AB	MUTUAL PHARM	2.5MG	N75896 001	Nov 02, 2004	Nov	NEWA
>A>	AB		5MG	N75896 002	Nov 02, 2004	Nov	NEWA
>A>	AB		10MG	N75896 003	Nov 02, 2004	Nov	NEWA

PLENDIL

>D>		ASTRAZENECA	2.5MG	N19834 004	Sep 22, 1994	Nov	CFTG
>A>	AB		2.5MG	N19834 004	Sep 22, 1994	Nov	CFTG
>D>			5MG	N19834 001	Jul 25, 1991	Nov	CFTG
>A>	AB		5MG	N19834 001	Jul 25, 1991	Nov	CFTG
>D>	+		10MG	N19834 002	Jul 25, 1991	Nov	CFTG
>A>	AB	+	10MG	N19834 002	Jul 25, 1991	Nov	CFTG

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

>A>		RELIANT PHARMS INC	43MG	N21695 001	Nov 30, 2004	Nov	NEWA
>A>			87MG	N21695 002	Nov 30, 2004	Nov	NEWA
>A>	+		130MG	N21695 003	Nov 30, 2004	Nov	NEWA

TABLET; ORAL

TRICOR

>A>		ABBOTT	48MG	N21656 001	Nov 05, 2004	Nov	NEWA
>A>	+		145MG	N21656 002	Nov 05, 2004	Nov	NEWA

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

AP	+	HOSPIRA	EQ 10MG BASE/ML	N19922 001	Sep 23, 1997	May	CAHN
----	---	---------	-----------------	------------	--------------	-----	------

FENOLDOPAM MESYLATE

AP		BEDFORD LABS	EQ 10MG BASE/ML	N76582 001	Oct 12, 2004	Oct	NEWA
----	--	--------------	-----------------	------------	--------------	-----	------

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC

+	ALZA	0.6MG/24HR	N19813 004	Aug 07, 1990	Jul	CTEC
		1.2MG/24HR	N19813 003	Aug 07, 1990	Jul	CTEC
		1.8MG/24HR	N19813 002	Aug 07, 1990	Jul	CTEC
		2.4MG/24HR	N19813 001	Aug 07, 1990	Jul	CTEC

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP		HOSPIRA	EQ 0.05MG BASE/ML	N19115 001	Jan 12, 1985	May	CAHN
----	--	---------	-------------------	------------	--------------	-----	------

INJECTABLE; INJECTION						
FENTANYL CITRATE PRESERVATIVE FREE						
AP	HOSPIRA	EQ 0.05MG BASE/ML	N72786 001	Sep 24, 1991	May CAHN	
TROCHE/LOZENGE; ORAL						
ACTIQ						
	CEPHALON	EQ 0.2MG BASE	N20747 001	Nov 04, 1998	Feb CAHN	
		EQ 0.4MG BASE	N20747 002	Nov 04, 1998	Feb CAHN	
+		EQ 0.4MG BASE	N20747 002	Nov 04, 1998	Sep CRLD	
		EQ 0.6MG BASE	N20747 003	Nov 04, 1998	Feb CAHN	
		EQ 0.8MG BASE	N20747 004	Nov 04, 1998	Feb CAHN	
		EQ 1.2MG BASE	N20747 005	Nov 04, 1998	Feb CAHN	
+		EQ 1.6MG BASE	N20747 006	Nov 04, 1998	Feb CAHN	
		EQ 1.6MG BASE	N20747 006	Nov 04, 1998	Sep CRLD	
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>						
TABLET, EXTENDED RELEASE; ORAL						
ALLEGRA D 24 HOUR						
+	AVENTIS PHARMS	180MG;240MG	N21704 001	Oct 19, 2004	Oct NEWA	
<u>FLUCONAZOLE</u>						
FOR SUSPENSION; ORAL						
DIFLUCAN						
AB	PFIZER	50MG/5ML	N20090 001	Dec 23, 1993	Jul CFTG	
AB	+	200MG/5ML	N20090 002	Dec 23, 1993	Jul CFTG	
FLUCONAZOLE						
AB	RANBAXY	50MG/5ML	N76332 001	Jul 29, 2004	Jul NEWA	
AB		200MG/5ML	N76332 002	Jul 29, 2004	Jul NEWA	
AB	ROXANE	50MG/5ML	N76246 001	Jul 29, 2004	Jul NEWA	
AB		200MG/5ML	N76246 002	Jul 29, 2004	Jul NEWA	
INJECTABLE; INJECTION						
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	+	PFIZER	200MG/100ML	N19950 003	Sep 29, 1992	Jul CFTG
DIFLUCAN IN SODIUM CHLORIDE 0.9%						
AP	+	PFIZER	200MG/100ML	N19950 001	Jan 29, 1990	Jul CFTG
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP	+	PFIZER	200MG/100ML	N19950 002	Jan 29, 1990	Jul CFTG
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP		HOSPIRA	200MG/100ML	N76304 001	Jul 29, 2004	Jul NEWA
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%						
AP		AM PHARM PARTNERS	200MG/100ML	N76145 001	Jul 29, 2004	Jul NEWA
AP		BEDFORD	200MG/100ML	N76087 001	Jul 29, 2004	Jul NEWA
AP		SICOR PHARMS	200MG/100ML	N76653 001	Jul 29, 2004	Jul NEWA
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	200MG/100ML	N76766 001	Jul 29, 2004	Jul NEWA
AP		HOSPIRA	200MG/100ML	N76303 001	Jul 29, 2004	Jul NEWA
AP	+	MAYNE PHARMA USA	200MG/100ML	N76617 001	Jul 29, 2004	Jul NEWA
AP			200MG/100ML	N76617 001	Jul 29, 2004	Aug CRLD
TABLET; ORAL						
DIFLUCAN						
AB	PFIZER	50MG	N19949 001	Jan 29, 1990	Jul CFTG	
AB		100MG	N19949 002	Jan 29, 1990	Jul CFTG	
AB		150MG	N19949 004	Jun 30, 1994	Jul CFTG	
AB	+	200MG	N19949 003	Jan 29, 1990	Jul CFTG	
FLUCONAZOLE						
AB	DR REDDYS LABS INC	50MG	N76658 001	Jul 29, 2004	Jul NEWA	
AB		100MG	N76658 002	Jul 29, 2004	Jul NEWA	
AB		150MG	N76658 003	Jul 29, 2004	Jul NEWA	

TABLET; ORAL
FLUCONAZOLE

AB	DR REDDYS LABS INC	200MG	N76658 004	Jul 29, 2004	Jul	NEWA
AB	GEDEON RICHTER USA	50MG	N76432 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76432 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76432 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76432 004	Jul 29, 2004	Jul	NEWA
AB	GENPHARM	50MG	N76042 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76042 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76042 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76042 004	Jul 29, 2004	Jul	NEWA
AB	IVAX PHARMS	50MG	N76077 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76077 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76077 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76077 004	Jul 29, 2004	Jul	NEWA
AB	MYLAN	50MG	N76351 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76351 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76351 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76351 004	Jul 29, 2004	Jul	NEWA
AB	PLIVA	50MG	N76424 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76424 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76424 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76424 004	Jul 29, 2004	Jul	NEWA
AB	RANBAXY	50MG	N76386 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76386 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76386 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76386 004	Jul 29, 2004	Jul	NEWA
AB	ROXANE	50MG	N76213 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76213 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76213 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76213 004	Jul 29, 2004	Jul	NEWA
AB	SANDOZ	50MG	N76086 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76086 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76086 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76086 004	Jul 29, 2004	Jul	NEWA
AB	TARO	50MG	N76507 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76507 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76507 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76507 004	Jul 29, 2004	Jul	NEWA
AB	TEVA	50MG	N74681 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N74681 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N74681 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N74681 004	Jul 29, 2004	Jul	NEWA
AB	TORPHARM	50MG	N76665 001	Jul 29, 2004	Jul	NEWA
AB		100MG	N76665 002	Jul 29, 2004	Jul	NEWA
AB		150MG	N76665 003	Jul 29, 2004	Jul	NEWA
AB		200MG	N76665 004	Jul 29, 2004	Jul	NEWA

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

ICN

250MG

N17001 001

Nov CAHN

+

500MG

N17001 002

Nov CAHN

VALEANT PHARM INTL

250MG

N17001 001

Nov CAHN

+

500MG

N17001 002

Nov CAHN

FLUDARABINE PHOSPHATEINJECTABLE; INJECTION
FLUDARABINE PHOSPHATE

+ GENSIA SICOR PHARMS 50MG/2ML (25MG/ML) N76661 001 Apr 28, 2004 Apr NEWA

FLUDEOXYGLUCOSE F-18INJECTABLE; INJECTION
FLUDEOXYGLUCOSE F 18
@ DOWNSTATE CLINCL

4-90mCi/ML N20306 002 Sep 25, 2001 May DISC

INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F 18

+ WEILL MEDCL COLL 10-100mCi/ML N21768 001 Aug 05, 2004 Aug NEWA

FLUMAZENILINJECTABLE; INJECTION
FLUMAZENIL

AP	AM PHARM	0.5MG/5ML (0.1MG/ML)	N76955 002	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76955 001	Oct 12, 2004	Oct	NEWA
AP	APOTEX	0.5MG/5ML (0.1MG/ML)	N76755 002	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76755 001	Oct 12, 2004	Oct	NEWA
AP	BAXTER HLTHCARE	0.5MG/5ML (0.1MG/ML)	N76787 002	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76787 001	Oct 12, 2004	Oct	NEWA
AP	BEDFORD LABS	0.5MG/5ML (0.1MG/ML)	N76256 002	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76256 001	Oct 12, 2004	Oct	NEWA
AP	GENSIA SICOR PHARMS	0.5MG/5ML (0.1MG/ML)	N76589 002	Oct 12, 2004	Oct	NEWA
AP		1MG/10ML (0.1MG/ML)	N76589 001	Oct 12, 2004	Oct	NEWA
	ROMAZICON					
AP	+ HLR	1MG/10ML (0.1MG/ML)	N20073 001	Dec 20, 1991	Oct	CFTG
AP		0.5MG/5ML (0.1MG/ML)	N20073 002	Dec 20, 1991	Oct	CFTG

FLUNISOLIDESPRAY, METERED; NASAL
FLUNISOLIDE

+ BAUSCH AND LOMB 0.025MG/SPRAY N74805 001 Feb 20, 2002 Jun CRLD

NASALIDE

@ IVAX RES 0.025MG/SPRAY N18148 001 Jun DISC

FLUOCINONIDECREAM; TOPICAL
FLUOCINONIDE EMULSIFIED BASE

AB2 ALTANA 0.05% N76586 001 Jun 23, 2004 Jun NEWA

FLUOROURACILINJECTABLE; INJECTION
FLUOROURACIL

AP BIGMAR BIOREN PHARMS 50MG/ML N40291 001 Mar 24, 1999 Jul CAHN

AP 50MG/ML N40379 001 Nov 15, 2000 Jul CAHN

FLUOXETINE HYDROCHLORIDECAPSULE; ORAL
FLUOXETINE

AB IVAX PHARMS EQ 40MG BASE N75245 003 Sep 28, 2004 Sep NEWA

SOLUTION; ORAL
FLUOXETINE HCL

AA PAR PHARM EQ 20MG BASE/5ML N76458 001 May 14, 2004 May NEWA

<u>TABLET; ORAL</u>							
FLUOXETINE							
AB	IVAX PHARMS	EQ 40MG BASE	N75865 003	Aug 30, 2004	Aug	NEWA	
FLUOXETINE HCL							
AB	IVAX PHARMS	EQ 10MG BASE	N75865 001	Feb 28, 2002	Aug	CAHN	
<u>FLUPHENAZINE DECANOATE</u>							
INJECTABLE; INJECTION							
FLUPHENAZINE DECANOATE							
	@ MAYNE PHARMA USA	25MG/ML	N74966 001	Apr 16, 1998	Apr	CAHN	
<u>FLUPHENAZINE HYDROCHLORIDE</u>							
CONCENTRATE; ORAL							
PERMITIL							
	@ SCHERING	5MG/ML	N16008 001		Jun	DISC	
<u>FLURAZEPAM HYDROCHLORIDE</u>							
CAPSULE; ORAL							
FLURAZEPAM HCL							
	@ MUTUAL PHARM	15MG	N70454 001	Aug 04, 1986	Aug	CAHN	
	@	30MG	N70455 001	Aug 04, 1986	Aug	CAHN	
<u>FLUTICASONE PROPIONATE</u>							
AEROSOL, METERED; INHALATION							
FLOVENT HFA							
	GLAXOSMITHKLINE	0.044MG/INH	N21433 003	May 14, 2004	May	NEWA	
		0.11MG/INH	N21433 002	May 14, 2004	May	NEWA	
	+	0.22MG/INH	N21433 001	May 14, 2004	May	NEWA	
CREAM; TOPICAL							
CUTIVATE							
AB	+ GLAXOSMITHKLINE	0.05%	N19958 001	Dec 18, 1990	May	CFTG	
FLUTICASONE PROPIONATE							
AB	ALTANA	0.05%	N76451 001	May 14, 2004	May	NEWA	
AB	ATRIX	0.05%	N76633 001	May 14, 2004	May	NEWA	
AB	CLAY PARK	0.05%	N76793 001	May 14, 2004	May	NEWA	
AB	KV PHARM	0.05%	N76865 001	Sep 10, 2004	Sep	NEWA	
OINTMENT; TOPICAL							
CUTIVATE							
AB	+ GLAXOSMITHKLINE	0.005%	N19957 001	Dec 14, 1990	May	CFTG	
FLUTICASONE PROPIONATE							
AB	ALTANA	0.005%	N76300 001	May 14, 2004	May	NEWA	
AB	CLAY PARK	0.005%	N76668 001	May 14, 2004	May	NEWA	
<u>FOLLITROPIN ALFA/BETA</u>							
INJECTABLE; IM-SC							
FOLLISTIM							
BX	ORGANON USA INC	75 IU/VIAL	N20582 001	Sep 29, 1997	Mar	CDFR	
	@	75 IU/VIAL	N20582 001	Sep 29, 1997	Aug	DISC	
	+	75 IU/VIAL	N20582 001	Sep 29, 1997	Jun	CTEC	
BX		150 IU/VIAL	N20582 002	Sep 29, 1997	Mar	CDFR	
	@	150 IU/VIAL	N20582 002	Sep 29, 1997	Aug	DISC	
	+	150 IU/VIAL	N20582 002	Sep 29, 1997	Jun	CTEC	
INJECTABLE; SUBCUTANEOUS							
FOLLISTIM AQ							
	ORGANON USA INC	300 IU/0.525ML	N21211 001	Mar 23, 2004	Mar	NEWA	
	+	600 IU/0.885ML	N21211 002	Mar 23, 2004	Mar	NEWA	

INJECTABLE; SUBCUTANEOUS

GONAL-F						
	SERONO INC	37.5 IU/VIAL	N21765	001	Mar 25, 2004	Mar NEWA
	@	37.5 IU/VIAL	N21765	001	Mar 25, 2004	May DISC
	@	75 IU/VIAL	N20378	001	Sep 29, 1997	Jun DISC
BX		75 IU/VIAL	N20378	001	Sep 29, 1997	Mar CDFR
		75 IU/VIAL	N21765	002	Mar 25, 2004	Mar NEWA
+		75 IU/VIAL	N21765	002	Mar 25, 2004	Jun CRLO
	@	150 IU/VIAL	N20378	002	Sep 29, 1997	Jun DISC
BX		150 IU/VIAL	N20378	002	Sep 29, 1997	Mar CDFR
+		150 IU/VIAL	N21765	003	Mar 25, 2004	Mar NEWA
	@	150 IU/VIAL	N21765	003	Mar 25, 2004	May DISC
		450 IU/VIAL	N20378	005	Mar 26, 2004	Mar NEWA
+		1,200 IU/VIAL	N20378	004	Feb 28, 2001	Mar CAIN
+		1,050 IU/VIAL	N20378	004	Feb 28, 2001	Apr CPOI
GONAL-F RFF PEN						
	SERONO INC	300 IU/0.5ML	N21684	001	May 25, 2004	May NEWA
		450 IU/0.75ML	N21684	002	May 25, 2004	May NEWA
+		900 IU/1.5ML	N21684	003	May 25, 2004	May NEWA

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

+	NOVARTIS	6.6MG/ML	N20961	001	Aug 26, 1998	Jan CAHN
---	----------	----------	--------	-----	--------------	----------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

+	FONDA BV	5MG/0.4ML	N21345	002	May 28, 2004	May NEWA
+		7.5MG/0.6ML	N21345	003	May 28, 2004	May NEWA
+		10MG/0.8ML	N21345	004	May 28, 2004	May NEWA
+	GLAXOSMITHKLINE	2.5MG/0.5ML	N21345	001	Dec 07, 2001	Aug CAHN
+		5MG/0.4ML	N21345	002	May 28, 2004	Aug CAHN
+		7.5MG/0.6ML	N21345	003	May 28, 2004	Aug CAHN
+		10MG/0.8ML	N21345	004	May 28, 2004	Aug CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB	ANDRX PHARMS	10MG	N76620	001	Oct 15, 2004	Oct NEWA
AB		20MG	N76620	002	Oct 15, 2004	Oct NEWA
AB		40MG	N76620	003	Oct 15, 2004	Oct NEWA
AB	EON	10MG	N76483	001	Apr 23, 2004	Apr NEWA
AB		20MG	N76483	002	Apr 23, 2004	Apr NEWA
AB		40MG	N76483	003	Apr 23, 2004	Apr NEWA
AB	RANBAXY	10MG	N76580	001	Apr 23, 2004	Apr NEWA
AB		20MG	N76580	002	Apr 23, 2004	Apr NEWA
AB		40MG	N76580	003	Apr 23, 2004	Apr NEWA
AB	SANDOZ	10MG	N76188	001	Oct 08, 2004	Oct NEWA
AB		20MG	N76188	002	Oct 08, 2004	Oct NEWA
AB		40MG	N76188	003	Oct 08, 2004	Oct NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>A>						
>A>	AB	ANDRX PHARMS	10MG;12.5MG	N76608	001	Dec 03, 2004 Nov NEWA

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>A>	AB	ANDRX PHARMS	20MG;12.5MG	N76608 002	Dec 03, 2004	Nov	NEWA
>A>		MONOPRIL-HCT					
>D>		BRISTOL MYERS SQUIBB	10MG;12.5MG	N20286 002	Nov 30, 1994	Nov	CFTG
>A>	AB		10MG;12.5MG	N20286 002	Nov 30, 1994	Nov	CFTG
>D>	+		20MG;12.5MG	N20286 001	Nov 30, 1994	Nov	CFTG
>A>	AB	+	20MG;12.5MG	N20286 001	Nov 30, 1994	Nov	CFTG

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

+	ENDO PHARMS	EQ 2.5MG BASE	N21006 001	Nov 08, 2001	Aug	CAHN
+	VERNALIS	EQ 2.5MG BASE	N21006 001	Nov 08, 2001	May	CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP	HOSPIRA	10MG/ML	N18667 001	May 28, 1982	May	CAHN
AP		10MG/ML	N70578 001	Jul 08, 1987	May	CAHN
AP		10MG/ML	N72080 001	Aug 13, 1991	May	CAHN
AP		10MG/ML	N74337 001	Oct 31, 1994	May	CAHN
AP		10MG/ML	N75241 001	May 28, 1999	May	CAHN

TABLET; ORAL

FUROSEMIDE

	@ MUTUAL PHARM	20MG	N70043 001	Sep 26, 1985	Aug	CAHN
	@	40MG	N18790 001	Nov 29, 1983	Aug	CAHN
	@	80MG	N70100 001	Jan 26, 1988	Aug	CAHN
AB	VINTAGE PHARMS	20MG	N76796 001	Mar 26, 2004	Mar	NEWA
AB		40MG	N76796 002	Mar 26, 2004	Mar	NEWA
AB		80MG	N76796 003	Mar 26, 2004	Mar	NEWA
	@ WATSON LABS	40MG	N70413 001	Feb 26, 1986	Sep	DISC

GABAPENTIN

CAPSULE; ORAL

GABAPETIN

AB	TEVA PHARMS	100MG	N75435 001	Oct 08, 2004	Oct	NEWA
AB		300MG	N75435 002	Oct 08, 2004	Oct	NEWA
AB		400MG	N75435 003	Oct 08, 2004	Oct	NEWA

TABLET; ORAL

GABAPENTIN

	IVAX PHARMS	100MG	N76017 001	Apr 28, 2004	Apr	NEWA
		300MG	N76017 002	Apr 28, 2004	Apr	NEWA
		400MG	N76017 003	Apr 28, 2004	Apr	NEWA
AB	PUREPAC PHARM	600MG	N75694 001	Oct 21, 2004	Oct	NEWA
AB		800MG	N75694 002	Oct 21, 2004	Oct	NEWA
	NEURONTIN					
AB	PFIZER PHARMS	600MG	N20882 001	Oct 09, 1998	Oct	CFTG
AB	+	800MG	N20882 002	Oct 09, 1998	Oct	CFTG

GADOENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS

MULTIHANCE

>A>	+	BRACCO	2.645GM/5ML (529MG/ML)	N21357 001	Nov 23, 2004	Nov	NEWA
>A>	+		5.29GM/10ML (529MG/ML)	N21357 002	Nov 23, 2004	Nov	NEWA
>A>	+		7.935GM/15ML (529MG/ML)	N21357 003	Nov 23, 2004	Nov	NEWA
>A>	+		10.58GM/20ML (529MG/ML)	N21357 004	Nov 23, 2004	Nov	NEWA

>A>	INJECTABLE; INTRAVENOUS					
>A>	MULTIHANCE MULTIPACK					
>A>	+ BRACCO	26.45GM/50ML (529MG/ML)	N21358 001	Nov 23, 2004	Nov	NEWA
>A>	+	52.9GM/100ML (529MG/ML)	N21358 002	Nov 23, 2004	Nov	NEWA

GANIRELIX ACETATE

	INJECTABLE; INJECTION					
	GANIRELIX ACETATE INJECTION					
	+ ORGANON USA INC	EQ 250UGM BASE/0.5ML	N21057 001	Jul 29, 1999	Jun	CTWA

GATIFLOXACIN

	SUSPENSION; ORAL					
	TEQUIN					
	+ BRISTOL MYERS SQUIBB	200MG/5ML	N21678 001	Aug 27, 2004	Aug	NEWA

GEMIFLOXACIN MESYLATE

	TABLET; ORAL					
	FACTIVE					
	+ OSCIENT	EQ 320MG BASE	N21158 001	Apr 04, 2003	Apr	CAHN

GENTAMICIN SULFATE

	INJECTABLE; INJECTION					
	GENTAMICIN SULFATE					
AP	HOSPIRA	EQ 10MG BASE/ML	N62420 001	Aug 15, 1983	May	CAHN
AP		EQ 10MG BASE/ML	N62612 004	Feb 20, 1986	May	CAHN
AP		EQ 40MG BASE/ML	N62420 002	Aug 15, 1983	May	CAHN
	GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	HOSPIRA	EQ 1.2MG BASE/ML	N62414 001	Aug 15, 1983	May	CAHN
	@	EQ 1.2MG BASE/ML	N62588 001	Jan 06, 1986	May	CAHN
AP		EQ 1.4MG BASE/ML	N62414 002	Aug 15, 1983	May	CAHN
	@	EQ 1.4MG BASE/ML	N62588 002	Jan 06, 1986	May	CAHN
AP		EQ 1.6MG BASE/ML	N62414 003	Aug 15, 1983	May	CAHN
	@	EQ 1.6MG BASE/ML	N62588 003	Jan 06, 1986	May	CAHN
AP		EQ 1.8MG BASE/ML	N62414 004	Aug 15, 1983	May	CAHN
	@	EQ 1.8MG BASE/ML	N62588 004	Jan 06, 1986	May	CAHN
AP		EQ 2MG BASE/ML	N62414 005	Aug 15, 1983	May	CAHN
	@	EQ 2MG BASE/ML	N62588 005	Jan 06, 1986	May	CAHN
AP		EQ 60MG BASE/100ML	N62414 006	Aug 15, 1983	May	CAHN
	@	EQ 60MG BASE/100ML	N62588 006	Jan 06, 1986	May	CAHN
AP		EQ 70MG BASE/100ML	N62414 007	Aug 15, 1983	May	CAHN
	@	EQ 70MG BASE/100ML	N62588 007	Jan 06, 1986	May	CAHN
AP		EQ 80MG BASE/100ML	N62414 008	Aug 15, 1983	May	CAHN
	@	EQ 80MG BASE/100ML	N62588 008	Jan 06, 1986	May	CAHN
AP		EQ 90MG BASE/100ML	N62414 009	Aug 15, 1983	May	CAHN
	@	EQ 90MG BASE/100ML	N62588 009	Jan 06, 1986	May	CAHN
AP		EQ 100MG BASE/100ML	N62414 010	Aug 15, 1983	May	CAHN
	@	EQ 100MG BASE/100ML	N62588 010	Jan 06, 1986	May	CAHN
	OINTMENT; OPHTHALMIC					
	GENTAMICIN SULFATE					
AT	+ AKORN	EQ 0.3% BASE	N64093 001	Aug 31, 1995	Jul	CFTG
AT	ALTANA	EQ 0.3% BASE	N65024 001	Jul 30, 2004	Jul	NEWA
	SOLUTION/DROPS; OPHTHALMIC					
	GARAMYCIN					
AT	+ SCHERING	EQ 0.3% BASE	N50039 002		Jan	CDFR
	GENTAMICIN SULFATE					
AT	ALTANA	EQ 3% BASE	N65121 001	Jan 30, 2004	Jan	NEWA

GLIPIZIDE

TABLET; ORAL		GLIPIZIDE							
AB	KALI LABS	5MG		N74550	001	Sep 11, 1997	Aug	CAHN	
AB		10MG		N74550	002	Sep 11, 1997	Aug	CAHN	

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+	NUTRITIONAL RESTART	5GM/PACKET		N21667	001	Jun 10, 2004	Jul	CMS2	
@		5GM/PACKET		N21667	001	Jun 10, 2004	Sep	DISC	

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

AB	BRISTOL MYERS SQUIBB	1.25MG;250MG		N21178	001	Jul 31, 2000	Feb	CFTG	
AB		2.5MG;500MG		N21178	002	Jul 31, 2000	Feb	CFTG	
AB	+	5MG;500MG		N21178	003	Jul 31, 2000	Feb	CFTG	

GLYBURIDE AND METFORMIN HCL

>A>	AB	COREPHARMA	1.25MG;250MG	N76731	001	Nov 19, 2004	Nov	NEWA	
>A>	AB		2.5MG;500MG	N76731	002	Nov 19, 2004	Nov	NEWA	
>A>	AB		5MG;500MG	N76731	003	Nov 19, 2004	Nov	NEWA	
	AB	IVAX PHARMS	1.25MG;250MG	N76345	001	Feb 18, 2004	Feb	NEWA	
	AB		2.5MG;500MG	N76345	002	Feb 18, 2004	Feb	NEWA	
	AB		5MG;500MG	N76345	003	Feb 18, 2004	Feb	NEWA	

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

AT	HOSPIRA	1.5GM/100ML		N17633	001		May	CAHN	
AT		1.5GM/100ML		N18315	001		May	CAHN	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

@	HOSPIRA	0.2MG/ML		N89393	001	Jun 15, 1988	May	CAHN	
---	---------	----------	--	--------	-----	--------------	-----	------	--

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

@	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL		N18123	001	Sep 30, 1982	Jun	DISC	
---	----------------------	--------------------	--	--------	-----	--------------	-----	------	--

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

KYTRIL

+	ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)		N20239	003	Sep 17, 2004	Sep	NEWA	
+		EQ 1MG BASE/ML (EQ 1MG BASE/ML)		N20239	004	Mar 11, 1994	Sep	NEWA	
+		EQ 4MG BASE/4ML (EQ 1MG BASE /ML)		N20239	002	Mar 11, 1994	Sep	CPOT	

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

FULVICIN-U/F

AB	+	SCHERING	250MG	N60569	002		Sep	CRLD	
----	---	----------	-------	--------	-----	--	-----	------	--

ST. LOUIS COLLEGE OF MASSAGE AND CHIROPY

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

@ SCHERING	125MG	N61996 001	Jun	DISC
@	250MG	N61996 002	Jun	DISC

FULVICIN P/G 165

@ SCHERING	165MG	N61996 003	Apr 06, 1982	Jun	DISC
------------	-------	------------	--------------	-----	------

FULVICIN P/G 330

@ SCHERING	330MG	N61996 004	Apr 06, 1982	Jun	DISC
------------	-------	------------	--------------	-----	------

GRIS-PEG

PEDINOL	125MG	N50475 001	Sep	CTEC
---------	-------	------------	-----	------

+

250MG	N50475 002	Jun	CRLD
-------	------------	-----	------

HALAZEPAM

TABLET; ORAL

PAXIPAM

@ SCHERING	20MG	N17736 003	Apr	DISC
@	40MG	N17736 004	Apr	DISC

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@ MUTUAL PHARM	0.5MG	N71156 001	Jan 02, 1987	Aug	CAHN
----------------	-------	------------	--------------	-----	------

@	1MG	N71157 001	Jan 02, 1987	Aug	CAHN
---	-----	------------	--------------	-----	------

@	2MG	N71172 001	Jan 02, 1987	Aug	CAHN
---	-----	------------	--------------	-----	------

@	5MG	N71212 001	Jan 07, 1988	Aug	CAHN
---	-----	------------	--------------	-----	------

@	10MG	N71173 001	Jan 07, 1988	Aug	CAHN
---	------	------------	--------------	-----	------

@	20MG	N71177 001	Jan 07, 1988	Aug	CAHN
---	------	------------	--------------	-----	------

AB + SANDOZ

2MG	N71208 001	Nov 17, 1986	Oct	CRLD
-----	------------	--------------	-----	------

20MG	N71211 001	Mar 11, 1988	Oct	CRLD
------	------------	--------------	-----	------

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@ MAYNE PHARMA USA	EQ 50MG BASE/ML	N75176 001	Feb 09, 2000	Apr	CAHN
@	EQ 100MG BASE/ML	N75176 002	Feb 09, 2000	Apr	CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

>D> AA	COPLEY PHARM	EQ 2MG BASE/ML	N71617 001	Dec 01, 1988	Nov	CRLD
--------	--------------	----------------	------------	--------------	-----	------

>A> AA	+	EQ 2MG BASE/ML	N71617 001	Dec 01, 1988	Nov	CRLD
--------	---	----------------	------------	--------------	-----	------

>D> AA	+	TEVA	EQ 2MG BASE/ML	N71015 001	Aug 25, 1987	Nov	DISC
--------	---	------	----------------	------------	--------------	-----	------

>A>	@	EQ 2MG BASE/ML	N71015 001	Aug 25, 1987	Nov	DISC
-----	---	----------------	------------	--------------	-----	------

INJECTABLE; INJECTION

HALOPERIDOL

AP	APOTEX	EQ 5MG BASE/ML	N76774 001	Aug 25, 2004	Aug	NEWA
----	--------	----------------	------------	--------------	-----	------

AP		EQ 5MG BASE/ML	N76791 001	Aug 25, 2004	Aug	NEWA
----	--	----------------	------------	--------------	-----	------

AP		EQ 5MG BASE/ML	N76828 001	Aug 25, 2004	Aug	NEWA
----	--	----------------	------------	--------------	-----	------

AP	SABEX 2002	EQ 5MG BASE/ML	N76464 001	Sep 29, 2004	Sep	NEWA
----	------------	----------------	------------	--------------	-----	------

HALOTHANE

LIQUID; INHALATION

HALOTHANE

AN	+	HOSPIRA	99.99%	N83254 001	May	CAHN
----	---	---------	--------	------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

AP	HOSPIRA	10 UNITS/ML	N05264 001		May	CAHN
AP		10 UNITS/ML	N40082 001	Feb 28, 1995	May	CAHN
AP		10 UNITS/ML	N88097 001	Apr 28, 1983	May	CAHN
AP		10 UNITS/ML	N88346 001	May 18, 1983	May	CAHN
	@	100 UNITS/ML	N05264 010		May	CAHN
AP		100 UNITS/ML	N40082 002	Feb 28, 1995	May	CAHN
AP		100 UNITS/ML	N88098 001	Apr 28, 1983	May	CAHN
AP		100 UNITS/ML	N88347 001	May 18, 1983	May	CAHN
	HEPARIN LOCK FLUSH IN PLASTIC CONTAINER					
AP	HOSPIRA	10 UNITS/ML	N05264 015	May 21, 1985	May	CAHN
AP		100 UNITS/ML	N05264 016	May 21, 1985	May	CAHN
	HEPARIN SODIUM					
	@ HOSPIRA	2,500 UNITS/ML	N88099 001	Apr 28, 1983	Aug	DISC
AP +		2,500 UNITS/ML	N88099 001	Apr 28, 1983	May	CAHN
AP		5,000 UNITS/ML	N88100 001	Apr 28, 1983	May	CAHN
	@	10,000 UNITS/ML	N40095 001	Jul 26, 1996	May	CAHN
	@ LILLY	10,000 UNITS/ML	N05521 002		Jun	DISC
	@ MARSAM PHARMS LLC	1,000 UNITS/ML	N40007 001	Jun 07, 1996	Sep	DISC
	HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	HOSPIRA	200 UNITS/100ML	N18916 010	Jun 23, 1989	May	CAHN
	HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%					
	@ HOSPIRA	10,000 UNITS/100ML	N18911 006	Jan 30, 1985	May	CAHN
	HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	HOSPIRA	10,000 UNITS/100ML	N19339 003	Mar 27, 1985	May	CAHN
	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%					
	@ HOSPIRA	10,000 UNITS/100ML	N18911 001	Jan 30, 1985	May	CAHN
	@	10,000 UNITS/100ML	N18916 005	Jan 31, 1984	May	CAHN
	HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%					
	@ HOSPIRA	10,000 UNITS/100ML	N18911 003	Jan 30, 1985	May	CAHN
	@	10,000 UNITS/100ML	N18916 002	Jan 31, 1984	May	CAHN
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%					
	@ HOSPIRA	5,000 UNITS/100ML	N18911 007	Jan 30, 1985	May	CAHN
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
	HOSPIRA	5,000 UNITS/100ML	N19339 001	Mar 27, 1985	May	CAHN
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	HOSPIRA	5,000 UNITS/100ML	N18916 006	Jan 31, 1984	May	CAHN
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%					
	@ HOSPIRA	5,000 UNITS/100ML	N18911 005	Jan 30, 1985	May	CAHN
	@	5,000 UNITS/100ML	N18916 003	Jan 31, 1984	May	CAHN
	HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	HOSPIRA	200 UNITS/100ML	N18916 011	Jun 23, 1989	May	CAHN
	HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	HOSPIRA	4,000 UNITS/100ML	N19805 001	Jan 25, 1989	May	CAHN
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%					
	@ HOSPIRA	5,000 UNITS/100ML	N18911 009	Jan 30, 1985	May	CAHN
	@	10,000 UNITS/100ML	N18911 008	Jan 30, 1985	May	CAHN
	HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	HOSPIRA	5,000 UNITS/100ML	N19339 004	Mar 27, 1985	May	CAHN
AP		5,000 UNITS/100ML	N19805 002	Jan 25, 1989	May	CAHN
AP		10,000 UNITS/100ML	N19339 002	Mar 27, 1985	May	CAHN
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	HOSPIRA	5,000 UNITS/100ML	N18916 007	Jan 31, 1984	May	CAHN
		10,000 UNITS/100ML	N18916 008	Jan 31, 1984	May	CAHN

INJECTABLE; INJECTION										
		HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%								
		@ HOSPIRA	5,000 UNITS/100ML			N18911	004	Jan 30, 1985	May	CAHN
		HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
		@ HOSPIRA	5,000 UNITS/100ML			N18916	009	Jan 31, 1984	May	CAHN
		HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%								
		@ HOSPIRA	100 UNITS/ML			N18911	002	Jan 30, 1985	May	CAHN
		@	100 UNITS/ML			N18916	004	Jan 31, 1984	May	CAHN
		HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%								
		@ HOSPIRA	1,000 UNITS/100ML			N18916	001	Jan 31, 1984	May	CAHN
		HEPARIN SODIUM PRESERVATIVE FREE								
	+	HOSPIRA	2,000 UNITS/ML			N05264	013	Apr 07, 1986	May	CAHN
AP	+		2,500 UNITS/ML			N05264	014	Apr 07, 1986	May	CAHN
AP	+		10,000 UNITS/ML			N89522	001	May 04, 1987	May	CAHN
		@ MARSAM PHARMS LLC	1,000 UNITS/ML			N89464	001	Jun 03, 1986	Sep	DISC
		PANHEPRIN								
		@ HOSPIRA	1,000 UNITS/ML			N05264	004		May	CAHN
		@	5,000 UNITS/ML			N05264	006		May	CAHN
		@	10,000 UNITS/ML			N05264	007		May	CAHN
		@	20,000 UNITS/ML			N05264	008		May	CAHN
		@	40,000 UNITS/ML			N05264	009		May	CAHN

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS
VANTAS

	+	VALERA	50MG			N21732	001	Oct 12, 2004	Oct	NEWA
--	---	--------	------	--	--	--------	-----	--------------	-----	------

HYALURONIDASE

INJECTABLE; INJECTION
VITRASE

	+	ISTA PHARMS	6,200 UNITS/VIAL			N21640	001	May 05, 2004	May	NEWA
--	---	-------------	------------------	--	--	--------	-----	--------------	-----	------

INJECTABLE; SUBCUTANEOUS
AMPHADASE

	+	AMPHASTAR PHARM	150 UNITS/ML			N21665	001	Oct 26, 2004	Oct	NEWA
--	---	-----------------	--------------	--	--	--------	-----	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

	@	MUTUAL PHARM	10MG			N88728	001	Apr 11, 1985	Aug	CAHN
--	---	--------------	------	--	--	--------	-----	--------------	-----	------

	@		25MG			N84106	002		Aug	CAHN
--	---	--	------	--	--	--------	-----	--	-----	------

	@		50MG			N84107	002		Aug	CAHN
--	---	--	------	--	--	--------	-----	--	-----	------

	@		100MG			N88729	001	Apr 11, 1985	Aug	CAHN
--	---	--	-------	--	--	--------	-----	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

	@	MUTUAL PHARM	25MG; 15MG; 0.1MG			N88570	001	Apr 10, 1984	Aug	CAHN
--	---	--------------	-------------------	--	--	--------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

	@	MUTUAL PHARM	25MG			N83972	001		Aug	CAHN
--	---	--------------	------	--	--	--------	-----	--	-----	------

	@		50MG			N83972	002		Aug	CAHN
--	---	--	------	--	--	--------	-----	--	-----	------

	@		100MG			N83972	003		Aug	CAHN
--	---	--	-------	--	--	--------	-----	--	-----	------

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	APOTEX	12.5MG;10MG	N76674 001	Oct 05, 2004	Oct	NEWA
AB		12.5MG;20MG	N76674 002	Oct 05, 2004	Oct	NEWA
AB		25MG;20MG	N76674 003	Oct 05, 2004	Oct	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

AB	NOVARTIS	25MG;50MG	N18303 001	Dec 31, 1984	Aug	CFTG
AB		25MG;100MG	N18303 002	Dec 31, 1984	Aug	CFTG
AB	+	50MG;100MG	N18303 003	Dec 31, 1984	Aug	CFTG

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	25MG;50MG	N76792 001	Aug 20, 2004	Aug	NEWA
AB		25MG;100MG	N76792 002	Aug 20, 2004	Aug	NEWA
AB		50MG;100MG	N76792 003	Aug 20, 2004	Aug	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

AB	PFIZER PHARMS	12.5MG;EQ 10MG BASE	N20125 001	Dec 28, 1999	Mar	CFTG
AB		12.5MG;EQ 20MG BASE	N20125 002	Dec 28, 1999	Mar	CFTG
AB	+	25MG;EQ 20MG BASE	N20125 003	Dec 28, 1999	Mar	CFTG

QUINARETIC

AB	AMIDE PHARM	12.5MG;EQ 10MG BASE	N76374 001	Mar 31, 2004	Mar	NEWA
AB		12.5MG;EQ 20MG BASE	N76374 002	Mar 31, 2004	Mar	NEWA
AB		25MG;EQ 20MG BASE	N76374 003	Mar 31, 2004	Mar	NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	MUTUAL PHARM	25MG;25MG	N87267 001		Aug	CAHN
----	--------------	-----------	------------	--	-----	------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

BOEHRINGER INGELHEIM 12.5MG;80MG

+ 25MG;80MG

N21162 002	Nov 17, 2000	May	CRLD
N21162 003	Apr 19, 2004	May	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

+ INTERPHARM 5MG;200MG

AB 7.5MG;200MG

N76642 002	Mar 18, 2004	Mar	NEWA
N76642 001	Oct 12, 2004	Oct	NEWA

HYDROCORTISONE

CREAM; TOPICAL

ANUSOL HC

>D> AT PARKEDALE 2.5%

>A> AT SALIX PHARMS 2.5%

HYDROCORTISONE

AT VINTAGE PHARMS 2.5%

N88250 001	Jun 06, 1984	Nov	CAHN
N88250 001	Jun 06, 1984	Nov	CAHN

N40503 001	Mar 12, 2004	Mar	NEWA
------------	--------------	-----	------

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%

BX	BOCA PHARMA	1%;1%	N89440 001	May 17, 1986	Apr	CAHN
----	-------------	-------	------------	--------------	-----	------

HYDROCORTISONE BUTYRATE

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATE

AT	TARO PHARM INDS	0.1%	N76364 001	Jan 14, 2004	Jan	NEWA
----	-----------------	------	------------	--------------	-----	------

LOCOID

AT	+ FERNDALE LABS	0.1%	N19116 001	Feb 25, 1987	Jan	CFTG
----	-----------------	------	------------	--------------	-----	------

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

AP	HOSPIRA	EQ 100MG BASE/VIAL	N85929 001		May	CAHN
----	---------	--------------------	------------	--	-----	------

AP		EQ 250MG BASE/VIAL	N85930 001		May	CAHN
----	--	--------------------	------------	--	-----	------

AP		EQ 500MG BASE/VIAL	N85931 001		May	CAHN
----	--	--------------------	------------	--	-----	------

AP		EQ 1GM BASE/VIAL	N85932 001		May	CAHN
----	--	------------------	------------	--	-----	------

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

	PURDUE PHARMA LP	12MG	N21044 001	Sep 24, 2004	Sep	NEWA
--	------------------	------	------------	--------------	-----	------

+		16MG	N21044 002	Sep 24, 2004	Sep	NEWA
---	--	------	------------	--------------	-----	------

		24MG	N21044 003	Sep 24, 2004	Sep	NEWA
--	--	------	------------	--------------	-----	------

		32MG	N21044 004	Sep 24, 2004	Sep	NEWA
--	--	------	------------	--------------	-----	------

INJECTABLE; INJECTION

HYDROMORPHONE HCL

AP	HOSPIRA	10MG/ML	N74598 001	Jun 19, 1997	May	CAHN
----	---------	---------	------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

AP	HOSPIRA	25MG/ML	N87416 001		May	CAHN
----	---------	---------	------------	--	-----	------

	@	50MG/ML	N86821 001		May	CAHN
--	---	---------	------------	--	-----	------

AP		50MG/ML	N87546 001		May	CAHN
----	--	---------	------------	--	-----	------

TABLET; ORAL

HYDROXYZINE HCL

AB	ABLE	10MG	N40559 001	Jul 22, 2004	Jul	NEWA
----	------	------	------------	--------------	-----	------

AB		25MG	N40562 001	Jul 22, 2004	Jul	NEWA
----	--	------	------------	--------------	-----	------

AB		50MG	N40563 001	Jul 22, 2004	Jul	NEWA
----	--	------	------------	--------------	-----	------

	@ MUTUAL PHARM	10MG	N88409 001	Nov 15, 1983	Aug	CAHN
--	----------------	------	------------	--------------	-----	------

	@	25MG	N87857 001	Apr 18, 1983	Aug	CAHN
--	---	------	------------	--------------	-----	------

	@	50MG	N87860 001	Apr 18, 1983	Aug	CAHN
--	---	------	------------	--------------	-----	------

	@	100MG	N87862 001	Apr 18, 1983	Aug	CAHN
--	---	-------	------------	--------------	-----	------

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

AB	FERRIGO R AND D	100MG/5ML	N76925 001	Sep 23, 2004	Sep	NEWA
----	-----------------	-----------	------------	--------------	-----	------

TABLET; ORAL

IBUPROFEN

	@ MUTUAL PHARM	400MG	N70079 001	Jul 24, 1985	Aug	CAHN
--	----------------	-------	------------	--------------	-----	------

	@	600MG	N70080 001	Jul 24, 1985	Aug	CAHN
--	---	-------	------------	--------------	-----	------

TABLET; ORAL

IBUPROFEN

@ MUTUAL PHARM

800MG

N71448 001 Feb 18, 1987 Aug CAHN

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

+ FOREST LABS

450MG;5MG

N21378 001 Nov 26, 2004 Nov NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HCL

+ GENSLA SICOR PHARMS

5MG/VIAL

N65037 003 May 01, 2002 Feb CTEC

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE

AP + HOSPIRA

EQ 5MG BASE/ML

N74616 001 Aug 03, 1998 May CAHN

INDIUM IN 111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

+ AMERSHAM

2mCi/0.2ML

N19862 001 Dec 29, 1992 Nov CMS1

INDIUM IN 111 CHLORIDE

+ MALLINCKRODT

5mCi/0.5ML

N19841 001 Sep 27, 1994 Nov CMS1

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

@ MUTUAL PHARM

25MG

N70067 001 Oct 03, 1986 Aug CAHN

@

50MG

N70068 001 Oct 03, 1986 Aug CAHN

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

+ NOVO NORDISK

100 UNITS/ML

N20986 001 Jun 07, 2000 May CAIN

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

+ AVENTIS PHARMS

100 UNITS/ML

N21081 001 Apr 20, 2000 May CAIN

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA

@ AVENTIS PHARMS

100 UNITS/ML

N21629 001 Apr 16, 2004 Jun DISC

+

100 UNITS/ML

N21629 001 Apr 16, 2004 Apr NEWA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50

+ LILLY

50 UNITS/ML;50 UNITS/ML

N21018 001 Dec 22, 1999 May CAIN

HUMALOG MIX 75/25

+ LILLY

75 UNITS/ML;25 UNITS/ML

N21017 001 Dec 22, 1999 May CAIN

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG

+ LILLY 100 UNITS/ML N20563 001 Jun 14, 1996 May CAIN

HUMALOG PEN

+ LILLY 100 UNITS/ML N20563 002 Aug 06, 1998 May CAIN

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

GE HEALTHCARE 55% N20808 001 Aug 29, 1997 Jun CMFD

VISIPAQUE 320

GE HEALTHCARE 65.2% N20808 002 Aug 29, 1997 Jun CMFD

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

AP HOSPIRA 41% N74898 001 Dec 30, 1997 May CAHN

IOPAMIDOL-200 IN PLASTIC CONTAINER

AP HOSPIRA 41% N74636 001 Dec 30, 1997 May CAHN

IOPAMIDOL-250

AP HOSPIRA 51% N74898 002 Dec 30, 1997 May CAHN

AP 51% N75005 001 Feb 24, 1998 May CAHN

IOPAMIDOL-250 IN PLASTIC CONTAINER

AP HOSPIRA 51% N74636 002 Dec 30, 1997 May CAHN

IOPAMIDOL-300

AP HOSPIRA 61% N74898 003 Dec 30, 1997 May CAHN

AP 61% N75005 002 Feb 24, 1998 May CAHN

IOPAMIDOL-300 IN PLASTIC CONTAINER

AP HOSPIRA 61% N74636 003 Dec 30, 1997 May CAHN

AP 61% N74637 001 Apr 03, 1997 May CAHN

IOPAMIDOL-370

AP HOSPIRA 76% N74898 004 Dec 30, 1997 May CAHN

AP 76% N75005 003 Feb 24, 1998 May CAHN

IOPAMIDOL-370 IN PLASTIC CONTAINER

AP HOSPIRA 76% N74636 004 Dec 30, 1997 May CAHN

IOPANOIC ACID

TABLET; ORAL

TELEPAQUE

@ GE HEALTHCARE 500MG N08032 001 May DISC

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+ BERLEX 49.9% N21425 003 Mar 12, 2004 Mar NEWA

+ 62.3% N21425 001 Sep 20, 2002 Mar CPOT

+ 76.9% N21425 002 Sep 20, 2002 Mar CPOT

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION

VASCORAY

@ MALLINCKRODT 52%; 26% N16783 001 Jun DISC

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

>A>	+ BOEHRINGER INGELHEIM	0.021MG/INH	N21527 001	Nov 27, 2004	Nov	NEWA
-----	------------------------	-------------	------------	--------------	-----	------

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

AN	HOLOPACK INTL	0.02%	N75693 001	Jan 26, 2001	Apr	CAHN
----	---------------	-------	------------	--------------	-----	------

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

AN	HOSPIRA	99.9%	N74097 001	Jan 25, 1993	May	CAHN
----	---------	-------	------------	--------------	-----	------

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

+ SANDOZ	100MG/ML	N08662 001		Feb	CAHN
----------	----------	------------	--	-----	------

TABLET; ORAL

ISONIAZID

@ MUTUAL PHARM	100MG	N80136 001		Aug	CAHN
----------------	-------	------------	--	-----	------

AA		300MG	N83633 001		Aug	CAHN
----	--	-------	------------	--	-----	------

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HCL

AP	HOSPIRA	0.02MG/ML	N83283 001		May	CAHN
----	---------	-----------	------------	--	-----	------

		0.2MG/ML	N83346 001		May	CAHN
--	--	----------	------------	--	-----	------

ISUPREL

AP	+ HOSPIRA	0.2MG/ML	N10515 001		May	CAHN
----	-----------	----------	------------	--	-----	------

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

@ MUTUAL PHARM	5MG	N86166 002	Sep 19, 1986	Aug	CAHN
----------------	-----	------------	--------------	-----	------

@	10MG	N86169 001	Sep 19, 1986	Aug	CAHN
---	------	------------	--------------	-----	------

@	20MG	N86167 001	Sep 19, 1986	Aug	CAHN
---	------	------------	--------------	-----	------

@	30MG	N87564 001	Sep 18, 1986	Aug	CAHN
---	------	------------	--------------	-----	------

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@ MUTUAL PHARM	2.5MG	N84204 001	Sep 18, 1986	Aug	CAHN
----------------	-------	------------	--------------	-----	------

@	5MG	N86168 001	Sep 18, 1986	Aug	CAHN
---	-----	------------	--------------	-----	------

@	10MG	N87545 001	Sep 18, 1986	Aug	CAHN
---	------	------------	--------------	-----	------

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

IMDUR

AB	SCHERING PLOUGH	30MG	N20225 001	Aug 12, 1993	Apr	CRLD
----	-----------------	------	------------	--------------	-----	------

AB		60MG	N20225 002	Aug 12, 1993	Apr	CRLD
----	--	------	------------	--------------	-----	------

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

AB	EON	100MG	N76104 001	May 28, 2004	May	NEWA
----	-----	-------	------------	--------------	-----	------

SPORANOX

AB	+ JANSSEN PHARMA	100MG	N20083 001	Sep 11, 1992	May	CFTG
----	------------------	-------	------------	--------------	-----	------

ST. LOUIS COLLEGE OF PHARMACY LIBRARY

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HCL

AP	HOSPIRA	EQ 50MG BASE/ML	N74549 001	Jun 27, 1996	May	CAHN
AP		EQ 100MG BASE/ML	N74549 002	Jun 27, 1996	May	CAHN

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB	ALTANA	2%	N76294 001	Apr 28, 2004	Apr	NEWA
AB	+ TEVA	2%	N75581 001	Apr 25, 2000	Apr	CRLD

NIZORAL

@ JANSSEN PHARMA

		2%	N19084 001	Dec 31, 1985	Apr	DISC
--	--	----	------------	--------------	-----	------

SHAMPOO; TOPICAL

KETOCONAZOLE

AB	CLAY PARK	2%	N76419 001	Jan 07, 2004	Jan	NEWA
----	-----------	----	------------	--------------	-----	------

NIZORAL

AB	+ MCNEIL CONS SPECLT	2%	N19927 001	Aug 31, 1990	Jan	CFTG
----	----------------------	----	------------	--------------	-----	------

SUSPENSION; ORAL

NIZORAL

@ JANSSEN PHARMA

		100MG/5ML	N70767 001	Nov 07, 1986	Jul	CAHN
--	--	-----------	------------	--------------	-----	------

TABLET; ORAL

NIZORAL

AB	+ JANSSEN PHARMA	200MG	N18533 001		Jul	CAHN
----	------------------	-------	------------	--	-----	------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	AMPHASTAR PHARM	15MG/ML	N76209 001	Jul 21, 2004	Jul	NEWA
AP		30MG/ML	N76209 002	Jul 21, 2004	Jul	NEWA
AP	APOTEX	15MG/ML	N76722 001	Jul 27, 2004	Jul	NEWA
AP		30MG/ML	N76722 002	Jul 27, 2004	Jul	NEWA
AP	BAXTER HLTHCARE	15MG/ML	N75772 001	Jul 21, 2004	Jul	NEWA
AP		30MG/ML	N75772 002	Jul 21, 2004	Jul	NEWA
AP	+ BEDFORD	15MG/ML	N75222 001	Apr 26, 1999	Jan	CRLD
AP	+ @ HOSPIRA	30MG/ML	N75222 002	Apr 26, 1999	Jan	CRLD
		15MG/ML	N74801 001	Jun 05, 1997	May	CAHN
AP		15MG/ML	N74802 001	Jun 05, 1997	May	CAHN
AP		15MG/ML	N74993 001	Jan 27, 1999	May	CAHN
	@	30MG/ML	N74801 002	Jun 05, 1997	May	CAHN
AP		30MG/ML	N74802 002	Jun 05, 1997	May	CAHN
AP		30MG/ML	N74993 002	Jan 27, 1999	May	CAHN
AP	SABEX 2002	15MG/ML	N76271 001	Oct 06, 2004	Oct	NEWA
AP		30MG/ML	N76271 002	Oct 06, 2004	Oct	NEWA
	TORADOL					
	@ ROCHE PALO	15MG/ML	N19698 001	Nov 30, 1989	Jan	DISC
	@	30MG/ML	N19698 002	Nov 30, 1989	Jan	DISC

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ZADITOR

+	NOVARTIS	EQ 0.025% BASE	N21066 001	Jul 02, 1999	Feb	CAHN
---	----------	----------------	------------	--------------	-----	------

LABELALOL HYDROCHLORIDE

AP	INJECTABLE; INJECTION						
	LABELALOL HCL						
	HOSPIRA	5MG/ML	N75239	001	Nov 29, 1999	May	CAHN
AP		5MG/ML	N75240	001	Nov 29, 1999	May	CAHN
	NORMODYNE						
	@ SCHERING	5MG/ML	N18686	001	Aug 01, 1984	Sep	DISC
	TABLET; ORAL						
	NORMODYNE						
	@ SCHERING	100MG	N18687	001	Aug 31, 1987	Sep	DISC
	@	200MG	N18687	002	Aug 01, 1984	Sep	DISC
	@	300MG	N18687	003	Aug 01, 1984	Sep	DISC
	TRANDATE						
AB	+ PROMETHEUS LABS	300MG	N18716	003	Aug 01, 1984	Sep	CRLD

LAMIVUDINE

AP	TABLET; ORAL						
	EPIVIR						
	GLAXOSMITHKLINE	150MG	N20564	001	Nov 17, 1995	May	CRLD
	+	300MG	N20564	003	Jun 24, 2002	May	CRLD

LAMOTRIGINE

AP	TABLET; ORAL						
	LAMICTAL						
	+ GLAXOSMITHKLINE	25MG	N20241	005	Dec 27, 1994	Apr	CRLD
		200MG	N20241	003	Dec 27, 1994	Apr	CRLD

LANSOPRAZOLE

AP	FOR SUSPENSION, DELAYED RELEASE; ORAL						
	PREVACID						
	TAP PHARM	15MG/PACKET	N21281	001	May 03, 2001	Jul	CDFR
	+	30MG/PACKET	N21281	002	May 03, 2001	Jul	CDFR
	INJECTABLE; INTRAVENOUS						
	PREVACID IV						
	+ TAP PHARM	30MG/VIAL	N21566	001	May 27, 2004	May	NEWA
	TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL						
	PREVACID						
	TAP PHARM	15MG	N21428	001	Aug 30, 2002	Jul	CDFR
	+	30MG	N21428	002	Aug 30, 2002	Jul	CDFR

LANTHANUM CARBONATE

AP	TABLET, CHEWABLE; ORAL						
	FOSRENOL						
	SHIRE PHARM	250MG	N21468	001	Oct 26, 2004	Oct	NEWA
	+	500MG	N21468	002	Oct 26, 2004	Oct	NEWA

LEFLUNOMIDE

AP	TABLET; ORAL						
	ARAVA						
	+ AVENTIS PHARMS	100MG	N20905	003	Sep 10, 1998	Jul	CMFD

LEUCOVORIN CALCIUM

AP	INJECTABLE; INJECTION						
	LEUCOVORIN CALCIUM						
	@ PHARMACHEMIE USA	EQ 100MG BASE/VIAL	N89915	001	Apr 17, 1997	Aug	DISC

INJECTABLE; INJECTION						
LEUCOVORIN CALCIUM PRESERVATIVE FREE						
AP	BIGMAR BIOREN PHARMS	EQ 200MG BASE/VIAL	N40258 001	Feb 26, 1999	Jul	CAHN
+		EQ 500MG BASE/VIAL	N40286 001	Feb 26, 1999	Jul	CAHN
AP	HOSPIRA	EQ 10MG BASE/ML	N40147 001	Jun 25, 1997	May	CAHN
<u>LEVOBUPIVACAINE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
CHIROCAINE						
	@ PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N20997 001	Aug 05, 1999	May	DISC
	@	EQ 5MG BASE/ML	N20997 002	Aug 05, 1999	May	DISC
	@	EQ 7.5MG BASE/ML	N20997 003	Aug 05, 1999	May	DISC
<u>LEVOCABASTINE HYDROCHLORIDE</u>						
SUSPENSION/DROPS; OPHTHALMIC						
LIVOSTIN						
+	NOVARTIS	EQ 0.05% BASE	N20219 001	Nov 10, 1993	Feb	CAHN
<u>LEVOCARNITINE</u>						
SOLUTION; ORAL						
CARNITOR						
AA	+ SIGMA TAU	1GM/10ML	N19257 001	Apr 10, 1986	Aug	CFTG
AA	LEVOCARNITINE					
AA	LYNE	1GM/10ML	N76851 001	Aug 10, 2004	Aug	NEWA
TABLET; ORAL						
CARNITOR						
AB	+ SIGMA TAU	330MG	N18948 001	Dec 27, 1985	Sep	CFTG
AB	LEVOCARNITINE					
AB	COREPHARMA	330MG	N76858 001	Sep 20, 2004	Sep	NEWA
<u>LEVOFLOXACIN</u>						
SOLUTION/DROPS; OPHTHALMIC						
IQUIX						
+	SANTEN	1.5%	N21571 001	Mar 01, 2004	Mar	NEWA
SOLUTION; ORAL						
LEVAQUIN						
+	ORTHO MCNEIL PHARM	250MG/10ML	N21721 001	Oct 21, 2004	Oct	NEWA
TABLET; ORAL						
LEVAQUIN						
AB	ORTHO MCNEIL PHARM	250MG	N20634 001	Dec 20, 1996	Oct	CFTG
AB		500MG	N20634 002	Dec 20, 1996	Oct	CFTG
LEVOFLOXACIN						
AB	MYLAN	250MG	N76276 001	Oct 15, 2004	Oct	NEWA
AB		500MG	N76276 002	Oct 15, 2004	Oct	NEWA
<u>LEVONORGESTREL</u>						
TABLET; ORAL						
PLAN B						
+	DURAMED	0.75MG	N21045 001	Jul 28, 1999	Feb	CAHN
<u>LEVOTHYROXINE SODIUM</u>						
TABLET; ORAL						
LEVOLET						
BX	VINTAGE	0.025MG	N21137 001	Jun 06, 2003	Jul	CAHN
BX		0.05MG	N21137 002	Jun 06, 2003	Jul	CAHN
BX		0.075MG	N21137 003	Jun 06, 2003	Jul	CAHN
BX		0.088MG	N21137 004	Jun 06, 2003	Jul	CAHN

Product Name	Strength	Manufacturer	Product Code	Start Date	End Date	Agency
TABLET; ORAL						
LEVOLET						
VINTAGE						
BX	0.1MG		N21137 005	Jun 06, 2003	Jul	CAHN
BX	0.112MG		N21137 006	Jun 06, 2003	Jul	CAHN
BX	0.125MG		N21137 007	Jun 06, 2003	Jul	CAHN
BX	0.137MG		N21137 008	Jun 06, 2003	Jul	CAHN
BX	0.15MG		N21137 009	Jun 06, 2003	Jul	CAHN
BX	0.175MG		N21137 010	Jun 06, 2003	Jul	CAHN
BX	0.2MG		N21137 011	Jun 06, 2003	Jul	CAHN
BX	0.3MG		N21137 012	Jun 06, 2003	Jul	CAHN
LEVO-T						
ALARA PHARM						
AB2, AB3	0.025MG		N21342 001	Mar 01, 2002	Jun	CTEC
AB2, AB3	0.05MG		N21342 002	Mar 01, 2002	Jun	CTEC
AB2, AB3	0.075MG		N21342 003	Mar 01, 2002	Jun	CTEC
AB2, AB3	0.088MG		N21342 004	Mar 01, 2002	Jun	CTEC
AB2, AB3	0.1MG		N21342 005	Mar 01, 2002	Jun	CTEC
AB2, AB3	0.112MG		N21342 006	Mar 01, 2002	Jun	CTEC
AB2, AB3	0.125MG		N21342 007	Mar 01, 2002	Jun	CTEC
AB2, AB3	0.137MG		N21342 012	Dec 08, 2003	Jun	CTEC
AB2, AB3	0.15MG		N21342 008	Mar 01, 2002	Jun	CTEC
AB2, AB3	0.175MG		N21342 009	Mar 01, 2002	Jun	CTEC
AB2, AB3	0.2MG		N21342 010	Mar 01, 2002	Jun	CTEC
AB2, + AB3	0.3MG		N21342 011	Mar 01, 2002	Jun	CTEC
LEVOTHYROXINE SODIUM						
MYLAN						
AB1, AB2, AB3	0.025MG		N76187 001	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.05MG		N76187 002	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.075MG		N76187 003	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.088MG		N76187 004	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.1MG		N76187 005	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.112MG		N76187 006	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.125MG		N76187 007	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.15MG		N76187 008	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.175MG		N76187 009	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.2MG		N76187 010	Jun 05, 2002	Jun	CTEC
AB1, AB2, AB3	0.3MG		N76187 011	Jun 05, 2002	Jun	CTEC

ST. LOUIS COLLEGE OF PHARMACY

TABLET; ORAL

AB1, AB3	LEVOXYL							
AB1, AB3	JONES PHARMA	0.025MG	N21301 001	May 25, 2001	Jun	CTEC		
AB1, AB3		0.05MG	N21301 002	May 25, 2001	Jun	CTEC		
AB1, AB3		0.075MG	N21301 003	May 25, 2001	Jun	CTEC		
AB1, AB3		0.088MG	N21301 004	May 25, 2001	Jun	CTEC		
AB1, AB3		0.1MG	N21301 005	May 25, 2001	Jun	CTEC		
AB1, AB3		0.112MG	N21301 006	May 25, 2001	Jun	CTEC		
AB1, AB3		0.125MG	N21301 007	May 25, 2001	Jun	CTEC		
AB3		0.137MG	N21301 008	May 25, 2001	Jul	CTEC		
AB1, AB3		0.137MG	N21301 008	May 25, 2001	Jun	CTEC		
AB1, AB3		0.15MG	N21301 009	May 25, 2001	Jun	CTEC		
AB1, AB3		0.175MG	N21301 010	May 25, 2001	Jun	CTEC		
AB1, AB3		0.2MG	N21301 011	May 25, 2001	Jun	CTEC		
AB1, + AB3		0.3MG	N21301 012	May 25, 2001	Jun	CTEC		
	SYNTHROID							
AB2	ABBOTT	0.025MG	N21402 001	Jul 24, 2002	Jun	CFTG		
AB2		0.05MG	N21402 002	Jul 24, 2002	Jun	CFTG		
AB2		0.075MG	N21402 003	Jul 24, 2002	Jun	CFTG		
AB2		0.088MG	N21402 004	Jul 24, 2002	Jun	CFTG		
AB2		0.1MG	N21402 005	Jul 24, 2002	Jun	CFTG		
AB2		0.112MG	N21402 006	Jul 24, 2002	Jun	CFTG		
AB2		0.125MG	N21402 007	Jul 24, 2002	Jun	CFTG		
AB2		0.137MG	N21402 008	Jul 24, 2002	Jun	CFTG		
AB2		0.15MG	N21402 009	Jul 24, 2002	Jun	CFTG		
AB2		0.175MG	N21402 010	Jul 24, 2002	Jun	CFTG		
AB2		0.2MG	N21402 012	Jul 24, 2002	Jun	CFTG		
AB2 +		0.3MG	N21402 011	Jul 24, 2002	Jun	CFTG		
	THYRO-TABS							
>A> BX	LLOYD	0.137MG	N21116 012	Dec 07, 2004	Nov	NEWA		
	UNITHROID							
>D> AB1, AB3	STEVENS J	0.025MG	N21210 001	Aug 21, 2000	Nov	CTEC		
>A> AB1, AB2, AB3		0.025MG	N21210 001	Aug 21, 2000	Nov	CTEC		
>D> AB1, AB3		0.05MG	N21210 002	Aug 21, 2000	Nov	CTEC		
>A> AB1, AB2, AB3		0.05MG	N21210 002	Aug 21, 2000	Nov	CTEC		
>D> AB1, AB3		0.075MG	N21210 003	Aug 21, 2000	Nov	CTEC		
>A> AB1, AB2, AB3		0.075MG	N21210 003	Aug 21, 2000	Nov	CTEC		
>D> AB1, AB3		0.088MG	N21210 004	Aug 21, 2000	Nov	CTEC		
>A> AB1, AB2, AB3		0.088MG	N21210 004	Aug 21, 2000	Nov	CTEC		
>D> AB1, AB3		0.1MG	N21210 005	Aug 21, 2000	Nov	CTEC		

TABLET; ORAL
UNITHROID

CTEC	>A>	AB1, AB2, AB3	0.1MG	N21210 005	Aug 21, 2000	Nov	CTEC
CTEC	>D>	AB1, AB3	0.112MG	N21210 006	Aug 21, 2000	Nov	CTEC
CTEC	>A>	AB1, AB2, AB3	0.112MG	N21210 006	Aug 21, 2000	Nov	CTEC
CTEC	>D>	AB1, AB3	0.125MG	N21210 007	Aug 21, 2000	Nov	CTEC
CTEC	>A>	AB1, AB2, AB3	0.125MG	N21210 007	Aug 21, 2000	Nov	CTEC
CTEC	>D>	AB1, AB3	0.15MG	N21210 008	Aug 21, 2000	Nov	CTEC
CTEC	>A>	AB1, AB2, AB3	0.15MG	N21210 008	Aug 21, 2000	Nov	CTEC
CTEC	>D>	AB1, AB3	0.175MG	N21210 009	Aug 21, 2000	Nov	CTEC
CTEC	>A>	AB1, AB2, AB3	0.175MG	N21210 009	Aug 21, 2000	Nov	CTEC
CTEC	>D>	AB1, AB3	0.2MG	N21210 010	Aug 21, 2000	Nov	CTEC
CFTG	>A>	AB1, AB2, AB3	0.2MG	N21210 010	Aug 21, 2000	Nov	CTEC
CFTG	>D>	AB1, + AB3	0.3MG	N21210 011	Aug 21, 2000	Nov	CTEC
CFTG	>A>	AB1, + AB2, AB3	0.3MG	N21210 011	Aug 21, 2000	Nov	CTEC

LIDOCAINE

PATCH; TOPICAL
LIDODERM

CFTG	+ TEIKOKU PHARMA USA	5%	N20612 001	Mar 19, 1999	Sep	CDFR
------	----------------------	----	------------	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NEWA	LIDOCAINE HCL @ BAXTER HLTHCARE	1%	N80407 001		Aug	CAHN
CTEC	@	2%	N80407 002		Aug	CAHN
CTEC	AP HOSPIRA	0.5%	N88328 001	May 17, 1984	May	CAHN
CTEC	AP	1%	N40013 001	Jun 23, 1995	May	CAHN
CTEC	AP	1%	N83158 001		May	CAHN
CTEC	AP	1%	N88329 001	May 17, 1984	May	CAHN
CTEC	@	1.5%	N88330 001	May 17, 1984	May	CAHN
CTEC	AP	2%	N40078 001	Jun 23, 1995	May	CAHN
CTEC	AP	2%	N83158 002		May	CAHN
CTEC	AP	2%	N88294 001	May 17, 1984	May	CAHN
CTEC	AP	2%	N88331 001	May 17, 1984	May	CAHN
CTEC	AP	20%	N83158 003		May	CAHN
CTEC	LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER @ B BRAUN	200MG/100ML	N18967 001	Mar 30, 1984	Apr	DISC
CTEC	LIDOCAINE HCL 0.2% IN DEXTROSE 5% HOSPIRA	200MG/100ML	N83158 005		May	CAHN
CTEC	LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	200MG/100ML	N18388 001		May	CAHN
CTEC	LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER @ B BRAUN	400MG/100ML	N18967 002	Mar 30, 1984	Apr	DISC

INJECTABLE; INJECTION

	LIDOCAINE HCL 0.4% IN DEXTROSE 5%							
AP	HOSPIRA	400MG/100ML			N83158	006		May CAHN
	LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	HOSPIRA	400MG/100ML			N18388	002		May CAHN
	LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER @ B BRAUN	800MG/100ML			N18967	003	Mar 30, 1984	Apr DISC
	LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	HOSPIRA	800MG/100ML			N18388	003	Nov 05, 1982	May CAHN
	LIDOCAINE HCL IN PLASTIC CONTAINER							
AP	HOSPIRA	0.5%			N88325	001	Jul 31, 1984	May CAHN
AP		1%			N88299	001	Jul 31, 1984	May CAHN
AP		1.5%			N88326	001	Jul 31, 1984	May CAHN
AP		2%			N88327	001	Jul 31, 1984	May CAHN
AP		10%			N88367	001	Jul 31, 1984	May CAHN
AP		20%			N88368	001	Jul 31, 1984	May CAHN
	LIDOCAINE HCL PRESERVATIVE FREE							
AP	HOSPIRA	1%			N80408	001		May CAHN
AP		1.5%			N80408	002		May CAHN
AP		4%			N88295	001	May 17, 1984	May CAHN
	LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER							
AP	HOSPIRA	1%			N40302	001	Sep 28, 1998	May CAHN
AP		2%			N40302	002	Sep 28, 1998	May CAHN

INJECTABLE; SPINAL

LIDOCAINE HCL 5% AND DEXTROSE 7.5%

+ HOSPIRA 5% N83914 001 May CAHN

SOLUTION; TOPICAL

LTA II KIT

AT	HOSPIRA	4%			N80409	001		May CAHN
AT		4%			N88542	001	Jul 31, 1984	May CAHN
	PEDIATRIC LTA KIT							
AT	HOSPIRA	2%			N85995	001		May CAHN

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN

+	PFIZER	2%;50MG/ML			N60567	001		Feb CRLD
+		2%;125MG/ML			N60567	002		Feb CRLD

LIDOCAINE; PRILOCAINE

>D>	DISC; TOPICAL							
>D>	EMLA							
>D>	+ ASTRAZENECA	2.5%;2.5%			N20962	001	Feb 04, 1998	Nov DISC
>A>	@	2.5%;2.5%			N20962	001	Feb 04, 1998	Nov DISC

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB	ABLE	150MG			N76823	001	Jun 29, 2004	Jun NEWA
AB		300MG			N76823	002	Jun 29, 2004	Jun NEWA
AB		600MG			N76823	003	Jun 29, 2004	Jun NEWA
>A>	AB	APOTEX	300MG		N76795	001	Nov 22, 2004	Nov NEWA
AB	+ ROXANE	600MG			N17812	003	Jan 28, 1987	Jun CFTG
	TABLET, EXTENDED RELEASE; ORAL							
	LITHIUM CARBONATE							
AB	ROXANE	300MG			N76832	001	Oct 28, 2004	Oct NEWA
AB		450MG			N76691	001	Jan 05, 2004	Jan NEWA

CAHN	AB	+	JDS PHARMS	300MG	N18027 001	Sep	CAHN
TABLET, EXTENDED RELEASE; ORAL							
LITHOBID							
<u>LOPERAMIDE HYDROCHLORIDE</u>							
SOLUTION; ORAL							
DISC			IMODIUM				
CAHN			@ JANSSEN PHARMA	1MG/5ML	N19037 001	Jul 31, 1984	Jul CAHN
<u>LORAZEPAM</u>							
INJECTABLE; INJECTION							
LORAZEPAM							
CAHN	AP		BAXTER HLTHCARE	2MG/ML	N74496 001	Sep 28, 1998	Aug CAHN
CAHN			@	2MG/ML	N74496 001	Sep 28, 1998	Sep DISC
CAHN	AP			4MG/ML	N74496 002	Sep 28, 1998	Aug CAHN
CAHN			@	4MG/ML	N74496 002	Sep 28, 1998	Sep DISC
CAHN	AP		HOSPIRA	2MG/ML	N74243 001	Apr 12, 1994	May CAHN
CAHN	AP			2MG/ML	N74280 001	May 27, 1994	May CAHN
CAHN	AP			2MG/ML	N74282 001	May 27, 1994	May CAHN
CAHN	AP			2MG/ML	N74300 001	Apr 12, 1994	May CAHN
CAHN	AP			4MG/ML	N74243 002	Apr 12, 1994	May CAHN
CAHN	AP			4MG/ML	N74280 002	May 27, 1994	May CAHN
CAHN	AP			4MG/ML	N74282 002	May 27, 1994	May CAHN
CAHN	AP			4MG/ML	N74300 003	Mar 19, 1997	May CAHN
CAHN	>A>	AP	INTL MEDICATION SYS	2MG/ML	N76150 001	Nov 15, 2004	Nov NEWA
TABLET; ORAL							
LORAZEPAM							
CAHN			@ MUTUAL PHARM	0.5MG	N70472 001	Dec 10, 1985	Aug CAHN
CAHN			@	1MG	N70473 001	Dec 10, 1985	Aug CAHN
CAHN			@	2MG	N70474 001	Dec 10, 1985	Aug CAHN
CAHN	>D>	AB	WATSON LABS	1MG	N71087 001	Mar 23, 1987	Nov DISC
CAHN	>A>		@	1MG	N71087 001	Mar 23, 1987	Nov DISC
CAHN	>D>	AB		2MG	N71088 001	Mar 23, 1987	Nov DISC
CAHN	>A>		@	2MG	N71088 001	Mar 23, 1987	Nov DISC
<u>LOVASTATIN</u>							
TABLET, EXTENDED RELEASE; ORAL							
ALTOPREV							
CRLD			ANDRX	10MG	N21316 001	Jun 26, 2002	Jul CTNA
CRLD				20MG	N21316 002	Jun 26, 2002	Jul CTNA
				40MG	N21316 003	Jun 26, 2002	Jul CTNA
			+	60MG	N21316 004	Jun 26, 2002	Jul CTNA
DISC			ANDRX LABS LLC	10MG	N21316 001	Jun 26, 2002	Sep CAHN
DISC				20MG	N21316 002	Jun 26, 2002	Sep CAHN
				40MG	N21316 003	Jun 26, 2002	Sep CAHN
			+	60MG	N21316 004	Jun 26, 2002	Sep CAHN
<u>LOVASTATIN; NIACIN</u>							
TABLET, EXTENDED RELEASE; ORAL							
ADVICOR							
NEWA			+	KOS	20MG; 500MG	Dec 17, 2001	Feb CRLD
NEWA				@	20MG; 750MG	Dec 17, 2001	Jul DISC
NEWA			+		20MG; 750MG	Dec 17, 2001	Feb CRLD
CFTG							

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE

>A>	AB	MYLAN	EQ 5MG BASE	N76762 001	Nov 01, 2004	Nov	NEWA
>A>	AB		EQ 10MG BASE	N76762 002	Nov 01, 2004	Nov	NEWA
>A>	AB		EQ 25MG BASE	N76762 003	Nov 01, 2004	Nov	NEWA
>A>	AB		EQ 50MG BASE	N76762 004	Nov 01, 2004	Nov	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

+	SERONO INC	75 IU/VIAL		N21322 001	Oct 08, 2004	Oct	NEKA
---	------------	------------	--	------------	--------------	-----	------

MAFENIDE ACETATE

FOR SOLUTION; TOPICAL

SULFAMYLLON

+	MYLAN BERTEK	5%		N19832 003	Jun 05, 1998	Aug	CAHN
---	--------------	----	--	------------	--------------	-----	------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

>D>	AP	B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML ; 530MG/100ML; 500MG/100ML	N18252 001		Nov	DISC
-----	----	---------	---	------------	--	-----	------

>A>		@	30MG/100ML; 37MG/100ML; 370MG/100ML ; 530MG/100ML; 500MG/100ML	N18252 001		Nov	DISC
-----	--	---	---	------------	--	-----	------

NORMOSOL-R IN PLASTIC CONTAINER

		HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML ; 526MG/100ML; 502MG/100ML	N17586 001		May	CAHN
--	--	---------	---	------------	--	-----	------

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

		@ HOSPIRA	14MG/100ML; 37MG/100ML; 222MG/100ML ; 526MG/100ML; 502MG/100ML	N18406 001		May	CAHN
--	--	-----------	---	------------	--	-----	------

			30MG/100ML; 37MG/100ML; 222MG/100ML ; 526MG/100ML; 502MG/100ML	N17637 002	Jul 08, 1982	May	CAHN
--	--	--	---	------------	--------------	-----	------

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

		HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML ; 526MG/100ML; 502MG/100ML	N18406 002	Jul 08, 1982	May	CAHN
--	--	---------	---	------------	--------------	-----	------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

AP		HOSPIRA	500MG/ML	N75151 001	Apr 25, 2000	May	CAHN
----	--	---------	----------	------------	--------------	-----	------

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+		HOSPIRA	1GM/100ML	N20488 001	Jul 11, 1995	May	CAHN
---	--	---------	-----------	------------	--------------	-----	------

+			2GM/100ML	N20488 002	Jul 11, 1995	May	CAHN
---	--	--	-----------	------------	--------------	-----	------

MAGNESIUM SULFATE IN PLASTIC CONTAINER

+		HOSPIRA	80MG/ML	N20309 002	Jun 24, 1994	May	CAHN
---	--	---------	---------	------------	--------------	-----	------

+			4GM/100ML	N20309 001	Jun 24, 1994	May	CAHN
---	--	--	-----------	------------	--------------	-----	------

MALATHION

LOTION; TOPICAL

OVIDE

+		TARO PHARMS NORTH	0.5%	N18613 001	Aug 02, 1982	Jun	CAHN
---	--	-------------------	------	------------	--------------	-----	------

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

		HOSPIRA	EQ 0.1MG MANGANESE/ML	N18962 001	Jun 26, 1986	May	CAHN
--	--	---------	-----------------------	------------	--------------	-----	------

MANNITOL

INJECTABLE; INJECTION					
	MANNITOL 10%				
	@ HOSPIRA	10GM/100ML	N16269 002	May	CAHN
	MANNITOL 10% IN PLASTIC CONTAINER				
AP	HOSPIRA	10GM/100ML	N19603 002	Jan 08, 1987	May CAHN
	MANNITOL 15%				
	@ HOSPIRA	15GM/100ML	N16269 003	May	CAHN
	MANNITOL 15% IN PLASTIC CONTAINER				
AP	HOSPIRA	15GM/100ML	N19603 003	Jan 08, 1990	May CAHN
	MANNITOL 20%				
	@ HOSPIRA	20GM/100ML	N16269 004	May	CAHN
	MANNITOL 20% IN PLASTIC CONTAINER				
AP	HOSPIRA	20GM/100ML	N19603 004	Jan 08, 1990	May CAHN
	MANNITOL 25%				
	@ HOSPIRA	12.5GM/50ML	N16269 005	May	CAHN
AP		12.5GM/50ML	N16269 006	Aug 25, 1994	May CAHN
	MANNITOL 5%				
	@ HOSPIRA	5GM/100ML	N16269 001	May	CAHN
	MANNITOL 5% IN PLASTIC CONTAINER				
AP	HOSPIRA	5GM/100ML	N19603 001	Jan 08, 1987	May CAHN

MANNITOL; SORBITOL

SOLUTION; IRRIGATION					
	SORBITOL-MANNITOL				
	@ HOSPIRA	540MG/100ML; 2.7GM/100ML	N80224 001	May	CAHN
	SORBITOL-MANNITOL IN PLASTIC CONTAINER				
AT	HOSPIRA	540MG/100ML; 2.7GM/100ML	N17636 001	May	CAHN
AT		540MG/100ML; 2.7GM/100ML	N18316 001	May	CAHN

MAPROTIline HYDROCHLORIDE

TABLET; ORAL					
	LUDIOMIL				
	@ NOVARTIS	25MG	N17543 001	Jun	DISC
	@	50MG	N17543 002	Jun	DISC
	@	75MG	N17543 003	Sep 30, 1982	Jun DISC
	MAPROTIline HCL				
AB	+ MYLAN	50MG	N72285 001	Oct 03, 1988	Jun CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION					
	DEPO-PROVERA				
AB	+ PHARMACIA AND UPJOHN	150MG/ML	N20246 001	Oct 29, 1992	Jul CFTG
	MEDROXYPROGESTERONE ACETATE				
AB	SICOR PHARMS	150MG/ML	N76552 001	Oct 27, 2004	Oct NEWA
AB		150MG/ML	N76553 001	Jul 28, 2004	Jul NEWA

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL					
	MEFLOQUINE HCL				
AB	ROXANE	250MG	N76523 001	Oct 01, 2004	Oct NEWA

MEGESTROL ACETATE

SUSPENSION; ORAL					
	MEGESTROL ACETATE				
>A> AB	MORTON GROVE	40MG/ML	N76721 001	Nov 01, 2004	Nov NEWA

MELOXICAM

SUSPENSION; ORAL

MOBIC

+ BOEHRINGER INGELHEIM 7.5MG/5ML N21530 001 Jun 01, 2004 Jun NEWA

MENOTROPINS (FSH;LH)

INJECTABLE; IM-SC

REPRONEX

+ FERRING 75 IU/VIAL;75 IU/VIAL N21047 001 Aug 27, 1999 Oct CDFR

INJECTABLE; INJECTION

PERGONAL

@ SERONO

75 IU/AMP;75 IU/AMP

N17646 001 May DISC

REPRONEX

+ FERRING 75 IU/VIAL;75 IU/VIAL N21047 001 Aug 27, 1999 May CTEC

INJECTABLE; SUBCUTANEOUS

MENOPUR

+ FERRING 75 IU/VIAL;75 IU/VIAL N21663 001 Oct 29, 2004 Oct NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

AP + HOSPIRA 25MG/ML N21171 001 May CAHN

AP + 50MG/ML N21171 002 May CAHN

AP + 75MG/ML N21171 003 May CAHN

AP + 100MG/ML N21171 004 May CAHN

MEPERIDINE HCL PRESERVATIVE FREE

AP + HOSPIRA 10MG/ML N88432 001 Aug 16, 1984 May CAHN

TABLET; ORAL

MEPERIDINE HCL

AA MUTUAL PHARM 50MG N80448 001 Aug CAHN

AA 100MG N80448 002 Aug CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

AP + HOSPIRA 1% N12250 001 May CAHN

AP + 1.5% N12250 005 May CAHN

AP + 2% N12250 002 May CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ MUTUAL PHARM

200MG

N80699 001 Aug CAHN

@

400MG

N80699 002 Aug CAHN

MERCAPTOPYRINE

TABLET; ORAL

MERCAPTOPYRINE

AB PROMETHEUS LABS 50MG N40461 001 Feb 11, 2004 Feb NEWA

AB ROXANE 50MG N40528 001 Feb 13, 2004 Feb NEWA

PURINETHOL

AB + TEVA 50MG N09053 002 Feb CFTG

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

PENTASA

SHIRE LABS 250MG N20049 001 May 10, 1993 Aug CRLD
 + 500MG N20049 002 Jul 08, 2004 Aug NEWA

ENEMA; RECTAL

MESALAMINE

AB CLAY PARK 4GM/60ML N76751 001 Sep 17, 2004 Sep NEWA
 AB TEVA 4GM/60ML N76841 001 Sep 30, 2004 Sep NEWA

ROWASA

AB + SOLVAY 4GM/60ML N19618 001 Dec 24, 1987 Sep CFTG

SUPPOSITORY; RECTAL

CANASA

>D> + AXCAN SCANDIPHARM 500MG N21252 001 Jan 05, 2001 Nov CRLD
 >A> 500MG N21252 001 Jan 05, 2001 Nov CRLD
 >A> + 1GM N21252 002 Nov 05, 2004 Nov NEWA

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP BEDFORD 100MG/ML N75739 001 Jan 09, 2004 Jan NEWA

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

SERENTIL

@ NOVARTIS EQ 25MG BASE/ML N16997 001 May DISC

TABLET; ORAL

SERENTIL

@ NOVARTIS EQ 25MG BASE N16774 002 May DISC

@ EQ 100MG BASE N16774 004 May DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FORTAMET

BX ANDRX 500MG N21574 001 Apr 27, 2004 Apr NEWA
 + 1GM N21574 002 Apr 27, 2004 Apr NEWA

BX ANDRX LABS LLC 500MG N21574 001 Apr 27, 2004 Sep CAHN
 + 1GM N21574 002 Apr 27, 2004 Sep CAHN

GLUCOPHAGE XR

AB BRISTOL MYERS SQUIBB 500MG N21202 001 Oct 13, 2000 Jan CFTG
 AB + 750MG N21202 004 Apr 11, 2003 Oct CFTG

METFORMIN HCL

AB ANDRX PHARMS 500MG N76172 001 Jun 16, 2004 Jun NEWA

AB BARR 750MG N76863 001 Oct 14, 2004 Oct NEWA

AB IMPAX LABS 500MG N76249 001 Jul 30, 2004 Jul NEWA

AB IVAX PHARMS 500MG N76545 001 Dec 01, 2003 Jan NEWA

AB PUREPAC PHARM 500MG N76450 001 Oct 01, 2004 Oct NEWA

AB RANBAXY 500MG N76413 001 Jun 18, 2004 Jun NEWA

AB TEVA 500MG N76269 001 Jun 18, 2004 Jun NEWA

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HCL

@ EON 5MG N40241 001 May 29, 1998 Aug DISC

AA MALLINCKRODT 5MG N40517 001 Apr 27, 2004 Apr NEWA

AA 10MG N40517 002 Apr 27, 2004 Apr NEWA

ST. JOHN'S COLLEGE OF PHARMACY

METHAMPHETAMINE HYDROCHLORIDE

	TABLET; ORAL					
	DESOXYN					
AB	+ OVATION PHARMS	5MG	N05378 002		Feb	CFTG
	METHAMPHETAMINE HCL					
AB	ABLE	5MG	N40529 001	Feb 25, 2004	Feb	NEWA

METHENAMINE HIPPURATE

	TABLET; ORAL					
	UREX					
AB	VATRING PHARMS	1GM	N16151 001		Aug	CAHN

METHIMAZOLE

	TABLET; ORAL					
	TAPAZOLE					
AB	KING PHARMS	5MG	N07517 002		Mar	CAHN
AB		10MG	N07517 004		Mar	CAHN

METHOCARBAMOL

	TABLET; ORAL					
	METHOCARBAMOL					
	@ MUTUAL PHARM	500MG	N84488 001		Aug	CAHN
	@	750MG	N84486 001		Aug	CAHN

METHOTREXATE SODIUM

	INJECTABLE; INJECTION					
	METHOTREXATE					
AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40263 001	Feb 26, 1999	Jul	CAHN
	METHOTREXATE PRESERVATIVE FREE					
AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40265 001	Feb 26, 1999	Jul	CAHN
AP		EQ 1GM BASE/VIAL	N40266 001	Feb 26, 1999	Jul	CARN

METHYL AMINOLEVULINATE HYDROCHLORIDE

	CREAM; TOPICAL					
	METHYL AMINOLEVULINATE					
	+ PHOTOCURE ASA	16.8%	N21415 001	Jul 27, 2004	Jul	NEWA

METHYLDOPA

	TABLET; ORAL					
	METHYLDOPA					
	@ ACCORD HEALTH	125MG	N70070 003	Oct 15, 1985	Jun	CAHN
AB		250MG	N70084 001	Oct 15, 1985	Jun	CAHN
AB		500MG	N70085 001	Oct 15, 1985	Jun	CAHN
	@ MUTUAL PHARM	125MG	N70073 001	Oct 09, 1986	Aug	CAHN
	@	250MG	N70060 001	Oct 09, 1986	Aug	CAHN
	@	500MG	N70074 001	Oct 09, 1986	Aug	CAHN

METHYLDOPATE HYDROCHLORIDE

	INJECTABLE; INJECTION					
	METHYLDOPATE HCL					
AP	HOSPIRA	50MG/ML	N70698 001	Jun 15, 1987	May	CAHN
AP		50MG/ML	N70699 001	Jun 15, 1987	May	CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

BX	CELLTECH PHARMS	10MG	N21259 003	May 27, 2003	May	CTEC
	RITALIN LA					
	NOVARTIS	10MG	N21284 004	Apr 10, 2004	Apr	NEWA
BX		10MG	N21284 004	Apr 10, 2004	May	CTEC

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HOSPIRA	EQ 40MG BASE/VIAL	N85853 001		May	CAHN
AP		EQ 125MG BASE/VIAL	N85855 001		May	CAHN
AP		EQ 500MG BASE/VIAL	N85854 001		May	CAHN
AP		EQ 500MG BASE/VIAL	N89173 001	Aug 18, 1987	May	CAHN
AP		EQ 1GM BASE/VIAL	N85852 001		May	CAHN
AP		EQ 1GM BASE/VIAL	N89174 001	Aug 18, 1987	May	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	AM PHARM	EQ 40MG BASE/VIAL	N40583 001	Jul 30, 2004	Jul	NEWA
AP		EQ 125MG BASE/VIAL	N40583 002	Jul 30, 2004	Jul	NEWA
AP		EQ 1GM BASE/VIAL	N40612 001	Aug 12, 2004	Aug	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

AP	HOSPIRA	EQ 5MG BASE/ML	N70505 001	Jun 23, 1989	May	CAHN
	e	EQ 5MG BASE/ML	N70506 001	Jun 22, 1989	May	CAHN
AP		EQ 5MG BASE/ML	N73117 001	Jan 17, 1991	May	CAHN
AP		EQ 5MG BASE/ML	N73118 001	Jan 17, 1991	May	CAHN
AP		EQ 5MG BASE/ML	N74147 001	Aug 02, 1996	May	CAHN

TABLET; ORAL

METOCLOPRAMIDE HCL

e MUTUAL PHARM

	EQ 10MG BASE	N70660 001	Feb 10, 1987	Aug	CAHN
--	--------------	------------	--------------	-----	------

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	MYLAN	5MG	N76698 002	Oct 19, 2004	Oct	NEWA
AB		10MG	N76698 003	Oct 19, 2004	Oct	NEWA
AB	ROXANE	10MG	N76482 002	Apr 29, 2004	Apr	NEWA
AB	TEVA	2.5MG	N76600 001	Jan 06, 2004	Jan	NEWA
AB		5MG	N76833 001	Mar 01, 2004	Mar	NEWA
AB	WATSON LABS	10MG	N76891 001	Jul 21, 2004	Jul	NEWA
	MYKROX					
	e CELLTECH PHARMS	0.5MG	N19532 001	Oct 30, 1987	Jan	DISC

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP	HOSPIRA	1MG/ML	N74133 001	Dec 21, 1993	May	CAHN
AP		1MG/ML	N75160 001	Jul 06, 1998	May	CAHN

TABLET; ORAL

LOPRESSOR

AB	NOVARTIS	100MG	N17963 002		Mar	CRLD
----	----------	-------	------------	--	-----	------

METOPROLOL TARTRATE

AB	CARACO	25MG	N76670 001	Jan 15, 2004	Mar	CTEC
----	--------	------	------------	--------------	-----	------

<u>TABLET; ORAL</u>						
<u>METOPROLOL TARTRATE</u>						
		CARACO	25MG	N76670 001	Jan 15, 2004	Jan NEWA
	+	MYLAN	25MG	N76704 001	Jan 16, 2004	Jan NEWA
AB			25MG	N76704 001	Jan 16, 2004	Mar CTEC
AB			50MG	N76704 002	Jan 16, 2004	Jan NEWA
AB	+		100MG	N76704 003	Jan 16, 2004	Mar CRLD
AB			100MG	N76704 003	Jan 16, 2004	Jan NEWA
<u>METRONIDAZOLE</u>						
<u>CAPSULE; ORAL</u>						
<u>METRONIDAZOLE</u>						
AB		KALI LABS	375MG	N76522 001	Jan 29, 2004	Jan NEWA
<u>CREAM; TOPICAL</u>						
<u>METROCREAM</u>						
AB	+	GALDERMA LABS LP	0.75%	N20531 001	Sep 20, 1995	May CFTG
<u>METRONIDAZOLE</u>						
AB		ALTANA	0.75%	N76408 001	May 28, 2004	May NEWA
<u>INJECTABLE; INJECTION</u>						
<u>METRONIDAZOLE IN PLASTIC CONTAINER</u>						
AP	+	HOSPIRA	500MG/100ML	N18890 002	Nov 18, 1983	May CAHN
<u>TABLET; ORAL</u>						
<u>METRONIDAZOLE</u>						
		@ MUTUAL PHARM	250MG	N18818 001	Feb 16, 1983	Aug CAHN
		@	500MG	N18818 002	Feb 16, 1983	Aug CAHN
<u>MICONAZOLE</u>						
<u>INJECTABLE; INJECTION</u>						
<u>MONISTAT</u>						
		@ JANSSEN PHARMA	10MG/ML	N18040 001		Jul CAHN
<u>MIDAZOLAM HYDROCHLORIDE</u>						
<u>INJECTABLE; INJECTION</u>						
<u>MIDAZOLAM HCL</u>						
		@ HOSPIRA	EQ 1MG BASE/ML	N75293 001	Jun 20, 2000	May DISC
AP			EQ 1MG BASE/ML	N75409 002	Jun 20, 2000	May CAHN
AP			EQ 1MG BASE/ML	N75856 001	Jun 13, 2002	May CAHN
AP	+		EQ 1MG BASE/ML	N75857 001	Jul 22, 2002	May CAHN
		@	EQ 5MG BASE/ML	N75293 002	Jun 20, 2000	May DISC
AP			EQ 5MG BASE/ML	N75409 001	Jun 20, 2000	May CAHN
AP			EQ 5MG BASE/ML	N75856 002	Jun 13, 2002	May CAHN
AP	+		EQ 5MG BASE/ML	N75857 002	Jul 22, 2002	May CAHN
AP		INTL MEDICATION	EQ 1MG BASE/ML	N76020 001	Jul 16, 2004	Jul NEWA
AP			EQ 5MG BASE/ML	N76020 002	Jul 16, 2004	Jul NEWA
<u>MIDODRINE HYDROCHLORIDE</u>						
<u>TABLET; ORAL</u>						
<u>MIDODRINE HCL</u>						
AB		EON	10MG	N76514 003	Jul 02, 2004	Jul NEWA
AB		IMPAX PHARMS	2.5MG	N76449 001	May 27, 2004	May NEWA
AB			5MG	N76449 002	May 27, 2004	May NEWA
>A>	AB	UPSHER SMITH	2.5MG	N76725 001	Nov 03, 2004	Nov NEWA
>A>	AB		5MG	N76725 002	Nov 03, 2004	Nov NEWA
>A>	AB		10MG	N76725 003	Nov 03, 2004	Nov NEWA

MILRINONE LACTATEINJECTABLE; INJECTION
MILRINONE LACTATE

AP	APOTEX	EQ 1MG BASE/ML	N76427 001	Sep 21, 2004	Sep	NEWA
AP	HOSPIRA	EQ 1MG BASE/ML	N75884 001	May 28, 2002	May	CAHN
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	B BRAUN	EQ 20MG BASE/100ML	N76414 001	Aug 18, 2004	Aug	NEWA
AP	HOSPIRA	EQ 20MG BASE/100ML	N75885 001	May 28, 2002	May	CAHN

MINOCYCLINE HYDROCHLORIDETABLET; ORAL
MINOCYCLINE HCL

AB	MEDICIS	EQ 50MG BASE	N65131 001	Apr 16, 2003	Jan	CFTG
AB		EQ 75MG BASE	N65131 002	Apr 16, 2003	Jan	CFTG
AB	+	EQ 100MG BASE	N65131 003	Apr 16, 2003	Jan	CFTG
AB	RANBAXY	EQ 50MG BASE	N65156 001	Jan 06, 2004	Jan	NEWA
AB		EQ 75MG BASE	N65156 002	Jan 06, 2004	Jan	NEWA
AB		EQ 100MG BASE	N65156 003	Jan 06, 2004	Jan	NEWA

MIRTAZAPINETABLET; ORAL
MIRTAZAPINE

AB	AUROBINDO	7.5MG	N76921 001	Oct 22, 2004	Oct	NEWA
AB		15MG	N76921 002	Oct 22, 2004	Oct	NEWA
AB		30MG	N76921 003	Oct 22, 2004	Oct	NEWA
AB		45MG	N76921 004	Oct 22, 2004	Oct	NEWA
	CARACO	7.5MG	N76541 004	Apr 22, 2004	Apr	NEWA
AB		15MG	N76541 001	Apr 22, 2004	Apr	NEWA
AB		30MG	N76541 002	Apr 22, 2004	Apr	NEWA
AB		45MG	N76541 003	Apr 22, 2004	Apr	NEWA

MOLINDONE HYDROCHLORIDECONCENTRATE; ORAL
MOBAN

® ENDO PHARMS	20MG/ML	N17938 001	May	DISC
---------------	---------	------------	-----	------

TABLET; ORAL
MOBAN

® ENDO PHARMS	100MG	N17111 008	May	DISC
---------------	-------	------------	-----	------

MORPHINE SULFATEINJECTABLE, LIPOSOMAL; EPIDURAL
DEPODUR

SKYEPHARMA	10MG/ML	N21671 001	May 18, 2004	May	NEWA
------------	---------	------------	--------------	-----	------

	15MG/1.5ML (10MG/ML)	N21671 002	May 18, 2004	May	NEWA
--	----------------------	------------	--------------	-----	------

+	20MG/2ML (10MG/ML)	N21671 003	May 18, 2004	May	NEWA
---	--------------------	------------	--------------	-----	------

INJECTABLE; INJECTION
MORPHINE SULFATE

AP	+	HOSPIRA	0.5MG/ML	N19917 001	Oct 30, 1992	May	CAHN
AP			0.5MG/ML	N71849 001	May 11, 1988	May	CAHN
AP			0.5MG/ML	N73509 001	Sep 30, 1992	May	CAHN
AP	+		1MG/ML	N19916 001	Oct 30, 1992	May	CAHN
AP			1MG/ML	N71850 001	May 11, 1988	May	CAHN
AP			1MG/ML	N73510 001	Sep 30, 1992	May	CAHN

ST. LOUIS COLLEGE OF PHARMACY

<u>TABLET, EXTENDED RELEASE; ORAL</u>					
MORPHINE SULFATE					
AB	KV PHARM	15MG	N76733 001	May 19, 2004	May NEWA
AB		60MG	N76720 001	May 19, 2004	May NEWA
ORAMORPH SR					
BC	+ AAIPHARMA	60MG	N19977 002	Aug 15, 1991	Mar CRLD
<u>MYCOPHENOLIC ACID</u>					
<u>TABLET, EXTENDED RELEASE; ORAL</u>					
MYFORTIC					
	NOVARTIS	180MG	N50791 001	Feb 27, 2004	Feb NEWA
	+	360MG	N50791 002	Feb 27, 2004	Feb NEWA
<u>NABILONE</u>					
<u>CAPSULE; ORAL</u>					
CESAMET					
	@ VALEANT	1MG	N18677 001	Dec 26, 1985	Jan CAHN
<u>NAFCILLIN SODIUM</u>					
<u>INJECTABLE; INJECTION</u>					
NAFCILLIN SODIUM					
	+ SANDOZ	EQ 500MG BASE/VIAL	N62527 001	Aug 02, 1984	Jun CAHN
AP		EQ 1GM BASE/VIAL	N62527 002	Aug 02, 1984	Jun CAHN
AP		EQ 2GM BASE/VIAL	N62527 003	Aug 02, 1984	Jun CAHN
AP		EQ 10GM BASE/VIAL	N62527 004	Aug 02, 1984	Jun CAHN
<u>NAFTIFINE HYDROCHLORIDE</u>					
<u>CREAM; TOPICAL</u>					
NAFTIN					
	MERZ PHARMS	1%	N19599 001	Feb 29, 1988	Jul CAHN
<u>GEL; TOPICAL</u>					
NAFTIN					
	+ MERZ PHARMS	1%	N19356 001	Jun 18, 1990	Jul CAHN
<u>NALBUPHINE HYDROCHLORIDE</u>					
<u>INJECTABLE; INJECTION</u>					
NALBUPHINE HCL					
AP	HOSPIRA	10MG/ML	N70914 001	Feb 03, 1989	May CAHN
AP		10MG/ML	N70915 001	Feb 03, 1989	May CAHN
AP		20MG/ML	N70916 001	Feb 03, 1989	May CAHN
AP		20MG/ML	N70918 001	Feb 03, 1989	May CAHN
	@ KING PHARMS	10MG/ML	N74471 001	Mar 19, 1998	Mar DISC
<u>NALIDIXIC ACID</u>					
<u>TABLET; ORAL</u>					
NALIDIXIC ACID					
	@ MUTUAL PHARM	250MG	N70270 001	Jun 29, 1988	Aug CAHN
	@	500MG	N70271 001	Jun 29, 1988	Aug CAHN
	@	1GM	N70272 001	Jun 29, 1988	Aug CAHN
<u>NALOXONE HYDROCHLORIDE</u>					
<u>INJECTABLE; INJECTION</u>					
NALOXONE					
	@ BAXTER HLTHCARE	0.4MG/ML	N70298 001	Sep 24, 1986	Aug CAHN
	@	0.4MG/ML	N70299 001	Sep 24, 1986	Aug CAHN

INJECTABLE; INJECTIONNALOXONE HCL

AP		HOSPIRA	0.02MG/ML	N70171 001	Sep 24, 1986	May	CAHN
AP			0.02MG/ML	N70252 001	Jan 16, 1987	May	CAHN
AP			0.02MG/ML	N70253 001	Jan 16, 1987	May	CAHN
		@	0.4MG/ML	N70172 001	Sep 24, 1986	May	CAHN
AP			0.4MG/ML	N70254 001	Jan 07, 1987	May	CAHN
AP			0.4MG/ML	N70255 001	Jan 07, 1987	May	CAHN
AP			0.4MG/ML	N70256 001	Jan 07, 1987	May	CAHN
AP			0.4MG/ML	N70257 001	Jan 07, 1987	May	CAHN

NALTREXONE HYDROCHLORIDETABLET; ORALREVIA

>D>	AB	+	BARR PHARMS	50MG	N18932 001	Nov 20, 1984	Nov	CAHN
>A>	AB	+	DURAMED	50MG	N18932 001	Nov 20, 1984	Nov	CAHN

NAPROXENTABLET; ORALNAPROXEN

		@	BAXTER HLTHCARE	250MG	N74105 001	Dec 21, 1993	Aug	DISC
		@		375MG	N74105 002	Dec 21, 1993	Aug	DISC
		@		500MG	N74105 003	Dec 21, 1993	Aug	DISC
AB			WESTWARD	250MG	N76494 001	Jan 14, 2004	Jan	NEWA
AB				375MG	N76494 002	Jan 14, 2004	Jan	NEWA
AB				500MG	N76494 003	Jan 14, 2004	Jan	NEWA

NAPROXEN SODIUMTABLET, EXTENDED RELEASE; ORALNAPRELAN

AB	+		STAT TRADE	EQ 375MG BASE	N20353 001	Jan 05, 1996	Jun	CAHN
AB	+			EQ 500MG BASE	N20353 002	Jan 05, 1996	Jun	CAHN
		@		EQ 750MG BASE	N20353 003	Jan 05, 1996	Jun	CAHN

NEDOCROMIL SODIUMAEROSOL, METERED; INHALATIONTILADE

	+		KING PHARMS	1.75MG/INH	N19660 001	Dec 30, 1992	Jan	CAHN
--	---	--	-------------	------------	------------	--------------	-----	------

NEFAZODONE HYDROCHLORIDETABLET; ORALNEFAZODONE HCL

		@	ROXANE	50MG	N76196 001	Sep 16, 2003	Jul	DISC
		@		100MG	N76196 002	Sep 16, 2003	Jul	DISC
		@		150MG	N76196 003	Sep 16, 2003	Jul	DISC
		@		200MG	N76196 004	Sep 16, 2003	Jul	DISC
		@		250MG	N76196 005	Sep 16, 2003	Jul	DISC

NIACINTABLET; ORALNIACIN

		@	MK LABS	500MG	N83525 001		Feb	DISC
		@	TABLICAPS	500MG	N84237 001		Feb	DISC
AA	+		UPSHER SMITH	500MG	N40378 001	May 03, 2000	Feb	CRLD

ST. LOUIS COLLEGE OF PHARMACY

<u>NIFEDIPINE</u>						
TABLET, EXTENDED RELEASE; ORAL						
NIFEDIPINE						
AB2	MARTEC	90MG	N75414	003	Mar 23, 2004	Mar NEWA
PROCARDIA XL						
AB2	+ PFIZER	90MG	N19684	003	Sep 06, 1989	Mar CFTG
<u>NITAZOXANIDE</u>						
TABLET; ORAL						
ALINIA						
	+ ROMARK	500MG	N21497	001	Jul 21, 2004	Jul NEWA
<u>NITROFURANTOIN, MACROCRYSTALLINE</u>						
CAPSULE; ORAL						
NITROFURANTOIN						
	@ MYLAN	100MG	N74967	002	Jul 09, 1997	Aug DISC
AB		100MG	N77025	001	Aug 18, 2004	Aug NEWA
<u>NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE</u>						
CAPSULE; ORAL						
MACROBID						
AB	+ PROCTER AND GAMBLE	75MG;25MG	N20064	001	Dec 24, 1991	Mar CFTG
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)						
AB	MYLAN	75MG;25MG	N76648	001	Mar 22, 2004	Apr CPOT
AB		EQ 75MG BASE;25MG	N76648	001	Mar 22, 2004	Mar NEWA
<u>NITROGLYCERIN</u>						
FILM, EXTENDED RELEASE; TRANSDERMAL						
NITROGLYCERIN						
AB1	KREMERS URBAN	0.2MG/HR	N75115	001	Aug 10, 2004	Aug NEWA
AB1		0.4MG/HR	N75115	002	Aug 10, 2004	Aug NEWA
INJECTABLE; INJECTION						
NITROGLYCERIN						
AP	+ HOSPIRA	5MG/ML	N18531	001		May CAHN
NITROGLYCERIN IN DEXTROSE 5%						
AP	HOSPIRA	0.1MG/ML	N74083	001	Oct 26, 1994	May CAHN
AP		10MG/100ML	N71846	001	Aug 31, 1990	May CAHN
AP		20MG/100ML	N71847	001	Aug 31, 1990	May CAHN
AP		40MG/100ML	N71848	001	Aug 31, 1990	May CAHN
<u>NIZATIDINE</u>						
SOLUTION; ORAL						
AXID						
	+ RELIANT PHARMS	15MG/ML	N21494	001	May 25, 2004	May NEWA
<u>NOREPINEPHRINE BITARTRATE</u>						
INJECTABLE; INJECTION						
LEVOPHED						
AP	+ HOSPIRA	EQ 1MG BASE/ML	N07513	001		May CAHN
NOREPINEPHRINE BITARTRATE						
AP	PHARMAFORCE		N40522	001	Sep 30, 2004	Sep NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HCL

@ LILLY

EQ 10MG BASE

N14684 001

Jun DISC

@

EQ 25MG BASE

N14684 002

Jun DISC

NYSTATIN

PASTILLE; ORAL

MYCOSTATIN

@ BRISTOL MYERS SQUIBB 200,000 UNITS

N50619 001 Apr 09, 1987 Jun DISC

POWDER; TOPICAL

NYSTATIN

AT KALI LABS

100,000 UNITS/GM

N65138 001 Jul 23, 2004 Jul NEWA

AT TANON

100,000 UNITS/GM

N65203 001 Jul 15, 2004 Jul NEWA

SUSPENSION; ORAL

MYCOSTATIN

@ APOTHECON

100,000 UNITS/ML

N61533 001

Aug DISC

NILSTAT

AA + GLENMARK PHARMA

100,000 UNITS/ML

N50299 001

Jul CAHN

NYSTATIN

@ BAUSCH AND LOMB

100,000 UNITS/ML

N64042 001 Feb 28, 1994 Aug DISC

AA + MORTON GROVE

100,000 UNITS/ML

N62512 001 Oct 29, 1984 Aug CRLD

AA VISTAPHARM

100,000 UNITS/ML

N64142 001 Jun 25, 1998 Aug CAHN

NYSTEX

@ SAVAGE LABS

100,000 UNITS/ML

N62519 001 Jul 06, 1984 Aug DISC

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

AT + ALLERGAN

0.3%

N19921 001 Jul 30, 1993 May CPTG

OFLOXACIN

AT ALCON

0.3%

N76231 001 May 14, 2004 May NEWA

AT BAUSCH AND LOMB

0.3%

N76622 001 May 14, 2004 May NEWA

AT HI TECH PHARMA

0.3%

N76615 001 May 14, 2004 May NEWA

AT NOVEX

0.3%

N76513 001 May 14, 2004 May NEWA

>A> AT PHARMAFORCE

0.3%

N76830 001 Aug 31, 2004 Nov CDFR

SOLUTION/DROPS; OTIC

FLOXIN OTIC

+ DAIICHI

0.3%

N20799 001 Dec 16, 1997 Jun CTNA

>D> SOLUTION; OPHTHALMIC

>D> OFLOXACIN

>D> AT PHARMAFORCE

EQ 0.3% BASE

N76830 001 Aug 31, 2004 Nov CDFR

AT EQ 0.3% BASE

N76830 001 Aug 31, 2004 Aug NEWA

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

ZYPREXA

+ LILLY

10MG/VIAL

N21253 001 Mar 29, 2004 Mar NEWA

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+ CELLTECH PHARMS

250MG

N19715 001 Jul 31, 1990 Jun CAHN

ST. LOUIS OFFICE OF THE ATTORNEY GENERAL

>A> OMEGA-3-ACID ETHYL ESTERS

>A> CAPSULE; ORAL

>A> OMACOR

>A> + ROSS PRODS 1GM N21654 001 Nov 10, 2004 Nov NEWA

OMEPRAZOLE

FOR SUSPENSION; ORAL

ZEGERID

+ SANTARUS 20MG/PACKET N21636 001 Jun 15, 2004 Jun NEWA

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	+	APOTHECON	EQ 250MG BASE/VIAL	N61490 001		Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	N61490 004		Mar	NEWA
AP			EQ 2GM BASE/VIAL	N62737 002	Dec 23, 1986	Mar	CRLD
AP	+	SANDOZ	EQ 250MG BASE/VIAL	N61490 001		Jun	CAHN
AP	+		EQ 500MG BASE/VIAL	N61490 002		Jun	CAHN
AP	+		EQ 1GM BASE/VIAL	N61490 003		Jun	CAHN
AP	+		EQ 2GM BASE/VIAL	N61490 004		Jun	CAHN
AP	+		EQ 10GM BASE/VIAL	N61490 006	May 09, 1991	Jun	CAHN

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

@ PFIZER

250MG N18069 001 Mar DISC

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB APOTEX 600MG N75987 001 Sep 02, 2004 Sep NEWA

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

@ GD SEARLE

600MG N20776 001 Oct 17, 2002 Sep DISC

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

@ MUTUAL PHARM

10MG N70957 001 Aug 10, 1987 Aug CAHN

@

15MG N71025 001 Aug 10, 1987 Aug CAHN

@

30MG N71026 001 Aug 10, 1987 Aug CAHN

SERAX

@ ALPHARMA

15MG N15539 004 Aug DISC

>D> @ ALPHARMA US PHARMS 15MG N15539 004 Nov CMFD

>A> AB 15MG N15539 004 Nov CMFD

TABLET; ORAL

OXAZEPAM

@ MUTUAL PHARM

15MG N70683 001 Jan 16, 1987 Aug CAHN

SERAX

+ ALPHARMA US PHARMS

15MG N15539 008 Nov DISC

>D> @ 15MG N15539 008 Nov DISC

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCODONE HCL

AB	ENDO PHARMS	10MG	N75923 001	Mar 23, 2004	Mar	NEWA
AB		20MG	N75923 002	Mar 23, 2004	Mar	NEWA
AB		40MG	N75923 003	Mar 23, 2004	Mar	NEWA
AB		80MG	N75923 004	Sep 29, 2004	Sep	NEWA
AB	IMPAX LABS	80MG	N76318 001	Sep 27, 2004	Sep	NEWA
AB	TEVA	80MG	N76168 001	Mar 23, 2004	Mar	NEWA

OXYCONTIN

AB	PURDUE PHARMA LP	10MG	N20553 001	Dec 12, 1995	Mar	CFTG
AB		20MG	N20553 002	Dec 12, 1995	Mar	CFTG
AB	+	40MG	N20553 003	Dec 12, 1995	Mar	CFTG
AB	+	80MG	N20553 004	Jan 06, 1997	Mar	CFTG
AB		80MG	N20553 004	Jan 06, 1997	Jun	CRLD

TABLET; ORAL

OXYCODONE HCL

AB	AMIDE PHARM	15MG	N76636 001	Feb 06, 2004	Feb	NEWA
AB		30MG	N76636 002	Feb 06, 2004	Feb	NEWA
AB	MALLINCKRODT	15MG	N76758 001	Jun 30, 2004	Jun	NEWA
AB		30MG	N76758 002	Jun 30, 2004	Jun	NEWA

ROXICODONE

AB	AAIPHARMA	15MG	N21011 001	Aug 31, 2000	Feb	CFTG
AB		30MG	N21011 002	Aug 31, 2000	Feb	CFTG

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

>>	AP	AM PHARM PARTNERS	10USP UNITS/ML	N18248 001		Nov	CRLD
>>	AP	+	10USP UNITS/ML	N18248 001		Nov	CRLD

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

>>	AP	SUPERGEN	6MG/ML	N75436 001	Nov 12, 2004	Nov	NEWA
----	----	----------	--------	------------	--------------	-----	------

PANCUONIUM BROMIDE

INJECTABLE; INJECTION

PANCUONIUM BROMIDE

AP	HOSPIRA	1MG/ML	N72320 001	Jan 19, 1989	May	CAHN
AP		2MG/ML	N72321 001	Jan 19, 1989	May	CAHN

PARICALCITOL

INJECTABLE; INJECTION

ZEMPLAR

ABBOTT

		0.002MG/ML	N20819 002	Feb 01, 2000	Mar	NEWA
--	--	------------	------------	--------------	-----	------

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HCL

AB	ALPHAPHARM	EQ 10MG BASE	N75716 001	Mar 08, 2004	Mar	NEWA
AB		EQ 20MG BASE	N75716 002	Mar 08, 2004	Mar	NEWA
AB		EQ 30MG BASE	N75716 003	Mar 08, 2004	Mar	NEWA
AB		EQ 40MG BASE	N75716 004	Mar 08, 2004	Mar	NEWA
AB	SANDOZ	EQ 10MG BASE	N75566 001	Mar 08, 2004	Mar	NEWA

ST. LOUIS OFFICE OF REGULATORY AFFAIRS

TABLET; ORAL
 PAROXETINE HCL
 AB SANDOZ EQ 20MG BASE N75566 002 Mar 08, 2004 Mar NEWA
 AB EQ 30MG BASE N75566 003 Mar 08, 2004 Mar NEWA
 AB EQ 40MG BASE N75566 004 Mar 08, 2004 Mar NEWA

PAROXETINE MESYLATE

TABLET; ORAL
 >D> PAROXETINE MESYLATE
 >D> SYNTHON PHARMS EQ 10MG BASE N21299 001 Jul 03, 2003 Nov CTNA
 >D> EQ 20MG BASE N21299 002 Jul 03, 2003 Nov CTNA
 >D> EQ 30MG BASE N21299 003 Jul 03, 2003 Nov CTNA
 >D> + EQ 40MG BASE N21299 004 Jul 03, 2003 Nov CTNA
 >A> PEXEVA
 >A> SYNTHON PHARMS EQ 10MG BASE N21299 001 Jul 03, 2003 Nov CTNA
 >A> EQ 20MG BASE N21299 002 Jul 03, 2003 Nov CTNA
 >A> EQ 30MG BASE N21299 003 Jul 03, 2003 Nov CTNA
 >A> + EQ 40MG BASE N21299 004 Jul 03, 2003 Nov CTNA

PEMETREXED DISODIUM

INJECTABLE; IV (INFUSION)
 ALIMTA
 + LILLY EQ 500MG BASE/VIAL N21462 001 Feb 04, 2004 Feb NEWA

PENICILLIN G PROCAINE

INJECTABLE; INJECTION
 PENICILLIN G PROCAINE
 >A> + KING PHARMS 300,000 UNITS/ML N60101 002 Nov CTNA
 >A> + 600,000 UNITS/ML N60101 001 Nov CTNA
 >D> WYCILLIN
 >D> + KING PHARMS 300,000 UNITS/ML N60101 002 Nov CTNA
 >D> + 600,000 UNITS/ML N60101 001 Nov CTNA

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION
 PENTAMIDINE ISETHIONATE
 AP HOSPIRA 300MG/VIAL N73479 001 Jun 30, 1992 May CAH

PENTAZOCINE LACTATE

INJECTABLE; INJECTION
 TALWIN
 + HOSPIRA EQ 30MG BASE/ML N16194 001 May CAH

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS
 PENTETATE CALCIUM TRISODIUM
 + HAMELN PHARMS EQ 1GM/5ML(EQ 200MG/ML) N21749 001 Aug 11, 2004 Aug NEWA

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS
 PENTETATE ZINC TRISODIUM
 + HAMELN PHARMS EQ 1GM/5ML(EQ 200MG/ML) N21751 001 Aug 11, 2004 Aug NEWA

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

@ OVATION PHARMS

30MG

N84095 001

May DISC

@

100MG

N83245 001

May DISC

SODIUM PENTOBARBITAL

+ VALEANT PHARM INTL

100MG

N83264 001

May CRLD

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ ORTHO MCNEIL PHARM

100MG

N20193 001 Sep 26, 1996 Jun CAHN

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

SOLVAY PHARMA

2MG

N20184 001 Dec 30, 1993 Nov CAHN

>D>

SOLVAY PHARMA

4MG

N20184 002 Dec 30, 1993 Nov CAHN

>D>

+

SOLVAY PHARMS

8MG

N20184 003 Dec 30, 1993 Nov CAHN

>D>

SOLVAY PHARMS

2MG

N20184 001 Dec 30, 1993 Nov CAHN

>A>

SOLVAY PHARMS

4MG

N20184 002 Dec 30, 1993 Nov CAHN

>A>

+

SOLVAY PHARMS

8MG

N20184 003 Dec 30, 1993 Nov CAHN

>A>

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

BONTRIL PDM

AA VALEANT

35MG

N85272 001

Aug CAHN

PHENYLBUTAZONE

CAPSULE; ORAL

PHENYLBUTAZONE

@ MUTUAL PHARM

100MG

N88994 001 Dec 04, 1985 Aug CAHN

TABLET; ORAL

PHENYLBUTAZONE

@ MUTUAL PHARM

100MG

N88863 001 Dec 04, 1985 Aug CAHN

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

AB TARO

125MG/5ML

N40521 001 Mar 08, 2004 Mar NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

@ HOSPIRA

50MG/ML

N89521 001 Mar 17, 1987 May CAHN

@

50MG/ML

N89744 001 Dec 18, 1987 May CAHN

PHYTONADIONE

INJECTABLE; INJECTION

VITAMIN K1

HOSPIRA

BP HOSPIRA

1MG/0.5ML

N87954 001 Jul 25, 1983 May CAHN

BP

HOSPIRA

10MG/ML

N87955 001 Jul 25, 1983 May CAHN

HOSPIRA

10MG/ML

N87956 001 Jul 25, 1983 May CAHN

ST. LOUIS, MISSOURI

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL
 >A> PILOCARPINE HCL
 >A> AB COREPHARMA 5MG N76746 001 Nov 16, 2004 Nov
 SALAGEN
 >D> MGI PHARMA INC 5MG N20237 001 Mar 22, 1994 Nov
 >A> AB 5MG N20237 001 Mar 22, 1994 Nov

PIPERACILLIN SODIUM

INJECTABLE; INJECTION
 PIPERACILLIN
 + AM PHARM EQ 40GM BASE/VIAL N65157 001 Jul 12, 2004 Jul

PIPERAZINE CITRATE

SYRUP; ORAL
 MULTIFUGE
 8 BLULINE EQ 500MG BASE/5ML N09452 001 Jul

PODOFILOX

SOLUTION; TOPICAL
 CONDYLOX
 AT + OCLASSEN 0.5% N19795 001 Dec 13, 1990 Sep

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
 GLYCOLAX
 AA SCHWARZ PHARMA 17GM/SCOOPFUL N76652 001 Jul 02, 2004 Jul
 MIRALAX
 AA + BRAINTREE 17GM/SCOOPFUL N20698 001 Feb 18, 1999 Jul

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL
 NULYTELY
 AA + BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 N19797 001 Apr 22, 1991 Feb
 1.2GM/BOT
 NULYTELY-FLAVORED
 AA + BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 N19797 002 Nov 18, 1994 Feb
 1.2GM/BOT
 TRILYTE
 AA SCHWARZ PHARMA 420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 N76491 001 Feb 05, 2004 Feb
 1.2GM/BOT

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL
 OCL
 + HOSPIRA 6GM/100ML;75MG/100ML;168MG/100ML; N19284 001 Apr 30, 1986 May
 146MG/100ML;1.29GM/100ML

POTASSIUM ACETATE

INJECTABLE; INJECTION
 POTASSIUM ACETATE IN PLASTIC CONTAINER
 + HOSPIRA 2MEQ/ML N18896 001 Jul 20, 1984 May

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
 POTASSIUM CHLORIDE
 8 HOSPIRA 1MEQ/ML N80205 003 May

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

	@ HOSPIRA	1MEQ/ML	N83345 003	May	CAHN			
	+	1.5MEQ/ML	N83345 001	May	CAHN			
NEWA	AP	+	2MEQ/ML	N80205 001	May	CAHN		
	AP		2MEQ/ML	N83345 002	May	CAHN		
CFTG		@	2.4MEQ/ML	N80205 004	May	CAHN		
CFTG		@	3.2MEQ/ML	N80205 005	May	CAHN		
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER								
	@ HOSPIRA	14.9MG/ML	N20161 005	Nov 30, 1992	May	CAHN		
	@	745MG/100ML	N20161 001	Nov 30, 1992	May	CAHN		
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER								
NEWA	AP	+ HOSPIRA	29.8MG/ML	N20161 006	Aug 11, 1998	May	CAHN	
		@	1.49GM/100ML	N20161 002	Nov 30, 1992	May	CAHN	
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER								
AP	+	HOSPIRA	2.24GM/100ML	N20161 003	Aug 11, 1998	May	CAHN	
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER								
DISC	AP	+	HOSPIRA	2.98GM/100ML	N20161 004	Aug 11, 1998	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

KAON CL-10

	@ SAVAGE LABS	10MEQ	N17046 002	Nov	CMFD		
	@	10MEQ	N17046 002	Nov	CMFD		
CAHN	AB						
		POTASSIUM CHLORIDE					
		EURAND	20MEQ	N76368 001	Aug 18, 2004	Aug	NEWA

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

NEWA	AP	HOSPIRA	149MG/100ML;900MG/100ML	N19686 001	Oct 17, 1988	May	CAHN
CFTG	AP	HOSPIRA	298MG/100ML;900MG/100ML	N19686 002	Oct 17, 1988	May	CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

	@ HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N13025 001	May	CAHN
--	-----------	----------------------------------	------------	-----	------

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

	@ EVERYLIFE	2.5MG	N84439 002	May	DISC
	@	5MG	N84439 003	May	DISC
	@ SPERTI	1MG	N80358 001	May	DISC
	@	2.5MG	N80358 002	May	DISC
	@	5MG	N80358 003	May	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDISOLONE SODIUM PHOSPHATE

NEWA	AA	MORTON GROVE	EQ 15MG BASE/5ML	N76895 001	Oct 04, 2004	Oct	NEWA
CAHN	AA	PADDOCK	EQ 5MG BASE/5ML	N75988 001	May 25, 2004	May	NEWA

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

VASOCIDIN

CAHN	AT	+	NOVARTIS	EQ 0.23% PHOSPHATE;10%	N18988 001	Aug 26, 1988	Aug	CAHN
------	----	---	----------	------------------------	------------	--------------	-----	------

PREDNISONE

TABLET; ORAL					
DELTASONE					
	@ PHARMACIA AND UPJOHN	2.5MG	N09986 005	Sep	DISC
	@	5MG	N09986 002	Oct	DISC
	@	10MG	N09986 006	Sep	DISC
	@	20MG	N09986 007	Jul	DISC
	@	50MG	N09986 008	Oct	DISC
PREDNISONE					
	@ MUTUAL PHARM	5MG	N80701 001	Aug	CAHN
	@	10MG	N86595 001	Aug	CAHN
	@	20MG	N84634 001	Aug	CAHN
	@	50MG	N86596 001	Aug	CAHN
AB	+ ROXANE	2.5MG	N87801 001	Apr 22, 1982	Oct CRLD
AB	+	5MG	N80352 001		Oct CRLD
AB	+	10MG	N84122 001		Oct CRLD
AB	+	20MG	N87342 001		Jul CRLD
AB	+	50MG	N84283 001		Oct CRLD
	@ SANDOZ	20MG	N85813 001		Aug DISC
AB	WEST WARD	2.5MG	N40538 001	Jan 08, 2004	Jan NEWA

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION					
PROCAINAMIDE HCL					
AP	HOSPIRA	100MG/ML	N89069 001	Feb 12, 1986	May CAHN
AP		500MG/ML	N89070 001	Feb 12, 1986	May CAHN
AP		500MG/ML	N89537 001	Aug 25, 1987	May CAHN

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION					
NOVOCAIN					
AP	+ HOSPIRA	1%	N85362 003		May CAHN
AP	+	2%	N85362 004		May CAHN
	+	10%	N86797 001		May CAHN
PROCAINE HCL					
AP	HOSPIRA	1%	N80416 001		May CAHN
AP		2%	N80416 002		May CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION					
PROCHLORPERAZINE EDISYLATE					
AP	BAXTER HLTHCARE	EQ 5MG BASE/ML	N89903 001	Aug 29, 1989	Aug CAHN
AP	BEDFORD	EQ 5MG BASE/ML	N40540 001	May 28, 2004	May NEWA
AP	HOSPIRA	EQ 5MG BASE/ML	N89703 001	Apr 07, 1988	May CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION					
PROMETHAZINE HCL					
AP	BEDFORD LABS	25MG/ML	N40524 001	Mar 17, 2004	Mar NEWA
AP		50MG/ML	N40524 002	Mar 17, 2004	Mar NEWA
AP	BIONICHE PHARMA	25MG/ML	N40471 001	Nov 21, 2002	Sep CAHN
AP	HOSPIRA	25MG/ML	N40372 001	Jun 08, 2000	May CAHN
AP		50MG/ML	N40372 002	Jun 08, 2000	May CAHN
AP		50MG/ML	N83638 002		May CAHN

	SYRUP; ORAL						
	PROMETH PLAIN						
	@ ALPHARMA	6.25MG/5ML	N85953 001		Feb	DISC	
	PROMETHAZINE HCL						
AA	+ HI TECH PHARMA	6.25MG/5ML	N40026 001	Sep 25, 1998	Feb	CRLD	
AA		6.25MG/5ML	N40026 001	Sep 25, 1998	May	CRLD	
	PROMETHAZINE PLAIN						
AA	+ MORTON GROVE	6.25MG/5ML	N87953 001	Nov 15, 1982	May	CRLD	
	TABLET; ORAL						
	PHENERGAN						
AB	WYETH PHARMS INC	12.5MG	N07935 002		Jul	CFTG	
	@	12.5MG	N07935 002		Sep	DISC	
AB		25MG	N07935 003		Jul	CTEC	
AB	+	50MG	N07935 004		Jul	CTEC	
	PROMETHAZINE HCL						
AB	ABLE	12.5MG	N40558 001	Jul 01, 2004	Jul	NEWA	
AB		25MG	N40558 002	Jul 01, 2004	Jul	NEWA	
AB		50MG	N40558 003	Jul 01, 2004	Jul	NEWA	
	@ MUTUAL PHARM	12.5MG	N84555 001		Aug	CAHN	
	@	25MG	N84554 001		Aug	CAHN	
	@	50MG	N84557 001		Aug	CAHN	
	<u>PROPAFENONE HYDROCHLORIDE</u>						
	TABLET; ORAL						
	PROPAFENONE HCL						
AB	PLIVA	150MG	N76550 001	Apr 23, 2004	Apr	NEWA	
AB		225MG	N76550 002	Apr 23, 2004	Apr	NEWA	
AB		300MG	N76550 003	Apr 23, 2004	Apr	NEWA	
	<u>PROPOXYPHENE HYDROCHLORIDE</u>						
	CAPSULE; ORAL						
	DARVON						
	@ AAIPHARMA LLC	32MG	N10997 001		Aug	DISC	
	PROPOXYPHENE HCL						
	@ MUTUAL PHARM	65MG	N83186 001		Aug	CAHN	
	<u>PROPRANOLOL HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	PROPRANOLOL						
AP	AM PHARM PARTNERS	1MG/ML	N75826 001	Aug 31, 2001	Jan	NEWA	
	TABLET; ORAL						
	PROPRANOLOL HCL						
	@ MUTUAL PHARM	10MG	N70319 001	Oct 22, 1985	Aug	CAHN	
	@	20MG	N70320 001	Oct 22, 1985	Aug	CAHN	
	@	40MG	N70103 001	Oct 22, 1985	Aug	CAHN	
	@	60MG	N70321 001	Sep 24, 1986	Aug	CAHN	
	@	80MG	N70322 001	Aug 04, 1986	Aug	CAHN	
	<u>PROPYLTHIOURACIL</u>						
	TABLET; ORAL						
	PROPYLTHIOURACIL						
	@ MUTUAL PHARM	50MG	N83982 001		Aug	CAHN	
	<u>PROTAMINE SULFATE</u>						
	INJECTABLE; INJECTION						
	PROTAMINE SULFATE						
	+ AM PHARM PARTNERS	10MG/ML	N89454 001	Apr 07, 1987	Mar	CRLD	

INJECTABLE; INJECTION
 PROTAMINE SULFATE
 @ LILLY

10MG/ML

N06460 002

Mar DISC

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
 VIVACTIL

@ ODYSSEY PHARMS

5MG

N16012 001

Jun CAHN

@

10MG

N16012 002

Jun CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
 RANITIDINE

>A>

>A> AP

BEDFORD

EQ 25MG BASE/ML

N74764 001 Nov 19, 2004 Nov NEWA

ZANTAC

>D>

+ GLAXOSMITHKLINE

EQ 25MG BASE/ML

N19090 001 Oct 19, 1984 Nov CFTG

>A> AP

+

GLAXOSMITHKLINE

EQ 25MG BASE/ML

N19090 001 Oct 19, 1984 Nov CFTG

TABLET, EFFERVESCENT; ORAL
 ZANTAC 25

GLAXOSMITHKLINE

EQ 25MG BASE

N20251 003 Apr 01, 2004 Apr NEWA

RIBAVIRIN

CAPSULE; ORAL
 REBETOL

AB

+ SCHERING PLOUGH RES

200MG

N20903 002 Jul 25, 2001 Apr CFTG

RIBASPHERE

AB

THREE RIVERS PHARMS

200MG

N76203 001 Apr 06, 2004 Apr NEWA

RIBAVIRIN

AB

SANDOZ

200MG

N76192 001 Apr 06, 2004 Apr NEWA

AB

TEVA

200MG

N76277 001 Oct 04, 2004 Oct NEWA

RIFAXIMIN

TABLET; ORAL
 XIFAXAN

+ SALIX PHARMS

200MG

N21361 001 May 25, 2004 May NEWA

RISPERIDONE

INJECTABLE; INTRAMUSCULAR
 RISPERDAL CONSTA

JANSSEN PHARMA

25MG/VIAL

N21346 001 Oct 29, 2003 Jul CAHN

37.5MG/VIAL

N21346 002 Oct 29, 2003 Jul CAHN

+

50MG/VIAL

N21346 003 Oct 29, 2003 Jul CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
 RISPERDAL

JANSSEN PHARMA

0.5MG

N21444 001 Apr 02, 2003 Jun CAHN

+

1MG

N21444 002 Apr 02, 2003 Jun CAHN

2MG

N21444 003 Apr 02, 2003 Jun CAHN

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
 RITODRINE HCL

+ HOSPIRA

10MG/ML

N71618 001 Feb 28, 1991 May CAHN

+

15MG/ML

N71619 001 Feb 28, 1991 May CAHN

RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

+ HOSPIRA

30MG/100ML

N71438 001 Jan 22, 1991 May CAHN

ROCURONIUM BROMIDE

DISC	INJECTABLE; INJECTION						
	ZEMURON						
	@	ORGANON USA INC	10MG/ML	N20214	002	Mar 17, 1994	Jul DISC
			10MG/ML	N20214	002	Mar 17, 1994	Jun CMFD
	ZEMURON (P/F)						
CAHN	+	ORGANON USA INC	50MG/5ML (10MG/ML)	N20214	001	Mar 17, 1994	Jul CPOT
CAHN	+		100MG/10ML (10MG/ML)	N20214	003	Mar 17, 1994	Jul NEWA

ROFECOXIB

	SUSPENSION; ORAL						
	VIOXX						
NEWA	@	MERCK	12.5MG/5ML	N21052	001	May 20, 1999	Sep DISC
	@		25MG/5ML	N21052	002	May 20, 1999	Sep DISC
	TABLET; ORAL						
	VIOXX						
CFTG	@	MERCK	12.5MG	N21042	001	May 20, 1999	Sep DISC
CFTG	@		25MG	N21042	002	May 20, 1999	Sep DISC
NEWA	@		50MG	N21042	003	Feb 25, 2000	Sep DISC

ROPINIROLE HYDROCHLORIDE

	TABLET; ORAL						
	REQUIP						
CFTG		GLAXOSMITHKLINE	EQ 5MG BASE	N20658	005	Sep 19, 1997	May CRLD

SAFFLOWER OIL; SOYBEAN OIL

	INJECTABLE; INJECTION						
	LIPOSYN II 10%						
NEWA	+	HOSPIRA	5%;5% (5GM/100ML)	N18997	001	Aug 27, 1984	May CAHN
NEWA	+			N18991	001	Aug 27, 1984	May CAHN
	LIPOSYN II 20%						
	+	HOSPIRA	10%;10% (10GM/100ML)	N18991	001	Aug 27, 1984	May CAHN

SECRETIN SYNTHETIC HUMAN

	FOR SOLUTION; INTRAVENOUS						
	CHIRHOSTIM						
NEWA	+	CHIRHOCLIN	16UGM/VIAL	N21256	001	Apr 09, 2004	Sep CTNA
	HUMAN SECRETIN						
	+	CHIRHOCLIN	16UGM/VIAL	N21256	001	Apr 09, 2004	Apr NEWA

SECRETIN SYNTHETIC PORCINE

	FOR SOLUTION; INTRAVENOUS						
	SECREMAX						
CAHN	+	CHIRHOCLIN	16UGM/VIAL	N21136	001	Apr 04, 2002	Jul CAIN

SELEGILINE HYDROCHLORIDE

	TABLET; ORAL						
	SELEGILINE HCL						
>D>	AB	APOTEX	5MG	N74871	001	Jun 06, 1997	Nov CRLD
>A>	AB	+	5MG	N74871	001	Jun 06, 1997	Nov CRLD
	@	SOMERSET	5MG	N19334	001	Jun 05, 1989	Aug DISC

SEVELAMER HYDROCHLORIDE

	CAPSULE; ORAL						
	RENAGEL						
CAHN	@	GENZYME	403MG	N20926	001	Oct 30, 1998	Jun DISC

SIROLIMUS

TABLET; ORAL

RAPAMUNE

	WYETH PHARMS INC	2MG	N21110 002	Aug 22, 2002	Feb	CRLD
+		5MG	N21110 003	Feb 23, 2004	Feb	NEWA

SODIUM ACETATE, ANHYDROUS

INJECTABLE; INJECTION

SODIUM ACETATE IN PLASTIC CONTAINER

+	HOSPIRA	2MEQ/ML	N18893 001	May 04, 1983	May	CAHN
---	---------	---------	------------	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	HOSPIRA	9MG/ML	N18800 001	Oct 29, 1982	May	CAHN
----	---	---------	--------	------------	--------------	-----	------

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		HOSPIRA	450MG/100ML	N18090 001		May	CAHN
----	--	---------	-------------	------------	--	-----	------

AP			450MG/100ML	N19759 001	Jun 08, 1988	May	CAHN
----	--	--	-------------	------------	--------------	-----	------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		HAEMONETICS	900MG/100ML	N76316 001	Oct 27, 2004	Oct	NEWA
----	--	-------------	-------------	------------	--------------	-----	------

AP		HOSPIRA	9MG/ML	N18803 001	Oct 29, 1982	May	CAHN
----	--	---------	--------	------------	--------------	-----	------

AP	+		9MG/ML	N19217 001	Jul 13, 1984	Jul	CRLD
----	---	--	--------	------------	--------------	-----	------

AP			9MG/ML	N19217 001	Jul 13, 1984	May	CAHN
----	--	--	--------	------------	--------------	-----	------

AP			9MG/ML	N19465 002	Jul 15, 1985	May	CAHN
----	--	--	--------	------------	--------------	-----	------

AP			900MG/100ML	N16366 001		May	CAHN
----	--	--	-------------	------------	--	-----	------

AP			900MG/100ML	N19465 001	Jul 15, 1985	May	CAHN
----	--	--	-------------	------------	--------------	-----	------

AP			900MG/100ML	N19480 001	Sep 17, 1985	May	CAHN
----	--	--	-------------	------------	--------------	-----	------

SODIUM CHLORIDE IN PLASTIC CONTAINER

HOSPIRA 2.5MEQ/ML

N18897 001	Jul 20, 1984	May	CAHN
------------	--------------	-----	------

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AT		HOSPIRA	450MG/100ML	N17670 001		May	CAHN
----	--	---------	-------------	------------	--	-----	------

@ 450MG/100ML

N18380 001		May	CAHN
------------	--	-----	------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT		HOSPIRA	900MG/100ML	N17514 001		May	CAHN
----	--	---------	-------------	------------	--	-----	------

AT			900MG/100ML	N18314 001		May	CAHN
----	--	--	-------------	------------	--	-----	------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

+	WATSON PHARMS	62.5MG/5ML	N20955 001	Feb 18, 1999	Feb	CAHN
---	---------------	------------	------------	--------------	-----	------

SODIUM IODIDE, I-131

SOLUTION; ORAL

SODIUM IODIDE I 131

@ CIS 50mCi/ML

N17315 001		Apr	DISC
------------	--	-----	------

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

AP		HOSPIRA	1.87GM/100ML	N18249 001		May	CAHN
----	--	---------	--------------	------------	--	-----	------

SODIUM LACTATE IN PLASTIC CONTAINER

HOSPIRA 5MEQ/ML

N18947 001	Sep 05, 1984	May	CAHN
------------	--------------	-----	------

SODIUM NITROPRUSSIDE

	INJECTABLE; INJECTION							
	NITROPRESS							
AP	+ HOSPIRA	25MG/ML	N71961	001	Aug 01, 1988	May	CAHN	
	+	50MG/VIAL	N70566	001	Jun 09, 1986	May	CAHN	

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

	INJECTABLE; INJECTION							
	SODIUM PHOSPHATES IN PLASTIC CONTAINER							
	HOSPIRA	142MG/ML; 276MG/ML	N18892	001	May 10, 1983	May	CAHN	

SODIUM TETRADECYL SULFATE

	INJECTABLE; INJECTION							
	SOTRADECOL							
>A>	BIONICHE PHARM USA	20MG/2ML (10MG/ML)	N40541	001	Nov 12, 2004	Nov	NEWA	
>A>	+	60MG/2ML (30MG/ML)	N40541	002	Nov 12, 2004	Nov	NEWA	

SOLIFENACIN SUCCINATE

	INJECTABLE; INJECTION							
	TABLET; ORAL							
	VESICARE							
>A>	YAMANOUCHI	5MG	N21518	001	Nov 19, 2004	Nov	NEWA	
>A>	+	10MG	N21518	002	Nov 19, 2004	Nov	NEWA	

SOMATROPIN RECOMBINANT

	INJECTABLE; INJECTION							
	NORDITROPIN NORDIFLEX							
	NOVO NORDISK	5MG/1.5ML	N21148	004	Oct 01, 2004	Oct	NEWA	
		10MG/1.5ML	N21148	005	Oct 01, 2004	Oct	NEWA	
		15MG/1.5ML	N21148	006	Oct 01, 2004	Oct	NEWA	
	SAIZEN							
	@ SERONO	6MG/VIAL	N19764	001	Oct 08, 1996	May	DISC	
	SEROSTIM							
BX	SERONO	4MG/VIAL	N20604	003	Jul 25, 1997	Jan	CTEC	
	@	8.8MG/VIAL	N20604	004	Sep 06, 2001	Jan	DISC	
	ZORBTIVE							
	@ SERONO INC	4MG/VIAL	N21597	001	Dec 01, 2003	May	DISC	
	@	5MG/VIAL	N21597	002	Dec 01, 2003	May	DISC	
	@	6MG/VIAL	N21597	003	Dec 01, 2003	May	DISC	

SOTALOL HYDROCHLORIDE

	TABLET; ORAL							
	SOTALOL HCL							
AB2	MUTUAL PHARM	80MG	N76576	001	Apr 08, 2004	Apr	NEWA	
AB2		120MG	N76576	002	Apr 08, 2004	Apr	NEWA	
AB2		160MG	N76576	003	Apr 08, 2004	Apr	NEWA	
AB2	TEVA	80MG	N76883	001	Jul 26, 2004	Jul	NEWA	
AB2		120MG	N76883	002	Jul 26, 2004	Jul	NEWA	
AB2		160MG	N76883	003	Jul 26, 2004	Jul	NEWA	

SOYBEAN OIL

	INJECTABLE; INJECTION							
	LIPOSYN III 10%							
AP	+ HOSPIRA	10%	N18969	001	Sep 24, 1984	May	CAHN	
	LIPOSYN III 20%							
AP	+ HOSPIRA	20%	N18970	001	Sep 25, 1984	May	CAHN	

INJECTABLE; INJECTION					
LIPOSYN III 30%					
AP	+	HOSPIRA	30%	N20181 001	Jan 13, 1998 May CAHN
<u>SPARFLOXACIN</u>					
TABLET; ORAL					
ZAGAM					
		@ MYLAN	200MG	N20677 001	Dec 19, 1996 Mar DISC
<u>SPIRONOLACTONE</u>					
TABLET; ORAL					
SPIRONOLACTONE					
AB		MUTUAL PHARM	25MG	N87265 001	Aug CAHN
<u>STAVUDINE</u>					
CAPSULE, EXTENDED RELEASE; ORAL					
ZERIT XR					
		@ BRISTOL MYERS SQUIBB	37.5MG	N21453 001	Dec 31, 2002 Jun DISC
		@	50MG	N21453 002	Dec 31, 2002 Jun DISC
		@	75MG	N21453 003	Dec 31, 2002 Jun DISC
		@	100MG	N21453 004	Dec 31, 2002 Jun DISC
<u>SUCCINYLCHOLINE CHLORIDE</u>					
INJECTABLE; INJECTION					
ANECTINE					
AP	+	SABEX 2002	20MG/ML	N08453 002	Jul CAHN
		@	50MG/ML	N08453 003	Jul CAHN
	+		500MG/VIAL	N08453 001	Jul CAHN
	+		1GM/VIAL	N08453 004	Jul CAHN
QUELICIN					
AP	+	HOSPIRA	20MG/ML	N08845 006	May CAHN
QUELICIN PRESERVATIVE FREE					
AP	+	HOSPIRA	20MG/ML	N08845 001	May CAHN
		@	50MG/ML	N08845 002	May CAHN
	+		100MG/ML	N08845 004	May CAHN
<u>SUCRALFATE</u>					
TABLET; ORAL					
CARAFATE					
AB	+	AXCAN SCANDIPHARM	1GM	N18333 001	Feb CAHN
<u>SUFENTANIL CITRATE</u>					
INJECTABLE; INJECTION					
SUFENTANIL CITRATE					
AP		BAXTER HLTHCARE	EQ 0.05MG BASE/ML	N74413 001	Dec 15, 1995 Aug CAHN
SULFENTANIL CITRATE					
AP		HOSPIRA	EQ 0.05MG BASE/ML	N74534 001	Dec 11, 1996 May CAHN
<u>SULFACETAMIDE SODIUM</u>					
SOLUTION/DROPS; OPHTHALMIC					
SULF-10					
AT		NOVARTIS	10%	N80025 001	Mar CMFD

SULFACYTINE

TABLET; ORAL

RENOQUID

@ GLENWOOD

250MG

N17569 001

Aug DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

>A> AP + MUTUAL PHARM 80MG/ML;16MG/ML

N18374 001

Nov CAHN

>D> AP + WOMEN FIRST HLTHCARE 80MG/ML;16MG/ML

N18374 001

Nov CAHN

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP BAXTER HLTHCARE 80MG/ML;16MG/ML

N70627 001 Dec 29, 1987 Aug CAHN

@ 80MG/ML;16MG/ML

N70627 001 Dec 29, 1987 Sep DISC

AP 80MG/ML;16MG/ML

N70628 001 Dec 29, 1987 Aug CAHN

AP HOSPIRA 80MG/ML;16MG/ML

N73199 001 Sep 11, 1992 May CAHN

TABLET; ORAL

BACTRIM

>A> AB MUTUAL PHARM 400MG;80MG

N17377 001

Nov CAHN

>D> AB WOMEN FIRST HLTHCARE 400MG;80MG

N17377 001

Nov CAHN

BACTRIM DS

>A> AB + MUTUAL PHARM 800MG;160MG

N17377 002

Nov CAHN

>D> AB + WOMEN FIRST HLTHCARE 800MG;160MG

N17377 002

Nov CAHN

SULFAMETHOPRIM-DS

@ PAR PHARM 800MG;160MG

N70032 001 Feb 15, 1985 Sep DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ MUTUAL PHARM 400MG;80MG

N70006 001 Nov 14, 1984 Aug CAHN

@ SANDOZ 400MG;80MG

N70889 001 Nov 13, 1986 Sep DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

@ MUTUAL PHARM 800MG;160MG

N70007 001 Nov 14, 1984 Aug CAHN

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

BERLEX LABS

N/A

N20887 001 Sep 14, 1998 Jun CAHN

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

+ BERLEX LABS N/A

N21012 001 Aug 03, 1999 Jun CAHN

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

DRAXIMAGE MDP

AP + DRAXIMAGE N/A

N18035 001

May CTNA

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION

TECHNESCAN

+ MALLINCKRODT N/A

N18321 001

Sep CRLD

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE

+ BRISTOL MYERS SQUIBB N/A

N19785 001 Dec 21, 1990 Jul CRLD

MIRALUMA

BRISTOL MYERS SQUIBB N/A

N19785 003 May 23, 1997 Nov CRLD

>D>

		INJECTABLE; INJECTION							
		MIRALUMA							
>A>	+	BRISTOL MYERS SQUIBB	N/A			N19785 003	May 23, 1997	Nov	CRLD
		<u>TELITHROMYCIN</u>							
		TABLET; ORAL							
		KETEK							
	+	AVENTIS PHARMS	400MG			N21144 001	Apr 01, 2004	Apr	NEWA
		<u>TEMAZEPAM</u>							
		CAPSULE; ORAL							
		TEMAZEPAM							
	@	MUTUAL PHARM	15MG			N71174 001	Jul 10, 1986	Aug	CARR
	@		30MG			N71175 001	Jul 10, 1986	Aug	CARR
		<u>TERAZOSIN HYDROCHLORIDE</u>							
		TABLET; ORAL							
		TERAZOSIN HCL							
>D>	AB	TEVA	EQ 1MG BASE			N74446 001	May 18, 2000	Nov	DISC
>A>	@		EQ 1MG BASE			N74446 001	May 18, 2000	Nov	DISC
>D>	AB		EQ 2MG BASE			N74446 002	May 18, 2000	Nov	DISC
>A>	@		EQ 2MG BASE			N74446 002	May 18, 2000	Nov	DISC
>D>	AB		EQ 5MG BASE			N74446 003	May 18, 2000	Nov	DISC
>A>	@		EQ 5MG BASE			N74446 003	May 18, 2000	Nov	DISC
>D>	AB		EQ 10MG BASE			N74446 004	May 18, 2000	Nov	DISC
>A>	@		EQ 10MG BASE			N74446 004	May 18, 2000	Nov	DISC
		<u>TERBINAFINE</u>							
		GEL; TOPICAL							
		LAMISIL							
		NOVARTIS	1%			N20846 001	Apr 29, 1998	Jan	CMFD
		<u>TERBUTALINE SULFATE</u>							
		INJECTABLE; INJECTION							
		BRETHINE							
AP	+	AAIPHARMA LLC	1MG/ML			N18571 001		Apr	CFTG
		TERBUTALINE SULFATE							
AP		AM PHARM	1MG/ML			N76887 001	May 26, 2004	May	NEWA
AP		BEDFORD	1MG/ML			N76770 001	Apr 23, 2004	Apr	NEWA
AP		SICOR PHARMS	1MG/ML			N76853 001	Jul 20, 2004	Jul	NEWA
		<u>TERCONAZOLE</u>							
		CREAM; VAGINAL							
		TERAZOL 3							
AB	+	ORTHO MCNEIL PHARM	0.8%			N19964 001	Feb 21, 1991	Apr	CFTG
		TERCONAZOLE							
BX	+	ALTANA	0.8%			N21735 001	Oct 01, 2004	Oct	NEWA
AB		TARO	0.8%			N75953 001	Apr 06, 2004	Apr	NEWA
		<u>TESTOSTERONE</u>							
		FILM, EXTENDED RELEASE; TRANSDERMAL							
		ANDRODERM							
	+	WATSON LABS	5MG/24HR			N20489 002	May 02, 1997	Aug	CTEC
		TESTODERM							
	@	ALZA	4MG/24HR			N19762 001	Oct 12, 1993	Aug	DISC
	@		6MG/24HR			N19762 002	Oct 12, 1993	Aug	DISC

FILM, EXTENDED RELEASE; TRANSDERMAL

TESTODERM TTS

@ ALZA	5MG/24HR	N20791 001	Dec 18, 1997	Aug	DISC
--------	----------	------------	--------------	-----	------

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HCL

AB	MUTUAL PHARM	250MG	N60736 001		Aug	CAHN
AB		500MG	N60736 002		Aug	CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

@ FLEMING PHARMS	65MG	N85075 003	Nov 24, 1986	Jun	DISC
------------------	------	------------	--------------	-----	------

AEROLATE JR

@ FLEMING PHARMS	130MG	N85075 002	Nov 24, 1986	Jun	DISC
------------------	-------	------------	--------------	-----	------

AEROLATE SR

@ FLEMING PHARMS	260MG	N85075 001	Nov 24, 1986	Jun	DISC
------------------	-------	------------	--------------	-----	------

THEOPHYLLINE

BC	INWOOD LABS	100MG	N40052 001	Feb 14, 1994	Oct	CTEC
BC		125MG	N40052 002	Feb 14, 1994	Oct	CTEC
BC		200MG	N40052 003	Feb 14, 1994	Oct	CTEC
BC	+	300MG	N40052 004	Feb 14, 1994	Oct	CTEC

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA	4MG/ML	N19211 007	Dec 14, 1984	May	CAHN
AP	+		40MG/100ML	N19211 001	Dec 14, 1984	May	CAHN
AP	+		80MG/100ML	N19211 002	Dec 14, 1984	May	CAHN
AP	+		160MG/100ML	N19211 003	Dec 14, 1984	May	CAHN
AP	+		200MG/100ML	N19211 004	Dec 14, 1984	May	CAHN
AP	+		320MG/100ML	N19211 006	Jan 20, 1988	May	CAHN
AP	+		400MG/100ML	N19211 005	Dec 14, 1984	May	CAHN

SOLUTION; ORAL

AEROLATE

@ FLEMING PHARMS	150MG/15ML	N89141 001	Dec 03, 1986	Jun	DISC
------------------	------------	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

THEOLAIR-SR

@ 3M	200MG	N88369 001	Jul 16, 1987	Jun	DISC
------	-------	------------	--------------	-----	------

@	250MG	N86363 002	Jul 16, 1987	Jun	DISC
---	-------	------------	--------------	-----	------

@	300MG	N88364 001	Jul 16, 1987	Jun	DISC
---	-------	------------	--------------	-----	------

@	500MG	N89132 001	Jul 16, 1987	Jun	DISC
---	-------	------------	--------------	-----	------

THEOPHYLLINE

AB	ABLE	300MG	N40548 001	Apr 30, 2004	Apr	NEWA
AB		400MG	N40543 001	Apr 27, 2004	Apr	NEWA
AB		450MG	N40546 001	Apr 30, 2004	Apr	NEWA
AB		600MG	N40539 001	Apr 27, 2004	Apr	NEWA

UNIPHYL

AB	+	PURDUE FREDERICK	400MG	N87571 001	Sep 01, 1982	Apr	CFTG
AB	+		600MG	N40086 001	Apr 15, 1996	Apr	CFTG

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

AP	BAXTER HLTHCARE	100MG/ML	N80575 001		Aug	CAHN
AP	HOSPIRA	100MG/ML	N40079 001	May 03, 1996	May	CAHN

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL					
	THIORIDAZINE HCL				
	@ MUTUAL PHARM	10MG	N88375 001	Nov 18, 1983	Aug CAHN
	@	15MG	N88461 001	Nov 18, 1983	Aug CAHN
	@	25MG	N87264 001	Nov 18, 1983	Aug CAHN
AB	@	50MG	N88370 001	Nov 18, 1983	Aug CAHN
	@	100MG	N88379 001	Nov 16, 1983	Aug CAHN
	@	150MG	N88737 001	Sep 26, 1984	Aug CAHN
	@	200MG	N88738 001	Oct 16, 1984	Aug CAHN

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC					
ISTALOL					
BT	+ ISTA PHARMS	EQ 0.5% BASE	N21516 001	Jun 04, 2004	Sep CTEC
	+ SENJU	EQ 0.5% BASE	N21516 001	Jun 04, 2004	Jun NEWA
TIMOLOL MALEATE					
>D>	AT AKORN	EQ 0.25% BASE	N74465 001	Mar 25, 1997	Nov DISC
>A>	@	EQ 0.25% BASE	N74465 001	Mar 25, 1997	Nov DISC
AT	HI TECH PHARMA	EQ 0.5% BASE	N75163 001	Sep 10, 2002	Jun CDFR

TINIDAZOLE

TABLET; ORAL					
TINDAMAX					
	PRESUTTI LABS	250MG	N21618 001	May 17, 2004	May NEWA
	+	500MG	N21618 002	May 17, 2004	May NEWA

TIOTROPIUM BROMIDE MONOHYDRATE

CAPSULE; INHALATION					
SPIRIVA					
	+ BOEHRINGER INGELHEIM	EQ 0.018MG BASE	N21395 001	Jan 30, 2004	Jan NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL					
ZANAFLEX					
	ACORDA	EQ 2MG BASE	N21447 001	Aug 29, 2002	Aug CAHN
		EQ 4MG BASE	N21447 002	Aug 29, 2002	Aug CAHN
	+	EQ 6MG BASE	N21447 003	Aug 29, 2002	Aug CAHN
TABLET; ORAL					
TIZANIDINE HCL					
AB	IVAX PHARMS	EQ 2MG BASE	N76321 001	Sep 30, 2004	Sep NEWA
AB		EQ 4MG BASE	N76321 002	Sep 30, 2004	Sep NEWA
AB	TORPHARM	EQ 2MG BASE	N76533 001	Jan 16, 2004	Jan NEWA
AB		EQ 4MG BASE	N76533 002	Jan 16, 2004	Jan NEWA
	ZANAFLEX				
AB	ACORDA	EQ 2MG BASE	N20397 002	Feb 04, 2000	Aug CAHN
AB	+	EQ 4MG BASE	N20397 001	Nov 27, 1996	Aug CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION					
NEBCIN					
	@ LILLY	EQ 10MG BASE/ML	N50477 005		Jun DISC
	@	EQ 10MG BASE/ML	N62008 004		Jun DISC
	@	EQ 10MG BASE/ML	N62707 001	Apr 29, 1987	Jun DISC
	@	EQ 40MG BASE/ML	N62008 001		Jun DISC

INJECTABLE; INJECTION

	NEBCIN							
	@ LILLY	EQ 1.2GM BASE/VIAL	N50519 001		Jun	DISC		
	TOBRAMYCIN							
	AM PHARM	EQ 1.2GM BASE/VIAL	N50789 001	Jul 13, 2004	Jul	NEWA		
	+ PHARMA TEK	EQ 1.2GM BASE/VIAL	N65013 001	Aug 17, 2001	Jul	CTEC		
AP	+ TOBRAMYCIN SULFATE	EQ 1.2GM BASE/VIAL	N65013 001	Aug 17, 2001	Jun	CRLD		
AP	+ HOSPIRA	EQ 10MG BASE/ML	N63080 001	Apr 30, 1991	Jun	CRLD		
AP		EQ 10MG BASE/ML	N63080 001	Apr 30, 1991	May	CAHN		
AP		EQ 10MG BASE/ML	N63112 001	Apr 30, 1991	May	CAHN		
AP		EQ 40MG BASE/ML	N63111 001	Apr 30, 1991	May	CAHN		
AP	+	EQ 40MG BASE/ML	N63116 001	May 18, 1992	May	CAHN		
AP		EQ 40MG BASE/ML	N63161 001	May 29, 1991	May	CAHN		
	TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	+ HOSPIRA	EQ 1.2MG BASE/ML	N63081 003	Jul 31, 1990	May	CAHN		
	+	EQ 1.6MG BASE/ML	N63081 006	Jun 02, 1993	May	CAHN		
	+	EQ 80MG BASE/100ML	N63081 001	Jul 31, 1990	May	CAHN		

TOLAZAMIDE

	TABLET; ORAL							
	TOLAZAMIDE							
	@ WATSON LABS	100MG	N70513 001	Jan 09, 1986	Aug	DISC		

TOLCAPONE

	TABLET; ORAL							
	TASMAR							
	VALEANT	100MG	N20697 001	Jan 29, 1998	Aug	CAHN		
	+	200MG	N20697 002	Jan 29, 1998	Aug	CAHN		

TOLMETIN SODIUM

	CAPSULE; ORAL							
	TOLMETIN SODIUM							
	@ TEVA	EQ 400MG BASE	N73519 001	May 29, 1992	Sep	DISC		

TOPIRAMATE

	CAPSULE; ORAL							
	TOPAMAX SPRINKLE							
	ORTHO MCNEIL PHARM	15MG	N20844 001	Oct 26, 1998	Jul	CAHN		
	+	25MG	N20844 002	Oct 26, 1998	Jul	CAHN		
	@	50MG	N20844 003	Oct 26, 1998	Jul	CAHN		
	TABLET; ORAL							
	TOPAMAX							
	ORTHO MCNEIL PHARM	50MG	N20505 005	Dec 24, 1996	Jun	CMFD		

TORSEMIDE

	TABLET; ORAL							
	TORSEMIDE							
AB	PLIVA PHARM IND	100MG	N76346 004	Oct 19, 2004	Oct	NEWA		

TRAVOPROST

	SOLUTION/DROPS; OPHTHALMIC							
	TRAVATAN							
	+ ALCON	0.004%	N21257 001	Mar 16, 2001	May	CAHN		

TREPROSTINIL SODIUM

>A>	INJECTABLE; IV (INFUSION)-SC				
>A>	REMODULIN			N21272 001	May 21, 2002 Nov CDFR
>A>	UNITED THERAP	1MG/ML		N21272 002	May 21, 2002 Nov CDFR
>A>		2.5MG/ML		N21272 003	May 21, 2002 Nov CDFR
>A>		5MG/ML		N21272 004	May 21, 2002 Nov CDFR
>A>	+	10MG/ML			
>D>	INJECTABLE; SUBCUTANEOUS				
>D>	REMODULIN			N21272 001	May 21, 2002 Nov CDFR
>D>	UNITED THERAP	1MG/ML		N21272 002	May 21, 2002 Nov CDFR
>D>		2.5MG/ML		N21272 003	May 21, 2002 Nov CDFR
>D>		5MG/ML		N21272 004	May 21, 2002 Nov CDFR
>D>	+	10MG/ML			

TRETINOIN

	CREAM; TOPICAL				
	AVITA				
AB	MYLAN BERTEK	0.025%		N20404 003	Jan 14, 1997 Aug CAHN
	GEL; TOPICAL				
	AVITA				
BT	MYLAN BERTEK	0.025%		N20400 001	Jan 29, 1998 Aug CAHN

TRIAMCINOLONE

	TABLET; ORAL				
	ARISTOCORT				
BP	+ FUJISAWA HLTHCARE	4MG		N11161 007	Jun CRLD
	KENACORT				
	@ BRISTOL MYERS SQUIBB	8MG		N11283 010	Jun DISC
	TRIAMCINOLONE				
	@ WATSON LABS	4MG		N84270 001	Jun DISC

TRIAMCINOLONE ACETONIDE

	AEROSOL, METERED; INHALATION				
	AZMACORT				
	+ KOS	0.1MG/INH		N18117 001	Apr 23, 1982 Apr CAHV
	SPRAY, METERED; NASAL				
	NASACORT HFA				
	+ AVENTIS PHARMS	0.055MG/SPRAY		N20784 001	Apr 07, 2004 Apr NEWA

TRIAMCINOLONE DIACETATE

	INJECTABLE; INJECTION				
	ARISTOCORT				
	@ SABEX 2002	25MG/ML		N11685 003	Jun DISC
	@	40MG/ML		N12802 001	Jun DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

	INJECTABLE; INJECTION				
	TRIMETHOBENZAMIDE HCL				
AP	HOSPIRA	100MG/ML		N88804 001	Apr 03, 1987 May CAHN

TRIMETHOPRIM

	TABLET; ORAL				
	TRIMETHOPRIM				
	@ MUTUAL PHARM	100MG		N70494 001	Jan 22, 1986 Aug CAHN
	@	200MG		N70495 001	Sep 24, 1986 Aug CAHN

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

ODYSSEY PHARMS

EQ 25MG BASE

N16792 001

Jun CAHN

EQ 50MG BASE

N16792 002

Jun CAHN

+

EQ 100MG BASE

N16792 003 Sep 15, 1982 Jun CAHN

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+ WATSON LABS

11.25MG/VIAL

N21288 001 Jun 29, 2001 Nov CAHN

+ WATSON PHARMS

11.25MG/VIAL

N21288 001 Jun 29, 2001 Nov CAHN

+

11.25MG/VIAL

N21288 001 Jun 29, 2001 Sep CAHN

TRELSTAR DEPOT

+ WATSON LABS

EQ 3.75MG BASE/VIAL

N20715 001 Jun 15, 2000 Nov CAHN

+ WATSON PHARMS

EQ 3.75MG BASE/VIAL

N20715 001 Jun 15, 2000 Nov CAHN

+

EQ 3.75MG BASE/VIAL

N20715 001 Jun 15, 2000 Sep CAHN

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC

CERUMENEX

@ PURDUE FREDERICK

10%

N11340 002

May DISC

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+ HOSPIRA

3.6GM/100ML

N13025 002

May CAHN

TROSPIMUM CHLORIDE

TABLET; ORAL

SANCTURA

+ INDEVUS

20MG

N21595 001 May 28, 2004 May NEWA

TROVAFLOXACIN MESYLATE

TABLET; ORAL

TROVAN

@ PFIZER

EQ 100MG BASE

N20759 001 Dec 18, 1997 Jun DISC

@

EQ 200MG BASE

N20759 002 Dec 18, 1997 Jun DISC

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION

TUBOCURARINE CHLORIDE

+ BRISTOL MYERS SQUIBB

3MG/ML

N05657 001

Jun CTEC

@

3MG/ML

N05657 001

Jul DISC

@ HOSPIRA

3MG/ML

N06095 001

Jun DISC

AP

+

3MG/ML

N06095 001

May CAHN

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

+ NOVARTIS

0.15%

N21214 001 Aug 03, 2000 Aug CAHN

UREA

INJECTABLE; INJECTION

STERILE UREA					
@ HOSPIRA	40GM/VIAL	N17698 001		May	CAHN
UREAPHIL					
+ HOSPIRA	40GM/VIAL	N12154 001		May	CAHN

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE					
+ FERRING	75 IU/VIAL	N21289 001	May 06, 2002	Oct	CTEC

INJECTABLE; SUBCUTANEOUS

FERTINEX					
@ SERONO	75 IU/AMP	N19415 005	Aug 23, 1996	Oct	DISC

UROKINASE

INJECTABLE; INJECTION

ABBOKINASE					
+ ABBOTT	250,000 IU/VIAL	N21846 001		Nov	CMS1

URSODIOL

TABLET; ORAL

URSO 250					
AXCAN SCANDIPHARM	250MG	N20675 001	Dec 10, 1997	Jul	CTNA

URSO FORTE					
+ AXCAN SCANDIPHARM	500MG	N20675 002	Jul 21, 2004	Sep	CTNA

URSODIOL					
+ AXCAN SCANDIPHARM	500MG	N20675 002	Jul 21, 2004	Jul	NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALTREX					
+ GLAXOSMITHKLINE	EQ 1GM BASE	N20487 002	Jun 23, 1995	Feb	CRLD

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HCL					
LILLY	EQ 125MG BASE	N50606 001	Apr 15, 1986	Nov	CARN
	EQ 250MG BASE	N50606 002	Apr 15, 1986	Nov	CAHN
+ VIROPHARMA	EQ 125MG BASE	N50606 001	Apr 15, 1986	Nov	CAHN
	EQ 250MG BASE	N50606 002	Apr 15, 1986	Nov	CAHN

FOR SOLUTION; ORAL

VANCOCIN HCL					
@ LILLY	EQ 250MG BASE/5ML	N61667 002	Jul 13, 1983	Jun	DISC
@	EQ 500MG BASE/6ML	N61667 001		Jun	DISC

INJECTABLE; INJECTION

VANCOCIN HCL					
@ LILLY	EQ 500MG BASE/VIAL	N60180 001		Jun	DISC
@	EQ 500MG BASE/VIAL	N62476 001	Mar 15, 1984	Jun	DISC
@	EQ 500MG BASE/VIAL	N62716 001	Mar 13, 1987	Jun	DISC
@	EQ 500MG BASE/VIAL	N62812 001	Nov 17, 1987	Jun	DISC
@	EQ 1GM BASE/VIAL	N60180 002	Mar 21, 1986	Jun	DISC
@	EQ 1GM BASE/VIAL	N62476 002	Mar 21, 1986	Jun	DISC
@	EQ 1GM BASE/VIAL	N62716 002	Mar 13, 1987	Jun	DISC
@	EQ 1GM BASE/VIAL	N62812 002	Nov 17, 1987	Jun	DISC
@	EQ 10GM BASE/VIAL	N62812 003	Nov 17, 1987	Jun	DISC

INJECTABLE; INJECTION

AP	INJECTABLE; INJECTION						
	VANCOMYCIN HCL						
	HOSPIRA	EQ 500MG BASE/VIAL	N62911	001	Aug 04, 1988	May	CAHN
AP		EQ 500MG BASE/VIAL	N62931	001	Oct 29, 1992	May	CAHN
AP		EQ 1GM BASE/VIAL	N62912	001	Aug 04, 1988	May	CAHN
AP		EQ 1GM BASE/VIAL	N62933	001	Oct 29, 1992	May	CAHN
AP		EQ 5GM BASE/VIAL	N63076	001	Dec 21, 1990	May	CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

AP	VECURONIUM BROMIDE						
	+ ABBOTT	4MG/VIAL	N75558	001	Sep 11, 2001	Apr	CAHN
	+ HOSPIRA	4MG/VIAL	N75558	001	Sep 11, 2001	May	CAHN
AP		10MG/VIAL	N75164	001	Oct 21, 1999	May	CAHN
AP		20MG/VIAL	N75164	002	Oct 21, 1999	May	CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

EFFEXOR

+	WYETH PHARMS INC						
		EQ 50MG BASE	N20151	003	Dec 28, 1993	Oct	CRLD
		EQ 50MG BASE	N20151	003	Dec 28, 1993	May	CRLD
		EQ 100MG BASE	N20151	005	Dec 28, 1993	Oct	CRLD
		EQ 100MG BASE	N20151	005	Dec 28, 1993	May	CRLD

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HCL

AP	HOSPIRA						
AP		2.5MG/ML	N70577	001	Feb 02, 1987	May	CAHN
AP		2.5MG/ML	N70737	001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N70738	001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N70739	001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N70740	001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N75136	001	Oct 20, 1998	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HCL

AB	BARR						
AB		120MG	N75072	001	May 25, 1999	May	CMFD
AB		240MG	N75072	003	May 25, 1999	May	CMFD
AB	KALI LABS	120MG	N75072	001	May 25, 1999	Aug	CAHN
AB		240MG	N75072	003	May 25, 1999	Aug	CAHN

TABLET; ORAL

VERAPAMIL HCL

@ MUTUAL PHARM

@

80MG	N70482	001	Sep 24, 1986	Aug	CAHN
120MG	N70483	001	Sep 24, 1986	Aug	CAHN

VINCRISTINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

@ LILLY

1MG/ML	N14103	003	Mar 07, 1984	Mar	DISC
--------	--------	-----	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

BAXTER HLTHCARE

EQ 10MG BASE/ML	N75992	001	Jun 10, 2003	Aug	CAHN
-----------------	--------	-----	--------------	-----	------

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

+ PFIZER

20MG

N20825 001 Feb 05, 2001 Sep CRLD

80MG

N20825 004 Feb 05, 2001 Sep CRLD

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN

SANOFI SYNTHELABO

5MG

N19908 001 Dec 16, 1992 Apr CAHN

+

10MG

N19908 002 Dec 16, 1992 Apr CAHN

05/1/2006 AM 11:58 AM

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

+ NOVARTIS 0.5%;0.05% N18746 002 Jul 11, 1994 Feb CAHN

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

+ BAYER 500MG N21317 001 Oct 18, 2001 Nov DISC

@ 500MG N21317 001 Oct 18, 2001 Nov DISC

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

+ SCHERING PLOUGH 3%;7.5%;3% N20045 001 Dec 07, 1992 Oct CAIN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT 3

+ BAYER 2% N20421 001 Dec 21, 1995 Jun CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

HIBICLENS

+ REGENT 4% N17768 001 Sep CAHN

HIBISTAT

+ REGENT 0.5% N18300 001 Sep CAHN

SPONGE; TOPICAL

HIBICLENS

+ REGENT 4% N18423 001 Sep CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP FREPP

+ MEDI FLEX HOSP 2%;70% N20832 001 Jul 14, 2000 Jun CTNA

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ MEDI FLEX HOSP 2%;70% N21555 001 Oct 07, 2002 Jun CAIN

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

@ SANDOZ 12MG N70797 001 Aug 12, 1988 Apr DISC

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

@ SCHERING PLOUGH 8MG N07638 001 Sep DISC

EFIDAC 24 CHLORPHENIRAMINE MALEATE

+ ALZA 16MG N19746 002 Nov 18, 1994 Mar CRLD

@ 16MG N19746 002 Nov 18, 1994 Sep DISC

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+	WYETH CONS	1MG/5ML;100MG/5ML;15MG/5ML	N21587 001	Feb 24, 2004	Feb	NEWA
---	------------	----------------------------	------------	--------------	-----	------

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

ADAMS LABS

30MG;600MG

N21620 002 Apr 29, 2004 Apr NEWA

+		60MG;1.2GM	N21620 001	Apr 29, 2004	Apr	NEWA
---	--	------------	------------	--------------	-----	------

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

LNK

25MG

N40564 001 Aug 27, 2004 Aug NEWA

EPINEPHRINE

AEROSOL, METERED; INHALATION

EPINEPHRINE

ARMSTRONG PHARMS

0.2MG/INH

N87907 001 May 23, 1984 Oct CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MUCINEX D

ADAMS

600MG;60MG

N21585 001 Jun 22, 2004 Nov CAHN

>D>		600MG;60MG	N21585 001	Jun 22, 2004	Jun	NEWA
-----	--	------------	------------	--------------	-----	------

>D>	+	1.2GM;120MG	N21585 002	Jun 22, 2004	Nov	CAHN
-----	---	-------------	------------	--------------	-----	------

>D>	+	1.2GM;120MG	N21585 002	Jun 22, 2004	Jun	NEWA
-----	---	-------------	------------	--------------	-----	------

>A>		600MG;60MG	N21585 001	Jun 22, 2004	Nov	CAHN
-----	--	------------	------------	--------------	-----	------

>A>	+	1.2GM;120MG	N21585 002	Jun 22, 2004	Nov	CAHN
-----	---	-------------	------------	--------------	-----	------

>A>						
-----	--	--	--	--	--	--

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ELIXSURE

TARO

100MG/5ML

N21604 001 Jan 07, 2004 Jan NEWA

TABLET, CHEWABLE; ORAL

IBUPROFEN

PERRIGO

50MG

N76359 001 Jan 16, 2004 Jan NEWA

100MG

N76359 002 Jan 16, 2004 Jan NEWA

TABLET; ORAL

IBUPROFEN

LNK

100MG

N76741 001 Jun 17, 2004 Jun NEWA

@ MUTUAL PHARM

200MG

N70493 001 Dec 24, 1985 Aug CAHN

@

200MG

N70908 001 Sep 26, 1986 Aug CAHN

@

200MG

N71462 001 Oct 02, 1986 Aug CAHN

IBUPROFEN POTASSIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

+	WYETH CONS	200MG;30MG	N21374 001	May 30, 2002	Mar	CAHN
---	------------	------------	------------	--------------	-----	------

LORATADINE

SYRUP; ORAL

LORATADINE

APOTEX

1MG/ML

N75565 001 Oct 05, 2004 Oct NEWA

<u>SYRUP; ORAL</u>						
<u>LORATADINE</u>						
MORTON GROVE	1MG/ML	N75815	001	Aug 20, 2004	Aug	NEWA
PERRIGO	1MG/ML	N75728	001	Aug 20, 2004	Aug	NEWA
RANBAXY	1MG/ML	N76529	001	Aug 20, 2004	Aug	NEWA
TARO	1MG/ML	N76805	001	Aug 20, 2004	Aug	NEWA
<u>TABLET; ORAL</u>						
<u>LORATADINE</u>						
PERRIGO	10MG	N21512	001	Jun 24, 2004	Jun	NEWA
	10MG	N76301	001	Jun 25, 2004	Jun	NEWA
<u>LORATADINE; PSEUDOEPHEDRINE SULFATE</u>						
<u>TABLET, EXTENDED RELEASE; ORAL</u>						
<u>CLARITIN-D</u>						
@ SCHERING	5MG;120MG	N19670	002	Nov 27, 2002	Aug	DISC
<u>LORATADINE AND PSEUDOEPHEDRINE SULFATE</u>						
ANDRX PHARMS	5MG;120MG	N76208	001	Jan 28, 2004	Jan	NEWA
+ IMPAX LABS	5MG;120MG	N76050	001	Jan 30, 2003	Aug	CRLD
	10MG;240MG	N75989	001	Mar 04, 2004	Mar	NEWA
RANBAXY	10MG;240MG	N76557	001	Sep 22, 2004	Sep	NEWA
<u>MICONAZOLE NITRATE</u>						
<u>CREAM, SUPPOSITORY; TOPICAL, VAGINAL</u>						
<u>MICONAZOLE 7 COMBINATION PACK</u>						
G AND W LABS	2%,100MG	N76585	001	Mar 26, 2004	Mar	NEWA
<u>CREAM; TOPICAL, VAGINAL</u>						
<u>MICONAZOLE 3 COMBINATION PACK</u>						
PERRIGO	2%,4%	N76357	001	Mar 30, 2004	Mar	NEWA
<u>MONISTAT 3 COMBINATION PACK</u>						
PERSONAL PRODS	2%,4%	N21261	003	Jun 17, 2003	Aug	CRLD
<u>MINOXIDIL</u>						
<u>SOLUTION; TOPICAL</u>						
<u>THEROXIDIL</u>						
HARMONY LABS	5%	N76239	001	Aug 24, 2004	Aug	NEWA
<u>NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE</u>						
<u>TABLET, EXTENDED RELEASE; ORAL</u>						
<u>NAPROXEN SODIUM AND PSEUDOEPHEDRINE HCL</u>						
PERRIGO	EQ 200MG BASE;120MG	N76518	001	Mar 17, 2004	Mar	NEWA
<u>NICOTINE POLACRILEX</u>						
<u>GUM, CHEWING; BUCCAL</u>						
<u>NICOTINE POLACRILEX</u>						
PERRIGO	EQ 2MG BASE	N76775	001	Sep 16, 2004	Sep	NEWA
	EQ 4MG BASE	N76789	001	Sep 16, 2004	Sep	NEWA
WATSON LABS	EQ 2MG BASE	N76568	001	Jul 29, 2004	Jul	NEWA
	EQ 2MG BASE	N76569	001	Jul 29, 2004	Jul	NEWA
	EQ 4MG BASE	N76568	002	Jul 29, 2004	Jul	NEWA
	EQ 4MG BASE	N76569	002	Jul 29, 2004	Jul	NEWA
<u>NICOTINE POLACRILEX (MINT)</u>						
PERRIGO	EQ 2MG BASE	N76777	001	Sep 16, 2004	Sep	NEWA
	EQ 4MG BASE	N76779	001	Sep 16, 2004	Sep	NEWA
<u>NICOTINE POLACRILEX (ORANGE)</u>						
PERRIGO	EQ 2MG BASE	N76776	001	Sep 16, 2004	Sep	NEWA
	EQ 4MG BASE	N76778	001	Sep 16, 2004	Sep	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

ZANTAC 150									
+ PFIZER CONS HLTHCARE	EQ 150MG BASE			N21698 001	Aug 31, 2004	Aug	NEWA		
ZANTAC 75									
WARNER LAMBERT	EQ 75MG BASE			N20520 001	Dec 19, 1995	Aug	CRLD		

TERBINAFINE HYDROCHLORIDE

SPRAY; TOPICAL

LAMISIL AT									
+ NOVARTIS	14			N21124 002	Mar 17, 2000	Feb	NEWA		

**This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.**

Orphan Products Designations and Approvals List
November 2004

Generic Name: Indication Designated:
Treatment for patients with brain stem glioma

Trade Name (if present):
A10 & AS2-1 Antineoplaston

Sponsor and Address
Burzynski Research Institute, Inc.
9432 Old Katy Road
Houston TX 77055

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-
imino-D-ribose hydrochloride

Indication Designated:
Treatment of chronic lymphocytic leukemia and related leukemias
to include prolymphocytic leukemia, adult T-cell leukemia, and
hairy cell leukemia

Trade Name (if present):

Sponsor and Address
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 8/10/2004
Marketing Exclusivity Date:

Generic Name:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-
imino-D-ribose hydrochloride

Indication Designated:
Treatment of acute lymphoblastic leukemia.

Trade Name (if present):

Sponsor and Address
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 8/13/2004
Marketing Exclusivity Date:

Generic Name:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-
imino-D-ribose hydrochloride

Indication Designated:
Treatment of T-cell non-Hodgkin's lymphoma

Trade Name (if present):

Sponsor and Address
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 1/29/2004
Marketing Exclusivity Date:

Generic Name:
3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-
benzoic acid

Indication Designated:
For use in the treatment of cystic fibrosis resulting from a nonsense
(premature stopcodon) mutation in the cystic fibrosis
transmembrane conductance regulatory gene.

Trade Name (if present):

Orphan Products Designations and Approvals List

November 2004

<p>Date Designated: 9/1/2004 Marketing Exclusivity Date:</p>	<p>Sponsor and Address PTC Therapeutics 100 Corporate Court South Plainfield NJ 07080</p>
.....	
<p>Generic Name: (6R,S)5,10-methylene-tetrahydrofolic acid</p> <p>Trade Name (if present): CoFactor</p> <p>Date Designated: 8/13/2004 Marketing Exclusivity Date:</p>	<p>Indication Designated: For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer</p> <p>Sponsor and Address Adventrx Pharmaceuticals, Inc. 6725 Mesa Ridge Road Suite 100 San Diego CA 92121</p>
.....	
<p>Generic Name: 17-allylamino-17-demethoxygeldanamycin (17-AGG)</p> <p>Trade Name (if present):</p> <p>Date Designated: 9/9/2004 Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of multiple myeloma.</p> <p>Sponsor and Address Kosan Biosciences, Inc 3832 Bay Center Place Hayward CA 94545</p>
.....	
<p>Generic Name: 17-allylamino-17-demethoxygeldanamycin (17-AGG)</p> <p>Trade Name (if present):</p> <p>Date Designated: 9/3/2004 Marketing Exclusivity Date:</p>	<p>Indication Designated: For the treatment of Chronic Myelogenous Leukemia</p> <p>Sponsor and Address Kosan Biosciences, Inc. 3832 Bay Center Place Hayward CA 94545</p>
.....	
<p>Generic Name: 1-Deoxygalactonojirimycin</p> <p>Trade Name (if present):</p> <p>Date Designated: 2/25/2004 Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of Fabry Disease</p> <p>Sponsor and Address Amicus Therapeutics, Inc. 675 US Route 1 North Brunswick NJ 08902</p>
.....	
<p>Generic Name: 3-carboxy-2,3-dihydroxy-propionate 2-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-5-(1H-indol-2-yl)-3-</p>	<p>Indication Designated: Treatment of chronic lymphocytic leukemia</p>

Orphan Products Designations and Approvals List

November 2004

methoxy-2H-pyrrolium

Trade Name (if present):

Sponsor and Address
Gemin X, Inc.
5 Great Valley Parkway
Malvern PA 19355

Date Designated: 10/8/2004

Marketing Exclusivity Date:

Generic Name:
5-methyl-1-phenyl-2-(1H)-pyridone(CAS 53179-13-8)

Indication Designated:
Treatment of idiopathic pulmonary fibrosis

Trade Name (if present):
Pirfenidone

Sponsor and Address
InterMune, Inc.
3280 Bayshore Blvd
Brisbane CA 94005

Date Designated: 3/5/2004

Marketing Exclusivity Date:

Generic Name:
90Y-hPAMA4

Indication Designated:
Treatment of pancreatic cancer

Trade Name (if present):
PAN-Cide

Sponsor and Address
Immunomedics, Inc.
300 American Road
Morris Plains NJ 07950

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Generic Name:
Allogeneic retinal epithelial cells transfected with
plasmid vector expressing ciliary neurotrophic
growth factor

Indication Designated:
Treatment of retinitis pigmentosa

Trade Name (if present):

Sponsor and Address
Neurotech USA, Inc.
6 Blackstone Valley Place
Lincoln RI 02865

Date Designated: 9/1/2004

Marketing Exclusivity Date:

Generic Name:
Alpha-1-acid glycoprotein

Indication Designated:
Treatment of cocaine overdose

Trade Name (if present):

Sponsor and Address
Bio Products Laboratory
Dagger Lane, Elstree
WD6 3BX

Date Designated: 3/5/2004

Marketing Exclusivity Date:

UNITED KINGDOM

Orphan Products Designations and Approvals List

November 2004

Generic Name: Alpha-1-acid glycoprotein
 Indication Designated: Treatment of tricyclic antidepressant poisoning

Trade Name (if present):

Sponsor and Address
 Bio Products Laboratory
 Dagger Lane
 Elstree, Hertfordshire

Date Designated: 3/17/2004

Marketing Exclusivity Date:

UNITED KINGDOM

Generic Name: Alpha1-Proteinase Inhibitor (Human) [API]

Indication Designated: Treatment of Cystic Fibrosis

Trade Name (if present):
 ARC-API

Sponsor and Address
 Kamada Ltd.
 Kiryat Weizmann

Date Designated: 9/1/2004

Marketing Exclusivity Date:

ISRAEL

Generic Name: Ambrisentan

Indication Designated: Treatment of pulmonary arterial hypertension

Trade Name (if present):

Sponsor and Address
 Myogen, Inc.
 7575 West 103rd Avenue
 Suite 102
 Westminster CO 80021-5426

Date Designated: 7/16/2004

Marketing Exclusivity Date:

Generic Name: Antivenin crotaline (pit-viper) equine immune F(ab)2

Indication Designated: Treatment of envenomation by Crotaline snakes

Trade Name (if present):
 Antivipmyn

Sponsor and Address
 Rare Disease Therapeutics, Inc.
 1101 Kermit Drive,
 Suite 608
 Nashville TN 37217

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Generic Name: Aplidin

Indication Designated: Treatment of Acute Lymphoblastic Leukemia

Trade Name (if present):

Sponsor and Address
 PharmaMar USA, Inc
 320 Putnam Avenue
 Cambridge MA 02139

Date Designated: 6/18/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

November 2004

.....

<p>Generic Name: Autologous incubated macrophage in</p> <p>Trade Name (if present):</p> <p>Date Designated: 9/3/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Therapy to improve the motor and sensory neurological outcome acute cases of spinal cord injury</p> <p>Sponsor and Address Proneuron Biotechnologies, Inc. Weizmann Science Park P. O. Box 277 Ness-Ziona 74101 ISRAEL</p>
---	--

.....

<p>Generic Name: Bevacizumab</p> <p>Trade Name (if present): Avastin</p> <p>Date Designated: 10/20/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of pancreatic cancer</p> <p>Sponsor and Address Genentech, Inc. 1 DNA Way, MS #242 South San Francisco CA 94080-4990</p>
--	--

.....

<p>Generic Name: Buffered Ursodeoxycholic Acid</p> <p>Trade Name (if present): Ursocarb</p> <p>Date Designated: 9/3/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: For the treatment of pruritus in patients with Alagille Syndrome</p> <p>Sponsor and Address Digestive Care, Inc. 1120 Win Drive Bethlehem PA 18017</p>
---	--

.....

<p>Generic Name: C1 esterase inhibitor (human)</p> <p>Trade Name (if present):</p> <p>Date Designated: 7/16/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of Angioedema</p> <p>Sponsor and Address Lev Pharmaceuticals, Inc. 236 Old Lancaster Road Merion Station PA 19066</p>
---	---

.....

<p>Generic Name: Chenodeoxycholic acid</p> <p>Trade Name (if present): Chenofalk</p>	<p>Indication Designated: Treatment of cerebrotendinous xanthomatosis</p> <p>Sponsor and Address Dr. Falk Pharma GmbH</p>
--	---

Orphan Products Designations and Approvals List

November 2004

<p>Date Designated: 1/29/2004 Marketing Exclusivity Date:</p>	<p>Leinenweberstrasse 5 9041 Freiburg, GERMANY</p> <p>GERMANY</p>

<p>Generic Name: Coagulation factor VIIa (recombinant)</p> <p>Trade Name (if present): NovoSeven</p> <p>Date Designated: 7/21/2004 Marketing Exclusivity Date:</p>	<p>Indication Designated: Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX</p> <p>Sponsor and Address Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton NJ 08540</p>

<p>Generic Name: Coagulation factor VIIa (recombinant)</p> <p>Trade Name (if present): NovoSeven</p> <p>Date Designated: 6/18/2004 Marketing Exclusivity Date:</p>	<p>Indication Designated: Prevention of bleeding episodes in Glanzmann's thrombasthenia</p> <p>Sponsor and Address Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton NJ 08540</p>

<p>Generic Name: Coagulation factor VIIa (recombinant)</p> <p>Trade Name (if present): NovoSeven</p> <p>Date Designated: 9/10/2004 Marketing Exclusivity Date:</p>	<p>Indication Designated: Prevention of bleeding episodes in patients with congenital Factor VII deficiency</p> <p>Sponsor and Address Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton NJ 08540</p>

<p>Generic Name: Coagulation Factor VIIa (Recombinant)</p> <p>Trade Name (if present): NovoSeven</p> <p>Date Designated: 7/16/2004 Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX</p> <p>Sponsor and Address Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton NJ 08540</p>

<p>Generic Name: Coagulation factor VIIa (recombinant) B,</p>	<p>Indication Designated: Prevention of bleeding episodes in patients with hemophilia A or</p>

Orphan Products Designations and Approvals List

November 2004

with or without inhibitors

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 6/18/2004

Marketing Exclusivity Date:

Generic Name:
Coagulation factor VIIa (Recombinant)

Indication Designated:
Treatment of bleeding episodes in Glanzmann's thrombasthenia

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 6/18/2004

Marketing Exclusivity Date:

Generic Name:
Coagulation factor VIIa (recombinant)

Indication Designated:
Treatment of bleeding episodes in patients with congenital factor VII deficiency

Trade Name (if present):
NovoSeven

Sponsor and Address
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton NJ 08540

Date Designated: 9/10/2004

Marketing Exclusivity Date:

Generic Name:
Cyclosporin A

Indication Designated:
Treatment of amyotrophic lateral sclerosis and its variants

Trade Name (if present):
Cyclosporin

Sponsor and Address
Maas BiolAB
1934 Quail Run Loop NE
Albuquerque NM 87122

Date Designated: 10/29/2004

Marketing Exclusivity Date:

Generic Name:
Cyoctumdin

Indication Designated:
Treatment of multiple myeloma

Trade Name (if present):
Aplidin

Sponsor and Address
PharmaMar USA, Inc.
320 Putnam Avenue
Cambridge MA 02139-4616

Date Designated: 9/30/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

November 2004

Generic Name:
DEAE-rebeccamycin

Indication Designated:
Treatment of bile duct tumors

Trade Name (if present):

Sponsor and Address
Exelixis, Inc.
170 Harbor Way
South San Francisco CA 94083-0511

Date Designated: 3/1/2004

Marketing Exclusivity Date:

.....

Generic Name:
Deferitrin

Indication Designated:
Treatment of iron overload

Trade Name (if present):

Sponsor and Address
Genzyme Corporation
153 Second Avenue
Waltham MA 02451

Date Designated: 4/14/2004

Marketing Exclusivity Date:

.....

Generic Name:
Depsipeptide

Indication Designated:
Treatment of cutaneous T-cell lymphoma

Trade Name (if present):

Sponsor and Address
Gloucester Pharmaceuticals, Inc.
One Broadway
Cambridge MA 02142

Date Designated: 9/30/2004

Marketing Exclusivity Date:

.....

Generic Name:
Desmoglein 3 synthetic peptide (PI-0824)

Indication Designated:
Treatment of pemphigus vulgaris

Trade Name (if present):

Sponsor and Address
Peptimmune, Inc.
64 Sidney Street
Cambridge MA 02139-4170

Date Designated: 10/26/2004

Marketing Exclusivity Date:

.....

Generic Name:
dexanabinol

Indication Designated:
For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain

injury

Trade Name (if present):

Sponsor and Address
Pharmos Corporation
99 Wood Avenue
Suite 311
Iselin NJ 08830

Date Designated: 8/11/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

November 2004

Generic Name:
Dexrazoxane

Indication Designated:
Treatment of anthracycline extravasation during chemotherapy

Trade Name (if present):

Sponsor and Address
Topo Target A/S
Fruebjergvej 3, 2100
Copenhagen

Date Designated: 3/25/2004

Marketing Exclusivity Date:

DENMARK

Generic Name:
diethylenetriaminepentaacetate (DPTA)

Indication Designated:
For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.

Trade Name (if present):

Sponsor and Address
CIS-US
10 DeAngelo Drive
Bedford MA 01730

Date Designated: 4/14/2004

Marketing Exclusivity Date:

Generic Name:
Diethylenetriaminepentaacetic acid (DTPA)

Indication Designated:
Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.

Trade Name (if present):

Sponsor and Address
Hameln Pharmaceuticals gmbh
Langes Feld 13
Hameln
8/11/2004
GERMANY

Date Designated: 4/28/2004

Marketing Exclusivity Date:

Generic Name:
Diethylnorspermine (DENSPM)

Indication Designated:
Treatment for hepatocellular carcinoma

Trade Name (if present):

Sponsor and Address
Genzyme Corporation
153 Second Avenue
Waltham MA 02451

Date Designated: 5/25/2004

Marketing Exclusivity Date:

Generic Name:
Doripenem

Indication Designated:
Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.

Trade Name (if present):

Sponsor and Address

Orphan Products Designations and Approvals List

November 2004

Date Designated: 7/16/2004
 Marketing Exclusivity Date:

Peninsula Pharmaceuticals, Inc.
 1751 Harbor Bay Parkway
 Alameda CA 94502

Generic Name: Efaproxiral
 Indication Designated: Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer

Trade Name (if present):

Date Designated: 7/28/2004
 Marketing Exclusivity Date:

Sponsor and Address
 Allos Therapeutics, Inc.
 11080 CirclePoint Road
 Suite 200
 Westminster CO 80020

Generic Name: heat killed Mycobacterium w immunomodulator
 Indication Designated: To be used as an adjuvant to chemotherapy for multi drug resistant tuberculosis.

Trade Name (if present):
 CADI Mw

Date Designated: 9/3/2004
 Marketing Exclusivity Date:

Sponsor and Address
 CPL, Inc.
 16020 Swingley Ridge Road
 Chesterfield MO 63017

Generic Name: Human anti-CD30 monoclonal antibody
 Indication Designated: Treatment of Hodgkin's Disease

Trade Name (if present):

Date Designated: 9/27/2004
 Marketing Exclusivity Date:

Sponsor and Address
 Medarex, Inc.
 519 Route 173 West
 Bloomsbury NJ 08804

Generic Name: human anti-CD4 monoclonal antibody
 Indication Designated: Treatment of mycosis fungoides

Trade Name (if present):
 HuMax-CD4

Date Designated: 8/13/2004
 Marketing Exclusivity Date:

Sponsor and Address
 Genmab A/S
 Tolbodgade 33
 DK-1253 Copenhagen K
 DENMARK

Generic Name: human anti-transforming growth factor-B1,2,3
 Indication Designated: Treatment of idiopathic pulmonary fibrosis

Orphan Products Designations and Approvals List

November 2004

Trade Name (if present):

Sponsor and Address
Genzyme Corporation
500 Kendall Street
Cambridge MA 02142

Date Designated: 7/9/2004

Marketing Exclusivity Date:

Generic Name:

Human immunoglobulin (IgG1k)antiCTLA-4
monoclonal antibody

Indication Designated:

Treatment of high risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor and Address
Medarex, Inc.
519 Route 173 West
Bloomsbury NJ 08804

Date Designated: 6/3/2004

Marketing Exclusivity Date:

Generic Name:

Hydralazine

Indication Designated:

Treatment of severe intrapartum hypertension (diastolic blood
pressure greater than or equal to 110 or systolic blood pressure less
than or equal to 160) associated with severe

preeclampsia/eclampsia

Trade Name (if present): of pregnancy

Sponsor and Address
Esp Pharma, Inc.
2035 Lincoln Hwy.
Suite 2150
Edison NJ 08817

Date Designated: 4/9/2004

Marketing Exclusivity Date:

Generic Name:

Icatibant acetate

Indication Designated:

Treatment of burn patients hospitalized with burn-induced edema

Trade Name (if present):

Sponsor and Address
Jerini AG
Invalidenstr, 130
10115 Berlin

Date Designated: 5/5/2004

Marketing Exclusivity Date:

GERMANY

Generic Name:

Idebenone (INN)

Indication Designated:

Treatment of cardiomyopathy associated with Friedreich's ataxia

Trade Name (if present):

Sponsor and Address
Santhera Pharmaceuticals LLC
Hammerstrasse 25
CH-4410 Liestal

Date Designated: 3/25/2004

Marketing Exclusivity Date:

SWITZERLAND

Orphan Products Designations and Approvals List

November 2004

.....

Generic Name: Iloprost inhalation solution	Indication Designated: Treatment of pulmonary arterial hypertension
---	--

Trade Name (if present): Ventavis	Sponsor and Address CoTherix, Inc. 5000 Shoreline Court South San Francisco CA 94080
Date Designated: 8/12/2004	
Marketing Exclusivity Date:	

.....

Generic Name: Immortalized human liver cells found in the extracorporeal liver assist device	Indication Designated: Treatment of fulminant hepatic failure (acute liver failure)
Trade Name (if present): ELAD	Sponsor and Address Vital Therapies, Inc. 15222 Avenue of Science Suite C San Diego CA 92128
Date Designated: 7/16/2004	
Marketing Exclusivity Date:	

.....

Generic Name: Immune Globulin (Human)	Indication Designated: Treatment of chronic inflammatory demyelinating polyneuropathy
Trade Name (if present): Gamunex	Sponsor and Address Bayer Corporation 800 Dwight Way Berkeley CA 94701-1986
Date Designated: 7/27/2004	
Marketing Exclusivity Date:	

.....

Generic Name: Immune Globulin (Human) containing high titers of West Nile virus antibodies	Indication Designated: Treatment of the West Nile virus infection
Trade Name (if present): Omr-IgG-am (tm) 5% (WNV)	Sponsor and Address OMRIX Biopharmaceuticals, Ltd. Plasma Fractionation Institute Ramat Gan 52621
Date Designated: 3/17/2004	
Marketing Exclusivity Date:	ISRAEL

.....

Generic Name: Immune Globulin Intravenous (human)	Indication Designated: Treatment for Guillain Barre Syndrome
Trade Name (if present): Carimune NF	Sponsor and Address ZLB Bioplasma AG Wankdorfstrasse 10 CH-3000 Bern 22
Date Designated: 5/4/2004	

Orphan Products Designations and Approvals List

November 2004

Marketing Exclusivity Date:

SWITZERLAND

Generic Name:
Immune Globulin Subcutaneous (Human)

Indication Designated:
Treatment of patients with primary immune deficiency (PID) that are intolerant to immune globulin intravenous (IGIV) due to severe adverse events or poor venous access

Trade Name (if present):
Vivaglobin P (proposed)

Sponsor and Address
Aventis Behring, L.L.C.
1020 First Avenue
P.O. Box 61501

Date Designated: 9/22/2004

King of Prussia PA 19406-0901

Marketing Exclusivity Date:

Generic Name:
Implitapide

Indication Designated:
Treatment of homozygous familial hypercholesterolemia

Trade Name (if present):

Sponsor and Address
Medical Research Laboratories International
2 Tesseneer Drive
Highland Heights KY 41076

Date Designated: 8/13/2004

Marketing Exclusivity Date:

Generic Name:
Implitapide

Indication Designated:
Treatment of patients with Fredrickson type I or V hyperlipoproteinemia

Trade Name (if present):

Sponsor and Address
Medical Research Laboratories International
2 Tesseneer Drive
Highland Heights KY 41076

Date Designated: 8/18/2004

Marketing Exclusivity Date:

Generic Name:
Lenalidomide

Indication Designated:
Treatment of myelodysplastic syndromes

Trade Name (if present):
Revimid

Sponsor and Address
Celgene Corporation
7 Powder Horn Drive
Warren NJ 07059

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Generic Name:
Liarozole

Indication Designated:
The treatment of congenital ichthyosis

Trade Name (if present):

Sponsor and Address
Barrier Therapeutics, Inc

Orphan Products Designations and Approvals List

November 2004

Date Designated: 6/18/2004
 Marketing Exclusivity Date:

600 College Road East
 Princeton NJ 08540

Generic Name:
 L-tyrosine-L-serine-L-leucine

Indication Designated:
 Treatment of hepatocellular carcinoma.

Trade Name (if present):
 CMS-024

Sponsor and Address
 Pepharm R&D Limited
 Room 1404, 14th Floor
 #39 Healthy Street East

Date Designated: 9/10/2004
 Marketing Exclusivity Date:

North Point
 HONG KONG

Generic Name:
 mannopentaose phosphate sulfate

Indication Designated:
 Treatment of high-risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor and Address
 Progen Industries Limited
 P. O. Box 28
 Richlands 4077

Date Designated: 4/27/2004
 Marketing Exclusivity Date:

AUSTRALIA

Generic Name:
 meclorethamine or nitrogen mustard

Indication Designated:
 Treatment of mycosis fungoides.

Trade Name (if present):

Sponsor and Address
 Yaupon Therapeutics, Inc.
 259 Radnor Chester Road
 Radnor PA 19087

Date Designated: 8/12/2004
 Marketing Exclusivity Date:

Generic Name:
 Melatonin

Indication Designated:
 Treatment of non-24-hour sleep-wake disorder in blind individuals
 without light perception

Trade Name (if present):
 Circadin

Sponsor and Address
 Neurim Pharmaceuticals, Ltd.
 8 Hanechoshet St.
 Tel-Aviv

Date Designated: 7/9/2004
 Marketing Exclusivity Date:

ISRAEL

Generic Name:
 mepolizumab
 syndrome

Indication Designated:
 For first-line treatment in patients with hypereosinophilic

Orphan Products Designations and Approvals List

November 2004

Trade Name (if present):

Sponsor and Address
 GlaxoSmithKline Pharmaceuticals
 P.O. Box 7929
 Philadelphia PA 19101

Date Designated: 5/28/2004

Marketing Exclusivity Date:

Generic Name:

Multi-ligand somatostatin analogue

Indication Designated:

Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somatostatinoma, GRFoma, VIPoma and glucagonoma.

Trade Name (if present):

Sponsor and Address
 Novartis Pharmaceuticals Corporation
 One Health Plaza
 East Hanover NJ 07936-1080

Date Designated: 7/27/2004

Marketing Exclusivity Date:

Generic Name:

multi-vitamin infusion without vitamin K complications

Indication Designated:

Prevention of vitamin deficiency and thromboembolic

in people receiving home parenteral nutrition and warfarin-type

Trade Name (if present):

M.V.I.-12

Sponsor and Address
 Mayne Pharma (USA) Inc.
 Mack-Cali Centre II
 Second Floor

Date Designated: 3/8/2004

Marketing Exclusivity Date:

9/9/2004 Paramus NJ 07652

Generic Name:

N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide

Indication Designated:

Treatment of neuroblastoma

Trade Name (if present):

Sponsor and Address
 Abbott Laboratories
 Pharmaceuticals Products Division
 D-491, AP30-1E

Date Designated: 9/30/2004

Marketing Exclusivity Date:

Abbott Park IL 60064-6157

Generic Name:

N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide

Indication Designated:

Treatment of stages IIB-IV melanoma

Trade Name (if present):

Sponsor and Address
 3M Pharmaceuticals
 3M Center
 Building 270-3A-08
 St. Paul MN 55144-1000

Date Designated: 8/13/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

November 2004

<p>Generic Name: nelarabine</p> <p>Trade Name (if present):</p> <p>Date Designated: 8/10/2004</p> <p>Marketing Exclusivity Date:</p> <p>.....</p>	<p>Indication Designated: Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma</p> <p>Sponsor and Address GlaxoSmithKline One Franklin Plaza Phildelphia PA 19101</p>
<p>Generic Name: Nitric oxide</p> <p>Trade Name (if present): INOmax</p> <p>Date Designated: 9/27/2004</p> <p>Marketing Exclusivity Date:</p> <p>.....</p>	<p>Indication Designated: To reduce the risk of chronic lung disease in premature neonates</p> <p>Sponsor and Address INO Therapeutics 6 Route 173 Clinton NJ 08809</p>
<p>Generic Name: Nucleic acid aptamer binding to tumor cell nucleolin</p> <p>Trade Name (if present):</p> <p>Date Designated: 8/11/2004</p> <p>Marketing Exclusivity Date:</p> <p>.....</p>	<p>Indication Designated: Treatment of pancreatic cancer</p> <p>Sponsor and Address Aptamera, Inc. 640 S. Fourth Street Louisville KY 40202</p>
<p>Generic Name: oral unfractionated heparin</p> <p>Trade Name (if present):</p> <p>Date Designated: 1/29/2004</p> <p>Marketing Exclusivity Date:</p> <p>.....</p>	<p>Indication Designated: Treatment of sickle cell disease</p> <p>Sponsor and Address TRF Technologies, Inc. 108 Eagle Trace Drive Half Moon Bay CA 94019</p>
<p>Generic Name: pentetate trisodium</p> <p>Trade Name (if present): diethylenetriaminepentaacetate</p> <p>Date Designated: 4/12/2004</p> <p>Marketing Exclusivity Date:</p>	<p>Indication Designated: Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.</p> <p>Sponsor and Address Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. Goerzallee 253 Fedderal of Republic of Germany</p> <p>GERMANY</p>

Orphan Products Designations and Approvals List

November 2004

Generic Name:
posaconazole

Indication Designated:
Treatment of zygomycosis

Trade Name (if present):
Posoril

Sponsor and Address
Schering Corporation
2000 Galloping Hill Road
Kenilworth NJ 07033

Date Designated: 7/16/2004
Marketing Exclusivity Date:

Generic Name:
PR1 Vaccine
therapy.

Indication Designated:
Treatment of myelodysplastic syndromes (MDS) requiring

Trade Name (if present):

Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name:
PR1 Vaccine

Indication Designated:
Treatment of acute myelogenous leukemia

Trade Name (if present):

Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name:
PR1 Vaccine

Indication Designated:
Treatment of chronic myelogenous leukemia.

Trade Name (if present):

Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name:
Quinine Sulfate

Indication Designated:
Treatment of malaria

Trade Name (if present):

Sponsor and Address
Mutual Pharmaceutical Company, Inc.
1100 Orthodox Street
Philadelphia PA 19124

Date Designated: 6/3/2004

Orphan Products Designations and Approvals List

November 2004

Marketing Exclusivity Date:

.....

Generic Name:
recombinant human fibroblast growth factor-20

Indication Designated:
Treatment of radiation induced oral mucositis

Trade Name (if present):

Sponsor and Address
CuraGen Corporation
322 East Main Street
Branford CT 06405

Date Designated: 1/29/2004

Marketing Exclusivity Date:

.....

Generic Name:
Recombinant Porcine Factor VIII, B-domain Deleted

Indication Designated:
Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII

Trade Name (if present):

Sponsor and Address
Ipsen Limited
190 Bath Road
Berkshire S11 3XE

Date Designated: 3/16/2004

Marketing Exclusivity Date:

UNITED KINGDOM

.....

Generic Name:
rh-microplasmin

Indication Designated:
Adjunct to surgery in cases of pediatric vitrectomy

Trade Name (if present):

Sponsor and Address
ThromboGenics Ltd
Unit 14
Bridgecourt Office Park
Dublin 12
IRELAND

Date Designated: 3/16/2004

Marketing Exclusivity Date:

.....

Generic Name:
Rituximab

Indication Designated:
Treatment of chronic lymphocytic leukemia

Trade Name (if present):
Rituxan

Sponsor and Address
Biogen IDEC, Inc.
5200 Research Place
San Diego CA 92122

Date Designated: 1/29/2004

Marketing Exclusivity Date:

.....

Generic Name:
rofecoxib

Indication Designated:
Treatment of juvenile rheumatoid arthritis

Trade Name (if present):
VIOXX

Sponsor and Address

Orphan Products Designations and Approvals List

November 2004

<p>Date Designated: 3/16/2004 Marketing Exclusivity Date:</p> <p>.....</p>	<p>MERCK & Co., Inc. 126 East Lincoln Ave. Rahway NJ 07065</p>
<p>Generic Name: Rufinamide</p> <p>Trade Name (if present):</p>	<p>Indication Designated: For the treatment of Lennox-Gastaut Syndrome.</p> <p>Sponsor and Address Eisai Medical Research, Inc. 55 Challenger Road Ridgefield NJ 07660</p>
<p>Date Designated: 10/8/2004 Marketing Exclusivity Date:</p> <p>.....</p>	<p>Indication Designated: Treatment of amyotrophic lateral sclerosis (ALS)</p> <p>Sponsor and Address Phytopharm plc Corpus Christi House Godmanchester, Cambridgeshire PE29 2HY</p>
<p>Generic Name: sarsasapogenin</p> <p>Trade Name (if present):</p>	<p>Indication Designated: Treatment of amyotrophic lateral sclerosis (ALS)</p> <p>Sponsor and Address Phytopharm plc Corpus Christi House Godmanchester, Cambridgeshire PE29 2HY</p>
<p>Date Designated: 6/18/2004 Marketing Exclusivity Date:</p> <p>.....</p>	<p>UNITED KINGDOM</p>
<p>Generic Name: SGN-30 (anti-CD30 antibody)</p> <p>Trade Name (if present):</p>	<p>Indication Designated: Treatment of CD30 positive T-cell lymphomas</p> <p>Sponsor and Address Seattle Genetics, Inc. 21823 30th Drive Southeast Bothell WA 98021</p>
<p>Date Designated: 2/18/2004 Marketing Exclusivity Date:</p> <p>.....</p>	<p>Indication Designated: Treatment of multiple myeloma.</p> <p>Sponsor and Address Seattle Genetics, Inc. 21823 30th Drive Southeast Bothell WA 98021</p>
<p>Generic Name: SGN-40 (anti-CD40 antibody)</p> <p>Trade Name (if present):</p>	<p>Indication Designated: Treatment of multiple myeloma.</p> <p>Sponsor and Address Seattle Genetics, Inc. 21823 30th Drive Southeast Bothell WA 98021</p>
<p>Date Designated: 8/13/2004 Marketing Exclusivity Date:</p> <p>.....</p>	<p>Indication Designated: Prevention of platinum-induced ototoxicity in pediatric patients</p>
<p>Generic Name: Sodium thiosulfate</p>	<p>Indication Designated: Prevention of platinum-induced ototoxicity in pediatric patients</p>

Orphan Products Designations and Approvals List

November 2004

Trade Name (if present):

Sponsor and Address
Adherex Technologies, Inc.
600 Peter Morand Crescent
Ottawa, Ontario

Date Designated: 3/17/2004

Marketing Exclusivity Date:

CANADA

Generic Name:
Somatropin

Indication Designated:
Treatment of patients with HIV-associated adipose redistribution syndrome

Trade Name (if present):
Serostim

Sponsor and Address
Serono, Inc.
One Technology Place
Rockland MA 02370

Date Designated: 3/16/2004

Marketing Exclusivity Date:

Generic Name:
Sorafenib

Indication Designated:
Treatment of renal cell carcinoma.

Trade Name (if present):

Sponsor and Address
Bayer Pharmaceutical Corporation
400 Morgan Lane
West Haven CT 06516

Date Designated: 10/8/2004

Marketing Exclusivity Date:

Generic Name:
Staphylococcus aureus Immune Globulin (Human)

Indication Designated:
Prophylaxis against Staphylococcus aureus infections in low birth weight neonates

Trade Name (if present):
Altastaph

Sponsor and Address
Nabi Biopharmaceuticals
12276 Wilkins Avenue
Rockville MD 20852

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Generic Name:
Suberoylanilide hydroxamic acid

Indication Designated:
Treatment of T-cell non-Hodgkin's lymphoma

Trade Name (if present):

Sponsor and Address
Merck & Co., Inc.
P. O. Box 2000, RY 32-605
Rahway NJ 07065-0900

Date Designated: 3/16/2004

Marketing Exclusivity Date:

Generic Name:

Indication Designated:

Orphan Products Designations and Approvals List

November 2004

Suberoylanilide hydroxamic acid

Treatment of mesothelioma

Trade Name (if present):

Sponsor and Address
Merck & Co., Inc.
P. O. Box 2000, RY 32-605
Rahway NJ 07065-0900

Date Designated: 3/17/2004

Marketing Exclusivity Date:

Generic Name:
temocillin sodium

Indication Designated:
Treatment of pulmonary infections caused by Burkholderia cepacia

Trade Name (if present):
Negaban

Sponsor and Address
Belpharma N.V.
67 Winston Churchill Avenue
Brussels

Date Designated: 4/21/2004

Marketing Exclusivity Date:

BELGIUM

Generic Name:
Temozolomide

Indication Designated:
Treatment of newly diagnosed high grade glioma

Trade Name (if present):
Temodal

Sponsor and Address
Schering-Plough Research Institute
2000 Galloping Hill Road
Kenilworth NJ 07033

Date Designated: 10/18/2004

Marketing Exclusivity Date:

Generic Name:
Terlipressin (INN)

Indication Designated:
Treatment of Hepatorenal Syndrome

Trade Name (if present):

Sponsor and Address
Orphan Therapeutics, LLC
3 Werner Way
Round Valley Executive Center
Lebanon NJ 08833

Date Designated: 10/29/2004

Marketing Exclusivity Date:

Generic Name:
tetrahydrobiopterin

Indication Designated:
For treatment of hyperphenylalaninemia

Trade Name (if present):

Sponsor and Address
Biomarin Pharmaceutical Inc.
371 Bel Marin Blvd.
Novato CA 94949

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

November 2004

Generic Name: Thalidomide
 Indication Designated: Treatment of Myelodysplastic Syndrome

Trade Name (if present): Thalomid

Sponsor and Address
 Celgene Corporation
 7 Powder Horn Drive
 Warren NJ 07059

Date Designated: 9/27/2004

Marketing Exclusivity Date:

Generic Name: Thymosin beta 4
 Indication Designated: Treatment of epidermolysis bullosa

Trade Name (if present):

Sponsor and Address
 RegeneRx Biopharmaceuticals, Inc.
 3 Bethesda Metro Center
 Suite 700

Date Designated: 5/28/2004

Marketing Exclusivity Date:

Bethesda MD 20814

Generic Name: Tipifarnib
 Indication Designated: Treatment of acute myeloid leukemia

Trade Name (if present): Zarnestra

Sponsor and Address
 Johnson & Johnson Pharmaceutical Research & Dev.
 920 U.S. Highway 202
 Raritan NJ 08869

Date Designated: 7/6/2004

Marketing Exclusivity Date:

Generic Name: trabectedin
 Indication Designated: Treatment of soft tissue sarcoma.

Trade Name (if present): Yondelis

Sponsor and Address
 Johnson & Johnson Pharmaceutical Research & Dev.
 920 US Highway 202
 Raritan NJ 08869

Date Designated: 9/30/2004

Marketing Exclusivity Date:

Generic Name: Trisodium zinc Diethylenetriaminepentaacetate
 Indication Designated: Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.

Trade Name (if present):

Sponsor and Address
 CustomCare Pharmacy
 5710 Hoover Blvd
 Tampa FL 33634

Date Designated: 2/27/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List

November 2004

.....

Generic Name: Ubiquinol	Indication Designated: Treatment of Huntington's Disease
----------------------------	---

Trade Name (if present): Ubi-Q-Nol, Li-Q-Nol	Sponsor and Address Gel-Tec Division of Tishcon Corp P. O. Box 331 Westbury NY 11590
Date Designated: 4/12/2004	
Marketing Exclusivity Date:	

.....

Generic Name: Ubiquinol, coenzyme Q10, ubiquinone	Indication Designated: Treatment of pediatric congestive heart failure
--	---

Trade Name (if present): UBI-Q-NOL	Sponsor and Address Gel-Tec, Division of TISHCON Corporation 30 New York Avenue P.O. Box 331 Westbury NY 11590
Date Designated: 4/12/2004	
Marketing Exclusivity Date:	

.....

Generic Name: Vaccinia Immune Globulin (Human) Intravenous	Indication Designated: Treatment of complications of vaccinia vaccination
---	--

Trade Name (if present): CNJ-016	Sponsor and Address Cangene Corporation 104 Chancellor Matheson Road Winnipeg, Manitoba R3T 5Y3
Date Designated: 6/18/2004	
Marketing Exclusivity Date:	

CANADA

.....

Generic Name: Vaccinia Immune Globulin (Human) Intravenous	Indication Designated: Treatment of severe complications from the smallpox vaccine
---	---

Trade Name (if present):	Sponsor and Address DynPort Vaccine Company LLC 64 Thomas Johnson Drive Frederick MD 21702
Date Designated: 6/18/2004	
Marketing Exclusivity Date:	

.....

Generic Name: Vapreotide	Indication Designated: Treatment of symptomatic carcinoid tumors
-----------------------------	---

Trade Name (if present): Sanvar	Sponsor and Address H3 Pharma, Inc. 666 Sherbrooke Street West Suite 1400 Montreal, Quebec,
Date Designated: 4/6/2004	

Orphan Products Designations and Approvals List

November 2004

Marketing Exclusivity Date:

CANADA



DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 2004 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021652 001	ABACAVIR SULFATE; EPZICOM	5034394 5089500 6294540 5047407 5905082 6417191 6180639	DEC 18, 2011 JUN 26, 2009 MAY 14, 2018 NOV 17, 2009 MAY 18, 2016 MAR 28, 2016 JAN 30, 2018	DS DP U257 DS DP U257 DS DP U257 DS DP DP U257 DP U257	D-40 D-40	AUG 02, 2007 AUG 02, 2007
020977 001	ABACAVIR SULFATE; ZIAGEN	5968895	DEC 11, 2016	DP		
020978 001	ABACAVIR SULFATE; ZIAGEN	6180608	DEC 11, 2016	DP U549		
021320 001	ABARELIX; PLENAXIS	6423686 6455499 5843901 6699833	JUN 07, 2015 JUN 07, 2015 DEC 01, 2015 DEC 11, 2016	DS DS DP DS DP DP		
021431 001	ACAMPROSATE CALCIUM; CAMPRAL	6451340	JUL 23, 2018	DS DP U470	NCE ODE	JUL 29, 2009 JAN 23, 2011
021539 001	ACETYLCHOLINE; ACETADOTE	5663159	SEP 02, 2014	DS DP U470		
021449 001	ADEFOVIR DIPIVOXIL; HEPSERA	6635278	DEC 15, 2018	DS DP		
020899 001	ALBUMIN HUMAN; OPTISON	6723303	APR 20, 2021	DP		
020949 001	ALBUTEROL SULFATE; ACCUNE	6702997	DEC 28, 2021	U558 U558		
020949 002	ALBUTEROL SULFATE; ACCUNE	6702997	DEC 28, 2021	U558 U558		
021457 001	ALBUTEROL SULFATE; ALBUTEROL SULFATE HF	6315173	DEC 23, 2017	DP	NP	OCT 29, 2007
020983 001	ALBUTEROL SULFATE; VENTOLIN HFA	6510969	DEC 23, 2017	DP		
		6131566	APR 14, 2015	DP U599		
		6532955	APR 14, 2015	DP U590		
020560 005	ALENDRONATE SODIUM; FOSAMAX	5932622	AUG 03, 2016	U562	D-87	APR 16, 2007
021575 001	ALENDRONATE SODIUM; FOSAMAX	6710066	JUL 28, 2009	U289	D-87	APR 16, 2007
020886 001	ALITRETINOIN; FANRETIN	5273995	DEC 28, 2010	DS DP U162	NDF	SEP 29, 2007
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE; LEVULAN	6455574	JUN 28, 2011	DS DP U162	NC	JAN 30, 2007
021727 001	AMLODIPINE BESYLATE; CADUET	5969156	AUG 11, 2018	U552		
021540 001	AMLODIPINE BESYLATE; CADUET	5969156*PED	JUL 08, 2016	DS		
		5686104	JAN 08, 2017	DP U213		
		5686104*PED	NOV 11, 2014	DP		
		6126971	MAY 11, 2015	DP		
		6126971*PED	JAN 19, 2013	DP		
		4681893	JUL 19, 2013	DS DP U161		
		4681893*PED	SEP 24, 2009	DS DP		
		4879303	MAR 24, 2010	DS DP		
		4879303*PED	MAR 25, 2007	DS DP		
		4572909	SEP 25, 2007	DS DP U3		
		4572909*PED	JUL 31, 2006	DS DP U3		
021540 002	AMLODIPINE BESYLATE; CADUET	4572909*PED	JAN 31, 2007	DS DP U161	NC	JAN 30, 2007
		4681893	SEP 24, 2009	DS DP U161		
		4681893*PED	MAR 24, 2010	DS DP		
		4879303	MAR 25, 2007	DS DP U3		
		4879303*PED	MAR 25, 2007	DS DP U3		
		4572909	SEP 25, 2007	DS DP U162		
		4572909*PED	JAN 31, 2007	DS DP U162		
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011	DS DP U162		

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021540 006	AMLODIPINE BESYLATE; CADUET	4681893	SEP 24, 2009	DS DP U161	NC	JAN 30, 2007
		4681893*PED	MAR 24, 2010	DS DP		
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007	DS DP U3		
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007	DS DP U162		
		5273995	DEC 28, 2010	DS DP U162		
		5273995*PED	JUN 28, 2011	U552		
		6455574	AUG 11, 2018	DS		
		5969156	JUL 08, 2016	DS		
		5969156*PED	JAN 08, 2017	DP U213		
		5686104	NOV 11, 2014	DP		
		5686104*PED	MAY 11, 2015	DS DP U161	NC	JAN 30, 2007
		6126971	JAN 19, 2013	DS DP		
		6126971*PED	JUL 19, 2013	DS DP U161		
		4681893	SEP 24, 2009	DS DP		
		4879303	MAR 24, 2010	DS DP		
4879303*PED	MAR 25, 2007	DS DP U3				
4572909	SEP 25, 2007	DS DP U3				
4572909*PED	JUL 31, 2006	DS DP U162				
5273995	JAN 31, 2007	DS DP U162				
5273995*PED	DEC 28, 2010	U552				
6455574	AUG 11, 2018	DS				
5969156	JUL 08, 2016	DS				
5969156*PED	JAN 08, 2017	DP U213				
5686104	NOV 11, 2014	DP				
5686104*PED	MAY 11, 2015	DS DP U161	NC	JAN 30, 2007		
6126971	JAN 19, 2013	DS DP				
6126971*PED	JUL 19, 2013	DS DP U161				
4681893	SEP 24, 2009	DS DP				
4879303	MAR 24, 2010	DS DP				
4879303*PED	MAR 25, 2007	DS DP U3				
4572909	SEP 25, 2007	DS DP U3				
4572909*PED	JUL 31, 2006	DS DP U162				
5273995	JAN 31, 2007	DS DP U162				
5273995*PED	DEC 28, 2010	U552				
6455574	AUG 11, 2018	DS				
5969156	JUL 08, 2016	DS				
5969156*PED	JAN 08, 2017	DP U213				
5686104	NOV 11, 2014	DP				
5686104*PED	MAY 11, 2015	DS DP U161	NC	JAN 30, 2007		
6126971	JAN 19, 2013	DS DP				
6126971*PED	JUL 19, 2013	DS DP U161				
4681893	SEP 24, 2009	DS DP				
4879303	MAR 24, 2010	DS DP				
4879303*PED	MAR 25, 2007	DS DP U3				
4572909	SEP 25, 2007	DS DP U3				
4572909*PED	JUL 31, 2006	DS DP U162				
5273995	JAN 31, 2007	DS DP U162				
5273995*PED	DEC 28, 2010	U552				
6455574	AUG 11, 2018	DS				
5969156	JUL 08, 2016	DS				
5969156*PED	JAN 08, 2017	DP U213				
5686104	NOV 11, 2014	DP				
5686104*PED	MAY 11, 2015	DS DP U161	NC	JAN 30, 2007		
6126971	JAN 19, 2013	DS DP				
6126971*PED	JUL 19, 2013	DS DP U161				
4681893	SEP 24, 2009	DS DP				
4879303	MAR 24, 2010	DS DP				
4879303*PED	MAR 25, 2007	DS DP U3				
4572909	SEP 25, 2007	DS DP U3				
4572909*PED	JUL 31, 2006	DS DP U162				
5273995	JAN 31, 2007	DS DP U162				
5273995*PED	DEC 28, 2010	U552				
6455574	AUG 11, 2018	DS				
5969156	JUL 08, 2016	DS				
5969156*PED	JAN 08, 2017	DP U213				
5686104	NOV 11, 2014	DP				
5686104*PED	MAY 11, 2015	DS DP U161	NC	JAN 30, 2007		
6126971	JAN 19, 2013	DS DP				
6126971*PED	JUL 19, 2013	DS DP U161				
4681893	SEP 24, 2009	DS DP				
4879303	MAR 24, 2010	DS DP				
4879303*PED	MAR 25, 2007	DS DP U3				
4572909	SEP 25, 2007	DS DP U3				
4572909*PED	JUL 31, 2006	DS DP U162				
5273995	JAN 31, 2007	DS DP U162				
5273995*PED	DEC 28, 2010	U552				
6455574	AUG 11, 2018	DS				
5969156	JUL 08, 2016	DS				
5969156*PED	JAN 08, 2017	DP U213				
5686104	NOV 11, 2014	DP				
5686104*PED	MAY 11, 2015	DS DP U161	NC	JAN 30, 2007		
6126971	JAN 19, 2013	DS DP				
6126971*PED	JUL 19, 2013	DS DP U161				
4681893	SEP 24, 2009	DS DP				
4879303	MAR 24, 2010	DS DP				
4879303*PED	MAR 25, 2007	DS DP U3				
4572909	SEP 25, 2007	DS DP U3				
4572909*PED	JUL 31, 2006	DS DP U162				
5273995	JAN 31, 2007	DS DP U162				
5273995*PED	DEC 28, 2010	U552				
6455574	AUG 11, 2018	DS				
5969156	JUL 08, 2016	DS				
5969156*PED	JAN 08, 2017	DP U213				

021540 008 AMLODIPINE BESYLATE; CADUET

021540 009 AMLODIPINE BESYLATE; CADUET

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
011522 007	AMPHETAMINE ASPARTATE; ADDERALL 10	6384020*PED	JAN 06, 2021		ODE	MAR 14, 2004
011522 012	AMPHETAMINE ASPARTATE; ADDERALL 12.5	6384020*PED	JAN 06, 2021		PED	SEP 14, 2004
011522 013	AMPHETAMINE ASPARTATE; ADDERALL 15	6384020*PED	JAN 06, 2021		ODE	MAR 14, 2004
011522 008	AMPHETAMINE ASPARTATE; ADDERALL 20	6384020*PED	JAN 06, 2021		PED	SEP 14, 2004
011522 010	AMPHETAMINE ASPARTATE; ADDERALL 30	6384020*PED	JAN 06, 2021		NCE	APR 20, 2009
011522 009	AMPHETAMINE ASPARTATE; ADDERALL 5	6384020*PED	JAN 06, 2021		ODE	APR 20, 2011
011522 011	AMPHETAMINE ASPARTATE; ADDERALL 7.5	6384020*PED	JAN 06, 2021		NCE	APR 20, 2009
021007 001	AMPRENNAVIR; AGENERASE	6730679	NOV 11, 2017	DP	ODE	APR 20, 2011
021007 002	AMPRENNAVIR; AGENERASE	6730679	NOV 11, 2017	DP	ODE	APR 20, 2011
020333 001	ANAGRELIDE HYDROCHLORIDE; AGRYLIN				I-437	SEP 29, 2007
020333 002	ANAGRELIDE HYDROCHLORIDE; AGRYLIN				I-437	SEP 29, 2007
021264 001	APOMORPHINE HYDROCHLORIDE; APOKYN				I-437	SEP 29, 2007
021264 002	APOMORPHINE HYDROCHLORIDE; APOKYN				I-437	SEP 29, 2007
021436 001	ARIPIRAZOLE; ABILIFY				I-434	JUL 30, 2007
021436 002	ARIPIRAZOLE; ABILIFY				M-36	JUL 30, 2007
021436 003	ARIPIRAZOLE; ABILIFY				I-434	JUL 30, 2007
021436 004	ARIPIRAZOLE; ABILIFY				M-36	JUL 30, 2007
021436 005	ARIPIRAZOLE; ABILIFY				I-437	SEP 29, 2007
021436 006	ARIPIRAZOLE; ABILIFY				I-437	SEP 29, 2007
021248 001	ARSENIC TRIOXIDE; TRISENOX				I-437	SEP 29, 2007
008809 006	ASCORBIC ACID; M.V.I.-12 (WITHOUT V				ODE	SEP 09, 2011
021567 001	ATAZANAVIR SULFATE; REYATAZ				D-89	JUL 06, 2007
021567 002	ATAZANAVIR SULFATE; REYATAZ				D-89	JUL 06, 2007
021567 003	ATAZANAVIR SULFATE; REYATAZ				D-89	JUL 06, 2007
020702 001	ATORVASTATIN CALCIUM; LIPITOR				I-434	JUL 30, 2007
020702 002	ATORVASTATIN CALCIUM; LIPITOR				M-36	JUL 30, 2007
020702 003	ATORVASTATIN CALCIUM; LIPITOR				I-434	JUL 30, 2007
020702 004	ATORVASTATIN CALCIUM; LIPITOR				M-36	JUL 30, 2007
050794 001	AZACITIDINE; VIDAZA				I-434	JUL 30, 2007
020114 001	AZELASTINE HYDROCHLORIDE; ASTELIN				M-36	JUL 30, 2007
020610 001	BALSALAZIDE DISODIUM; COLAZAL				ODE	MAY 19, 2011

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	6713446	JAN 25, 2022	DP	M-30	MAR 02, 2007
019851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	6747150	OCT 28, 2014	DP	PED	SEP 02, 2007
019851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	6686346	APR 29, 2017	DP U557	M-30	MAR 02, 2007
019851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	6886346	APR 29, 2017	DP U557	M-30	MAR 02, 2007
021551 001	BISACODYL; HALFLYTEL	5989588*PED	MAR 30, 2016	DP	M-30	MAR 02, 2007
021602 001	BORTEZOMIB; VELCADE	6221392	APR 09, 2018	DP	PED	SEP 02, 2007
020746 001	BUDESONIDE; RHINOCORT	6221392	APR 09, 2018	DP	M-30	MAR 02, 2007
020746 002	BUDESONIDE; RHINOCORT	6221392	APR 09, 2018	DP	PED	SEP 02, 2007
020958 001	CALCIUM CARBONATE, PRECIPITATED; PEPCID COMPLETE	4657927	APR 14, 2004	DP	NP	MAY 10, 2007
020712 001	CARBAMAZEPINE; CARBATROL	4657927*PED	OCT 14, 2004	DP U175		
020712 002	CARBAMAZEPINE; CARBATROL	4657927	APR 14, 2004	DP		
019880 001	CARBOPLATIN; PARAPLATIN	4657927*PED	OCT 14, 2004	DP U175		
019880 002	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	DP		
019880 003	CARBOPLATIN; PARAPLATIN	4657927*PED	OCT 14, 2004	DP U175		
020452 001	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	DP		
020452 002	CARBOPLATIN; PARAPLATIN	4657927*PED	OCT 14, 2004	DP U175		
020452 003	CARBOPLATIN; PARAPLATIN	4657927	APR 14, 2004	DP		
020452 004	CARBOPLATIN; PARAPLATIN	4657927*PED	OCT 14, 2004	DP U175		
020637 001	CARMUSTINE; GLIADEL	5952300	MAR 28, 2017	DP	ODE	FEB 25, 2010
021227 001	CASPOFUNGIN ACETATE; CANCIDAS	5378804	MAR 16, 2013	DS	I-438	SEP 29, 2007
021227 002	CASPOFUNGIN ACETATE; CANCIDAS	5514650	MAR 16, 2013	DS		
021227 002	CASPOFUNGIN ACETATE; CANCIDAS	5792746	MAR 16, 2013	DS		
021227 002	CASPOFUNGIN ACETATE; CANCIDAS	6136783	MAR 28, 2017	DP		
021227 002	CASPOFUNGIN ACETATE; CANCIDAS	5952300	MAR 28, 2017	DP		
021227 002	CASPOFUNGIN ACETATE; CANCIDAS	5378804	MAR 16, 2013	DS		
021621 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	5514650	MAR 16, 2013	DS		
021621 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	5792746	MAR 16, 2013	DS		
021621 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	6136783	MAR 28, 2017	DP		
021621 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2007	DS		
021621 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358*PED	DEC 25, 2007	DS		
021621 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	6455533	JUL 02, 2018	DP		
021621 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2007	DS		
021621 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358*PED	DEC 25, 2007	DS		
021621 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	6455533	JUL 02, 2018	DP		
020989 002	CEVIMELINE HYDROCHLORIDE; EVOXAC	5340821	JUL 07, 2013	DP	NP	FEB 24, 2007
021587 001	CHLORPHENIRAMINE MALEATE; CHILDREN'S ADVIL ALL	5767251	JUN 16, 2015	DS		
021149 002	CHORIOGNADOTROPIN ALFA; OVIDREL	6706681	MAR 16, 2021	DP		
021688 001	CINACALCET HYDROCHLORIDE; SENSIPAR	6031003	DEC 14, 2016	DS		
021688 001	CINACALCET HYDROCHLORIDE; SENSIPAR	6211244	OCT 23, 2015	DS		
021688 001	CINACALCET HYDROCHLORIDE; SENSIPAR	6313146	DEC 14, 2016	DS		
021688 001	CINACALCET HYDROCHLORIDE; SENSIPAR	6011068	DEC 14, 2016	DS		

>ADD>
>ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020989 002	CEVIMELINE HYDROCHLORIDE; EVOXAC	5767251	JUN 16, 2015	DS	NP	FEB 24, 2007
021587 001	CHLORPHENIRAMINE MALEATE; CHILDREN'S ADVIL ALL	6706681	MAR 16, 2021	DP		
021149 002	CHORIOGNADOTROPIN ALFA; OVIDREL	6031003	DEC 14, 2016	DS		
021688 001	CINACALCET HYDROCHLORIDE; SENSIPAR	6211244	OCT 23, 2015	DS		
021688 001	CINACALCET HYDROCHLORIDE; SENSIPAR	6313146	DEC 14, 2016	DS		
021688 001	CINACALCET HYDROCHLORIDE; SENSIPAR	6011068	DEC 14, 2016	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021688 002	CINACALCET HYDROCHLORIDE; SENSIPAR	6031003 6211244 6313146 6011068 6031003 6211244 6313146 6011068	DEC 14, 2016 OCT 23, 2015 DEC 14, 2016 DEC 14, 2016 DEC 14, 2016 OCT 23, 2015 DEC 14, 2016 DEC 14, 2016	DS DP U560 DS DP DS DP DS DP DS DP U559 DS DP U560 DS DP DS DP	ODE NCE	MAR 08, 2011 MAR 08, 2009
021688 003	CINACALCET HYDROCHLORIDE; SENSIPAR	6031003 6211244 6313146 6011068	DEC 14, 2016 OCT 23, 2015 DEC 14, 2016 DEC 14, 2016	DS DP U560 DS DP DS DP DS DP	ODE NCE	MAR 08, 2011 MAR 08, 2009
019537 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO	5965549	JUN 06, 2015	DP	I-421 PED	MAR 25, 2007 SEP 25, 2007
019537 002	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-421 PED	MAR 25, 2007 SEP 25, 2007
019537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-421 PED	MAR 25, 2007 SEP 25, 2007
019537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO				I-421 PED	MAR 25, 2007 SEP 25, 2007
020805 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO HC				PC	FEB 05, 2005
075593 002	CIPROFLOXACIN HYDROCHLORIDE; CIPROFLOXACIN				I-421 PED	MAR 25, 2007 SEP 25, 2007
019847 001	CIPROFLOXACIN; CIPRO				I-421 PED	MAR 25, 2007 SEP 25, 2007
020780 001	CIPROFLOXACIN; CIPRO				I-421 PED	MAR 25, 2007 SEP 25, 2007
020780 002	CIPROFLOXACIN; CIPRO				I-421 PED	MAR 25, 2007 SEP 25, 2007
019857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%				I-421 PED	MAR 25, 2007 SEP 25, 2007
019858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLORO				I-421 PED	MAR 25, 2007 SEP 25, 2007
021473 002	CIPROFLOXACIN; CIPRO XR	4670444 4705789 4957922 4808583 4670444*PED 4705789*PED 4808583*PED 4957922*PED 4670444 4670444*PED	DEC 09, 2003 NOV 10, 2004 SEP 18, 2007 FEB 28, 2006 JUN 09, 2004 MAY 10, 2005 AUG 28, 2006 MAR 18, 2008 DEC 09, 2003 JUN 09, 2004	DS DP U555 U427 U427 DP U611 DP U427 U427 U572	NS PED NDF	AUG 28, 2006 FEB 28, 2007 FEB 05, 2007
021644 001	CLOBETASOL PROPIONATE; CLOBEX	4659716	APR 21, 2005	U427		
021165 001	DESLOXATADINE; CLARINEX	4659716*PED 4659716 6314520	OCT 21, 2005 APR 21, 2005 JUN 01, 2018	U427 U427 DP U611 DP	NCE PED	DEC 21, 2006 JUN 21, 2007
021300 001	DESLOXATADINE; CLARINEX	6314520 4659716*PED 4659716 4659716*PED	JUN 01, 2018 OCT 21, 2005 APR 21, 2005 OCT 21, 2005	DP U611 DP U427 U427		
021312 001	DESLOXATADINE; CLARINEX	4659716 4659716*PED 6716867 6528530 6528530 6528530 6528530 6372252 6372252 6372252	APR 21, 2005 OCT 21, 2005 MAR 31, 2019 DEC 04, 2015 DEC 04, 2015 DEC 04, 2015 DEC 04, 2015 APR 28, 2020 APR 28, 2020 APR 28, 2020	DS DP DS DP DS DP DS DP DS DP DS DP DS DP DP DP DP		
021038 001	DEXMETOMIDINE; PRECEDEX	6716867	MAR 31, 2019	U572		
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6528530	DEC 04, 2015	DS DP		
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6528530	DEC 04, 2015	DS DP		
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN	6528530	DEC 04, 2015	DS DP		
021620 001	DEXTROMETHORPHAN HYDROBROMIDE; MUCINEX DM	6372252	APR 28, 2020	DP		
021620 002	DEXTROMETHORPHAN HYDROBROMIDE; MUCINEX DM	6372252	APR 28, 2020	DP		
021392 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA				I-133	APR 09, 2007
021392 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA				I-133	APR 09, 2007

>AID>
>AID>
>AID>

>AID>
>AID>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLJS EXPIRES
021437 001	EPLERENONE; INSPRA	6747020	NOV 05, 2019		NCE	NOV 18, 2009
021437 002	EPLERENONE; INSPRA	6747020	NOV 05, 2019	U587	NCE	NOV 18, 2009
021437 003	EPLERENONE; INSPRA	6747020	NOV 05, 2019	U587	NCE	NOV 18, 2009
>ADD>	ERLOTINIB HYDROCHLORIDE; TARCEVA				NDF	AUG 20, 2007
>ADD>	ERLOTINIB HYDROCHLORIDE; TARCEVA				NDF	AUG 20, 2007
>ADD>	ERLOTINIB HYDROCHLORIDE; TARCEVA				NDF	AUG 20, 2007
021633 001	ERLOTINIB HYDROCHLORIDE; TARCEVA				NDF	AUG 20, 2007
021633 002	ERLOTINIB HYDROCHLORIDE; TARCEVA				NDF	AUG 20, 2007
021633 003	ERLOTINIB HYDROCHLORIDE; TARCEVA				NDF	AUG 20, 2007
021371 001	ESTRADIOL ACETATE; FEMTRACE				NDF	OCT 09, 2006
021166 001	ESTRADIOL ACETATE; FEMTRACE				NDF	FEB 09, 2007
021674 001	ESTRADIOL HEMIHYDRATE; ESTRASORB	5629021	JAN 31, 2015	DP	NP	JUN 08, 2007
	ESTRADIOL; MENOSTAR					
021040 001	ESTRADIOL; PREFEST	5891868	NOV 21, 2017	DP U594		
020992 002	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN	6692763	NOV 21, 2017	DP U594		
020992 003	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN	5223261	JUN 29, 2010	DP U594		
020992 004	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN	6747019	MAR 20, 2020	U311		
020992 006	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN					
021443 003	ESTROGENS, CONJUGATED SYNTHETIC B; ENJUJIVA					
021443 004	ESTROGENS, CONJUGATED SYNTHETIC B; ENJUJIVA					
021490 001	ETHINYL ESTRADIOL; OVCON-35					
021687 001	EZETIMIBE; VYTORIN	6667050	JUN 12, 2021	DP U1		
		4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
021687 002	EZETIMIBE; VYTORIN	5846966	SEP 21, 2013	DS DP U593		
		RE37721	JUN 16, 2015	DS DP		
021687 003	EZETIMIBE; VYTORIN	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
		5846966	SEP 21, 2013	DS DP U593		
021687 004	EZETIMIBE; VYTORIN	RE37721	JUN 16, 2015	DS DP		
020363 001	FAMCICLOVIR; FAMVIR	4444784	DEC 23, 2005	DS DP U592	NCE	OCT 25, 2007
		5846966	SEP 21, 2013	DS DP U593		
020363 002	FAMCICLOVIR; FAMVIR	RE37721	JUN 16, 2015	DS DP		
		5840763	SEP 01, 2015	U96		
		5866581	OCT 04, 2014	U96		
		5916893	SEP 01, 2015	U96		
		6124304	SEP 01, 2015	U96		
020363 003	FAMCICLOVIR; FAMVIR	6124304	OCT 04, 2014	U96		
		5840763	SEP 01, 2015	U96		
		5866581	OCT 04, 2014	U96		
		5916893	SEP 01, 2015	U96		
		6124304	SEP 01, 2015	U96		
>ADD>	FELODIPINE; FELODIPINE					
>ADD>	FELODIPINE; FELODIPINE					
>ADD>	FELODIPINE; FELODIPINE					
>ADD>	FENOLDOPAM MESYLATE; CORLOPAM					
>ADD>	FEXOFENADINE HYDROCHLORIDE; ALLEGRA D 24 HOUR					
075896 001	FELODIPINE; FELODIPINE	6399632	MAY 11, 2012	U612	PC	APR 27, 2005
075896 002	FELODIPINE; FELODIPINE	6613357	DEC 25, 2020	DP U612	PC	APR 27, 2005
075896 003	FELODIPINE; FELODIPINE	5578610	NOV 26, 2013	DS	PC	APR 27, 2005
019922 001	FENOLDOPAM MESYLATE; CORLOPAM	6004582	MAY 29, 2018	DP	I-422	APR 01, 2007
021704 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA D 24 HOUR	6187791	MAY 11, 2012	U612		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>		6037353	MAR 17, 2017	U612		
>ADD>		6037353*PED	SEP 14, 2017			
>ADD>		6187791*PED	NOV 11, 2012			
>ADD>		6399632*PED	NOV 11, 2012			
>ADD>		5578610*PED	MAY 26, 2014			
020180 001	FINASTERIDE; PROSCAR	4760071	JUN 19, 2006	DS DF U262		
		5886184	NOV 19, 2012	DS		
		6046183	MAR 20, 2011	DP U577		
019949 001	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019949 002	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019949 003	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019949 004	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020090 001	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020090 002	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 003	FLUCONAZOLE; DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 005	FLUCONAZOLE; DIFLUCAN IN DEXTROSE	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 001	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 002	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
019950 004	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216	JAN 29, 2004			
		4404216*PED	JUL 29, 2004			
020985 001	FLUCOURACIL; CARAC	6670335	JUN 02, 2021	DP U68		
021235 001	FLUOXETINE HYDROCHLORIDE; PROZAC WEEKLY	5910319	MAY 29, 2017	U396	M-33	APR 21, 2007
		5985322	MAY 29, 2017	U397	NP	MAY 14, 2007
021077 001	FLUTICASONE PROPIONATE; ADVAIR DISKUS 100/50	6170717	DEC 23, 2017	DP		
021433 001	FLUTICASONE PROPIONATE; FLOVENT HFA	6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021433 002	FLUTICASONE PROPIONATE; FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		
021433 003	FLUTICASONE PROPIONATE; FLOVENT HFA	6170717	DEC 23, 2017	DP	NP	MAY 14, 2007
		6315173	DEC 23, 2017	DP		
		6510969	DEC 23, 2017	DP		
		6743413	JUN 01, 2021	DP U581		
		6253762	APR 14, 2015	DP U582		
		6546928	APR 14, 2015	DP U583		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	GABAPENTIN; GABAPENTIN	075694 002			PC	JUN 11, 2005
	GABAPENTIN; GABAPENTIN	076017 001			PC	FEB 14, 2005
	GABAPENTIN; GABAPENTIN	076017 002			PC	FEB 14, 2005
	GABAPENTIN; GABAPENTIN	076017 003			PC	FEB 14, 2005
>ADD>	GADOBENATE DIMEGGLUMINE; MULTIHANCE	021357 001			NCE	NOV 23, 2009
>ADD>	GADOBENATE DIMEGGLUMINE; MULTIHANCE	021357 002			NCE	NOV 23, 2009
>ADD>	GADOBENATE DIMEGGLUMINE; MULTIHANCE	021357 003			NCE	NOV 23, 2009
>ADD>	GADOBENATE DIMEGGLUMINE; MULTIHANCE	021357 004			NCE	NOV 23, 2009
>ADD>	GADOBENATE DIMEGGLUMINE; MULTIHANCE MULTIPACK	021358 001			NCE	NOV 23, 2009
>ADD>	GADOBENATE DIMEGGLUMINE; MULTIHANCE MULTIPACK	021358 002			NCE	NOV 23, 2009
>ADD>	GALANTAMINE HYDROBROMIDE; REMINYL	021169 001	DEC 14, 2008	U322		
>ADD>	GALANTAMINE HYDROBROMIDE; REMINYL	021169 002	DEC 14, 2008	U322		
>ADD>	GALANTAMINE HYDROBROMIDE; REMINYL	021169 003	DEC 14, 2008	U322		
>ADD>	GALANTAMINE HYDROBROMIDE; REMINYL	021224 001	DEC 14, 2008	U322		
>ADD>	GATIFLOXACIN; TEQUIN	021061 001		DS	I-432	JUN 30, 2007
>ADD>	GATIFLOXACIN; TEQUIN	021061 002		DS	I-432	JUN 30, 2007
>ADD>	GATIFLOXACIN; TEQUIN	021062 001		DS	I-432	JUN 30, 2007
>ADD>	GATIFLOXACIN; TEQUIN	021062 002		DS	I-432	JUN 30, 2007
>ADD>	GATIFLOXACIN; TEQUIN	021062 003		DS	I-432	JUN 30, 2007
>ADD>	GATIFLOXACIN; TEQUIN	021062 004		DS	I-432	JUN 30, 2007
>ADD>	GATIFLOXACIN; TEQUIN	021678 001		DS	NCE	DEC 17, 2004
				DS	I-329	OCT 17, 2005
021493 001	GATIFLOXACIN; ZYMAR	4980470	DEC 25, 2007	DS		
		5880283	DEC 05, 2015	DS		
		6589955	MAY 09, 2022	DS	U603	
		4980470	DEC 25, 2007	DS		
		6333045	AUG 20, 2019	DP		
		4808614	MAY 15, 2010	DS		
020509 001	GEMCITABINE HYDROCHLORIDE; GEMZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2004
020509 002	GEMCITABINE HYDROCHLORIDE; GEMZAR	4808614	MAY 15, 2010	DS	I-428	MAY 19, 2007
021158 001	GEMIFLOXACIN MESYLATE; FACTIVE	6723734	MAR 20, 2018	DS DP		
		6803376	SEP 21, 2019	DS DP	U608	
		6803376	SEP 21, 2019	U609		
021667 001	GLUTAMINE; NUTRESTORE				NCE	JUN 10, 2009
					ODE	JUN 10, 2011
021178 001	GLYBURIDE; GLUCOVANCE				M-37	MAR 15, 2007
021178 002	GLYBURIDE; GLUCOVANCE				PED	SEP 15, 2007
021178 003	GLYBURIDE; GLUCOVANCE				M-37	MAR 15, 2007
					PED	SEP 15, 2007
					M-37	MAR 15, 2007
					PED	SEP 15, 2007
076345 001	GLYBURIDE; GLYBURIDE AND METFOR				PC	OCT 31, 2004
076345 002	GLYBURIDE; GLYBURIDE AND METFOR				PC	OCT 31, 2004
076345 003	GLYBURIDE; GLYBURIDE AND METFOR				PC	OCT 31, 2004
021585 001	GUAIFENESIN; MUCINEX D	6372252	APR 28, 2020	DP		
>ADD>	GUAIFENESIN; MUCINEX D	6372252	APR 28, 2020	DP		
>ADD>	GUAIFENESIN; MUCINEX D	5292515	MAR 08, 2011	DP		
>ADD>	HISTRELIN ACETATE; VANTAS	5266325	NOV 30, 2010	DP	NDF	OCT 12, 2007
021665 001	HYALURONIDASE; AMPHADASE				NCE	OCT 26, 2009
021640 001	HYALURONIDASE; VITRASE				NCE	MAY 05, 2009
020758 001	HYDROCHLOROTHIAZIDE; AVALIDE					
020758 002	HYDROCHLOROTHIAZIDE; AVALIDE	5270317	SEP 30, 2011			
		5994348	JUN 07, 2015			
		5270317*PED	MAR 30, 2012			
		5994348*PED	DEC 07, 2015			
		5270317	SEP 30, 2011			
		5994348	JUN 07, 2015			
		5270317*PED	MAR 30, 2012			
		5994348*PED	DEC 07, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
------------------	-----------------------------	---------------	-------------------------	----------------	-------------	----------------

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLJS CODE	EXCLJS EXPIRES
>ADD> >ADD>		5968976 5968976	MAR 19, 2016 MAR 19, 2016	DP U613 DP U613	NCE NCE M-32 PED M-32 PED M-32 M-32 M-32 PED	OCT 26, 2009 OCT 26, 2009 MAR 05, 2007 SEP 05, 2007 MAR 05, 2007 SEP 05, 2007 MAR 05, 2007 SEP 05, 2007
020905 002	LEFLUNOMIDE; ARAVA	6083993	JAN 05, 2010	U332		
020905 003	LEFLUNOMIDE; ARAVA	6451289	MAR 21, 2021	DP		
020837 004	LEVALBUTEROL HYDROCHLORIDE; XOPENEX	5362755	NOV 08, 2011	U332		
		5547994	AUG 20, 2013	U332		
		5760090	JAN 05, 2010	U332		
		5844002	JAN 05, 2010	U5		
		6696493	JAN 18, 2021	U433		
020182 001	LEVOCARNITINE; CARNITOR	5053407	DEC 20, 2010	DS DP U600	NP	MAR 01, 2007
021571 001	LEVOFLOXACIN; IQUIX	5785053	DEC 05, 2015	DP		
021225 001	LEVONORGESTREL; MIRENA	6031007	APR 01, 2017	DP U553		
021451 001	LIDOCAINE; ORAQIX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
021130 001	LINEZOLID; ZYVOX	6559305	JAN 29, 2021	DS		
021130 002	LINEZOLID; ZYVOX	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
021131 001	LINEZOLID; ZYVOX	6559305	JAN 29, 2021	DS		
021132 001	LINEZOLID; ZYVOX	6559305	JAN 29, 2021	DS		
021226 001	LOPINAVIR; KALETRA	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
021251 001	LOPINAVIR; KALETRA	6559305	JAN 29, 2021	DS		
075505 001	LORATADINE; LORATADINE	5688792	NOV 18, 2014	DS U319	I-431	JUN 23, 2007
020386 001	LOSARTAN POTASSIUM; COZAAR	6559305	JAN 29, 2021	DS		
020386 002	LOSARTAN POTASSIUM; COZAAR	6703403	JUN 26, 2016	U257		
020386 003	LOSARTAN POTASSIUM; COZAAR	6703403	JUN 26, 2016	U257		
020803 001	LOTEPRENOL ETABONATE; ALREX	5747061	OCT 25, 2013	DP U576	PC	AUG 20, 2004
020583 001	LOTEPRENOL ETABONATE; LOTEMAX	5747061	OCT 25, 2013	DP U575	NPP	MAR 11, 2007
021249 001	LOVASTATIN; ADVICOR	6676967	SEP 20, 2013	U548	PED	SEP 11, 2007
021249 002	LOVASTATIN; ADVICOR	6746691	SEP 20, 2013	U586	NPP	MAR 11, 2007
021249 003	LOVASTATIN; ADVICOR	6676967	SEP 20, 2013	U548	PED	SEP 11, 2007
		6676967	SEP 20, 2013	U586	NPP	MAR 11, 2007
		6746691	SEP 20, 2013	U586	PED	SEP 11, 2007
021663 001	MENOTROPINS (FSH; LH); MENOPUR	5767251	JUN 16, 2015	DS	NP	OCT 29, 2007
>ADD> >ADD>		5650390	JUL 22, 2014	DP	ODE	OCT 08, 2011
020938 001	MELOXICAM; MOBIC	6184220	MAR 25, 2019	DP	I-430	JUL 16, 2007
020938 002	MELOXICAM; MOBIC				I-430	JUL 16, 2007
021530 001	MELOXICAM; MOBIC				I-430	JUL 16, 2007
>ADD> >ADD>		6683102	DEC 03, 2021	U189	NCE	APR 13, 2005
					NS	NOV 05, 2007
					D-92	NOV 05, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
013217 003	METAXALONE; SKELAXIN	6683102	DEC 03, 2021	U189		
021574 001	METFORMIN HYDROCHLORIDE; FORTAMET	6790459	MAR 17, 2021	U604	NP	APR 27, 2007
		6495162	MAR 20, 2018	DP		
		6099859	MAR 20, 2018	DP		
021574 002	METFORMIN HYDROCHLORIDE; FORTAMET	6790459	MAR 17, 2021	U604	NP	APR 27, 2007
		6495162	MAR 20, 2018	DP		
		6099859	MAR 20, 2018	DP		
076172 001	METFORMIN HYDROCHLORIDE; METFORMIN HCL				PC	DEC 14, 2004
076545 001	METFORMIN HYDROCHLORIDE; METFORMIN HCL				PC	MAY 29, 2004
021415 001	METHYL AMINOLEVULINATE HYDROCHLORIDE; METHYL AMINOLEVULIN				NE	JUL 27, 2007
021284 001	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP		
021284 002	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	6635284	DEC 04, 2015	DP	U591	
		5837284	DEC 04, 2015	DP		
021284 003	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	6635284	DEC 04, 2015	DP	U591	
		5837284	DEC 04, 2015	DP		
021284 004	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	6635284	DEC 04, 2015	DP	U591	
		5837284	DEC 04, 2015	DP		
021308 001	MICONAZOLE NITRATE; MONISTAT 1 COMBINATI	6635284	DEC 04, 2015	DP	U591	
076307 001	MIRTAZAPINE; MIRTAZAPINE				RTO	JUN 29, 2004
076307 002	MIRTAZAPINE; MIRTAZAPINE				D-90	OCT 01, 2007
020762 001	MOMETASONE FUROATE MONOHYDRATE; NASONEX				PC	JUN 14, 2004
					PC	JUN 14, 2004
021671 001	MORPHINE SULFATE; DEPODUR	6723713	JAN 27, 2014	U574		
		6723713 *PED	JUL 27, 2014			
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6241999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997899	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL. EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021598 001	MOXIFLOXACIN HYDROCHLORIDE; VIGANOX	6716830 6716830*PED	SEP 20, 2019 MAR 29, 2020	DP	NCE PED	DEC 10, 2004 JUN 10, 2005
>ADD>		RE38628	AUG 22, 2012	U304		
021009 001	NEDOCROMIL SODIUM; ALOCRIL	6746691	SEP 20, 2013	U586		
020381 001	NIACIN; NIASPAN	6676967	SEP 20, 2013	U548		
020381 002	NIACIN; NIASPAN	6746691	SEP 20, 2013	U586		
020381 003	NIACIN; NIASPAN	6676967	SEP 20, 2013	U548		
020381 004	NIACIN; NIASPAN	6746691	SEP 20, 2013	U586		
020381 005	NIACIN; NIASPAN TITRATION ST	6676967	SEP 20, 2013	U548		
021497 001	NITAZOXANIDE; ALINIA	6746691	SEP 20, 2013	U586		
021498 001	NITAZOXANIDE; ALINIA					
076648 001	NITROFURANTOIN; NITROFURANTOIN (MONO					
021494 001	NIZATIDINE; AXID	5229382	APR 23, 2011	DS DP U149	NDF	JUL 21, 2007
020592 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U547	NCE	NOV 22, 2009
020592 002	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	ODE	NOV 22, 2009
020592 003	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U547	NPP	JUL 21, 2007
020592 004	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	ODE	NOV 22, 2009
020592 005	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U547	FC	SEP 19, 2004
020592 006	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	NDF	MAY 25, 2007
021253 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	U547	I-417	JAN 14, 2007
021086 001	OLANZAPINE; ZYPREXA ZYDIS	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
021086 002	OLANZAPINE; ZYPREXA ZYDIS	5229382	APR 23, 2011	U547	I-417	JAN 14, 2007
021086 003	OLANZAPINE; ZYPREXA ZYDIS	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
021086 004	OLANZAPINE; ZYPREXA ZYDIS	5229382	APR 23, 2011	U547	I-417	JAN 14, 2007
>ADD>		5616599	APR 25, 2016	DS DP U500	NDF	MAR 29, 2007
>ADD>		5616599	APR 25, 2016	DS DP U500	NP	MAR 29, 2007
>ADD>		5616599	APR 25, 2016	DS DP U500	I-417	JAN 14, 2007
>ADD>		5840737	JUL 16, 2016	U588	I-400	JUL 10, 2006
>ADD>		6645988	JUL 16, 2016	DS DP	I-417	JAN 14, 2007
>ADD>		6489346	JUL 16, 2016	DS DP	I-400	JUL 10, 2006
>ADD>		6699885	JUL 16, 2016	DS DP	I-417	JAN 14, 2007
>ADD>		6780882	JUL 16, 2016	DS DP	I-400	JUL 10, 2006
>ADD>		4753789	JUN 24, 2006	U44	I-417	JAN 14, 2007
>ADD>		4695578	JAN 25, 2005	U44	I-400	JUL 10, 2006
>ADD>		5578628	FEB 16, 2005		I-417	JAN 14, 2007
>ADD>		4695578*PED	JUL 25, 2005		I-400	JUL 10, 2006
>ADD>		4753789*PED	DEC 24, 2006		I-417	JAN 14, 2007
>ADD>		5578628*PED	AUG 16, 2005		I-400	JUL 10, 2006
020007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAM					
>ADD>						
>ADD>						
>ADD>						
>ADD>						
>ADD>						

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL. EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
------------------	-----------------------------	---------------	--------------------------	----------------	-------------	----------------

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U44		
>ADD>		4695578	JAN 25, 2005			
>ADD>		5578628	FEB 16, 2005	U44		
>ADD>		5344658	SEP 06, 2011			
>ADD>		4695578*PED	JUL 25, 2005			
>ADD>		4753789*PED	DEC 24, 2006			
>ADD>		5344658*PED	MAR 06, 2012			
>ADD>		5578628*PED	AUG 16, 2005			
020103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U44		
>ADD>		4695578	JAN 25, 2005			
>ADD>		5578628	FEB 16, 2005	U44		
>ADD>		5344658	SEP 06, 2011			
>ADD>		4695578*PED	JUL 25, 2005			
>ADD>		4753789*PED	DEC 24, 2006			
>ADD>		5344658*PED	MAR 06, 2012			
>ADD>		5578628*PED	AUG 16, 2005			
020103 003	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5344658	SEP 06, 2011			
>ADD>		5578628	FEB 16, 2005	U44		
>ADD>		4753789	JUN 24, 2006	U44		
>ADD>		4695578	JAN 25, 2005			
>ADD>		4695578*PED	JUL 25, 2005			
>ADD>		4753789*PED	DEC 24, 2006			
>ADD>		5344658*PED	MAR 06, 2012			
>ADD>		5578628*PED	AUG 16, 2005			
020403 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4753789	JUN 24, 2006	U44		
>ADD>		4695578	JAN 25, 2005			
>ADD>		5578628	FEB 16, 2005	U44		
>ADD>		4695578*PED	JUL 25, 2005			
>ADD>		4753789*PED	DEC 24, 2006			
>ADD>		5578628*PED	AUG 16, 2005			
020605 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5578628	FEB 16, 2005	U44		
>ADD>		4753789	JUN 24, 2006	U44		
>ADD>		4695578	JAN 25, 2005			
>ADD>		5854270	NOV 20, 2015	U183		
>ADD>		4695578*PED	JUL 25, 2005			
>ADD>		4753789*PED	DEC 24, 2006			
>ADD>		5578628*PED	AUG 16, 2005			
>ADD>		5854270*PED	MAY 20, 2016			
020007 003	ONDANSETRON HYDROCHLORIDE; ZOFRAN PRESERVATIVE	5578628	FEB 16, 2005	U44		
>ADD>		4695578	JAN 25, 2005			
>ADD>		4753789	JUN 24, 2006	U44		
>ADD>		4695578*PED	JUL 25, 2005			
>ADD>		4753789*PED	DEC 24, 2006			
>ADD>		5578628*PED	AUG 16, 2005			
>ADD>		5955488	NOV 14, 2015			
>ADD>		6063802	NOV 14, 2015			
>ADD>		5578628	FEB 16, 2005	U330		
>ADD>		4695578	JAN 25, 2005	U330		
>ADD>		4753789	JUN 24, 2006	U330		
>ADD>		4695578*PED	JUL 25, 2005			
>ADD>		4753789*PED	DEC 24, 2006			
>ADD>		5578628*PED	AUG 16, 2005			
>ADD>		5955488*PED	MAY 14, 2016			
>ADD>		6063802*PED	MAY 14, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020781 002	ONDANSETRON; ZOFRAN ODT	5955488 5578628 4695578 4753789 4695578*PED 4753789*PED 5578628*PED 5955488*PED 6063802*PED 6063802 5763483 5866601 5952375 5763483*PED 5866601*PED 5952375*PED 5866601 5952375 5763483 5763483*PED 5866601*PED 5952375*PED	NOV 14, 2015 FEB 16, 2005 JAN 25, 2005 JUN 24, 2006 JUL 25, 2005 DEC 24, 2006 AUG 16, 2005 MAY 14, 2016 NOV 14, 2015 DEC 27, 2016 FEB 02, 2016 FEB 02, 2016 JUN 27, 2017 AUG 02, 2016 AUG 02, 2016 FEB 02, 2016 FEB 02, 2016 DEC 27, 2016 JUN 27, 2017 AUG 02, 2016	U330 U330 U330	NCE PED	OCT 27, 2004 APR 27, 2005
021087 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	6828313 5872147 6670351 6576659 6090799 6828313 5872147 6670351 6576659 6090799 6743441 6780881	DEC 05, 2017 DEC 05, 2017 OCT 20, 2012 DEC 05, 2017 JUL 18, 2017 DEC 05, 2017 DEC 05, 2017 OCT 20, 2012 DEC 05, 2017 JUL 18, 2017 APR 26, 2020 NOV 17, 2021	U585 U585 U585 U585 U585 U585 U585 U585 U585 U585 U585 U585	PC M-31 PED M-31 PED	SEP 26, 2004 MAR 31, 2007 OCT 01, 2007 MAR 31, 2007 OCT 01, 2007
021246 001	OSELTAMIVIR PHOSPHATE; TAMIFLU	5246925 5246925*PED 5587497 5587497*PED 6136799 6136799*PED 6361758 6361758*PED	APR 17, 2012 OCT 17, 2012 DEC 24, 2013 JUN 24, 2014 APR 08, 2018 OCT 08, 2019 APR 08, 2018 OCT 08, 2018	U314	DP	JAN 27, 2007 JAN 27, 2007 JAN 27, 2007
021492 001	OXALIPLATIN; ELOXATIN					
021492 002	OXALIPLATIN; ELOXATIN					
013718 001	OXANDROLONE; OXANDRIN					
013718 002	OXANDROLONE; OXANDRIN					
021351 002	OXYBUTYRIN; OXYTROL					
076168 001	OXYCODONE HYDROCHLORIDE; OXYCODONE HCL					
020988 001	PANTOPRAZOLE SODIUM; PROTONIX IV					
020819 001	PARICALCITOL; ZEMPLAR					
020819 002	PARICALCITOL; ZEMPLAR					
020936 001	PAROXETINE HYDROCHLORIDE; PAXIL CR					
020936 002	PAROXETINE HYDROCHLORIDE; PAXIL CR					
020936 003	PAROXETINE HYDROCHLORIDE; PAXIL CR					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
------------------	-----------------------------	---------------	-------------------------	----------------	-------------	----------------

021462 001	PENMETREXED DISODIUM;ALIMTA	5217974	MAR 29, 2011	U551	NCE	FEB 04, 2009
020629 001	PENCICLOVIR SODIUM;DENAVIR	5344932	SEP 06, 2011	DS DP	ODE	FEB 04, 2011
		5840763	SEP 01, 2015	U501		
		5866581	SEP 04, 2014	U501		
		5916893	SEP 01, 2015	U501		
		6124304	SEP 04, 2014	U501		
021749 001	PENTETATE CALCIUM TRISODIUM;PENTETATE CALCIUM TR	4879288	SEP 26, 2011	DS DP U550	NCE	AUG 11, 2009
021751 001	PENTETATE ZINC TRISODIUM;PENTETATE ZINC TRISO	4879288	SEP 26, 2011	DS DP U550	ODE	AUG 11, 2011
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4879288	SEP 26, 2011	DS DP U550	NCE	AUG 11, 2009
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4879288	SEP 26, 2011	DS DP U550	ODE	AUG 11, 2011
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4879288	SEP 26, 2011	DS DP U550	M-35	NOV 26, 2006
020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	M-35	NOV 26, 2006
020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-418	JAN 12, 2007
020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-419	JAN 12, 2007
020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-418	JAN 12, 2007
020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	6797719	MAR 10, 2017	DP	NP	AUG 31, 2007
021698 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	6677358	JUN 12, 2018	DS DP U546		
020741 001	REPAGLINIDE;FRANDIN	6677358	JUN 12, 2018	DS DP U546		
020741 002	REPAGLINIDE;FRANDIN	6677358	JUN 12, 2018	DS DP U546		
020741 003	REPAGLINIDE;FRANDIN	6177074	NOV 01, 2016	U454		
020903 002	RIBAVIRIN;REBETOL	6177074*PED	MAY 01, 2017	U454		
		6461605	NOV 01, 2016	U478		
		6461605*PED	MAY 01, 2017	U478		
		6472373	SEP 21, 2017	U479		
		6472373*PED	MAR 21, 2018	U479		
		6524570	NOV 01, 2016	U499		
		6524570*PED	MAY 01, 2017	U499		
076203 001	RIBAVIRIN;RIBASPHERE	6465443	AUG 14, 2018	DP	PC	OCT 03, 2004
076192 001	RIBAVIRIN;RIBAVIRIN	6432932	JUL 17, 2018	DP	PC	OCT 03, 2004
021361 001	RIFAXIMIN;XIFAXAN	6703403	JUN 26, 2016	U564	NCE	MAY 25, 2009
020835 003	RISEDRONATE SODIUM;ACTONEL	6703403	JUN 26, 2016	U564		
		5474995	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004
		5691374	MAY 18, 2015	U602	I-353	APR 11, 2005
		6063811	MAY 06, 2017	U602	M-27	AUG 06, 2006
		6239173	JUN 24, 2013	DS DP U602	PED	NOV 20, 2004
		6239173*PED	DEC 24, 2013	U602	I-423	MAR 26, 2007
		5474995*PED	JUN 24, 2013	DS DP U602	NCE	MAY 20, 2004
		5691374*PED	NOV 18, 2015	U602	I-353	APR 11, 2005
		6063811*PED	NOV 06, 2017	U602	M-27	AUG 06, 2006
		6239173*PED	DEC 24, 2013	DS DP U602	PED	NOV 20, 2004
		5474995	JUN 24, 2013	DS DP U602	PED	OCT 11, 2005
		5691374	MAY 18, 2015	U602	PED	FEB 06, 2007
		6063811	MAY 06, 2017	U602	PED	MAR 26, 2007
		6239173	JUN 24, 2013	DS DP U602	I-423	MAY 20, 2004
		5474995*PED	DEC 24, 2013	U602	NCE	MAY 20, 2004
021042 002	ROFECOXIB;VIOXX	5691374	MAY 18, 2015	U602	I-353	APR 11, 2005
		6063811	MAY 06, 2017	U602	M-27	AUG 06, 2006
		6239173	JUN 24, 2013	DS DP U602	PED	NOV 20, 2004
		5474995*PED	DEC 24, 2013	U602	PED	OCT 11, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>		5100899*PED	DEC 06, 2009			
>ADD>		5212155*PED	NOV 18, 2010			
>ADD>		5308847*PED	NOV 03, 2011			
>ADD>		5403833*PED	OCT 04, 2012			
>ADD>		5536729*PED	MAR 30, 2014			
>ADD>		5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
>ADD>	SIROLIMUS; RAPAMUNE	5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
>ADD>		5308847	MAY 03, 2011	U292	PED	MAR 15, 2005
>ADD>		5403833	APR 04, 2012	U293	PED	OCT 11, 2006
>ADD>		5989591	MAR 11, 2018			
>ADD>		5100899*PED	DEC 06, 2009			
>ADD>		5212155*PED	NOV 18, 2010			
>ADD>		5308847*PED	NOV 03, 2011			
>ADD>		5403833*PED	OCT 04, 2012			
>ADD>		5989591*PED	SEP 11, 2018			
>ADD>	SIROLIMUS; RAPAMUNE	5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
>ADD>		5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
>ADD>		5308847	MAY 03, 2011	U292	PED	MAR 15, 2005
>ADD>		5403833	APR 04, 2012	U293	PED	OCT 11, 2006
>ADD>		5989591	MAR 11, 2018			
>ADD>		5100899*PED	DEC 06, 2009			
>ADD>		5212155*PED	NOV 18, 2010			
>ADD>		5308847*PED	NOV 03, 2011			
>ADD>		5403833*PED	OCT 04, 2012			
>ADD>		5989591*PED	SEP 11, 2018			
021110 001	SIROLIMUS; RAPAMUNE	6780889	DEC 22, 2019	DP	NCE	SEP 15, 2004
021110 002	SIROLIMUS; RAPAMUNE	4968299	JUN 28, 2008	DP	I-386	APR 11, 2006
021110 003	SIROLIMUS; RAPAMUNE	5096885	MAR 17, 2009	DP	NCE	NOV 19, 2009
020955 001	SODIUM FERRIC GLUCONATE COMPLEX; FERRELECIT	5096885	MAR 17, 2009	DP	NCE	NOV 19, 2009
021196 001	SODIUM OXYBATE; XYREM	5763394	JUN 09, 2015	DP	I-439	NOV 01, 2007
021518 001	SOLIFENACIN SUCCINATE; VESICARE	5763394	JUN 09, 2015	DP	I-439	NOV 01, 2007
021518 002	SOLIFENACIN SUCCINATE; VESICARE			DP	I-439	NOV 01, 2007
020280 004	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT			DP	I-439	NOV 01, 2007
021148 001	SOMATROPIN RECOMBINANT; NORDITROPIN			DP	I-439	NOV 01, 2007
021148 002	SOMATROPIN RECOMBINANT; NORDITROPIN			DP	I-439	NOV 01, 2007
021148 003	SOMATROPIN RECOMBINANT; NORDITROPIN			DP	I-439	NOV 01, 2007
021148 004	SOMATROPIN RECOMBINANT; NORDITROPIN			DP	I-439	NOV 01, 2007
021148 005	SOMATROPIN RECOMBINANT; NORDITROPIN			DP	I-439	NOV 01, 2007
021148 006	SOMATROPIN RECOMBINANT; NORDITROPIN			DP	I-439	NOV 01, 2007
020168 001	SOMATROPIN RECOMBINANT; NUTROPIN			DP	I-439	NOV 01, 2007
020168 002	SOMATROPIN RECOMBINANT; NUTROPIN			DP	I-439	NOV 01, 2007
020522 001	SOMATROPIN RECOMBINANT; NUTROPIN AQ			DP	I-439	NOV 01, 2007
020522 002	SOMATROPIN RECOMBINANT; NUTROPIN AQ			DP	I-439	NOV 01, 2007
019764 001	SOMATROPIN RECOMBINANT; SAIZEN			DP	I-440	AUG 26, 2007
019764 002	SOMATROPIN RECOMBINANT; SAIZEN			DP	I-440	AUG 26, 2007
019764 003	SOMATROPIN RECOMBINANT; SAIZEN			DP	I-440	AUG 26, 2007
020080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006	U72	I-440	AUG 26, 2007
		5037845	AUG 06, 2008	U72	I-440	AUG 26, 2007
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020132 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020132 002	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020132 003	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008	U72		
		4816470	DEC 28, 2006	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
		6020001*PED	SEP 02, 2012			
		6368627*PED	SEP 02, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5863559*PED	JUL 26, 2016			
020626 001	SUMATRIPTAN; IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		5307953	DEC 02, 2012	U232		
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011			
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			
020626 002	SUMATRIPTAN; IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		5307953	DEC 02, 2012	U232		
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011			
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			
020626 003	SUMATRIPTAN; IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		5307953	DEC 02, 2012	U232		
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011			
		5554639*PED	MAR 10, 2014			
		5705520*PED	JUN 10, 2012			
		4816470*PED	JUN 28, 2007			
		5037845*PED	FEB 06, 2009			
		5307953*PED	JUN 02, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL./PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021618 002	TINIDAZOLE;TINDAMAX	5610163	MAR 11, 2014	DS DP U566	NCE	MAY 17, 2009
		6777423	SEP 24, 2021	DS DP	ODE	MAY 17, 2011
021682 001	TINIDAZOLE;TINDAMAX	5658929	SEP 27, 2010		ODE	MAY 17, 2011
021395 001	TIOFIBAN BROMIDE MONOHYDRATE;SPIRIVA	5658929	SEP 27, 2010	DP U544	ODE	MAY 17, 2011
020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	6770295	AUG 26, 2019		ODE	MAY 17, 2011
021228 001	TOLTERODINE TARTRATE;DETROL LA	6770295*PED	FEB 26, 2020	DP U544	NCE	JAN 30, 2009
021228 002	TOLTERODINE TARTRATE;DETROL LA	6770295	AUG 26, 2019			
		6770295*PED	FEB 26, 2020	DS DP U83	D-88	DEC 16, 2006
020505 001	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2008	DS DP U83	D-88	DEC 16, 2006
		5998380	SEP 13, 2015	U598		
020505 002	TOPIRAMATE;TOPAMAX	6503884	OCT 13, 2015	DS DP U83	D-88	DEC 16, 2006
		4513006	SEP 26, 2008	U598		
020505 003	TOPIRAMATE;TOPAMAX	6503884	OCT 13, 2015	DS DP U83	D-88	DEC 16, 2006
		4513006	SEP 13, 2015	U598		
020505 004	TOPIRAMATE;TOPAMAX	6503884	OCT 13, 2015	DS DP U83	D-88	DEC 16, 2006
		4513006	SEP 26, 2008	U598		
020505 005	TOPIRAMATE;TOPAMAX	6503884	OCT 13, 2015	DS DP U83	D-88	DEC 16, 2006
		4513006	SEP 13, 2015	U598		
020505 006	TOPIRAMATE;TOPAMAX SPRINKLE	6503884	OCT 13, 2015	DS DP U83	D-88	DEC 16, 2006
		4513006	SEP 26, 2008	U598		
020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	6503884	OCT 13, 2015	DS DP U83	D-88	DEC 16, 2006
		4513006	SEP 13, 2015	U598		
020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	6503884	OCT 13, 2015	DS DP U83	D-88	DEC 16, 2006
		4513006	SEP 26, 2008	U598		
020844 003	TOPIRAMATE;TOPAMAX SPRINKLE	6503884	OCT 13, 2015	DS DP U83	D-88	DEC 16, 2006
		4513006	SEP 13, 2015	U598		
021257 001	TRAVOPROST;TRAVATAN	6011062	SEP 13, 2015	DP		
		5849792	DEC 22, 2014	DP U383		
		5889052	DEC 02, 2014	DP U383		
		5510383	AUG 03, 2013	DP U383		
		6765117	OCT 24, 2017	DS		
021272 001	TREPROSTINIL SODIUM;REMEDIOLIN	6765117	OCT 24, 2017	DS		
021272 002	TREPROSTINIL SODIUM;REMEDIOLIN	6765117	OCT 24, 2017	DS		
021272 003	TREPROSTINIL SODIUM;REMEDIOLIN	6765117	OCT 24, 2017	DS		
021272 004	TREPROSTINIL SODIUM;REMEDIOLIN	6765117	OCT 24, 2017	DS		
020404 003	TRETINOIN;AVITA	4859660	NOV 19, 2007			
021595 001	TROSPIUM CHLORIDE; SANCTURA	5116844	AUG 11, 2009	DP U540	NCE	MAY 24, 2007
020675 001	URSODIOL;URSO 250	5364938	NOV 15, 2011	DS	NCE	NOV 14, 2006
021630 001	VORICONAZOLE;VFEND	5567817	OCT 22, 2013	DS DP U540	I-409	
		5773443	JAN 25, 2011	DS DP U540		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLJS CODE	EXCLJS EXPIRES
020825 001	ZIPRASIDONE HYDROCHLORIDE; GEODON	4831031 5312925 6150366 6245766	MAR 02, 2007 SEP 01, 2012 MAY 27, 2019 DEC 18, 2018	DS DP DS DP DP U601		
020825 002	ZIPRASIDONE HYDROCHLORIDE; GEODON	4831031 6150366 6245766	MAR 02, 2007 MAY 27, 2019 DEC 18, 2018	DS DP DP U601		
020825 003	ZIPRASIDONE HYDROCHLORIDE; GEODON	5312925 4831031 5312925	SEP 01, 2012 MAR 02, 2007 SEP 01, 2012	DS DP DS DP DS DP		
020825 004	ZIPRASIDONE HYDROCHLORIDE; GEODON	6150366 6245766 4831031	MAY 27, 2019 DEC 18, 2018 MAR 02, 2007	DP U601 DS DP		
021450 004	ZOLMITRIPTAN; ZOMIG	5312925 6150366 6245766 6750237 6750237*PED	SEP 01, 2012 MAY 27, 2019 DEC 18, 2018 NOV 28, 2020 MAY 28, 2021	DP DP DP DP DP		

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
 DS = Drug Substance claim
 DP = Drug Product claim
 U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at <http://www.fda.gov/cder/orange/patex.htm>
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 24TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION. THE MOST CURRENT COMPLETE LIST OF ALL PATENT AND EXCLUSIVITY TERMS IS AVAILABLE AT [HTTP://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM](http://www.fda.gov/cder/orange/patex.htm).

PATENT & EXCLUSIVITY ABBREVIATIONS

W EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
 D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
 D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
 D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL
 D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
 D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
 D-91 ALTERNATE INTERMITTENT DOSING REGIMEN
 D-92 ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME

EXCLUSIVITY INDICATION

I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
 I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
 I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
 I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
 I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E. COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
 I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
 I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
 I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
 I-425 FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
 I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
 I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
 I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
 I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
 I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS

- I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
- I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS

EXCLUSIVITY MISCELLANEOUS

- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
- M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
- M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL

PATENT USE

- U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
- U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
- U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
- U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
- U-550 TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA
- U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
- U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
- U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIODONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIODONTAL POCKETS
- U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
- U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
- U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING

- PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
- U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
- U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
- U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
- U-576 ALREX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH

- PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFA)
 - U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
 - U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
 - U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
 - U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
 - U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
 - U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
 - U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
 - U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
 - U-601 TREATMENT OF BIPOLAR DISORDERS
 - U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
 - U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
 - U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
 - U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
 - U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER
 - U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
 - U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
 - U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
 - U-610 RELIEF OF NAUSEA AND VOMITTING
 - U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
 - U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
 - U-613 REDUCTION OF SERUM PHOSPHATE
 - U-614 TREATMENT OF SEXUAL DYSFUNCTION

